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ABSTRACT
This thesis centres on an exploration of the nature, effects and determinants of beliefs
about medication in the context of chronic illness. The literature review begins with a
critical evaluation of adherence research with particular emphasis on the application of
social cognition models and self-regulatory theory. Following this there is an overview of
research eliciting beliefs about medicines which will clarify the outstanding questions.
The empirical section is divided into three parts. The first focuses on the nature of
medication beliefs. Items derived from interviews with patients (n=35) and from themes
identified in the literature were subjected to principal components analysis to identify the
core dimensions underlying beliefs about medication prescribed for a particular illness
(Specific) and more general beliefs about medicines as a whole (General). These
dimensions form the Beliefs about Medicines Questionnaire (BMQ), which was found to
have satisfactory psychometric properties. The BMQ was then used to investigate the
distribution, effects and determinants of medication beliefs in a series of analyses on cross-
sectional data obtained from 524 patients from a range of chronic illness groups.
The results show that lay beliefs about medicines are structured around four simple
factors which were stable across illness groups. Core beliefs about prescribed medication
are its perceived necessity for maintaining health (Specific-Necessity) and concerns about
long-term effects and the potential for dependence (Specific-Concerns). The core beliefs
about medicines in general are that they are intrinsically harmful, addictive substances
(General-Harm ) which are overused by doctors (General-Overuse). There were quite large
differences in medication beliefs between and within illness groups. Although 87% of
patients believed that their prescribed medicines were necessary, over a third expressed
strong concerns. Age and beliefs about prescribed medication explained 27% of the
variance in reported adherence. Patients with stronger concerns about their medication
and weaker beliefs in its necessity reported lower adherence as did younger patients. A
critique of the findings identifies directions for future research and practical applications.
I0
INTRODUCTION
This thesis is concerned with the exploration of patients' beliefs about medicines. It arises
from the well documented problems in adherence to medication. The main aim of the
research is to identify and quantify patients' beliefs about medicines in order to explore
their explanatory role in medication adherence.
Thus the literature review begins with an overview of adherence research which is
followed by an examination of the role of beliefs and cognition in health, with particular
emphasis on social cognition models and self regulatory theory. The final part of the
literature review examines existing studies which have specifically focused on medication
beliefs, primarily from a qualitative perspective. This identifies the outstanding questions,
arising from the limitations of existing research which are addressed in the empirical
section of the thesis
II
CHAPTER I
Adherence to medication: definitions and
measurement
I. I Medicine taking in context: rationale for the study of
adherence to medication
One of the dominant features in the development of medicine during the twentieth
century has been the exponential growth in the number of effective drug treatments. The
discovery of potent antibiotics during the 1940's was followed by a "therapeutic
revolution" in which the burgeoning pharmaceutical industry produced a range of
pharmacological active compounds for use in a wide variety of diseases. The prescription
of a medicine is now one of the most common medical interventions and accounts for
approximately I I % of expenditure within the UK National Health Service (NHS) (National
Association of Health Authorities and Trusts, I 994).
The delivery of health care within the United Kingdom and other developed economies is
based on a biomedical model in which ill-health is attributed to diseases which arise from
disturbances in physiological functioning. Interventions based on this model are therefore
characterised by the search for a specific disease label and the selection of a particular
treatment which is deemed to be suitable for that particular disease. The biomedical model
assumes that diseases are manifested in the body and are separate from psychological and
social interactions of the mind. Outcome is determined by the nature and extent of the
disease and the efficacy of the treatment. However, the suitability of this model in
explaining differentials in health outcomes has been called into question (Engel, 1977) and
it is now widely recognised that psychological (Kaplan, 1990; Berkman and Breslow, I 983;
Pennebaker, I 982) and socio-economic factors (Wilkinson, I 990; Marmot et al. I 984) may
have a profound influence on the aetiology and outcome of disease. The limitation of the
biomedical model in explaining health outcomes stimulated the adoption of the
biopsychosocial model which conceptualises health and illness as the product of a complex
interaction between psychological, social and biological factors (Engel, 1980). This
approach underpins the discipline of health psychology which is concerned with the study
of psychological and behavioural processes in health and health care Oohnston, 1994).
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Few issues identify the limitations of the biomedical model with greater clarity than that of
adherence to medication, since it is generally acknowledged that many patients fail to
follow prescription instructions and non-adherence to medication is viewed as a significant
health problem (Ryan and Birch, 1991; Meichenbaum and Turk, 1987). If the prescription
was appropriate and potentially effective then the degree of benefit to the patient will, to
an extent, depend on how closely they follow the instructions for use. Non-adherence is a
concern for those providing, receiving or funding care because it not only entails a waste
of resources but also a missed opportunity for therapeutic benefit. Whilst attempting to
explain the nature and extent of medication non-adherence the remainder of this chapter
will highlight issues and controversies concerning the definition and assessment of
adherence.
1.2 The nature of adherence: concepts and controversies
Major advances in medical technology which have occurred in the latter half of the
twentieth century mean that the mortality and morbidity associated with many common
diseases has been greatly reduced. Thus, in developed economies a key challenge for
health intervention is to maximise the benefit of existing therapies by facilitating the
appropriate self-management of common chronic illnesses, such as heart disease, asthma
and diabetes. Non-adherence to medication is perceived as a significant barrier to this aim
and has been identified as a cause for concern in most serious illnesses including heart
disease (Horwitz et al. I 990; Monane et al. I 994), asthma (Yueng et al. I 994), diabetes
(Glasgow et al. I 986), cancer (Lilleyman and Lennard, I 996), kidney disease (Cleary et al.
1995) and following organ transplantation (Hilbrands et al. 1995).
The incidence of reported medication non-adherence varies greatly from 4-92% across
studies, converging at 30-50% in chronic illness (Meichenbaum and Turk, I 987; Haynes et
al. 1979). The reasons for such a wide variation in the reported incidence are complex and
relate to discrepancies in the definition and measurement of adherence across studies. The
remainder of the chapter will outline some of the issues and problems associated with the
definition and measurement of medication adherence. Before doing so, it is necessary to
explain the rationale for the use of the term 'adherence'.
Until relatively recently the most common term for following treatment instructions was
'compliance'. However, this term has been criticised on the grounds that it has
unfavourable connotations in terms of the doctor-patient relationship (Stimson, I 974).
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Compliance seems to denote a relationship in which the patient has a passive role and is
expected to 'follow the doctor's orders'. Failure to do so may be regarded as deviant
behaviour and non-compliance may be seen as the patient's fault. The term 'adherence' has
been adopted by many as an alternative to compliance, in an attempt to emphasise that the
patient is free to decide whether to adhere to the doctor's recommendations and that
failure to do so should not be a reason to blame the patient. Thus the impetus for a
change in terminology from compliance to adherence was not simply a desire to be
'politically correct', but an attempt to acknowledge the role that patients should play as
active collaborators in the therapeutic experiment. It follows that health care professionals
(HCPs) have a responsibility to facilitate adherence to the treatment regimen they
prescribe, rather than assuming that it is the patient's responsibility to comply with their
instructions. These issues will be dealt with in the following sections which outline some
of the main issues in the conceptualisation of the adherence/compliance construct. In the
remainder of this thesis the term 'adherence' will be used in the spirit of conceptualising
medicine-taking as a partnership between patient and HCP.
1.3 Controversies in the definition of medication adherence
Adherence may be simply defined as:
"The extent to which the patient's behaviour coincides with the clinical prescription" (Sackett
and Haynes, 1976)
This is a succinct and pragmatic definition but it raises several conceptual and
methodological issues (Gordis, 1979). The key problem here is how to define non-
adherence. This is simple if adherence may be conceptualised as an "all or nothing"
response in which the patient either follows the prescriber's instruction to the letter
(adherence) or deviates from it in some way (non-adherence). However, the clinical utility
of such a strict categorical definition is limited. For most medicines, the need for total
adherence is questionable. Medication dosage regimens are usually derived from dose-
response data obtained from clinical trials. Variations in response to standard doses of
medication observed between and within individuals mean that standard recommended
dosages for most medicines are approximate. They represent the dose which is most likely
to accrue maximal therapeutic benefit with minimal harm for most patients most of the
time. Thus, small deviations in adherence may add little to the variation in response
inherent within the use of standardised dosages (Gibaldi, I 991).
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The fact that less than 100% adherence may be sufficient to bring about the desired
therapeutic response led Gordis to produce an alternative criteria for conceptualising non-
adherence as:
"The point below which the desired preventative or desired therapeutic result is unlikely to be
achieved" (Gordis, 1979)
This definition raises the important question: "When does non-adherence become
clinically significant?" Many researchers and clinicians are understandably attracted to the
idea of being able to categorise a patient as adherent or nonadherent. Indeed, this practice
was once considered essential (Gordis, I 979). However, Gordis also identifies a drawback
of dichotomising adherence behaviours by providing an example of how a range of
behaviour patterns could be labelled as 50% adherence as illustrated in Figure I . I, which
typifies the limitations inherent in a concept of adherence as uniform construct of doing or
not doing as instructed (Karoly, 1993). The problem is where to draw the line separating
adequate adherence from inadequate adherence.
Patient I	 -	 -	 -	 -	 -	 +	 ^	 +	 +	 +
Patient 2	 +	 +	 +	 +	 +	 -	 -
Patient 3
	
+	 -	 +	 -	 +	 +	 -	 +
Patient4	 +	 +	 -	 -	 -	 +	 +	 -	 +
Figure 1.1 Hypothetical results of sequential tests in four "50% compliers"
(Gordis, 1979)
The percentage adherence necessary to achieve the desired effect varies between
medications and between and within individuals. Thus, ideally the percentage adherence
necessary to achieve benefit would need to be established for each individual patient and
medication. Faced with this problem, most researchers have taken a pragmatic approach,
contending that if the selection of the type and dose of medication has been made on the
basis of clinical trial results and is appropriate, it is reasonable to assume, that the more
the patients' behaviour approaches the prescriber's instructions then the more likely they
are to benefit from the treatment This can be applied to an incremental or categorical
conception of adherence. Evidence suggests that this approach is not unreasonable. For
example, in a study of hypertensive patients, 80% adherence to the regimen was sufficient





pressure (Luscher et al. 1985). A separate study of recovery rates following myocardial
infraction revealed that patients who took >75% of prescribed medication were
approximately three times as likely to have survived after one year than those who took
<75% (Horwitz et al. 1990).
However, a uniform approach in which adherence behaviour is dichotomised into
"adherence and "nonadherence" remains problematic as the precise cut-off point will vary
between patients and treatments. Moreover , the point at which nonadherence becomes
detrimental will also depend on whether the prescription was appropriate. Sackett and
Haynes (1976) conceptualise treatment as a 'therapeutic experiment', the outcome of
which is influenced by actions of the practitioner, in selecting an appropriate diagnosis and

















Figure 1.2 Possible outcomes in the therapeutic experiment. Adapted from
Sackett, Haynes and Tugwell (1985)
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Recognising the fallibility of the practitioner as prescriber emphasises the point that high
adherence does not necessarily result in benefit to the patient It highlights the fact that
patients and practitioner carry mutual responsibility for the outcome of the therapeutic
experiment The notion of shared responsibility is now generally extended to the issue of
adherence. Most current reviewers maintain that HCPs have a responsibility not only to
select the appropriate treatment but also to facilitate adherence to the regimen. This is in
sharp contrast with the view that it is the patient's responsibility to take the medication as
instructed and that failure to do so is a fault of the patient alone. The notion of shared
responsibility for adherence has arisen in response to some of the ethical dilemmas raised
by nonadherence. These issues are summarised in the following section but are discussed
more comprehensively by Jonsen (I 979)
1.4 Ethical issues in conceptualising adherence
Certain ethical issues are raised by the conceptualisation of adherence. The first concerns
blame. Health Care Providers are often frustrated by non-adherence and there may be a
tendency to view the "non-compliant patient" as deviant or ungrateful and that this
behaviour should be corrected. Approaching the issue from this standpoint is at odds with
the "ethical ideal of freedom, mutual understanding and mutual responsibility" set out by
J onsen (I 979). This ethical ideal is represented in Fink's consensual regimen:
"A negotiated mutual contract in which both provider and client can be
said to have given 'informed consent which is practical in terms of the
current set of health problems and resources, 'no-fault' attitudes towards
noncom pliant behaviour, and mutual responsibility for outcome"
(Fink, 1976)
Implicit in Fink's approach is the notion that Health Care Providers have a responsibility to
facilitate adherence to their treatment regimen rather than assuming that it is the patient's
responsibility to comply with their instructions. Accepting this premise intensifies the need
for a greater understanding of why patients do or do not adhere to treatment instructions,
in order to guide interventions which facilitate appropriate consensual adherence. Haynes,
Taylor and Sackett (1979) have suggested several criteria which must be met before
intervention is deemed to be ethical:
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• The diagnosis must be correct (and the treatment appropriate)
• The therapy must do more harm than good
The patient should be an informed willing partner in any intervention designed to alter
behaviour
1.5 Types of nonadherence to medication
Three broad categories of medication non-adherence have been described in the
literature:
Original prescription not filled Studies have shown that 5-20% of primary care patients fail to
present the prescription for dispensing in the first place and this has been termed primary
non-compliance (Beardon et al. 1993; Rashid, 1982; Begg, 1984).
Refills not obtained This problem was illustrated by a recent study in which only 10% of a
sample of over 7000 patients with chronic heart failure filled enough prescriptions to
ensure a regular daily supply of medication (Monane et al. 1994).
Incorrect dosing Most of the published studies in the adherence area have focused on what
the patient does with the medication once it has been dispensed. In this context adherence
may be categorical or incremental. In categorical definitions patients are judged to be
adherent or non-adherent based on the amount of medication taken in relation to a
defined 'cut-off' point. Incremental definitions conceptualise adherence as a continuum.
1.6 Active and passive non-adherence
Non-adherence behaviours may be categorised according to the degree of volition. Active
non-adherence (AnA) arises when the patient makes a strategic decision not to take the
treatment as instructed. This has also been called "intelligent non-compliance" in
recognition of the fact that viewed from the patient's perspective non-adherence may be
the result of a rational decision (Weintraub, 1990). This term is problematic as some might
see it as value-laden, implying that unintentional nonadherence is somehow characteristic
of a lack of intelligence.
18
In active nonadherence (AnA), the behaviour is under-pinned by a strategic motive. The
patient makes a decision not to follow the treatment regimes or deliberately alters it or
some reason. An example of this type of behaviour was found among hypertensive
patients who, believed that they could judge when their blood pressure was high by the
presence of symptoms such as stress or headache and thus took anti-hypertensive
medication only when these symptoms were experienced (Baumann et al. 1989; Meyer and
Leventhal, I 985). Active nonadherence behaviour has been noted among several chronic
illness groups including asthma (Becker et al. I 978; Woller et al. 1993), rheumatoid
arthritis (Lorish et al. 1990), epilepsy (Conrad, I 985) and hypertension (Morgan and
Watkins, 1988).
Passive non-adherence (PnA) may be unintentional when the patient's intentions to take
the medication are thwarted by barriers such as forgetting, and inability to follow
treatment instructions because of a lack of understanding or physical problems such as
poor eyesight or impaired manual dexterity. PnA may not be completely without volition
since it might arise from a lack of motivation to adhere to the regimen, rather than an
active decision to adjust or omit doses (Cooper et al. 1982).
1.7 Measurement of adherence
As with many other areas of scientific research, an accurate measurement technique is
necessary to characterise the prevalence and determinants of adherence and to evaluate
interventions to enhance it. Unfortunately, the measurement of adherence is as
problematic as its conceptualisation and definition, and poses many challenges, some of
which are unique to medication while others apply to most behaviours. The following
section will summarise key issues in assessing medication adherence, followed by a brief
overview of the available methods. Three methods of adherence assessment which are
considered to be particularly relevant to this project will be reviewed in more detail.
These are the low dose phenobarbitone (LDPB) marker, medication event monitoring
system (MEMS) and patient self-reports.
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1.8 Methodological issues in the assessment of adherence to
medication
1.8.1 Accuracy
Two aspects of accuracy are particularly salient in adherence measurement, namely
specificity and sensitivity. Specificity refers to the proportion of false negatives and is
typically expressed as the proportion of cases of nonadherence identified by the test
method which are corroborated by a 'gold standard' measure. Sensitivity based on the
frequency of false positives and refers to the proportion of cases of high adherence
identified by the test measure which are corroborated by the 'gold standard' (Morisky et
at. I 986) measure. Sometimes a test measure is expressed as a percentage accuracy
reflecting the percentage of cases which were correctly classified by it.
1.8.2 Reliability
In the psychometric literature the reliability of a test refers to its reproducibility. In the
adherence literature 'reliability is often confused with accuracy. Authors sometimes use
the term 'reliability' when discussing the accuracy of an adherence measure in terms of the
rates of false positives or false negatives compared to some standard criteria, rather than
the test-retest reproducibility. Good test-retest reliability does not mean that the method
is accurate. It may simply be that inaccuracies are consistently reproduced (Caron, I 985).
However, reliability is a key issue if the method is to be used to detect changes in
adherence behaviour.
1.8.3 Measurement as a source of bias
One of the difficulties of measuring behaviour is that the act of measurement can itself
influence behaviour. The tendency for observation to influence behaviour is often referred
to as the Hawthorne effect after the series of experiments investigating employee
satisfaction and productivity conducted in Hawthorne, Chicago (Roethlisberger and
Dickson, 1939). Thus, if the patient is aware that their adherence is being monitored this
might stimulate adherence simply by drawing attention to the activity. The tendency of
attention from others to influence behaviour is known in psychology as reactivity (Reynolds,
I 982; Haynes and Horn, I 982). The measurement of adherence is also vulnerable to self-
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presentational bias on the part of the patient (Sheeran and Orbell, 1996). Patients may
perceive that adherence to treatment is one of the duties expected of the "good patient"
and may be reluctant to display non-adherence because they fear that this will offend or
disappoint their doctor or risk their disapproval. Consequently, in an attempt to present
themselves as more adherent, patients may create a falsely elevated adherence score by
taking more medication immediately prior to testing or by under-reporting nonadherence
(Rudd, 1993).
1.8.4 Characterising adherence behaviours
As discussed in the previous section, patients adherence behaviour may vary over time.
Thus, assigning a patient to an adherent vs. nonadherent category on the basis of a single
isolated measurement may be less meaningful than detailing the type (e.g. active vs.
passive) and its profile over time.
1.8.5 Ethical issues
Researchers wishing to measure adherence face a dilemma. Making the patient aware that
their behaviour is being assessed may alter it or lead to self presentational bias.
Conversely, failure to inform patients that they are being monitored may be deemed
unethical. This is particularly salient when the method of assessment is invasive and
permission to conduct the assessment must be obtained in advance. Eliciting permission
might alert the patient to the fact that are being monitored and thus act a source of bias.
Moreover, the discovery of surreptitious monitoring by the patient may have an adverse
effect on the patient-practitioner relationship.
1.9 An overview of techniques for measuring medication
adherence
Adherence measures can be divided into two broad categories according to whether the
assessment is direct or indirect Direct measurement entails observing the ingestion of the
drug or by detecting its presence in body fluids. Indirect measures assume ingestion based
on proxy evidence such as the patients report or number of dosages removed from a
container. The strengths and weaknesses of available direct and indirect methods have
been extensively reviewed (Creer, 1993; Rand and Wise, I 994; Rudd, I 993; Gordis, I 979)
and these are briefly discussed below and summarised in Table 1.1 and Table 1.2.
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Table I. I Strengths and weaknesses of direct measures used in










	 2. Pharmacokinetic interactions with other medications
may interfere with assay
3. Timing of assays in relation to dose
4. Long-term versus short-term medications
5. Pain and inconvenience to patients
6. Specialised equipment required
7. Lack of standardised criteria for judging compliance
8. Ethical restraints
9. Does not provide a profile of behaviour
Tracers or Markers
I. Objective	 I. Timing of testing
2. Direct	 2. Specialised equipment required
3. Marker of tracer may interact with other substances
4. Provides qualitative rather than quantitative data
5. Does not provide a profile of behaviour
Direct Observation
1. Objective	 1. Obtrusive
2. Direct	 2. Reactivity is likely to occur (observation may
3. Yields quantifiable data	 constitute an intervention)
4. May provide a profile	 3. Observer may become involved
of behaviour	 4. Requires training of observers








1. Few ethical restraints 	 1. Overestimated adherence
2. Easily obtained information	 2. Underreport nonadherence
3. Inexpensive	 3. Less accurate than other methods
4. Measures which are psychometrically sound have	 4. Subject to recall and self-presentational bias
construct and predictive validity
5. Non-invasive
Pill and Liquid Medications Assessment
I. Easily obtained	 1. May overestimate compliance
2. Inexpensive	 •	 pills may be removed but not ingested
3. Surreptitious assessment may be reasonably	 •	 does not delineate consumption patterns
accurate (but may be unethical) 	
•	 pills may be taken by other family members
4. Non-invasive	 2. Inherent difficulties occur in measuring liquid
medications
3. Does not provide a profile of behaviour
Electronic Measurement Devices
1. Objective	 1. Assesses use of containers or devices, not
2. Provides a profile of adherence behaviour 	 medication
2.	 Requires expensive equipment
3. Instrument malfunction may occur
4. Reactivity may occur if patient is informed of
monitoring
Treatment Outcomes
1. Readily available to clinician	 1.	 Lacks precision
2. Non-invasive	 2. Influenced by such factors as:
•	 misdiagnosis
•	 incorrect treaUnent
•	 spontaneous remission of symptoms
3. Does not provide a profile of behaviour
Prescription Refill Records
I. Unintrusive and surreptitious 	 I. Indicates collection of medication not usage
2. May be used to augment self-report	 2. Requires co-operation of doctor and pharmacist
3. Inexpensive	 3.	 Patient may present prescriptions to different
pharmacies
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I. I 0 Direct methods
These methods are termed 'direct' because assessment focuses on the presence of a drug
or a tracer compound such as riboflavin (Creer, 1993), in body fluids as evidence that the
medication has been taken. At first sight this might appear to be the best way to assess
adherence as other methods do not directly confirm that the medication has been ingested
(Caron, I 985) However, these techniques are fraught with problems, chiefly that the
relationship between the amount of medication or tracer taken and the concentration
found in body fluids is at best precarious. There is often considerable variation in drug
absorption, distribution, metabolism and elimination between individuals and within the
same individual over time (Gibaldi, 1991). It is particularly difficult to relate urinary drug or
tracer concentrations to administered dose, and drug/urine concentration is regarded as a
qualitative indicator of whether some of the drug has been taken, rather than a
quantitative measure of how much (Gordis, 1979). The validity of serum drug
concentrations as a measure of amount of drug ingested is also compromised by
differences in drug handling between and within individuals. For many drugs, particularly
those which are quickly eliminated from the body the results obtained depend on the time
of sampling.
The major drawback of direct methods is that they are invasive, expensive, of questionable
reliability and provide no indication of the type or time-course of nonadherent behaviour.
Additionally, valid reliable assays are routinely available for relatively few drugs.
The recent use of low dose phenobarbitone as a pharmacological tracer has stimulated
renewed interest in direct measures and has been hailed by some as a potential gold
standard (McGavock, 1996). In this technique, the medication under study is combined a
small dose of phenobarbitone. The fact that phenobarbitone is only slowly eliminated from
the body coupled with the use of sophisticated Baysian statistical modelling techniques,
provides a quantitative indication of the amount of drug ingested. A further advantage is
that phenobarbitone can be accurately and reliably measured in serum concentrations
which are thought to be low enough to avoid adverse effects (Pullar et al. 1989; Feely et al.
1987).
However, the method has several limitations. Its accuracy is dependent on time of
sampling in relation to the administered dose (Pullar et al. I 991). In practice, this means
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that if a patient's observed plasma PB concentration is similar to that expected, the
researcher must question whether this is attributable to a high adherence level or
represents a peak plasma level (taken about 6-8 hours after administration of the dose)
obtained from a patient with lower adherence. This means that even this apparently
objective method of adherence assessment may be at least partially compromised by the
perceived subjectivity of patient self-report. In most cases, the source of information
about the time when the last dose was taken is likely to be provided by the patient. The
method shares the ethical limitations of other direct methods. The fact that medication
has to specially formulated to include the marker adds to the cost and may give the patient
advance notice that their adherence is being monitored and introduce reactivity and self-
presentational bias. Thus, although the LDPI technique represents a technological advance
the inherent limitations outlined above mean that it cannot be adopted as a "gold
standard" for routine use in adherence studies. It is most commonly used in clinical trials in
combination with other adherence assessments.
I. I I Direct observation
The patient's medication taking behaviour is observed directly by a researcher or clinical
or member of the patient's family. This method is prone to reactivity bias and is impractical
in most research situations. Moreover, asking family members to gather data on the
patients' adherence behaviour is ethically problematic as it might compromise their
relationship. Patient diary cards have also been used to assess adherence but this is clearly
an intervention which might influence adherence in its own right. Also asking the patient to
fill out a diary represents another instruction which is subject to variations in adherence
(Rand and Wise, I 994).
1.12 Indirect methods
1.12.1 Pill counts
A commonly used method for assessing adherence is to count the number of dosage units
left in the container and compare this to the number which would have been left had the
patient followed the instructions. This method has the advantages of being technologically
simple and inexpensive. However, some studies have shown that pill count may under-
estimate the true level of nonadherence (Rudd et at. I 990; Kruse et al. I 993). Although
one can be reasonably sure that if the pill is in the container it has not been taken by the
patient, there is no guarantee that a pill which has been removed for the container has
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actually been ingested. Patients may remove medication for reasons other than to use it.
They might give the medication to someone else, or transfer it to another container, or
may deliberately discard doses prior to monitoring to create an impression of high
adherence. This practice - known as 'dose-dumping' may be reduced by not alerting the
patient to the fact that their pills will be counted. But this can be risky. For example in one
study Haynes and colleagues (1978) used the rather bold technique of asking Canadian
steel workers to 'provide a urine sample' and then surreptitiously counting their tablets
while they were indisposed. Although this strategy appears to have been effective in this
case, an early return, resulting in discovery of the researchers deception, might have
irrevocably damaged researcher-patient rapport (Haynes et al. I 980).
A further source of inaccuracy associated with the method arises from the need to know
when the container was started. Relying on the date of dispensing - included on the
packaging label- may be misleading. Many patients receiving treatment for a chronic illness
will obtain a supply of their medication in advance to avoid running out and so may start
the package after it was dispensed. Patient's report of when they started the pack is
subject to recall-bias. One problem that pill counts share with direct measures is that they
do not provide a profile of medication taking.
1.12.2 Electronic monitors
These techniques involve the incorporation of electronic devices into the medicine
container to record the time and date of usage. Early versions were bulky and
inconvenient to use (McGavock, 1996), but recent advances in micro-electronic and
computer technology have resulted in monitoring systems for tablet bottles, metered dose
inhalers and eye drop-containers. Attention has focused on the Medication Event
Monitoring System (MEMS) which comprises a microprocessor incorporated into the cap
of an otherwise standard container (Cramer et al. 1989). Studies evaluating the MEMS
illustrate the strengths and weakness of electronic measures in general.
The major advantage of these devices is that they potentially provide a profile of
medication taking rather than simply detailing how much was taken (Kruse et al. 1993;
Rudd et al. 1990; Kruse and Weber, 1990). However, as with the pill count method, a
dose removed is not necessarily a dose taken. Furthermore, if inclusion of the monitoring
devise changes the appearance of the medicinal product this will alert the patient to the
fact that they are being monitored and may change behaviour. The devices are also
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expensive and often need to be sent away for processing which may cause significant delay
(Matsui et al. 1994) Several studies comparing the MEMS with pill count or self report
indicate that other methods under-estimate the degree of non-adherence relative to MEMS
(Rudd et al. I 989; Waterhouse et al. I 993). Other studies suggest that significant numbers
of patients experience problems using the containers (Kruse et al. 1992), or remove
medication for later use, leading to an overestimate of nonadherence (Matsui et al. I 994).
The device is also limited if the dosage regimen requires the patient to take more than one
dosage unit at a time.
In technical terms, the MEMS is the best available method for giving a profile of medicine
taking over time and has a clear application in clinical trials. However, the above limitations
mean that these techniques may not be appropriate for all studies. For example if the aim
is to grade patients according to overall adherence rather than to provide a detailed
picture of timing and frequency of dosing, then MEMS may offer no real advantage over pill
counts (Matsui et al. I 994).
1.12.3 Patient self-report
One of the most commonly used methods of assessing adherence is simply to ask the
patient. and self-report measures are widely used in adherence studies. However opinions
about the value of this method are sharply divided. Some reviewers consider it to be
useless because it overestimates adherence (Caron, I 985). Others maintain that it is a
valid indicator of medication adherence which is practical and useful in a wide variety of
research settings (Ley and Llewellyn, I 995; Meichenbaum and Turk, 1987). Why such a
polarised view? One problem with self-reported adherence (SR.A) is that questions about
medicine taking are often presented at a time and place which is quite distant from the
actual event and so reports are subject to recall effects. In particular, even when they
admit to non-adherent behaviour, people tend to overestimate the extent of their
adherence (Ley and Llewellyn, 1995). For example, in one study of hypertensive steel
workers, even those who reported nonadherence overestimated the extent of their
adherence by an average of I 7% (Haynes et al. I 980). Recall bias of this type seems to
increase with longer periods of requested recall and Rudd has suggested that the outer
limit for reasonably accurate recall is about two weeks (Rudd, 1993).
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Another issue relates to the truthfulness of SRA. Reviewers and PhD students are fond of
pointing out that Hippocrates observed over 2,500 years ago that
"(Physicians should) keep watch also on the faults of patients which often make
them lie about the taking of things prescribed"
This observation is corroborated by more recent authors demonstrating that patients
often under-report non-adherence (Dunbar and Waszak, I 990; Gordis, 1979; Gordis et al.
1969). The accuracy of self-report as measure of adherence has been assessed by
comparison with other, more objective, methods or evaluated on the basis of correlation
between self-reported adherence and clinical outcome measures. In the main these studies
show that the accuracy of self-report varies according to the type of adherence behaviour
reported. Reports of low adherence are generally considered to be accurate as there is no
evidence that patients misrepresent themselves as non-adherers (Rand and Wise, 1994).
However, patient's reports of high adherence are often less accurate and discrepancies
occur between the number of patients reporting high adherence and those registering high
adherence rates by other methods. Thus SRA is often considered to have high specificity
but low sensitivity. In some studies self-report may fail to detect approximately 50% of
patients with low adherence (Haynes et al. 1980; Gordis et al. I 969).
Why does this rather disappointing statistic not curtail interest in this approach.? To
answer this question we need to take a closer look at the methodologies used in these
studies. A surprising number of studies by experienced and respected researchers provide
very few details about the self-report measure. This is problematic because a key reason
for under-reporting nonadherence is self-presentational bias (SPB) on the part of the
patient. SPB may be reduced by altering situational variables, such as the phrasing of
adherence related questions, to facilitate more truthful reporting by reducing the social
pressures which lead to self-presentational . Thus, in judging the validity of self-report as a
technique for assessing adherence it is important to consider the face validity of the items
used to elicit reported adherence. In earlier studies, the self-report measures are crude
with little attempt to control for SPB. For example, in one study which is often quoted in
evidence against self-report, participants were simply asked by the attending physician if
they had taken their medication that morning (Gordis et al. I 969) thus exerting social
pressure to give an affirmative answer. In other studies few details of the adherence
questions or the frequency of responses are given (Waterhouse et al. I 993; Roth and
Caron, 1978). Even when attempts are made to control SPB, the questions used are
psychometrically unsophisticated offering simple dichotomous responses rather than
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continuous scales (Haynes et al. 1980). Another methodological problem is that SRA
measures may be compared against 'objective measures' of questionable validity (Gordis et
al. 1969). Stetcher and colleagues (1989) have pointed out that most studies revealing high
rates of miss-reporting established only one cut-off point for determining whether or not
the patient was adherent and argue that major deviations tend to be more accurately
reported than minor ones.
It has been suggested that the validity of SRA measures can be enhanced by concurrent
use of a clinical measure such as blood pressure control (lnui et al. I 981). However a few
studies have demonstrated that SR measures alone are reasonably sensitive. For example
in one study in which home interviews were conducted with patients ten days after they
had received a prescription from a community physician, patients report that they had not
missed a dose, were corroborated by surreptitious tablet count in 80% of cases (Stewart,
1987). Other studies have found a strong correlation between self report and direct
measures of serum drug concentrations (Fletcher et al. I 979; Becker et al. 1978) and
between self-report and pill counts (Waterhouse et al. I 993). Becker and colleagues
(1978) found a high correlation (r0.9) between mothers' reports of theophylline
administration and covert assay of serum theophylline concentrations in 80 asthmatic
children attending an emergency room. However, the emergency room situation may have
exerted an external pressure on the mothers to accurately report their adherence and
these results may not be easily extrapolated to other, less urgent, situations.
The validity of self-report measures of adherence seems to increase with the psychometric
sophistication of the measure (Kravitz et al. 1993). Morisky and colleagues (1986) showed
that a four item scale of adherence to anti-hypertensive medication had acceptable internal
consistency (Cronbach alpha =0.6), and was moderately predictive of blood pressure
control at 2 and 5 year follow ups. Respondents were asked to reply (yes/no) to each of
four items shown in Table 1.3.
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Table 1.3 Self-reported medication adherence scale (Morisky et at.
1986)
• Do you ever forget to take your medicine?
• Are you careless at times about taking your medicine?
• When you feel better do you sometimes stop taking your medicines?
• Sometimes if you feel worse when you take your medicine do you stop taking it?
The discriminant validity of a 6-item self-report scale of adherence to asthma medication
based on Morisky's SRA scale (1986) was confirmed by the ability of the scales to detect
the impact of an intervention to improve adherence (Brooks et al. 1994). A psychometric
limitation of these scales is that responses to adherence questions are dichotomous.
Extending the range of questions and using a 6-point scale (from none of the time to all of
the time) for responses, resulted in the Medical Outcomes Study (MOS) adherence scale.
This has acceptable criterion-related validity as demonstrated by correlation between scale
scores and clinical outcome in a range of diagnostic groups: hypertension, diabetes and
myocardial infarction (DiMatteo et al. I 993; Kravitz et al. 1993). However, this scale is not
specific to medication. Further evidence in support of the validity of self-report measures
comes from a study of medication adherence among paediatric and adolescent cancer
patients (Tebbi et al. 1986). Medication adherence was measured by responses to non-
threatening questions, about the frequency of missed doses during the preceding month
were grouped into three categories of: no misses, occasional misses and frequent misses.
Serum corticosteroid assays conducted in 16 patients corroborated self-report in every
case.
A more detailed inspection of the SPA measures described above identifies room for
improvement in the method used to control self-presentational bias or in the psychometric
sophistication of the scale. For example the MOS-adherence measures items which are
phrased in a non-judgemental way in an attempt to limit self-presentational bias (e.g. 'I had
a hard time doing what the doctor suggested I do'). One criticism of this approach,
however is that the sanctioning of non-adherence is implicit (i.e. adherence is difficult) and
that self-presentational bias may be more effectively reduced by stating the sanction more
explicitly. This is demonstrated by Fletcher and colleagues (I 979) who preceded their
adherence questions with the statement 'Many patients have told me that they find it
difficult to take all their medicine exactly as the doctor prescribed'. Patients were then
presented with cards asking them to rate how often they took their medication rated as
0%, 25%, 50%, 74% and 100%. This approach is limited by the single item response. It is
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also possible that numerical (eg 1-5) or statement (eg often, sometimes) are more easily
interpreted by respondents than percentages.
In conclusion, although SRA may not provide an exact profile of the amount of medication
taken over time, and is subject to inaccuracies of overestimating adherence, these can be
reduced by controlling self-presentational bias and using psychometrically sound methods
of eliciting SRA. In such circumstances there is evidence to support Ley's conclusion that
SRA is: 'a useful method of grading patients on the adherence continuum' (Ley and
Llewellyn, 1995). However there is room for improvement in existing measures. The
availability of sophisticated electronic measuring devices such the MEMS should encourage
further studies into the sensitivity and specificity of sophisticated SRA measures.
1.12.4 Other methods
Clinicians estimates: generally prove to be grossly inaccurate (Rudd, I 993; Norell, I 981)
and do not improve with professional experience or familiarity with the patient (Roth and
Caron, 1978), possibly because clinicians tend to base their estimates on patient's
personality or sociodemographic factors.
Therapeutic outcome: as a measure of adherence is based on the assumption that there
is a close relationship between adherence to treatment and clinical benefit.. Research has
shown this to be true for certain effective treatments, appropriately prescribed (Horwitz
and Horwitz, 1993). However, adherence does not guarantee benefit and the relationship
between adherence and health outcome is rarely linear and quantifiable (Gordis, I 979).
Although this relationship is used as a test of predictive validity of the measurement
technique (Haynes et al. 1980; Morisky et al. I 986), it is not generally considered to be a
valid measure of adherence behaviour.
Prescription-refill records: Pharmacy records have been used as a measure of primary
nonadherence (Beardon et al. I 993) and as an indicator of adherence to chronic
medication (Hamilton and Briceland, 1992). The frequency with which the patient orders
and presents prescriptions for dispensing is compared with the expected frequency if the
patient were using the medication as instructed. Deviations from expected usage indicate
nonadherence. This method relies on the patient presenting their prescription to a single
pharmacy. Studies are needed to determine the value of this rarely used but potentially
helpful, method as a cross check of self-report data. For example, it might alert a
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researcher to false self-report if the patient reports high adherence but has a very low
refill rate.
1.13 Choosing an adherence measure
There is currentiy no 'gold standard' measure of adherence which can be used within the
resource restraints of studies of illness behaviour outside the controlled conditions of
clinical trials. Interpreting studies comparing the performance of various adherence
measures is therefore difficult. Each of the methods discussed above has certain flaws
which limit the accuracy, reliability or practical application of the technique. With the
possible exception of electronic measurement devices such as the MEMS, most of the
available techniques function as indicators of adherence rather than exact, quantitative
measures of behaviour.
Thus the choice of adherence measures represents a compromise in which accuracy and
comprehensiveness of the measure is balanced against reactivity, and practical ethical and
cost limitations. In this analysis pychometrically sophisticated SRA measures appear to
offer advantages in many situations. If there is any consensus in this complex issue it is that
a variety of measures should be used where possible (Rand and Wise, I 994; Rudd, 1993;
Meichenbaum and Turk, 1987; Gordis, 1979).
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CHAPTER 2
An overview of adherence research
Despite the ethical and conceptual limitations of the adherence construct, a plethora of
research studies have been conducted , over the last 25 years or so, in an attempt to
identify the determinants of adherence and to develop effective interventions to enhance
it. Adherence research has been characterised by three broad approaches:
(a) Atheortical approaches
Much of the early research and a portion of the later is atheoretical in its approach
and represents a pragmatic attempt to identify the antecedents of nonadherent
behaviour or to evaluate interventions to change it. The philosophical starting
point for much of this research appears to be the notion of nonadherence as a
state characteristic which may be linked to certain sociodemographic or
dispositional features of the patient or as a simple lack of knowledge about the
treatment regimen and how to use it.
(b) The communication model
This approach focuses on the role of communication and the nature of
interactions between patients and HCPs. Although this work does not appear to
be explicitly theory driven, it draws on an implicit theory that the quality of the
patient's interaction with the HCP is of prime importance. This approach, which is
typified by the work of Ley (1982, 1988), stems from the observation that patients
often misunderstand or forget treatment instructions or may lack motivation to
take the treatment because they are dissatisfied with some aspect of the doctor-
patient relationship.
(c) The social cognition models and self-regulatory theory
This approach focuses on patient's beliefs and the sociocultural context in which
they occur. It draws on a range of theoretical models, commonly refereed to as
social cognition models (SCMs), which attempt to explain health-related behaviours
in relation to specific cognitions (Stroebe and Stroebe, I 995). These include
expectancy-value models such as the Health Belief Model (HBM) and Theory of
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Reasoned Action (TRA) in which the decision whether or not to follow the
treatment advice is based on the patient's expectations of what the treatment will
achieve and the value which they place upon it. In contrast, Leventhal's self-
regulatory theory views adherence as the product of a dynamic interaction
between the patients experience of and beliefs about the illness, their emotional
reaction to it and their appraisal of the impact of adherence/nonadherence on
their well-being.
Each of the above approaches has been applied to two key questions: 'What are the
determinants of adherence?' and 'How can adherence be enhanced?' The remainder of the
chapter presents a summary of existing knowledge about the determinants of medication
adherence derived from research using atheoretical approaches and the 'communication
model'. A further section summarises the scope and limitations of intervention studies
based on these approaches and their contribution to knowledge. This will be followed in
Chapters 3 and 4 by a review of Social Cognition Models and Leventhal's Self-Regulatory
Theory and their application to the study of adherence to medication.
2.1 The determinants of non-adherence: atheoretical and
communications approaches
Early studies highlighting the prevalence of sub-optimal medicine taking were followed by
an intense search for the determinants of non-adherent behaviours, which identified over
100 possible causes of adherence (Sackett and Haynes, I 976). It is not surprising that so
many possible causes were identified given that most studies investigated univariate
correlations between variables with few attempts to see whether associations held across
socio-demographic or illness/treatment categories or to control for possible confounders
(Rudd, 1993). Moreover, an assessment of the relative contribution of various factors to
variance in adherence was rarely conducted and many single factors were found to be
unimportant when interactions between variables were assessed or when studies were
pooled or compared (Haynes et al. 1979; Sackett and Haynes, 1976).
It is possible to summarise the determinants of adherence identified in earlier studies into
three categories:
• Characteristics of the disease and treatment regimen
• Patient characteristics
• Quality of interactions between patient and health care practitioner (HCP).
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These categories are obviously not mutually exclusive and there is likely to be considerable
overlap between them. However, they are often used as a convenient way of summarising
the complex array of adherence antecedents identified in early studies (Meichenbaum and
Turk, 1987).
2.2 Characteristics of the disease as determinants of
adherence
There is circumstantial evidence that general levels of adherence may be higher in some
conditions than others. For example Horwitz and colleagues (I 990), reported that only
10% of patients recovering from a myocardial infraction were classed as non-adherent,
whereas studies involving patients with hypertension tend to report higher levels with
nonadherence rates averaging around 50% (Meichenbaum and Turk, 1987; Haynes, I 976).
Similarly, adherence rates in acute conditions are often higher than in chronic disease,
especially where treatment of the latter seems to produce little symptomatic benefit. Also,
low adherence rates are thought to be particularly prevalent among patients with
psychotic illnesses (Meichenbaum and Turk, 1987; Haynes et al. 1979). However, the fact
that considerable variation in adherence is noted among patients with the same disease
supports an interpretation that differential adherence rates arise from the effect of the
disease on the individual, rather than from a property of the disease which has a
generalisable effect on adherence in all patients. The focus for investigation should
therefore be the patient and how they interpret or manage the challenges imposed by the
disease.
2.3 Characteristics of the Treatment Regimen as
determinants of adherence
2.3.1 Physical barriers to adherence
The formulation or packaging of the medication may act as a barrier to adherence. For
example some patients may have difficulty in swallowing large capsules or may lack the
manual dexterity to use complex dosage forms such as metered dose inhalers or to open
blister packs or child-resistant containers. Patients with arthritic conditions may be
particularly prone to these problems.
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2.3.2 Complexity of the therapeutic regimen
There is fairly strong evidence to support the common-sense notion that the more
complex the treatment demands then the lower the adherence (Meichenbaum and Turk,
1987; Haynes, 1976). There are several sources of complexity: the prescription of a large
number of individual medications, the need to take medication at frequent intervals, or
medications which are difficult to use, such as inhaler devices. Complex regimens carry the
risk of information overload and related problems of poor understanding or low recall of
instructions. Additionally, a complex regimen may be so disruptive to the patient's daily
routine that they become demotivated and may avoid or delay doses (Meichenbaum and
Turk, I 987). The observed correlation between regimen complexity and nonadherence
seems to have led to the assumption in some quarters that simply reducing the frequency
of dosing is enough to prevent nonadherence. This is often evidenced in the marketing of
'once daily' pharmaceuticals. However, there is little evidence to support the efficacy of
this single strategy in enhancing adherence to medication (Haynes et al. I 979).
The fallacy of 'once daily dose' as a panacea for nonadherence is illustrated by a recent
prospective study in which 89 depressed out-patients were randomly allocated to one of
three, therapeutically equivalent, daily dosage schedules of the same antidepressant
medication (amitripyline and mianserin) (Myers and Branthwaite, I 992). Group A received
their medication at night, Group B in three divided doses and Group C were allowed a
free choice between regimen A or B. Adherence rates did not differ according to whether
the regimen was prescribed once or three times a day. However, patients who chose a
three-times a day regimen were significantly more adherent. This and other recent studies
reinforce the view that, although reducing the number of daily doses can facilitate
adherence if frequency of dosing is a barrier for the particular individual in question, the
routine choice of once-daily regimens is unjustified (Cramer et al. 1989; Eisen et al. I 990).
Complexity per se is not the key issue but how well the treatment fits in with the individual
patient's routine (Meichenbaum and Turk, 1987; Cockburn et al. I 987). It has been
suggested that increasing the complexity of a dosage regimen during the course of therapy
may reduce adherence because people find it difficult to 'step-up' existing routines
(Haynes, I 976) but further work is needed to verify this.
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2.3.3 Duration of treatment
Most authoritative reviews of the literature show that adherence rates often decline with
longer duration of treatment and nonadherence is more prevalent if the treatment is
prophylactic or is not perceived to produce symptomatic benefit (Meichenbaum and Turk,
1987; Haynes et al. 1979). Much of this evidence comes from prospective studies in which
adherence to newly prescribed regimens is assessed at regular time intervals. A more
recent study of adherence over a I 2 week period following initiation of anti-depressant
therapy suggests that the type of nonadherence may vary with duration of treatment early
nonadherence was characterised by discontinuation of the treatment and latter
nonadherence characterised by the tendency of the patient to vary the dosage of their
medication (Myers and Branthwaite, 1992). We currently know little about how patterns
of adherence might change over the course of treatment
2.3.4 Cost of treatment
It is thought that some patients may fail to redeem prescriptions because they cannot
afford to pay the prescription charge. In the UK over half the population are exempt from
prescription charges (McGavock, I 996). One study of primary nonadherence involving
nearly 5,000 patients attending a large general practice in England showed that non-exempt
patients redeemed significantly less prescriptions than those who were exempt from
charges (33% vs 17%). This suggests that cost may be a barrier to adherence for certain
patients/medications (Beardon et al. I 993). Others have suggested that increases in
prescription costs may lead to greater primary nonadherence and even deter patients from
visiting their GP (McGavock, 1996; Ryan and Birch, 1991).
2.4 Patient characteristics as determinants of adherence
2.4.1 Sociodemographic characteristics
Meichenbaum and Turk in their extensive review of the early adherence literature
conclude that 'the search for stable factors which comprise the nonadherent
uncooperative, or chronic defaulter patient has met with little success' (Meichenbaum and
Turk, 1987). A systematic review of 185 studies failed to identify stable socio-demographic
characteristics which were consistently associated with sub-optimal adherence (Sackett
and Haynes, I 976) No clear relationship emerged between race, gender, educational
experience, intelligence, marital status, occupational status, income and ethnic or cultural
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background and adherence behaviours. The only consistent finding was that nonadherence
was associated with extremes of age. Meichenbaum and Turk (I 987) suggest that this may
be because the very young are more averse to bad tasting medicine and the very old are
more susceptible to forgetfulness or self-neglect. However, a number of recent studies
which have compared adherence rates over a fairly wide range of ages, suggest that the
commonly held view that elderly patients are less adherent than their younger
counterparts is misguided (Bosley et al. 1995; Frazier et al. 1994; Lorenc and Branthwaite,
I 993; Sherbourne et al. 1992). Indeed there is growing evidence to suggest that adherence
rates are often lower in younger than in older adults (Daniels et al. 1994; Sherbourne et al.
I 992; Lorenc and Branthwaite, 1993; DiMatteo et al. I 993; Frazier et al. 1994). Recent
research suggests that the explanation for this finding may lie in age-related differences in
attitudes to health maintenance and management of illness (Leventhal E, A and Crouch,
I 996 in press). The relationship between age and medication adherence is discussed in
more detail in Chapter 7. There is little evidence that adherence behaviours can be
explained in terms of trait personality characteristics (Bosley et al. I 995; McKim et al.
I 990; Becker, I 979). Becker, (1979) pointed out that a socio-demographidpersonality trait
approach to adherence is fundamentally limited. Even if stable associations existed, they
would serve to identify certain "at risk" groups to facilitate targeting of interventions but
could do little to inform the type or content of interventions. Furthermore,
sociodemographic characteristics and personality traits are not generally amenable to
change and therefore present few opportunities for interventions to enhance adherence.
In practice, the idea that stable sociodemographic or dispositional characteristics are the
sole determinants of adherence is discredited by evidence that an individual's levels of
adherence may vary widely over time and between different aspects of the treatment
regimen (Hilbrands et al. 1995; Cleary et al. 1995; Kruse and Weber, 1990; Rudd et al.
1989). This is not to say that sociodemographic or dispositional characteristics are
irrelevant. Rather it would seem that associations with adherence may be indirect and best
explained by the influence of sociodemographic and dispositional characterises on other
relevant parameters such as illness-related cognitions (Leventhal et al. I 993; Leventhal and
Crouch, in press).
The lack of evidence for stable associations between sociodemographic I personality
factors, coupled with the inherent limitations of this approach has stimulated researchers
to switch attention to patient characteristics which might be amenable to change such as
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degree of understanding, knowledge and satisfaction and physical ability to manage the
medication.
2.4.2 Medication knowledge and adherence
Many patients lack basic knowledge about their medication (Cartwright, I 994; Eagleton et
al. I 993; al Mandy and Seymour, 1990). However, the relationship between a patient's
knowledge of their medication regimen and their adherence to it is by no means simple or
clear-cut. In his classic, systematic review of the adherence literature, Haynes concluded
that, although I 2 studies had demonstrated a positive association between knowledge and
adherence, at least twice as many, more methodologically sound studies, had failed to
demonstrate a link (Haynes, I 976). Studies conducted since then generally reinforce the
view that that associations between knowledge and adherence are at best small and
inconsistent (Lee et al. I 992; Eagleton et al. 1993) and that enhancing knowledge does not
necessarily improve adherence (George et al. 1983; Haynes et al. I 978).
Another reason for inconstancies in association between knowledge and adherence is that
medication knowledge is not a unitary concept, but rather comprises different knowledge
components. This is illustrated by the work of Ascione and colleagues (1986), who found
wide intra and inter-patient variations in level of knowledge about three aspects of
medication among 187 ambulatory cardiovascular patients. Patients knew most about the
purpose of the medication and how to take it. Fewer patients knew what to do if they
missed a dose and only a small minority could identify the common side-effects associated
with their treatment. Thus the observed inconsistencies in relations between medication
knowledge and adherence may be partially explained by variations in the way in which
medication knowledge is conceptualised and measured.
Why do many patients have such poor knowledge about their medication? At least part of
the answer to this question lies with patients' understanding and recall of information
provided by HCPs. Addressing these issues extends the scope of adherence research to
include the role of the physician (DiMatteo and DiN icola, I 982) and HCP-Patient
interactions (Ley, I 988).
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2.5 HCP-Patient interactions as determinants of adherence
Patients do not always understand prescription instructions (Sarriff et al. 1992) and often
forget considerable portions of what health care practitioners tell them (Weinman, I 987;
Ley and Llewellyn, 1995). For example, one early study found that approximately 50%
information provided by the doctor was forgotten within 5 minutes of leaving the surgery
(Joyce, 1969). It is well recognised that many patients have a poor understanding of
terminology which is often used by doctors in communicating details about illness
(Weinman, I 987; Boyle, 1970) and medication (Sarriff et al. 1992). Consequently, many
patients have little or no understanding of the details of their medication regimen (Cleary
et al. 1995; Eagleton et al. 1993; Lee et al. 1992).
The percentages of information recalled across a range of studies involving patients from
several diagnostic groups in various health care settings are presented in Table 2. I. A
detailed analysis of the influence of characteristics of the patient and material presented on
recall rates is beyond the scope of this thesis. However, Ley (1995) has recently
summarised the findings of research in this area.
Table 2.1 Summary of studies of recall of medical information (from
Ley, 1995)




















Further insights into the complex interaction between knowledge and adherence may arise
from consideration of the differential impact of medication knowledge on passive and active
adherence. For instance, if a patient is motivated to take their medication then poor
understanding or recall of how and when to use it could pose a significant barrier to
following the instructions and result in passive nonadherence. Conversely, some patients
may decide not to follow medication instructions (active nonadherence), despite being
well-informed.
There is increasing interest in the role of patient satisfaction as a mediator between
information provision, recall and adherence. Surveys conducted over the last 20 years or
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so suggest that many patients are dissatisfied with aspects of consultations with HCPs and
the amount of information offered to them about their illness and treatment (Cartwright,
1967; Hall et al. 1988; Ley, 1982; Gibbs and George, I 990). In a national UK survey of
patients' satisfaction with medicines information received, an average of over 70% of
subjects wanted more information than they were given (Gibbs and George, 1990).
Dissatisfaction with attributes of the practitioner or the amount of information and
explanation provided may act as a barrier to adherence by making the patient less
motivated towards the treatment (Hall et al. 1988). Ley has summarised the findings of
studies exploring links between understanding, recall, satisfaction and adherence in the





Figure 2.1 Relationships between understanding, memory, satisfaction and
compliance (Ley, 1995)
More recent studies have attempted to relate patient satisfaction to the degree to which
patient expectations about specific aspects of the consultation were fulfilled (Williams et al.
1995; Lassen, 1991). In a study involving 504 patients of 25 GPs in 10 London practices;
patient expectations - defined in terms of needs, requests and desires, prior to seeing the
doctor - and their fulfilment were assessed using validated questionnaires. Patients were
generally much more eager to obtain an 'explanation of their problem' than they were to
obtain 'support' or 'tests and diagnosis' and the degree to which their expectations were
met was predictive of satisfaction with the encounter.
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Further insight into the importance of addressing patients needs for clear explanations of
their illness and treatment is provided by the Medical Outcomes Study - a large study of
how patients fare with health care in the USA (Stewart and Ware, 1992). One aim of this
study was to examine the influence of physician's characteristics on patient adherence to a
range of treatments. In a cohort of over 8,000 patients, reported medication adherence at
2 years was related to reported medication adherence at baseline and to the tendency of
the physician to report that they saw a greater number of patients per week, and arranged
a specific follow up appointment. It is interesting that the socio-demographic characterises
of patients and doctors had no influence on adherence and that adherence to one aspect
of the treatment (e.g. medication) did not predict adherence to any other (e.g. diet,
exercise). The authors hypothesise that adherence was stimulated by scheduling frequent
follow up visits in which the patients' experience with medication could be monitored.
A further aspect of patient satisfaction in relation to medication use is the extent to which
their desire to be involved in the decision to prescribe is fulfilled. More studies are needed
to establish whether the patients' degree of perceived empowerment within the
prescribing decision is correlated with adherence (McCrea et al. I 993).
2.6 Interventions to enhance medication adherence
A cursory overview of published studies confirms Rudd's view that 'the arena of
interventions to enhance medication taking remains is an important barometer of
assumptions and prejudices about compliance itself' (Rudd, I 993). The tendency has been
to base interventions around single specific determinants of adherence which the
investigators believe to be salient. Thus interventions can be grouped into two broad
categories, based on the antecedents of nonadherence which they are designed to address.
Behavioural interventions: attempt to reduce the barriers to adherence by making the
regimen more convenient or less costly or by issuing the patient with reminders or cues.
Educational interventions are based on the principle that patients do not adhere to
treatment because they have not understood or do not recall what is expected of them.
Intervention focuses on redressing this by providing clear instructions, often in the form of
printed leaflets to aid recall.
There are several examples of studies, based on one or both of these approaches which
have enhanced adherence. For example reducing the number of daily doses (Baird et al.
I 984) or altering the packaging or formulation of the medication to improve access
(Murray et al. I 993) has produced moderate improvements in adherence in controlled
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trials. Tailoring the medication regimen to fit into the patients' daily routine seems to be
particularly effective (Logan et al. I 981). Other studies have focused on the provision of
educational materials designed to enhance patients' knowledge about their regimen.
Augmenting the basic information routinely provided on the medication label with written
information about what the medicine is for, common side effects and what to do if a dose
is forgotten improves satisfaction (Gibbs et al. I 990) but the effect of enhanced
information on adherence is inconsistent with some studies showing benefit and others
finding little effect (George et al. 1983; Weinman, 1990). Interestingly, George and
colleagues (I 983) noted a differential effect of information on adherence to particular
medication. Information was associated with higher adherence to penicillin antibiotics but
lower adherence to non-steroidal anti-inflammatory drugs (NSAIDs). Interventions using
behavioural and educational approaches in combination have also been shown to enhance
adherence (Lowe et al. I 995; Raynor et al. I 993; Logan et al. 1981) whereas others have
had no effect (Sackett et al. 1975).
On reviewing the 'adherence interventions literature' it quickly becomes apparent that
although one finds particular interventions which appear to have improved adherence in
specific situations, no single intervention seems to stand out as being consistently effective.
In a recent systematic review of this literature, Haynes and colleagues (1996) commented
that the majority of interventions are limited in scope and that most of the strategies
evaluated using rigorous controlled clinical trial methodologies were 'not very effective,
despite the amount of effort and resources they consumed'.
Does this mean then that non-adherence is an insurmountable problem ? Before concluding
that this rather bleak assessment is true, we need to ask why studies have failed to identify
interventions which are consistently effective. Broadly speaking, failure could be due to the
fact that the intervention was inadequate or that the study was flawed. Although, the
former applies in many cases, the latter is also a key factor. Several reviewers have
identified significant flaws in the design of studies assessing adherence interventions and
these are summarised in Table 2.2. The scale of the problem is illustrated by a recent
systematic review in which only 13 of over I 500 papers citations and abstracts screened
met the criteria for detailed review (Haynes et al. I 996). However, even methodologically
sound studies 'provided little evidence that medical adherence can be improved
consistently within the resources usually available in clinical settings'.
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Table 2.2 Summary of common methodological flaws in studies
assessing interventions to enhance medication adherence
Common methodological flaws
• Intervention is not clearly described or individual components not detailed
• Not randomised controlled trials
. No information on base-line adherence
• Lack of 'attention placebo means that it is difficult to distinguish between the specific effect of
intervention and those arising from increased attention alone.
• Short term follow up
• Numbers are too low so that study lacks statistical power
• Treatment outcome not measured and hence it is difficult to judge the whether changes in
adherence benefited the patient
The discovery of a single intervention which is effective in all situations is something of an
adherence Holy Grail' but the fact that it has not yet been found should not surprise us.
The search seems to rest on an implicit assumption that adherence is a unitary
phenomenon. However, it is clearly multifactorial with a large range of determinants. One
reason why the success of adherence interventions does not seem to be generalisable is
that adherence behaviours are not generalisable. It is likely that the salience of particular
determinants will vary between individuals and in the same individual across treatments
and over time. A further complication is that nonadherent behaviour may be the
intentional result of an active decision by the patient (Cooper et al. I 982). Thus, an
intervention which is effective in some situations (e.g. reminding the patient who forgets)
may be ineffective in another (e.g. if the patient avoids taking the medication because of
unpleasant side-effects).
The multifactorial nature of adherence and the fact that nonadherence is often volitional
has led to a shift in the conceptualisation of adherence and a change in the focus of
research. It is now recognised that adherence is best thought of as a state, rather than a
trait characteristic. Individual patients may adhere to some aspects of their treatment and
not others and adherence rates may vary over time. Interventions geared to making the
patient more effective at following the prescribed instructions are unlikely to work if the
patient has decided not to take a particular medication or if taking it is perceived as
unimportant. Consequently the emphasis of adherence research over the last decade or so
has moved away from attempts to identify stable trait factors which characterise the
nonadherent patient to achieving a greater understanding of how and why patients decide
to take some treatments and not others.
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CHAPTER 3
A review of social cognition models and self-
regulatory theory approaches to medication
taking
Social Cognition Models (SCMs) are theoretical approaches to understanding health-
related behaviour. They share a common assumption that attitudes and beliefs are major
determinants of behaviour. Many use an expectancy-value approach in which behaviour in
response to health threats or messages arises from an active decision based on two types
of cognition. These are expectancies or beliefs about the probability that a specific action
(e.g. taking medication) will lead to a set of outcomes (e.g. improved health) and the
subjective value placed on them. Some, such as the health belief model (HBM) have been
specifically developed to explain health-related behaviours, others, such as the theory of
reasoned action (TRA) are derived from general models of behaviour. In this chapter, I will
describe several SCMs. Although, there is some overlap between models, for the sake of
simplicity, each model will be discussed individually. This will be followed by a summary of
the contribution of each model to our understanding of medication adherence derived
from a critical review of published studies.
3.1 The Health Belief Model (HBM) (Rosenstock, 1974)
This model was developed to explain why people failed to take up disease prevention
measures or screening tests before the onset of symptoms (Rosenstock, I 974).The
original model proposed that the likelihood of someone carrying out a particular health
behaviour (eg attending for screening) was a function of their personal beliefs about the
perceived threat of the disease and an assessment of the risk/benefits of the recommended
course of action. Perceived threat, or vulnerability, is derived from beliefs about the
perceived seriousness of the threat and the individuals perceived susceptibility to it. The
individual then weighs up the perceived benefits of an action (e.g. taking medication might
ease symptoms) against the perceived barriers to the action (e.g. fear of side-effects or
costs of the treatment). A further component was added by Becker and Maiman (1975)
which makes the model more applicable to adherence to treatment regimens. They
stipulated that a cue to action or stimulus must occur to trigger cognitions about
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vulnerability and benefits/risks of action. This model is shown in Figure 3.1. Thus, the HBM
predicts that the likelihood of action is increased if the perceived threat of the disease is
high and if the benefits of behaviour are thought to outweigh the barriers and if certain
cues are in place.
DEMOGRAPHIC
VARIABLES
riass, gender. age, etc 	 ________________
Perceived susceptibility	
]Perceived seventy




Cues to actionPerceived barnersgroup pressure, etc	
]	 __________________________	 __________________________
Figure 3.1 The health belief model (adapted from Sheeran and
Abraham, 1996)
The original HBM is directed towards the individual's desire to avoid a specific disease
threat. Several revisions have been made to this original model by including modifications
as listed below:
• General health motivations which are seen as fairly non-specific
personal attributes which are stable across situation.
• Resusceptibility to an illness previously contacted and currently under
consideration.
• General orientation towards medicine.
• Characteristics of the doctor-patient relationship.
The HBM has also been modified for use in children by inclusion of certain developmental
factors which reflect the changing personal, social and environmental influences which are
pertinent to children (Bush and lannotti, I 990).
Empirical support for the HBM in predicting health-related behaviours is equivocal
(Marteau, 1995). In support of the model, Janz and Becker (Janz and Becker, I 984),
46
conclude that the majority of 46 studies of the HBM conducted prior to I 984 found
statistically significant relationships between barriers (89%), susceptibility (81%), benefits
(78%) and severity (65%) and health behaviours. Although, these data indicate that the
components of the model are related to behaviour, they should be interpreted with
caution. The percentages shown in brackets refer to the percentage of studies, in which
statistically significant correlations between a particular HBM component and health-
related behaviour had been found. However, this provides limited information about the
usefulness of the model in predicting behaviour. It gives little information about effect size
or about whether behaviour was influenced by an interaction between variables as
predicated by the model, or just by isolated components of the model.
The HBM or its components have been utJlised in a large number of research studies
investigating health-related behaviours. However, it is difficult to draw firm conclusions
about the viability of the model because of differences in the way in which it has been
operationalised and applied across studies. In the main, the HBM seems to work best
when it is used as originally intended as a predictive model for preventative behaviours
(Janz and Becker, I 984). A meta analysis of studies relating the HBM to preventative health
behaviours found that on average 24% of variations in behaviour was accounted for by
combined HBM variables (Zimmerman and Vernberg, 1994). Although this may seem a
relatively small effect, Abraham and Sheeran (in press) point out that "explaining 25% of
variance corresponds to a potential success rate increase from 25% to 75%". They
illustrate this effect with a hypothetical example in which 25% of a target population
currently carry out a behaviour. If an interaction based on the HBM was successful in
changing relevant cognitions in the 75% of the population who do not currently engage in
the behaviour, it would result in a behaviour change in 75% of the population.
3.2 The HBM applied to medication adherence
The HBM has also been applied to medication taking in acute and chronic conditions.
However, evaluating the value of the HBM in explaining adherence to medication is
hampered by the fact that relatively few studies have operationalised the model in its
entirety. Researchers tend to take a 'pick and mix' approach using only selected
components of the HBM, usually in combination with variables derived from other
theoretical approaches (Newell et al. 1986; Barnhoorn and Adriaanse, 1992).
Methodological flaws add another dimension of difficulty. Failure of the model to predict
adherence might be due to the use of an inappropriate methodology as much as to
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deficiencies in the model itself. This point is best illustrated by a more detailed evaluation
of the available studies which have used the HBM in the context of medication adherence.
Given the origin of the HBM as a theoretical interpretation of the antecedents of
preventative health-behaviours, one might imagine that it would be most usefully be
applied in situations where medication is prescribed as prophylaxis. Testing the predictive
power of the model, would be best achieved using a prospective design in which cognitions
at time I are related to adherence behaviour at time 2. The HBM might therefore be
particularly suitable for investigating adherence in hypertension and several studies have
addressed this.
3.2.1 Hypertension
An example of this was Taylor (1979) in a prospective involving a cohort of hypertensive
Canadian steel-workers selected from a larger intervention study (Sackett et al. I 975).
Health beliefs were measured prior to diagnosis (n230) and at 6 and I 2 month follow ups
(n I 28). Medication adherence was assessed by pill count and self-report during the follow
up visits. None of the HBM measures at baseline correlated with adherence at 6 or I 2
months. However, for the sample of patients who received a diagnosis of hypertension,
several HBM variables measured at 6 months were predictive of adherence at I 2 months.
Medication adherence, assessed respectively by pill count and self-report was correlated
with drug safety (r0.27,O.23), perceived seriousness of hypertension (r0.32,O.20) and
perceived degree of social dependency related to hypertension (r0.23,O.2 I). Linear
regression analysis showed that these cognitive variables explained a total of I 5% variance
in pill counts and 9% variance in self-reported adherence. Several methodological
limitations reduce the generalisability of these findings. It is unclear why the authors chose
not elicit HBM variables shortly after diagnosis, rather than before. Receiving the diagnosis
is likely to influence HBM cognitions, and might itself act as a behavioural cue. The survey
was a sub-set of a larger intervention study in which an educational and physician follow up
intervention was compared against standard care. The authors do not appear to have
controlled for the intervention in their findings and so it is not possible to judge whether
receipt of the intervention confounded the effect of HBM variables on adherence. Finally
the authors provide little information of how the HBM constructs were operationalised or
measured, so that it is difficult to judge the validity of their findings.
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A further prospective study of the HBM in hypertension was conducted by lnui and
colleagues (1976). This was essentially a controlled trial of a physician-based intervention
to improve patient adherence to medication. Physicians in the intervention group were
given tutorials on how to communicate health information to patients about their illness,
based around the concepts of the HBM. To evaluate the intervention, medication
adherence and blood pressure control of patients visiting these clinicians was compared, 7
days and 60 after clinic visits, with those attending control clinicians. Patients visiting
clinicians in the intervention group were more adherent with better blood pressure
control. This study represents one of the few cases where an intervention has been based
specifically on the HBM. However, as a test of the validity of the HBM as a predictor of
medication adherence it is spectacularly flawed. Chiefly, differences in adherence or
outcome between groups cannot be attributed to differences in HBM related cognitions of
patients since these were not measured. Rather one is left to assume that implementation
of the HBM based intervention influenced physician attitude and behaviour which in turn
influenced the attitudes and behaviour of the patients.
Nelson and colleagues (1978) in a study of 142 patients with hypertension, found a
statistically significant association between reported medication adherence and two HBM
components: 'perceived severity of own hypertension' and 'perceived experience of
medication side-effects'. The perceived benefits of treatment, conceptualised as perceived
efficacy of medication, did not influence reported medication adherence. Although this
study implies that certain cognitions, specified within the HBM, may be involved in
adherence decisions, a number of methodological problems alert us to interpret these
results cautiously. First, there are problems with the way in which the key dependent and
independent variables were operationalised. Adherence was assessed by interview in which
patients were asked to detail the frequency of missed doses over the previous 28 day
period. On the basis of their response participants were classed as adherent (none missed)
or nonadherent (one or more doses missed). Dichotomising the data in this way, may not
represent the most clinically valid interpretation of adherence and results in loss of
information provided by the interval data collected. The investigation also interpreted the
HBM variables rather loosely, including medication side effects as a 'modifying factor',
rather than as a 'barrier' as stipulated (Janz and Becker, 1984), and by adding new variables
such 'priority of health in life'. A further drawback, is that the cross-sectional design of the
study hampers the attribution of causality. This point is discussed in more detail later.
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3.2.2 Renal disease
The HBM has been used to investigate treatment adherence in patients with End Stage
Renal Failure in two studies. Cummings (1981) and colleagues found that self-reported
adherence to dietary recommendations and medication was correlated with susceptibility,
benefit and borders in a sample of I I 6 patients receiving haemodialysis. However, this study
was also part of a larger intervention study and was cross-sectional in design , so that it is
difficult to judge whether the effect of beliefs on adherence was causative or reactive. The
problems associated with the use of the HBM and other expectancy-value models in cross
sectional studies is illustrated by another study involving haemodialysis recipients (Hartman
and Becker, 1978). All HBM dimensions correlated with 'objective indicators' of adherence
(serum phosphate, serum potassium and inter-dialysis weight gain) to medication and
diet/fluid restrictions in a cross-sectional study of 50 haemodialysis recipients. However,
the correlation between adherence and 'susceptibility' was negative. This is contrary to the
HBM which predicts that high susceptibility scores would stimulate higher adherence. The
explanation for this apparent anomaly might lie in the fact that these data are cross-
sectional and that the perception of low susceptibility to future adverse effects of the
disease might be a consequence of high adherence ('I am following the doctor's advice and
will therefore be protected'). The issue of causal relationships and predictive validity of
SCMs will be dealt with in more detail later in this chapter.
3.2.3 Psychiatric illness
The HBM has also been applied to medication adherence among American psychiatric
out-patients (Kelly et al. 1987). In this study (n= 107), which is one of the few to adequately
describe the psychometric properties and distribution of scores on the scales used to
assess components of the model, HBM variables explained 20% of the variance in reported
adherence. Although in this study, some of the individual components of the HBM were
related to adherence, this does not constitute evidence that reported adherence was
predicted by the HBM for several reasons. First the data are cross-sectional and so cannot
be used to confirm the causal relationship between beliefs and behaviour stipulated within
the HBM. Second, reported adherence was predicted by particular components, rather
than by the model as a whole. Barriers, perceived susceptibility and cues made significant
contributions to the variance in reported adherence but severity and benefits did not make a
statistically significant contribution. In this study the items used to assess the various HBM
components reflect its application to the self-management of a chronic illness rather than
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to preventative health behaviours. Susceptibility was operationalised as the perceived risk of
future hospitalisation and barriers as the perceived experience of medication side effects.
Other studies have also shown that adherence to medication prescribed for psychotic
illness was related to patients perceptions of benefits and costs (Hogan et al. 1983; Ludwig
et al. I 990). The model has been applied in its entirety in only two studies in the
psychiatric area. In contrast to Kelly and colleagues (I 987), Pan and Tantam (I 989) found
no difference in health beliefs between adherent and non-adherent patients. In a recent
welt designed study of adherence to anti-psychotic medication Budd and colleagues (I 996)
found that certain HBM variables were related to adherence. Discriminant function
analysis showed that non-adherent patients (defined as those who had failed to attend
and/or refused medication for one third or more of all scheduled appointments) could be
distinguished from adherent patients on the basis of susceptibility, severity and benefits
dimension of the HBM but not on the basis of costs.
3.2.4 Diabetes
Browlee-Duffeck and colleagues (1987) applied the HBM to insulin treated diabetic
patients. Relations between HBM components, reported adherence and metabolic control
were evaluated in younger (n= 54; mean age= 18) and older (n=89; mean age =36) clinic
samples. Adherence was indicated by a composite scale assessing medication usage, diet
and monitoring and glycosylated haemoglobin results (G Hb) which provided an indication
of blood glucose control over the preceding three months. Certain components of the
HBM were related to the composite self-reported adherence scale in each of the samples
studied. However, it is particularly interesting to note that the 'predictive components'
differed considerably between samples. In the younger sample, perceived costs predicted
20% of the explained variance in reported adherence, with other HBM components adding
a further 3%. In contrast, in the older sample, perceived benefits were much more strongly




So what does the HBM contribute to our understanding of medication adherence?
Methodological limitations in the way in which the model has been operationalised and
applied in studies of medication taking prevent us from drawing firm conclusions. Common
flaws in existing studies include the use of cross-sectional designs to test a predictive
model, lack of explanation of how constructs were operationalised and validated and the
presence of cofounders such as interventions. However, despite these limitations this
work does further our understanding of medication adherence showing that medication
adherence is related to certain cognitions. Adherence was typically predicted by various
combinations of individual components rather than the precise interactions specified in the
model. Although medication adherence cannot be completely explained by the HBM, there
is evidence that some of the cognitions specified within the model influence to medication
taking. The available evidence supports the notion that our understanding of medication
adherence may be enhanced by examining patients' own ideas about their illness and
confirms the limitations of sociodemographic variables as predictors. However, it also
suggests that cognitive variables other than those specified in the HBM may also influence
medication adherence.
Although several studies have demonstrated the value of interventions based on the HBM
in facilitating health-related behaviours such as attending for medical check-ups (Haefner
and Kirscht, 1970) or using emergency care facilities in an acute asthma attack (Jones et al.
1987) few studies have applied this model to interventions to enhance medication
adherence.
3.3 The Theory of Reasoned Action
The HBM does not take account of social influences on behaviour or explain how
perceived threat and the cost-benefit analysis are translated into action. Such issues are
central to the theory of reasoned action (TR.A) (Ajzen and Fishbein, I 980; Fishbein and
Ajzen, 1975). The TRA was developed from research investigating relationships between
attitudes and behaviour. It is not specific to health but has been widely used in this context
(Stroebe and Stroebe, 1995). The central tenets of the TR.A are that the formation of
















towards the behaviour and subjective norms concerning the behaviour. Attitudes towards
the behaviour are defined as the product of beliefs about the likely outcome (e.g.
"Following the doctor's recommendations for using insulin will keep my diabetes under
control") and the perceived value of the outcome (e.g. "Keeping my diabetes under control
is important to me."). The person's subjective norm comprises beliefs regarding others
views about the behaviour (e.g. "My partner wants me to follow the recommendations")
and the motivation to support these views (e.g. "I wish to please my partner by following
the recommendations").
3.4 Theory of Planned Behaviour (TPB)
Perceived behavioural control and perceived barriers have been added to the TRA to form
the Theory of Planned Behaviour (TPB), shown in Figure 3.2 (Ajzen, I 985), and there is
evidence that this improves predictions of intentions and behaviour in a wide variety of
circumstances (Ajzen, I 991) including preventive health behaviours (Conner and Sparks,
1996).
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Figure 3.2 The theory of planned behaviour (TPB) (adapted from
Conner and Sparks, 1996)
The TRA and TPB have been shown to be of value in predicting a range of health related
behaviours including giving up smoking, engaging in an exercise programme, initiating a
healthy diet and using a condom during sexual intercourse. In the main there is broad
support for the assertion that behavioural intentions are influenced by attitudes and
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subjective norms although the strength of the relationship between intentions and
behaviour varies across studies and between behaviours (Eagly and Chaiken, I 993).
3.5 Application of the TRA and TPB to medication
adherence
Although the TR.A/TPB have been widely applied to preventative health behaviour,
relatively few studies have used it to investigate medication adherence. These are
reviewed below and have addressed medication prescribed for the treatment of urinary
tract infections (Ried and Christensen, 1988), bipolar affective disorders (Cochran and
Gitlin, 1988) and hypertension (Ried et al. 1985; Miller et al. 1992). Abraham and Sheeran
(Abraham and Sheeran, 1996) have pointed out that key HBM variables such as perceived
benefits, barriers and severity can be included as components of the attitude measure as
they refer to the perceived likelihood and consequences of taking or not taking action.
However, perceived personal susceptibility may need to be added to the TRA.
In an interesting study of adherence to antibiotic medication prescribed for acute urinary
tract infections, Reid and Christensen (I 988), used TRA variables together with four
components of the HBM as the salient beliefs which underpin attitudes to taking the
medication: perceived seriousness of medication nonadherence, perceived susceptibility to
illness in general and medication adherence benefits and barriers. This study used a
prospective design. Patients (n107) who had been prescribed penicillin for their UTI
completed questionnaires assessing salient beliefs about taking the medication. The authors
also included a variable termed 'belief strength'. This was conceptualised as the perceived
likelihood of experiencing UTI symptoms if medication were taken exactly as directed.
Additional measures included patients' attitudes to the medication, assessed using a simple
dichotomous scale, and their intention to take it. After 10 days, adherence to the regimen
was assessed by patient self-report during a telephone interview. Multiple linear regression
analysis showed that the HBM variables alone explained 10% of the variance in reported
adherence and the remaining TRA variables explained an additional 19% of the variance.
The most significant predictors of adherence, in terms of percentage variance explained,
were; 'belief strength' (I 2%), barriers (8%), outcome evaluation (3%), and intention (3%).
The 'belief strength' construct is a form of outcome expectancy. In view of its fairly strong
predictive value it is interesting to consider the type of cognitions which might underpin
this construct. which is presumably based on beliefs about the efficacy of the medication
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This study concurs with other research suggesting that certain TRA and HBM constructs
are prerequisites of medication taking. It is appropriate here to comment on the statistical
methods used. Multivariate techniques such as multiple linear regression are a useful
means of identifying which particular components within a model are predictive of
behaviour. However, these techniques are less useful for assessing the value of the model
as a whole. To do this one would need to assess the amount of variance in the dependent
variable (behaviour) which can be explained by the interactions between the components
specified in the theoretical model rather than by the individual components alone. Recent
advances in path analysis techniques and the availability of statistical software packages
such Lisrel® and EQS® have made it possible to evaluate the model as a whole (Dunn et
al. 1993). The remaining studies which I will discuss under this heading have all applied
path anatysis to study the value of the TRA in predicting medication adherence.
In a cross-sectional study of predictors of intentions to take to anti-hypertensive
medication, Ried and colleagues (I 985), used path analysis to examine the value of the
TRA. The model was operationalised in a similar way to that described above, using four
HBM components (benefits and barriers of non-adherence and severity and susceptibility
to the disease) as salient beliefs. A significant amount (37%) of the variance in intended
adherence could be explained by the TRA if minor modifications were made. These were
necessary because physician expectations had a direct effect on patients' attitudes and
perceived susceptibility to the negative consequences of hypertension had a direct effect
on intention. Physician expectations might contribute to the patients' subjective norms.
Others have suggested that health professionals' beliefs may have an important influence
on patients' beliefs and behaviours (Marteau, 1995), and that perceived susceptibility may
need to be added to TRA conceptions independently of the attitude construct (Abraham
and Sheeran, I 996).
A direct relationship between normative beliefs and attitude was also noted by Cochran
and Gitlin (1988) in their application of the TRA to reported lithium adherence in patients
with bipolar disorders. In this cross-sectional postal questionnaire survey of 48 lithium
outpatients, 53% of the variance in reported adherence was explained by a modified TRA.
In this model patients' attitudes and intentions, and hence adherence, were much more
strongly influenced by the perceived views of significant others such as family doctors and
friends, than by their own beliefs about the treatment. Patients' own beliefs did not directly
influence behavioural attitudes or intentions.
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Further empirical support for the IRA comes from another study of adherence to
treatment recommendations in 47 patients with hypertension (Ried et al. 1985). Path
analysis showed that TRA variables explained significant amounts of variance in reported
adherence to diet (28%), smoking cessation (53%), physical exercise (37%), stress
avoidance (I 1%) and medication taking (33%). Modifications to the TRA were necessary in
most cases. For example, in models predicting dietary and smoking adherence, perceived
beliefs of others had a direct influence on patients attitudes. For medication taking,
attitudes and subjective norms had a direct influence on reported adherence which did not
operate via intentions. A possible explanation for this anomaly lies in the way in which
medication adherence was assessed. For all other behaviours patients' self reports were
corroborated by their spouses. However, in the case of medication adherence, patients'
reports were only weakly correlated with their spouses (r0.23). It is therefore possible
that reported adherence was subjected to self-presentational bias and is more closely
related to patients' intentions rather than to their actual behaviour which was more
accurately reported by their spouses.
A further possible problem with cross-sectional studies of this type is that of response
bias. Budd and Spencer (1987) have cautioned against questionnaire based studies of the
TRA. They argue that the TRA forms part of a 'intuitive lay psychology of intention' and
that people filling out questionnaires assessing TRA components will attempt to create
consistency between their responses, so appearing to validate the model. An opposing
view is that the TRA is part of our intuitive model of intention because it reflects real
psychological processes and fundamental interactions between the way in which people
think and behave.
Few studies have applied this model to medication taking, although Hounsa and colleagues
(1993) found the TPB useful in predicting African mothers intentions to adhere to
recommendation for using oral rehydration therapy (ORT) for the treatment of their
children's' diarrhoea. In this study 40% of the variance in adherence intentions was
predicted by the perceived consequences of using ORT, perceived barriers to use and ease
of access to health care services.
The studies described above provide tentative empirical support for the utility of TRA and
TPB concepts in explaining medication adherence. However, it is clear that, as with the
HBM, medication taking behaviour is not often explained by the precise interaction
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between variables specified in the models. Rather the evidence suggests that, although
many of the constructs specified in the TRA and HBM are prerequisites for medication
adherence the relative importance of individual constructs and the interactions between
them may vary considerably in different contexts. While expectancy-value models such as
the HBM and TRA attempt to explain health behaviours in term of the nature of
interactions between cognitions, a different approach has focused on identifying the types
of cognitions which influence behaviour. This approach has drawn attention to the role of
attributions, and control and efficacy beliefs as determinants of health behaviour.
3.6 Control beliefs
The concept of perceived control was applied to health by Wallston and colleagues (I 978)
who developed a measure of health specific locus of control (HLOC). This categorised
people according to whether they attributed control over their health to internal or
external factors. Later this measure was revised and extended to form the
multidimensional health locus of control (MHLOC) scale (Wallston et al. 1978), since
research with patients indicated that control beliefs should be assigned to three separate
unipolar scales called internal, chance and powerful others.(Levenson, I 973a; Levenson,
I 973b). There is some evidence that HLOC beliefs are predictive of certain health
behaviours. For example people with an internal HLOC were more likely to be successful
in seeking out information on health issues or reducing smoking than those with an
external locus of control (Wallston and Wallston, 1982). However, the relationship
between measures of locus of control over health in general and specific health behaviours
is fairly weak. For this reason there has recently been a move away from the idea that
individuals have a general perception of control over all aspects of health. Instead, research
has focused on the assessment of perceived control over specific aspects of health or
illness such as control of diabetes (Bradley et al. I 990), giving up smoking (Georgiou and
Bradley, I 992), aspects of dental health (Beck, I 980) and other measures recently
reviewed by Furnham and Steele (1993).
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3.6.1 Empirical investigation of the role of control beliefs in medication
adherence
The main application of the locus of control (LOC) concept to medicine taking has been to
explain patients' desire for involvement in decisions (Wallston et al. I 991), choice of
treatment options (Bradley et al. I 987) and usage of patient controlled infusion devises for
administering medication (Reynaert et al. 1995)
Empirical studies investigating the role of LOC beliefs in medication adherence appear to
be inconclusive. Some studies have found no association between control beliefs and
adherence and in studies where associations were found, there is little consistency in the
type of control which is associated with adherence. However, an interesting pattern can be
discerned in these apparently anomalous findings.
Studies have failed to demonstrate significant interactions between peoples' beliefs about
control over their health in general (MHLOC) and adherence to medication in several
situations including affective disorders (Harvey and Peet, I 991; Harvey, I 992), renal
transplantation (Frazier et al. 1994; Kiley et al. I 993) and in predicting intended adherence
to an imaginary regimen in a study involving college students (McCallum et al. I 988).
However, the use of disease specific measures for assessing LOC improves the utility of
this construct in explaining medication related behaviour. For example, patients with high
scores on the powerful others dimension of a diabetic specific LOC scale were more likely
to accept a treatment option which they perceived to be a 'high-tech' method of
controlling their diabetes (Bradley et al. 1987). A further study showed that diabetic
patients who were receiving conventional insulin treatment had lower scores on the
powerful others dimension- but not internality- than those who were using an intensified
treatment regimen or continuous sub-cutaneous insulin infusion. Both the latter regimens
require the patent to play a much more active role in their own treatment (Kohlman et al.
I 993). It is interesting to note that patients receiving conventional treatment were older
and that other studies have shown that older patients tend to score more highly on the
powerful-others dimension (Lachman, 1986; Lumpkin, I 986).
An interesting example of where the MHLC construct may be salient is that of patient
controlled analgesia (PCA. In two studies, patients with high internality and low powerful-
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others scores on the MHLC scale were more satisfied with this treatment, to report less
pain and use less medication (Johnson et al. 1989; Reynaert et al. I 995). One
interpretation of these findings is that patients who like to take control over their health,
(high internality may be a marker for this), respond better in situations where they are
given direct control over administration of analgesic. Alternatively it may be that the
MHLOC scores are influenced by the patients' experience of PCA. PCA requires the
patient to learn to use this fairly complicated technique. Those who subsequently find this
difficult or are reluctant to administer their own medication for other reasons (e.g. fear of
side-effects) may use the devise inappropriately, (e.g. by administering large infrequent
doses rather than smaller regular ones as recommended) and so experience more pain.
Patients in this situation may justifiably think that they have less control over their health
than 'powerful others' such as clinician.
The above studies, suggesting the utility of the HLC concept are somewhat atypical, as
there is little empirical support for the LOC concept as a predictor of global indices of
preventative health behaviour (Norman and Bennett, 1996). The failure of generalised
control beliefs is consistent with Ajzen's point that specific measures are likely to be better
predictors of specific behaviours, as people might hold different control beliefs for different
behaviours (Ajzen and Fishbein, 1980). However, generalised control beliefs may be more
important in relatively novel situations as is illustrated by the PCA studies described above.
Application of the LOC construct to adherence to medication in chronic illness is fraught
with pitfalls. Much of the research involving HLC has focused on preventative behaviours,
and has tended to individually asses relations between the target behaviour and each of the
three LOC dimensions. This approach is derived from initial hypotheses that the degree of
internality was particularly salient in determining readiness to engage in preventative health
behaviours. However, Wallston (1992) suggests that an individual's LOC profile (i.e. a
combined measure of relative standing on each of the three dimensions) is more
important. This may be particularly true in the case of medication adherence where the
'ideal combination' might be sufficient internality to facilitate self-management of the
regimen, combined with enough belief in powerful others (the clinician) to be motivated to
follow the treatment recommendation. A further criticism of previous LOC research is
that it has failed to incorporate an assessment of the value which the individual places on
health in general or of carrying out a particular behaviour (Wallston, 1992; Lau et al.
I 986). Adding a value component is implicit within social learning theory which stresses
the interaction of expectancies (e.g. control beliefs) and values
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As one focuses attention on a specific behaviour (e.g. adhering to a prescription for the
regular use of a steroid inhaler), beliefs about the degree of control one has over the
behaviour may be closely related to other expectancies such as beliefs about one's
competency in being able to perform the behaviour.
3.7 Efficacy beliefs
Bandura (1986) has identified two types of efficacy beliefs as important outcome efficacy
which concerns beliefs about whether the behaviour will result in an effective outcome
(e.g. "Taking medication will reduce my blood pressure and so prevent renal
complications") and se!f-efficac> which covers the individuals beliefs as to whether they will
be able to carry out the behaviour (e.g. "I am confident that I will remember to take my
medication every day"). Individuals may acquire their sense of self-efficacy from their
assessment of the outcome of their own behaviour and the behaviour of others and
feedback about their own behaviour which they receive from significant others (Bandura,
1986). Several studies have demonstrated a relationship between perceived self-efficacy
and health-related behaviour such as giving up smoking (DiClemente et al. 1985) or
carrying out an exercise program (Kaplan et al. I 984). Efficacy and control beliefs are
strongly influenced by the individual's past experience of success or failure in specific
health-related domains, and should not be confused with unrealistic optimism.
The inclusion of self-efficacy beliefs in social cognition models such as the HBM and TRA
has been shown to enhance their ability to predict various preventative health behaviours
(Schwarzer and Fuchs, I 996), and adherence to medication for tuberculosis, in a study
conducted in India (Barnhoorn and Adriaanse, 1992). In general, self-efficacy beliefs are
likely to be more salient for complex or difficult behaviours, such as giving up smoking,
than for behaviours such as adherence to a simple medication regimen (Flanders and
McNamara, 1984). Beliefs about control over health and self-efficacy and outcome-
efficacies may be influenced by previous experience and other cognitions. In particular,
they may depend on the person's beliefs about the cause of certain events and the extent
to which their own behaviour was a key factor.
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3.8 Causal beliefs
Attribution Theory (Turncjuist et al. I 988) is concerned with the cognitive processes by
which people explain the causes and outcomes of events. Its application is based on the
notion that a fundamental response to adverse events such as illness is the search for
explanations about cause and outcomes. Causal explanations are related to past
experiences and can influence future response and adjustment to the illness.
Early research was mainly concerned with the extent of beliefs in internal (i.e. related to
their own behaviour)or external causes (i.e. blaming fate or others). Recent work on
attributional style and content has added further dimensions such as stability (i.e. whether
the cause of the illness is long lasting or temporary), globality (i.e. global versus specific
causes), universality (i.e. universal versus personal causal influences) and controllability
controllable versus uncontrollable influences). There is controversy over whether the
specific nature of the attributions or the existence of attributions per se is most
important. Some studies have found a positive association between the perceived severity
of the illness and the number of causal attributions made by the patient (Affleck et al.
1987; Affleck et al. I 985). Others have found that adjustment to illness was related to the
type of attribution, e.g. attributing cause to an environmental factor or to one's own
behaviour (Wright et al. I 990; Brewin, 1984). A number of studies have investigated the
specific application of attribution theory to health problems including end-stage renal
disease ESRD (Wright et al. I 990), life-style changes among pre-operative coronary
patients (Naea De Valle and Norman, I 992), depression, cancer (Taylor et al. I 984) and
the perception of symptoms (Robbins and Kirmayer, 1991). It is clear that causal
attributions are related to beliefs about cure and can influence the patient's behavioural
response and adaptation to illness.
However, it has not been possible to identify one type of attribution which is universally
adaptive. Certain attributions seem to adaptive in some situations but not others. For
example, patients who attributed the cause of their myocardial infarction to uncontrollable
factors such as fate were less likely to follow treatment recommendations. Additionally,
people who believed that their heart attack was caused by changeable aspects of their own
behaviour, such as smoking or eating had higher levels of adherence and better adjustment
(Naea De Valle and Norman, 1992). There is evidence that beliefs about control affect
whether attributions are adaptive or not. For example, people who attributed the cause of
an illness to controllable influences (e.g. changeable aspects of their own behaviour) were
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likely to adapt better than those whose causal attributions related to uncontrollable
influences such as fixed personality traits (Tennen et al. I 986).
3.9 SCMs: contributions and limitations
What has research involving SCM contributed to our understanding of health behaviours
in general and adherence to medication in particular? The social cognition approaches
outiined above have identified a set of cognitions which seem to be prerequisites to the
adoption of preventative health behaviours. Applied to medication-related behaviours they
have identified cognitions which are germane to decisions about whether or not to take
medication. In doing so they help to reframe adherence issues. Within a social cognition
framework medication taking can be seen as a volitional act which is, to some extent, the
result of a rational decision by the patient This contrasts with other adherence research
paradigms which, broadly speaking, tend to conceptualise nonadherence as a function of
patient incompetence and clinicians' failure to enhance it, or as an unavoidable
consequence of certain trait characteristics. Although limited in scope, SCM-related
adherence research has opened the door to a broader conception of adherence. This
recognises that medication adherence may reflect patients beliefs as well as their ability to
comprehend, remember and follow instructions.
As well as highlighting the positive contribution of SCMs to our understanding of
medication adherence, the research reviewed in this section has drawn attention to some
of the limitations of these models. Marteau (1995) has pointed out that although SCM
variables are often predictive of behaviour, the amount of variance explained by the
models is sometimes small. She goes on to suggest that there are at least two possible
explanations for this: the theories are invalid or that the theories are valid but have been
inadequately tested. The above review of studies has identified several problems with the
way in which SCMs have been applied to medicine taking, which, to some extent, mirror
those identified in the broader applications of these models to health-related behaviours.
Following Marteau (I 995), the perceived limitations of SCMs can be addressed under two
broad headings: those ariisng from methodological flaws in the way in which the models
have been evaluated and those which can be attributed to the inherent limitations of SCMs
as theoretical constructs.
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3.9.1 Methodological limitations in the evaluation of SCMs
Operationalising the models The first limitation concerns the way in which the models
have been operationalised. Early studies generally tended to pay scant regard to the
description or psychometric evaluation of measures of SCM constructs. This has resulted
in little or no consistency across studies making generalisation and comparison difficult.
Moreover, when assessing the belief constructs specified by the models, researchers have
tended to supply their version of 'model salient beliefs'. This may not reflect the patients'
perspective and so may fail to identify those beliefs which are of key importance in the
patient's decision (Leventhal, 1993). In a recent review, Norman and Conner (I 996) make
the point that most SCM studies use single-point determinations of behaviour and that
assessing patterns of behaviour over time may be more worthwhile. They also make the
plea for sounder psychometric evaluation of behaviour measures used in this context.
Methods of analysis Further limitations arise from the way in which data were analysed
in many studies. Interactions between the cognitive and behavioural components of the
model are often evaluated by univariate associations between individual components and
particular behaviours. Where multivariate approaches are used, these tend to be
regression analyses which identify those variables which contribute most to the variance in
behaviour. These approaches are useful in identifying salient cognitions related to
behaviour, but cannot characterise interactions between components or evaluate the
model as a whole. To this end, there is a growing interest in path analysis and other
techniques for modelling covariance (Dunn et al. 1993), which can be used to evaluate the
degree to which a particular model 'fits' the data.
Determining causality A further issue concerns the timeframe for evaluating interactions
between cognitions and behaviour. Many of the studies discussed above used cross-
sectional designs. Although these designs may be sufficient to identify the cognitions which
underlie behaviours (and are therefore useful) they cannot determine causality. In order to
establish the causal relationship between a set of beliefs and behaviour, it is necessary to
assess the degree to which current cognition correlates with future behaviour. This is key
to the evaluation of predictive models and requires prospective research designs.
However, applying these designs to SCM research is not without complication. A key issue
is the time-gap between measurement of cognition and behaviour: too long and the link
may have weakened. Today's behaviour may be more strongly influenced by today's
cognitions rather than yesterdays.
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3.9.2 Limitations of SCMs as explanatory models for health behaviours
Limitations to rationale decisions
One limitation of SCM is that they cannot easily explain health-related behaviour which is
apparently irrational, such as the patient who delays seeking treatment for a large and
visible tumour. Several studies investigating health behaviour have found future behaviour
to be more strongly predicted by past behaviour than by cognitions specified with SCM
such as the HBM and TRA. The influence of past behaviour has been noted in relation to
diet, exercise and smoking (Mullen et al. 1987), recreational drug use (Bender and
Speckhart, I 979)and wearing a seat belt (Sutton and Eiser, 1990). So does this mean that
cognition is irrelevant? In considering this question Norman and Connor (I 996) draw
attention to Ajzen's (1988) suggestion that the effects of past behaviour on future
behaviour are mediated by variables included in the social cognition models. (Past
experience of a behaviour may be an important source of expectations about and attitudes
towards repeating the behaviour in the future (Ajzen, 1991)). Relationship between past
and future behaviour may predominate because key cognitions have not been considered
or have been poorly operationalised. Also, the relationship may be inflated by congruence
between the methods of measuring past and future behaviour. A further explanation is
that some health behaviours become habitual or routine (e.g. brushing ones teeth before
bedtime) and are not always preceded by a rationale decision based on expectancy-value
considerations.
Stages to health behaviour
The fact that cognitions and behaviour change over time has major implications for the
validity of SCMs. First, the notion that interactions between behaviour and cognition may
be dynamic rather than static, leads us to question when inter-relations specified in the
model are particularly salient. It has been suggested that health behaviour may proceed in
stages and that different cognitions may be more important in particular stages than in
others: for example the thinking underlying initiation of a particular behaviours may be
qualitative different from that involved in maintenance of the behaviour. Several stage
models of health behaviour have been proposed in which health behaviours occur as the
result of several stages of cognition. For example, the Transtheoretical Model (TM)
(Prochaska and DiClemete, I 984) suggests that the maintenance of health behaviour
occurs in five progressive stages of change: pre-contemplation, contemplation, preparation,
action and maintenance. To date, the main application of the TM has been to








and there is as yet, little evidence to support its validity in health related behaviours such
medication adherence. A similar model is the Health Action Process (HAP) (Schwarzer,
1992), which is shown in Figure 3.3. The model is separated into two broad stages: a
motivational stage in which the individual forms an intention to act and an action phase in
which the intention is translated into a behaviour. As can be seen from Figure 3.3,
perceived self-efficacy is a crucial component having a direct influence on the formation of
intentions, action plans and action control (maintenance strategies). In this model,
perceptions of self-efficacy are thought to be more important than the expectancy-value
considerations which precede them (Schwarzer and Fuchs, 1996). There has been little
empirical evaluation of the model and it is too early to be able to judge the validity of the
model with any certainty.















Figure 3.3 The Health Action Process approach (adapted from
Schwarzer and Fuchs, 1996)
Weinstein (1988), suggests that some of the cognitive components of SCMs, such as
beliefs about personal susceptibility, are also best described in stages.(e.g. is aware of a
potential health risk, believes that others are susceptible, believes that they are personally
susceptible). He goes on to suggest that interventions to promote behaviour are likely to
be more effective if they are targeted at the particular cognitions which characterise the
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particular stage that the individual has reached in their thinking about or implementation of
the behaviour (Weinstein, I 988). There is considerable overlap between the Staged
models described above. In all of these, the expectancy-value deliberations implicit within
SCM occur as part of a motivation phase which must then be translated into action. In the
HAP self-efficacy beliefs are the link between motivation and action. Self-efficacy (and
hence the HAP) may be particularly relevant to behavioural changes which are perceived
as difficult, such as giving up addictions such as cigarettes or alcohol or adopting dietary
restrictions. However, it is more difficult to accept such a pivotal role for self-efficacy
beliefs when simpler behaviours such as taking a daily dose of medication are considered.
Stage models seem to be limited when one attempts to use them to explain variations in
intentional non-adherence to medication over the course of a chronic illness chronic
illness. The key issue here is maintenance of the behaviour. Although, the processes of
initiation and maintenance of behaviour are recognised in the HAP and TM, there is an
implicit assumption that the main cognitive barrier to maintenance is low self-efficacy. If
the patient is motivated to take it and believes realistically that they can carry out the
behaviour, then they will continue to do so.
Leventhal has suggested that once self-efficacy and outcome efficacy beliefs are in place,
continued behaviour depends on continued motivation and one criticism of SCMs and the
staged models derived from them is that they do not fully address the issue of how
motivation to continue with the health-behaviour is maintained (Leventhal, 1993). In an
attempt to explain the dynamic interaction between cognitions motivation and behaviour
Leventhal and colleagues have developed a Self-Regulatory Theory as a framework for
understanding illness behaviour. This is often referred to as Leventhal's Self-Regulatory
Model (SRM). The next chapter will describe this model and how it can applied to explain
variations in medication adherence among patients and within a single individual over time.
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CHAPTER 4
Leventhal's self-regulatory model of illness:
from social cognition to self-regulation
Leventhal's self-regulatory model (SRM) was derived from early work investigating the
impact of fear-arousing communications on preventive health behaviour. Studies showed
that although a threat message was often necessary to motivate people towards
preventative health behaviours such as taking a tetanus vaccination or giving up smoking,
the threat alone was often insufficient In order to achieve behavioural change it was
necessary to add an action plan to the threat message -e.g. by giving clear instructions for
successful action and helping the individual to incorporate this into their daily routine. This
cognitive -behavioural approach generated actions which lasted longer than any fear
aroused by the threat which had faded within a day or two. Leventhal surmised that the
combination of fear and action plan had changed the 'cognitive representation' of the
threat This stimulated interest in how people represented heath threats and the
interaction between representations and behaviour which led to the development of the
self-regulatory model (SRM).
4.1 The self-regulatory model: an overview
The fundamental premise of the SRM is a view of the patient as an active problem solver,
whose health-related behaviour is an attempt to close the perceived gap between current
health status and a future goal state. Threats to health and illness are regarded as a
problem and the patient's behaviour is seen as an attempt to solve the problem. Patients
respond to illness in a dynamic way based on their interpretation and evaluation of the
illness. The choice of a particular coping response (e.g. to take or not to take medication)
is influenced by whether it makes sense in the light of their own ideas about the illness and
personal experience of symptoms. Responses to illness follow three broad stages:
I. The cognitive representation of the health threat by which the patient identifies
the meaning of the health threat. This can be stimulated by internal (eg
symptoms) and or external (eg information) cues.
2. The development and implementation of an action plan or coping procedure to
deal with the threat.









Key features of this model are that the three stages of processing occur in parallel at a
cognitive and emotional level and that there is a dynamic interaction between the
processes of representation', coping and appraisal. In Figure 4.1 it can be seen that the
interaction proceeds in both directions.
Schema
abstract




Representation	 )' Coping	 )' Appraisal
of fear	 procedures
Figure 4.1 Parallel Processing Model for adaptation to health threats: internal and
external stimuli make contact with and are processed elaborated upon by both conceptual
(abstract) and concrete (perceptual) memory schemata to form representations
(experience) of both health threats (danger) and emotion (fear). The features of these
representations initiate and shape procedures for coping. The effects of coping upon the
representations are appraised in relation to expectations about the effectiveness of the
coping response and the nature of the representation (e.g. is the symptom a sign of a
transient or a serious, chronic condition). Appraisals feed back and update the
representation, changing, for example, the identify of the problem, its controllability, etc.
and changing expectations respecting the effectiveness of the coping procedure. Not
shown but also appraised is the individual's perception of his effectiveness in performing
these actions, and his perceptions of the effectiveness of his support (expert and non-
expert) system (from Leventhal, 1993).
For example, the patient's coping and appraisal may arise from a particular and individual
representation of the health threat, but equally the perceived outcome of coping may feed
back to influence the representation. In common with SCMs the SRM attempts to focus on
the individual's cognitive representation of the health threat as the key factor determining
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variations in behaviour. The SRM differs from SCMs and staged models in its emphasis on
appraisal processes and the resultant feedback effect on cognition and behaviour. The
interaction between cognition and behaviour is therefore seen as a dynamic process,
rather than the result of a single or staged decision. The selection of a coping procedure
(e.g. giving up smoking or taking medication) is determined by beliefs about the nature of
the illness threat (e.g. "This pain is a headache which needs to be treated. Taking aspirin is
easy and effective. My partner thinks I should take a tablet now. I will get a glass of water
and do so"). This is then followed by an appraisal stage in which the patient evaluates the
efficacy of their coping strategy (e.g. the pain is still there three hours after taking the
aspirin). If the patient appraises a particular coping strategy as being ineffective then this
might result in the selection of an alternative coping strategy (e.g. "I will try a stronger pain
killer") or even a change in the representation of the illness (e.g. "Aspirin hasn't worked,
this might be something more serious than a headache").
The fact that cognitive and emotional processing occur in parallel may be used to explain
responses to illness threats which are apparently irrational. For example, a patient may
believe that the lump in her breast is likely to be a tumour but delays seeking help because
she fears the diagnosis (Phelan et al. I 992). Her behavioural response (to delay seeking
help) can be seen as a way of coping with the emotion (fear/distress) generated by the
cognitive representation, which may be reinforced by her appraisal that the lump doesn't
get bigger and 'the less she thinks about it the better she feels'. The SRM also emphasises
the importance of concrete symptom experience in formulating representations and
guiding appraisal of the efficacy of the coping procedure. Perceptual experiences are seen
to be generally more persuasive than abstract ideas.
Personal representations of the illness drive coping and appraisal and the question of how
sick individuals conceptualise their illness is central to the SRM. An important difference
between the SRM and SCMs detailed in the previous section is in how relevant beliefs are
conceptualised. In both approaches, beliefs are of paramount importance in guiding
behaviour. However, in SCMs, beliefs are characterised as outcome expectancies and the
values placed on or are limited to beliefs about the behaviour. Leventhal asserts that the
models are deficient in that they 'attempt to explain the process underlying choices in the
absence of constituents of the choice process' (Leventhal E, A and Crouch, in press).
Thus, Leventhal and colleagues have devoted much attention to the cognitive
representations of illness and have identified two important aspects: content (an
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individual's ideas about the illness) and structure (how these ideas are cognitively
organised). They suggest that people form 'common-sense' models of disease and illness
organised around five components: identity, cause, consequences, time-line and cure.
Identity consists of concrete symptoms and signs and an abstract label associated with
them. Cause relates to perceived ideas about how one gets the disease. Time-line relates
to perceptions about the likely course of the condition and how long it will last
Consequences are the expected outcomes in physical, psychological and social terms and
cure deals with the person's beliefs about the potential for cure and control. Leventhal
argues that the specific content of each component is influenced by the cultural context
(Farmer and Good, I 991; Farmer, I 988; Blumhagen, 1980; Landrine and Kionoff, I 992) and
by other factors such as past experience and the views of significant others (Leventhal et al.
I 992a) and, although the particular content of the individual components of illness
representations often change (Meyer et al. 1985), the components are stable over time
(Bishop, 1991).
Before going on to outline the empirical support for the SRM, I will discuss the content
and structure of illness representations in more detail.
4.2 The structure of illness representations: empirical
studies
Significant empirical and theoretical contributions to the study of illness cognitions have
arisen from three disciplines: medical anthropology, medical sociology and health
psychology. For each discipline, the fundamental concern has been to understand the
meaning of illness from the patient's perspective(Croyle and Barger, I 993). Studies in
medical sociology and anthropology have focused on the content of illness
representations, eliciting detailed descriptions of lay ideas about illness (Radley, I 993)
whereas health psychologists have been concerned with how representations are
cognitively organised. Psychological approaches are characterised by a strong theoretical
basis (Leventhal, 1985; Meyer et al. 1985; Leventhal et al. I 980) and the application of
statistical methods and experimental research designs.
A more detailed exploration of how people think about illness may augment SCMs as
these tend to deal with the interactions between beliefs and their influence on behaviour,
and pay little attention to the nature of the beliefs. For example, the HBM illustrates the
importance of beliefs about personal susceptibility, but does not specify how an individual
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judges his/her degree of susceptibility. An exception to this is the locus of control
construct which suggests that beliefs about control are structured around three
dimensions: internal, chance/fate and powerful others. Knowledge of cognitive structures
can be used to identify the pivotal constructs which should be empirically assessed in
studies linking cognition and behaviour.
One of the first investigations of the structure of illness cognition was conducted in the
USA by Jenkins and colleagues (Jenkins, 1966; Jenkins and Zyzanski, I 968). Factor analysis
was used to identify the underlying structure of responses to a I 6-item semantic
differential scale assessing views about the seriousness, susceptibility and preventability of
several diseases including cancer, poliomyelitis, tuberculosis and mental illness. Three core
factors were identified and labelled as persona! involvement, human mastery and social
desirability. In developing an empirical approach to the question of illness cognition, this
work made a useful contribution to the field. The rationale for the study stemmed from a
public health perspective, rooted in the notion that a better understanding of how well
individuals conceptualise diseases could inform the development of preventative strategies.
However, the scope of the findings was limited by the fact that the items used in the
semantic differential scale were chosen by the researchers and therefore may not have
represented the way in which their subjects would normally conceptualise these illnesses.
There is limited empirical support for the theory that illness representations are
cognitively structured around the five components suggested by Leventhal (Schober and
Lacroix, I 991). Early studies in which patients from a range of chronic illness groups were
asked to talk openly about their illness. Multidimensional scaling of coded responses
showed that they tended to congregate around four dimensions labelled as identity, cause,
timeline and consequences (Leventhal and Nerenz, 1985). The list of attributes was
extended to include the cure component following a study examining beliefs about
common mild illness (Lau and Hartman, 1983). In this study, Lau and Hartnian found that
when 250 American college students were asked to recall a recent episode of minor illness
and to describe why they got ill and got better, most subjects had a ready explanation for
why they had recovered. A factor analysis of coded attributions for getting better
produced a three factor solution labelled as passive (e.g. it just went away) external (e.g.
doctor, treatment) and internal (e.g. change of habit, sleep, rest) control beliefs. Leventhal
has argued that these beliefs are also components of common-sense representations of
severe or chronic illness but may be more focused on controllability rather than cure of a
disease.
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A separate research group led by Bishop also found information about diseases to be
structured around the five components suggested by Leventhal (Bishop et al. I 987).
Undergraduate students were shown sets of symptoms which had supposedly been
experienced by 'a friend' and were asked to describe any other details with might be
associated with their friend's situation. In this experiment the two aspects of the identity
component, label and symptoms, were coded separately and, allowing for this, 91 % of the
open ended responses could be categorised in a way which was consistent with the 5-
components model: label (25%), symptoms, in addition to those specified by the
investigators (14%), cause (29%), control/cure (I 3%), consequences (8%) and timeline (3%).
A further exploration of the structure of representations of common illnesses provides
convergent data supporting the five-component model. Lau and colleagues asked over 450
college students to write about a recent illness in their own words. The responses were
independently coded into 89 items. The ease with which these could then be grouped into
the 5 illness components was taken by the authors as qualitative evidence of the suitability
of the 5-component structure. Similar groupings were chosen by 20 nad've participants
who were asked to group 65 responses into categories. The mean number of groups was
6 (range 4-8) and these could be readily assigned to the five components of identity,
cause, timeline, consequences and control/cure. Discrepancies were attributed to the
tendency of participants to assign label and symptom constituents of the identity
component into separate categories and to differentiate several different types of
consequences (e.g. social, emotional, behavioural). Illness accounts elicited over a three
separate time-points produced similar groupings suggesting that the components, though
not necessarily the content, of illness representations are stable. The authors also
presented additional evidence to corroborate their view in the form of a path analysis
using the tendency to visit the doctor over a three year period. The five components of
illness representation were identified as separate latent factors, which together with a
measure of self-rated health explained 29% of the variance in tendency to visit the doctor.
Further anecdotal support for the stable structure of illness representations has been
obtained from diaries and articles written during the Enlightenment Period (circa I 600-
1762). Content analysis of sections relating to illness showed that the material was
structured around the five components of illness representation identified by Leventhal
(Schober and Lacroix, 1991).
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The structure of illness cognition has also been studied by Turk, Rudy and Salovey (I 986)
in a sample of diabetic patients, healthy nurses and college students who completed
questionnaires about flu, diabetes and cancer. Factor analysis of the responses identified a
four-dimensional structure (seriousness, persona! responsibility, controllability and changeability)
which was confirmed on a second sample drawn from the same group. Although, at first
sight, this interpretation appears to have little in common with the five components
identified by Leventhal, the apparent discrepancy may be a feature of the type of analysis
used. Turk and colleagues used factor analysis (FA) to identify the core dimensions of
cognitions about three very different illnesses, whereas the Leventhal and Bishop groups
used multidimensional scaling (MDS) techniques. Lau and colleagues (1989) suggest that
different aspects of cognitive structure are identified by these techniques. MDS is used to
identify areas of consistency within qualitative data, whereas FA identifies the core
dimensions explaining variance within the data. Thus, the four factors identified by Turk's
group are analogous to cognitive categories used by participants to differentiate between
particular diseases. This solution is not incompatible with Leventhal's 5-component
structure and it has been suggested that these findings represent complimentary aspects of
the same phenomenon (Croyle and Barger, 1993; Bishop, 1991). For example, views about
seriousness, personal responsibility, changeability, and controllability might arise from
prototypic beliefs structured around identity, cause, consequences, timeline and cure. In
particular, the changeability of a disease is akin to its timeline and notions of personal
responsibility may arise from causal beliefs. Moreover, seriousness and controllability are
related to the consequences and control/cure components. It is therefore plausible that
people's ideas about different diseases are structured around the four factors identified by
the Turk group but that it is the perceived features of the disease in terms of identity,
cause, timeline, consequences and potential for cure/control which determines how a
particular disease is categorised. Bishop (1991) has suggested that while the components
approach deals with the specific content, and identifies the 'basic building blocks' of disease
representation, the dimensional (FA) approach identifies the cognitive dimensions by which
people evaluate the content. Further work is needed to establish the validity of the Turk
groupings in other samples and to explore how these relate to the five components
suggested by Leventhal.
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4.3 The interpretation of health threats: disease schema,
prototypes, and stereotypes
The research described in the above section provides limited evidence that people
structure their ideas about illness in common ways and that it is possible to identify core
dimensions by which illness threats are evaluated. A further topic of theoretical
speculation and empirical investigation relates to the mechanism by which illness
representations are formed and acted upon. Leventhal emphasises the importance of past
experience in the interpretation of disease threats. The past experience of the subject and
those of significant others is stored as a memory schema based around the concrete
experience of symptoms. These schemata play a prominent role in the interpretation of a
current health threat. For example, the experience of symptoms or being told that one has
a disease results in a cognitive process in which current concrete experience or abstract
information is evaluated in relation to an appropriate memory schema.
Pennebaker (I 982) has shown that illness schemata and symptom perceptions are closely
linked. Moreover, analogue studies of symptom perception in university students has
shown that the influence is bi-directional. Not only does the experience of symptoms
influence the content of illness schemata but arousal of a memory-based schema initiates a
search for confirmatory symptoms. The influence of illness representations on symptom
perception is further corroborated by recent studies in which people presented with a
false diagnosis tend to report symptoms which confirm their representation (Bishop,
I 991). These findings are relevant to the concept of illness as distinct from disease. It is
well recognised that there is often considerable discrepancy between, the subjective
impact of a disease (e.g. symptom reports) and the underlying pathology. This has led to a
distinction between disease and illness with illness defined as the subjective experience of a
disease (Mechanic, 1962). Thus illness schemata can be conceptualised as the link between
medical pathology and disability (Lacroix, I 991).
Bishop argues that people hold quite elaborate representations of common diseases which
he terms disease prototypes. He argues that when faced with a health threat (e.g.
experience of chest pain or being told that they have had a heart attack), people refer to
disease prototypes to confirm the diagnosis and decide what to do. (e.g. "This can't be a
heart attack, I walked to the Emergency department People with heart attacks are rushed
to hospital in an ambulance!"). This idea is not incompatible with Leventhal's emphasis on
past experience as this is likely to be an important determinant of the disease prototype.
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There is a degree of empirical support for the existence of disease prototypes and their
role in the interpretation of health threats. Studies in which adult volunteers were asked to
rate the perceived association between lists of symptoms and common diseases such as
sore throat, stroke and hay fever suggested that certain common diseases are associated
with particular symptom clusters. Furthermore, symptoms could be grouped according to
how well they fitted a particular disease prototype (Bishop and Converse, I 986).
Moreover, the perceived degree of prototypicality of a particular symptom set influenced
the accuracy and speed of recall, which was regarded as evidence that highly prototypic
symptoms were present in existing cognitive structures (Bishop et al. I 987). Other studies
indicate that prototypic beliefs about particular diseases and symptoms may be classified
according to their perceived causes (e.g. viral, non-viral) and consequences (contagious, life-
threatening) as well as according to the symptom clusters (identity) associated with them
(Bishop, 1991).
Croyle suggests that perceptions of a particular disease are affected by illness stereotypes
or beliefs about 'the type of people who contract it'. Laboratory studies using hypertension
as an example showed that the degree to which the disease was associated with positive
or negative personal attributes varied among student volunteers. The effect of disease
stereotype on perceptions of severity and symptom reporting was investigated in a second
study by manipulating a diagnosis of hypertension. Participants who were given false
information that their blood pressure was raised, together with data supporting a positive
stereotype of hypertension (e.g. research had shown that people with hypertension were
more likely to be academically successful and hold down professional jobs), rated the
condition as less severe and reported more symptoms than those who were supplied with
a diagnosis and negative stereotype (e.g. research had shown that people with
hypertension were more likely to fail academically, hold "dead-end" jobs and panic in a
crisis). (Croyle and Barger, I 993; Croyle and Williams, I 991). The idea that disease
stereotypes might influence the interpretation of symptoms has clear implications for delay
in seeking help, particularly in the case of acute myocardial infarction. Patients who
perceive themselves to be atypical in relation to the stereotype may delay seeking help
(e.g. "This can't be a heart attack, I'm not an overweight stressed executive, it's probably
indigestion"). Croyle also provides preliminary evidence that perceptions of the degree of
severity of a particular disease are strongly influenced by perceptions of its prevalence;
being told that a disease is common seems to reduce its perceived severity (Croyle and
Ditto, I 990).
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4.4 Empirical support for a self-regulatory model
In the above section I have described some of the empirical support for the notion that
people form common-sense representations of disease the content of which may be
structured around various themes. But what is the evidence that cognitive and emotional
aspects of illness representation drive the selection of coping procedures and provide a
framework for appraisal in accordance with the SRM ? Unfortunately, the SRM does not
readily lend itself to empirical evaluation. The strength of the SRM is that it encompasses
emotional and cognitive antecedents of health-related behaviour in a flexible feedback
model which also allows for the influence of cultural and social-environmental factors.
However, this inherent complexity makes it very difficult to operationalise the model as a
whole.
A further impairment to the empirical testing of the model is that, although the relevant
components of the cognitive representation of illness are clearly specified, there was until
recentJy no standard method for operationalising the representations construct.
Consequently, there is little uniformity across studies published before 1995. This problem
has recently been addressed by the development of the Illness Perception Questionnaire
(IPQ), a validated method for the quantitative assessment of the 5 components of illness
representations (Wein man et al. 1996)
In the absence of a full validation of the SRM as a whole one is left to judge the merits of
the self-regulatory approach on the basis of studies which have empirically evaluated
certain key tenets of the model. Some of these studies provide indirect support for a self-
regulatory approach whereas others have specifically used the model to conceptualise
their research question.
4.4.1 Illness representations have concrete (symptoms) and abstract
(label) features, and influence behaviour (coping) in response to health
threats
The importance of symptom perception in influencing illness representations and
behaviour was reinforced by work with diabetic individuals who used perceived symptoms
to indicate their blood glucose levels and to guide self-treatment. However, patients'
beliefs about their symptoms, and blood glucose estimations based on them, were often
erroneous and resulted in poor diabetic control (Gonder-Frederick and Cox, I 991).
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Further evidence of the importance of illness representations was obtained by Meyer and
colleagues who noted a clear relationship between representations and behaviour in their
study of hypertensive patients (Meyer et al. 1985). Timeline representations at baseline
influenced subsequent drop-out from the treatment programme. Patients who held an
acute representation of hypertension were more likely to drop out of treatment than
those who believed it to be a chronic condition. This study also showed that patients'
representations of the illness often conflicted with medical rationale and provided an
insight into the effects of a mismatch between the patients' representations and those of
their doctors. In a group of 50 patients who had continued in treatment 80% agreed with
the statement that" people cannot tell when their blood pressure is up". However, 92%
believed that they could tell when their own blood pressure was up by monitoring
symptoms such as tiredness , headache and stress. Furthermore, the patients tended to
behave in accordance with their own representations rather than those of their doctors in
that representations influenced treatment adherence. Patients who believed that their anti-
hypertensive medication improved symptoms were significantly more likely to take it. A
striking example of this was provided by 5 out of 17 patients who believed that their
medication affected symptoms. These patients took their anti-hypertensive medication only
when they judged their blood pressure to be up. The patients had understood and
accepted the abstract medical view of hypertension as an asymptomatic condition but their
concrete experience of symptoms caused them to hold contrasting beliefs and to behave
according to these.
4.4.2 Illness representations influence care-seeking
Studies conducted by the Leventhal group have shown that illness representations, in
particularly the identity component assessed as symptom reports, influence care-seeking
(Booth et al. 1986; Cameron et al. 1993). A further study showed that one of the factors
influencing delay in seeking medical care showed that that certain features of the cognitive
representation of illness were associated with delay in care-seeking. For example, patients
who acknowledged that they were ill but who imagined that the consequences of seeking
help would be severe (e.g. "picture myself lying on the operating table") were more likely
to delay care-seeking (Safer et al. 1979).
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4.4.3 Representations of illness influence disease outcome
Cognitive representations of illness were found to be the strongest predictors of
psychological adjustment in a postal survey of 233 patients with Chronic Fatigue Syndrome
(CFS). Using multiple linear regression analyses Moss-Morris and colleagues showed that
patients' responses to the IPQ, which assesses the five components of illness
representation, explained a significant proportion of the variance in dysfunction (37%),
psychological adjustment (30%) and vitality (42%). It is worthy of note that illness
representations had a much more powerful effect on outcome than did the coping
strategies used by patients.
Further support for the SRM comes from a prospective study of 143 patients with first
myocardial infarction in which patients beliefs, elicited shortly after their heart attack, were
predictive of outcome (Petrie et al. 1996). Return to work within 6 months was
significantly predicted by perceptions that the condition would be of short duration and
have less severe consequences. Initial beliefs that the heart attack would have severe
consequences predicted a higher degree of impairment of social interaction, recreational
activities and participation in housework at three and six month follow up. Relations
between representations and outcome were independent of clinical measures of MI
severity and number of days spent in hospital.
There is further evidence that, in chronic illness, patients' representations may be
mediators of distress and disability. Fisher and Johnston have investigated the role of
cognition and emotion as mediators between pain and disability among patients with
chronic pain. In one study perceived control (PC) over pain problems was successfully
manipulated using focused attention and selective recall. Cognitive manipulation was
associated with changes in control beliefs and disability in the predicted direction.
However, changes in disability could not be explained by changes in control beliefs as
these parameters were not significantly correlated (Fisher and Johnston, I 996a). In a
further study, mood appeared to mediate between control beliefs and disability (Fisher and
Johnston, I 996b). Although not based on the SRM, this study supports the general
principle that emotional and cognitive representation are related and may influence
outcome.
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4.4.4 Representations influence coping procedures
In their study of patients with CFS, Moss Morris and colleagues noted that cognitive
representations and coping were related in a conceptually logical fashion which was
consistent with earlier studies supporting a link between representations and coping and
suggested by the SRM (Leventhal et al. I 992a). However, relatively few other studies have
systematically evaluated interactions between representations and coping. One of the
impediments to this type of study is the paucity of reliable, valid measures of coping which
encompass the wide range of strategies used by patients. Most available measures
conceptualise coping in terms of broad dimensions such as problem-focused, emotion-
focused or avoidance-based strategies (Carver et al. 1989). The findings of Moss-Morris
and colleagues reinforce recent calls for a more complete assessment of the coping
process which takes account of the cognitions which determine the selection of the coping
strategy.
4.4.5 Representations influence adherence to treatment programmes
Despite a cogently argued rationale for the study of illness cognitions as determinants of
treatment adherence (Leventhal et al. I 992; Leventhal and Cameron, I 987; Leventhal et al.
1984), very few studies have utiuised this approach. Exceptions are the studies detailed
above in which illness representations were related to medication adherence in
hypertension (Meyer et al I 985), and regimen adherence in diabetes (Gonder-Frederick
and Cox, 1991). In a recent prospective study, attendance at rehabilitation classes after
discharge from hospital was predicted by illness beliefs (identity, consequences,
control/cure) elicited during hospital convalescence following a first myocardial infarction
(Petrie et al. I 996).
4.5 Applying the SRM to medication adherence
The SRM provides a useful conceptual framework for understanding intentional non-
adherence. If taking medication is seen as a form of coping procedure, then the model
posits that the decision to follow treatment recommendations will be influenced by the
patients' representations of the illness and their subsequent appraisal of the treatment
effects. The dynamic interaction between representations, coping (e.g. adherence to the
advised treatment) and appraisal (was adherence to treatment beneficial?) is guided by the
person's need to maintain coherence between these processes. In essence the patient self-
regulates their response to the illness threat in an attempt to achieve "common sense"
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coherence. Non-adherent behaviour can be seen as an attempt to maintain coherence
between representation and coping in a way which makes "common sense" and which is
heavily influenced by the experience of concrete signs and symptoms. ("Why take this
medicine when I don't feel ill?" or "When I take this medicine I feel drowsy and tired when
I stop taking it I feel fine. Maybe I'm not that ill and I'll just see how I get along without the
medicine"). Adherence is more likely if there is a high degree of coherence between the
abstract (ideas) and concrete (symptoms) aspects of the illness representation and if health
care providers advice seems "common sense" in the light of the patients' own experiences
and representations.
4.5.1 Treatment beliefs and the self-regulatory model
The SRM emphasises the central role of illness representations in guiding adherence
decisions. However, a possible limitation of this approach is that the self-regulatory patient
will not just have their own ideas about the illness but also about the treatment being
offered. Thus from Leventhal's view of the patient as an "active problem solver" it follows
that, in deciding whether to adhere to a treatment schedule, the patient has to think not
only about whether the illness warrants treatment but also whether the treatment is
appropriate for the illness. Thus a better understanding of the interplay between
representations of illness and treatment and treatment adherence might contribute to the
further development of Leventhal's' SRM.
Bishop (I 986, I 987) and Croyle (I 991) have shown that people often hold prototypic
beliefs about certain diseases which have an important role in illness cognition. It may also
be true that the prominent place of medicines in health care has resulted in the formation
of prototypic beliefs about medicines. People may have preconceptions or schema about
medicines in general which might influence attitudes towards prescribed medication and
personal beliefs about the most appropriate treatment for a particular disease.
The following chapter will focus on the issue of patients' beliefs about medication.
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CHAPTER 5
A resume of research into beliefs about
medicines
The published research dealing with people's beliefs about medicines falls into several
broad categories. The first is essentially exploratory research into patients' knowledge of
and views about medication which does not appear to have been guided by particular
psychological theories but has produced insights into lay beliefs about medicines. A second
type studies patients' beliefs about taking medication within the context of social cognition
models. A third category comprises qualitative research eliciting patients' perspectives of
illness which have identified lay representations of medication or which set out to discover
the content of people's representations of medicines. Finally, a few studies have
quantitatively assessed medication beliefs and systematically investigated relationships
between medication beliefs and other variables.
Taken collectively this work has shown that people form beliefs about their medication
and the meaning of medication-taking and suggests that such beliefs may influence self
regulation. Additionally, although these studies have involved a range of patients from
several diagnostic groups and socio-cultural backgrounds, they seem to have uncovered
common themes which will now be discussed in more detail.
5.1 Views about the general nature of medicines (healing
and harm - the dual nature of medicines)
An interesting insight into patients' beliefs about medicines was provided by Fallsberg
(1991), who used a phenomenographic approach to analyse conceptions of medicines
elicited during interviews conducted with 90 chronically ill Swedish patients who had been
prescribed regular medication for a range of conditions (asthma, hypertension and chronic
pain). She identified several broad "conceptions" - or value judgements -about medicines in
general. These included a singularly positive view of medicines derived from the beneficial
effects of medicines and the idea that medicines work in unison with the body to promote
health. Other patients expressed an essentially negative view which stressed the harmful
effects of medication and in which medicines were seen either as a form of poison which
should be avoided if possible, or as a "necessary evil". A third category emphasised the
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dual nature of medicines as carrying the potential for harm as well as benefit For this
group, the harmful effects of medication are intrinsic so that one cannot have the positive
effects without the negative. Efficacy and toxicity somehow go hand in hand and that more
effective medicines implicitly, have more side-effects (Lorish et al. I 990). Similar categories
were also identified by Britten in a more recent study of attitudes to medication in a
sample of general practice patients in the UK (Britten, I 994).
These finding are analogous to those obtained in an earlier study conducted in the USA,
which used the Theory of Reasoned Action (TRA) to guide the development of questions
to elicit rheumatoid arthritis patients' perspectives on missed dosages of their medicines
(Lorish et al. 1990). Patients' definitions of a "powerful" medicine were explored and
questionnaire responses revealed that "powerful" was defined solely by the degree of
symptom control (35%), solely by potential to cause harmful side-effects (33%) or by a
combination of both (32%).
Leventhal's group have shown that representations of the dual nature of medicines can
influence response to symptoms. In one study, a number of women with breast cancer
interpreted the experience of side-effects of chemotherapy as a sign that the drugs were
working. For these women, the absence of side-effects was a distressing indication that
"chemotherapy was not having enough beneficial impact upon the body" (Leventhal et al.
1986).
5.2 Beliefs about efficacy
It seems reasonable to hypothesise that a belief that prescribed medication is necessary
and potentially effective may be a key determinant of intention to adhere to treatment. It is
also not surprising that some people use the perceived effects of their treatment to judge
its efficacy. These judgements are usually based on symptom relief or the perceived effect
of drugs in bringing back or retaining normal functioning (Conrad, I 985; Arluke, I 980). It
is interesting that, although none of these studies have utilised Leventhal's SRM, they seem
to support the importance of concrete symptom experience in guiding self-regulation
(Leventhal et al. 1986; Leventhal et al. I 992).
Another representation related to efficacy has been identified in at least two studies. This
is the view that if medication is taken continuously it will become less effective. The notion
of becoming "immune" to the beneficial effects of the medication has been noted among
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rheumatology patients in the UK (Donovan and Blake, 1992) and in the USA (Lorish et al.
1990), who were concerned that regular use of the medication would reduce its analgesic
effects.
5.3 Negative views about medication
Several studies have identified beliefs which were associated with a negative view of
medi cation.
5.3.1 Addiction and dependence
A recurring theme associated with negative attitudes to medicine is the notion that chronic
use of medication carries the risk of dependence or addiction. It is difficult to pinpoint the
precise meaning of these terms and they are often used interchangeably. In a medical
context, "addiction" is usually defined as a state of psychological and physical dependence.
Relatively few medicines are thought to have this property, which is generally limited to
psycho-active/mood-altering drugs. However, fear of becoming addicted or "too
dependent" on medication has been cited as a key reason for intentional non-adherence by
patients receiving medication for a range of diseases including hypertension, epilepsy and
asthma (Fallsberg, 1991). Conrad, in his study of people with epilepsy, found that the
notion of addiction or dependence was linked to the perception of having to take
medication as a "threat to self reliance" and that some patients saw their medicines as
symbolic of the dependence created by having epilepsy. In this context self-regulation of
medication could be interpreted as a means of "gaining control" (Conrad, I 985).
5.3.2 Long-term dangers
In this representation the continuous use of medication is associated with obscure long-
term effects. For example, Morgan and Watkins (I 988) found that several patients decided
to stop taking their anti-hypertensive medication for periods of time lasting up to a few
months, in order to give the body a break from medication. People's concerns seem to
arise from perceptions of danger associated with medicines in general rather than from the
personal experience of adverse effects. This is illustrated by a study conducted in the USA
in which respondents who had never taken diazepam (a benzodiazepine tranquilliser)
attributed more dangers to its use than those who had taken the drug in the past
(Mansbridge and Fisher, I 984).
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5.3.3 Chemical vs natural
This representation relates to the perceived means of production of medicines. Although
the term "natural" was not clearly defined, labelling of a treatment in this context was
associated with a value judgement in which "natural" remedies were seen as safer than
"unnatural" medicines and that the dangerous aspects of medication were linked to their
chemical/unnatural origins (Conrad, I 985). People with this view may prefer to avoid
medication altogether. For example, in a study of women who had been prescribed
benzodiazepine tranquillisers for menopausal symptoms, several explained that they chose
not to take them because of concerns about the potential harm which could arise from the
use of "unnatural" medicines. The symptoms of the menopause, although uncomfortable,
were at least "natural" and were therefore perceived as a more favourable alternative to
medication (Gabe and Thorogood, 1986). Similarly, parents who had chosen not to have
their children vaccinated contrasted the "unnatural" process of immunisatJon with the
"natural" immunity possessed by the body, or the "natural" phenomena of pertussis
(whooping cough) (New and Senior, 1991).
5.3.4 Medicine as poison
The Ancient Greeks did not make a linguistic distinction between medicine and poison but
used the same word "pharmakon" to describe both types of substance (Bonuzzi, 1987).
This seems to be reflected in a contemporary representation of medicines found among
Fallsberg's (1991) sample of Swedish patients
5.4 Doctors' overuse of medicines
In an early UK study of general practice patients' views of medicines and prescribing, over
a third of the sample thought that doctors prescribed too many medicines, but the
prevalence of this view varied according to class of medicines, between antibiotics (23%),
antidepressants (30%) and tranquillisers (over 50%). People also had clear views about the
purpose of certain medicines and this seemed to influence their expectations for
treatment The fact that about a third of the sample thought that medicines were overused
by doctors implies an undercurrent of suspicion about medication. In a large survey of
public attitudes to benzodiazepines in the USA (Clinthorne, 1986) and in a recent
interview-based study conducted in the UK (Britten, I 994a), patients have also expressed
the view that doctors prescribe too readily and use too many medicines. However, several
studies have reported that patients use the number and dosage of medications prescribed
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for them as an indication of severity of their illness and fluctuations in dosage as markers
for improvement or deterioration (Donovan and Blake, 1992; Morgan and Watkins, I 988;
Leventhal et al. I 991 a).
5.5 Quantitative studies linking medication beliefs, illness
beliefs and health behaviour
Most of the representations of medication described above have been identified from
interview-based qualitative studies. Although this method provides detailed information
this type of data is time-consuming and expensive to collect and analyse and this obviously
limits the sample size. It is therefore difficult to obtain a clear insight into the prevalence of
certain beliefs. Furthermore, a systematic investigation of the relationship between specific
beliefs and behaviours is beyond the scope of qualitative methods. Surprisingly few studies
have attempted to quantify people's beliefs about medicine and to systematically investigate
the relationship between medication beliefs and other variables.
One exception is a study of 62 German patients with asthma in which those who
emphasised the threatening aspects of cortJcosteroid medication were less adherent to
treatment (Woller et al. I 993). The sub-scale which measured the "threatening aspect" of
steroids contained four items. These were responses to the statements "When I think of
cortisone tablets: (I) I'm afraid, (2) I feel threatened, (3) I feel despair, (4) I think I will get
addicted". This latter statement provides preliminary, evidence that the representation of
cortisone as potentially addictive contributed to avoidance of this medicine.
A further questionnaire based study conducted by Eagleton and colleagues (I 993) found
that attitudes to medication were not associated with medication adherence assessed by
tablet count in fifty UK patients interviewed at home within two weeks of being discharged
from hospital. Although the sample was too small to allow firm generalisation, this study
produced an interesting insight into medication beliefs. Over a third of the sample believed
a visit to the doctor should result in the prescription of a medicine and over 40% thought
that "Medicines always make you fee! better". This highlights the point that, although most
studies have identified beliefs about medication which are predominantly negative, positive
views about medication may also be prevalent.
In another study, Echabe and colleagues (I 992) investigated the impact of representations
of health, illness and medicines on coping strategies and health promoting behaviour in 902
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subjects from the Basque region. Representations of medicines were assessed using an I
item questionnaire derived from semi-structured interviews and focus groups. Cluster
analysis was used to assign respondents into groups based on their representations of
health, illness, medicines and locus of control over health. Three distinct clusters were
identified. The first accounted for 70% of the sample and comprised people with an
"against medicine" representation. These people conceptualised health as a balance
between mind and body, attributed illness to stress, pollution, lack of exercise and poverty,
had an internal locus of control and held a predominantly negative view of medication. The
second cluster was essentially "pro-medicine" and accounted for I 2% of the sample. Here
health was perceived as synonymous with being able to work and enjoy life. Control over
illness focused on diet and exercise but also externally, with physicians and medicines
being the factors contributing to recovery. Medicines were viewed positively. The third
cluster (18%), was a "half-way" position between the other two. This study is one of the
few to shed light on how people's beliefs about medication relate to other cognitions.
Additionally, cognitions were linked to coping styles in that people with an "against
medicine" representation tended to delay going for medical check-ups whereas those with
a "pro-medicines " or "halfway" representation were more likely to attend for check-ups
on time. The key finding here is that that views about health and illness and orientation
towards medication appear to cluster together in a logical way. It is interesting that cluster
analysis corroborates earlier qualitative evidence that attitudes to medication broadly fall
into three groups. However, this type of distribution of views (some positive, some
negative and some in between) could probably be identified for most issues! We are still
left with the question of which specific beliefs underlie these "positive", "negative" and "in-
between" attitudes to medicines.
5.6 Summary of literature review and implications for the
present study
The effective management of most chronic illness hinges on patient-self care, particularly
the appropriate use of medication. Many patients fail to do this and non-adherence to
medication presents a significant challenge to research and practice within the health care
domain.
Early research into medication adherence attempted to identify the features of a disease or
treatment which acted as barriers to adherence. It searched for demographic factors and
personality traits which identified "the noncompliant patient". The limitations of this
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research are highlighted by findings that adherence rates often vary between treatments
and over time within the same individuals. Most patients are non-adherent some of the
time.
A more rewarding avenue of research focused on the identification and removal of
barriers to adherence to individual treatment modalities which suggests that improving
communication with clear, easily remembered instructions and tailoring the regimen to fit
in with the patient's lifestyle enhances adherence in some situations. An interesting aspect
of this work was the inclusion of patients' satisfaction with practitioner- patient
interactions as a possible determinant of medication adherence. This acknowledges the
role of motivation and sees that nonadherence may not just be the unintentional
consequence of incompetence or lack of knowledge on the part of the patient The
recognition that what a patient thinks influences what they do stimulated more
psychologically based research into medication adherence.
Social cognition models (SCMs) such as the Health Belief Model and the Theory Of
Reasoned Action have been used to explain the interaction between peoples' beliefs and
their behaviour in relation to health and illness. Although several studies have
demonstrated the utility of these models in predicting adherence to medication they have
generally proved to be more useful in predicting preventative behaviours than response to
illness.
Leventhal and colleagues in the self-regulatory model (SRM) provide an additional
theoretical framework for understanding psychological and behavioural responses to illness
A key feature of the framework is that patients respond to illness in a dynamic way based
on their interpretation and evaluation of the illness and the perceived outcome of the
coping procedures which they adopt Illness representations - an individual's beliefs about
the identity, cause, consequences, time-line and potential for control or cure of their
illness -drive the selection and appraisal of the coping procedure. Thus, if adherence is
conceptualised as a coping procedure, the SRM suggests that a patient's own ideas about
their illness will influence adherence behaviour and there is evidence to support this
However, relatively few studies have considered patients' beliefs about treatment
Research using the SRM focuses on illness representation and studies using social cognition
models have tended to conceptualise beliefs about treatment as patients' perceptions of
the relative benefits of adherence or barriers to taking medication without systematically
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examining their underlying beliefs about medication. Greater emphasis on patients' beliefs
about treatment may increase the explanatory power of SCMs and the SRM as treatment
beliefs may be influential in shaping adjustment and behaviours such as adherence. Several
qualitative studies have identified lay beliefs about medicines which conflict with the
medical view and may influence treatment adherence. The representations of medicines,
identified in these studies, appear to be common across several illness and cultural groups.
However, a systematic comparison of findings is hampered by the fact that the few studies
which have quantitatively assessed medication beliefs have used different questionnaires or
have investigated medication beliefs in the broader context of views about the practice of
medicine. Furthermore, some studies have assessed peoples' ideas about medicines in
general whereas others have focused on specific medication prescribed for a particular
illness.
The research described above provides insights into the content of peoples' beliefs about
medicines together with a few hints as to how representations might influence attitudes
and adherence to treatment. However a number of key questions remain unanswered.
Although it identifies particular beliefs this research tells us little about the prevalence of
these beliefs. We do not know the proportion of people who hold them or how strongly
they are held. Furthermore, we know little about how medication beliefs are cognitively
organised. For example, whether individual beliefs, such as those identified in the studies,
described above, can be grouped together into core themes or components in the same
way that illness beliefs are structured around five components (Leventhal and Nerenz,
I 985). A key question here is the extent to which patients beliefs about medicines in
general are differentiated from their beliefs about specific medicines prescribed for their
illness. It is of theoretical and practical relevance to gain a better understanding of the
nature and extent of the relations between medication beliefs and treatment adherence,
particularly to identify which beliefs are associated with nonadherence to medication.
Finally, if medication beliefs appear to be related to adherence then there is need to
identify some of the salient factors which determine these beliefs.
These questions are clearly beyond the scope of qualitative studies alone as the
investigation of the structure and distribution of beliefs requires a method of assessing and
scoring beliefs and subsequent statistical evaluation of inter-relations between them. The
aim of the experimental section of this thesis was to contribute to existing knowledge by
systematically applying quantitative research methodologies to address the above
questions. Studies exploring the nature (structure and distribution) of medication beliefs
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among patients from a range of chronic illness groups are described in Chapter 7. The
effects of medication beliefs on adherence to treatment are evaluated in Chapter 8 and
further analyses investigating some of the determinants of medication beliefs are described
in Chapter 9. The findings are summarised in Chapter 10 together with an analysis of the




The literature review, detailed in Chapters I to 5 identified a number of outstanding
questions concerning the nature, effects and determinants of medication beliefs. The
empirical aspect of the thesis attempted to address some of these questions in a series of
cross-sectional studies involving patients from a range of illness groups and a sample of
university undergraduates. The current Chapter will list the empirical questions addressed
within this thesis. This will be followed by an overview of the empirical work to guide the
reader through the various studies and analyses addressing the nature, effects and
determinants of medication beliefs which are described in Chapters 7, 8 and 9. Further
sections will describe the samples and the measures used and the approach to statistical
analyses.
6.1 Empirical questions addressed within this thesis
I. What are the main beliefs that patients with chronic illnesses hold about medicines
prescribed for them?
2. What are the main beliefs that patients with chronic illnesses hold about medicines in
general?
3. How do patients' beliefs about their prescribed medication relate to their beliefs about
medicines in general?
4. How are the main specific and general medication beliefs distributed within and across
illness groups?
5. What is the nature and extent of the relationship between medication beliefs and
adherence to treatment?
6. How do beliefs about specific and general medication vary within and across socio-
demographic and cultural groups.
7. How do patients' beliefs about medication relate to their personal experience of the
beneficial or adverse effects of medicines?
8. How do patients' beliefs about medication relate to their beliefs about illness.?
An important aspect of the empirical was therefore to identify the 'main' beliefs about
medicines. These were conceptualised as the core themes underlying commonly-held
beliefs about medicines. The identification of these themes and hence the
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conceptualisation of 'main beliefs' is described in Chapter 7. Thus, questions 1-4 relate to
the nature of medication beliefs and are addressed in Chapter 7. Question 5 concerns the
effects of medication beliefs in relation to adherence behaviours and is addressed in
Chapter 8. Finally, questions 6, 7 and 8 refer to the determinants of medication beliefs and
these are addressed in Chapter 9.
6.2 Overview of the empirical work:
6.2.1 Rationale for the research strategy
Addressing the research questions outlined above was hampered by the lack of a standard
validated tool for assessing medication beliefs. Although Marteau (I 990) and Echabe and
colleagues (1992) had developed questionnaires which included questions about medicines,
these scales elicited views about medication in other contexts rather than focusing in detail
on representations of medication. A related problem was to decide which particular
medication beliefs to focus on. It was possible that peoples ideas about medicines might be
many and varied. The review of previous qualitative studies, described in Chapter 5, had
identified a number of individual beliefs about medicines which seemed to be common to
patients across a range of illness groups. However, these studies had not clarified which
were the main beliefs that influenced patients' attitudes and behaviour in relation to
medicines.
The present studies were among the first to systematically investigate the nature, effects
and determinants of medication beliefs in chronic illness. Therefore a primary goal was to
identify commonly held beliefs about specific and general medication and then to
investigate whether certain beliefs could be grouped together into 'common-themes' which
were relevant across various illness groups. If this could be achieved it would facilitate a
preliminary investigation of relations between medication beliefs and adherence as
attention could be focused on a small number of "common-themes", rather than a large
number of individual beliefs.
6.2.2 Plan of the empirical work
The empirical work was carried out in two stages. Stage A was to identify a small number
of 'common-themes', which might also be called core-constructs or factors, underlying
commonly held beliefs about medication. Stage B was to explore the nature and extent of
associations between these core-constructs and other parameters such as reported
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adherence or illness beliefs in order to identify the effects and some of the determinants of
medication beliefs.
Both stages of the investigation involved the analysis of cross-sectional data. The majority
of the analyses were conducted on the main sample comprising six illness groups
(asthma, diabetes, end-stage renal disease, chronic heart disease, psychiatric out-patients
and a sample of inpatients of a general medical ward). Data from this sample was used for
the majority of the analyses investigating the nature, determinants and effects of
medication beliefs. However, during the course of this thesis several research questions
arose which could not be addressed using data from the main sample. It was therefore
necessary to recruit auxiliary samples. The auxiliary samples comprised oncology
patients, undergraduate university students and a sample of patients seeking care from a
community pharmacy or homeopathidherbal practitioners.
Data from the main sample were therefore used for two purposes. First, to derive and
validate a Beliefs about Medicines Questionnaire (BMQ). Second to explore interactions
between the BMQ and other variables to investigate the determinants and effects of
medication beliefs in chronic illness. The empirical work proceeded in 5 steps:
Step 1 Data collection: A pool of items assessing medication beliefs was administered to
the main sample at the same time as a battery of questionnaires assessing other relevant
constructs. These constructs were chosen on the basis of hypothesised relations with
medication beliefs, and included measures of reported adherence to medication and beliefs
about illness, detailed in Section 6.4. The medication belief items comprised 34 statements
representing beliefs about prescribed medication (specific beliefs) and medicines in general
(general beliefs) as described in Chapter 7.
Step 2 ldentif,'ing core-constructs underlying common beliefs about medication: Principal
Component Analysis (PCA) of Likert scale responses to the 34 items assessing medication
beliefs was used to investigate whether this relatively large number of individual beliefs
about medicines could be grouped into a smaller number of factors.
Step 3 Psychometric evaluation of PCA factors as components of a Beliefs about Medicines
Questionnaire (BMQ): Evaluation of the psychometric properties of the factors using the
data set obtained from the main sample provided a preliminary validation of the PCA
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factors as components of a new questionnaire based method for assessing cognitive
representations of medication: the BMQ.
Step 4 Using the BMQ to explore the determinants and effects of medication beliefs in chronic
illness. These analyses were conducted on the same cross-sectional data set obtained from
the main sample from which the BMQ factors had been derived by PCA. Once the broad
range of medication beliefs had been simplified into core themes, represented by the BMQ
factors, these could be used as a basis for further investigation. Quantitative associations
between medication beliefs (BMQ factors) and other variables were used to explore the
determinants and effects of medication beliefs in chronic illness. For example the
distribution of scores on the BMQ factors was used to explore the distribution of the main
medication beliefs within the chronic illness samples. Similarly associations between factor
scores and adherence self-report scores were used to explore relations between
medication beliefs and adherence. Finally, interrelations between BMQ factors and other
variables (such as socio-demographic factors, type of illness and beliefs about illness) were
used to identify some of the possible determinants of medication beliefs. Some of the
findings provided further evidence for the criterion-related validity of the BMQ.
Step S Recruitment of an auxiliaty sample. The BMQ was administered to further samples to
address the effects of culture on medication beliefs (University undergraduate students),
the experience of side-effects as possible determinants of medication beliefs (oncology
patients) and to conduct additional tests on the discriminant validity of the BMQ (patients
seeking care from a community pharmacy or homeopathic/herbal practitioners).
6.3 Participants
6.3.1 Main sample
The chronic illness groups from which the patients were sampled were chosen to reflect a
variety of disease and treatment characteristics. Asthma was chosen as a symptomatic
condition with a fluctuating severity. Diabetes was chosen because of its high prevalence
and as an example of a severe illness requiring a high degree of self-management by the
patient. End stage renal disease (ESRD) was chosen as an example of a life-threatening
illness in which medication, although an essential component, is not the mainstay of
treatment Chronic heart disease was selected in view of its high prevalence and because
treatment is based on medication. Psychiatric out-patients were chosen because
93
medication is targeted at psychological rather than physical problems. Finally the general
hospital in-patient sample was included to represent a group of patients whose condition
had recently deteriorated resulting in admission to hospital.
A further reason for choosing the above range of illness groups was to represent
conditions where medication was likely to have differing effects on symptoms. For
example, medication often produces clear symptomatic benefit in asthma but patients with
chronic heart disease and psychiatric disorders may perceive a more tenuous link between
medication and symptomatic benefit and medication may produce little or no perceived
effect on symptoms in ESRD. Ethical committee approval was granted for the study in each
of the participating clinics and hospitals. The main characteristics of the six samples are
shown in Table 6.1 and the individual illness samples are described in more detail below.








Asthma	 Diabetic	 Renal	 Cardiac	 Psychiatric	 General
Clinic	 Clinic	 Dialysis	 IP	 Clinic	 Medical IP
IP
78	 99	 47	 120	 89	 91
37	 39	 49	 71	 37	 50













19.1	 7.1	 23.8	 4.7
Number of prescribed 	 3.5 (I .7)a #	 7.1(1.9)13	 3.5 (2.3)f3	 2.2 (1.4) a	 4.1 (3.2)13
medicines (mean, SD)
* Data unavailable
IP = Hospital In-patient
a = Patient report of number of prescribed medications
13 = Number of prescribed medication obtained from the patient's medical notes
# The exact number of medicines prescribed for each patient was not recorded. However the majority of
patients were prescribed only one medication (Insulin or a single oral anti-hypoglycaemic agent)
6.3.1.1 Asthma Sample
Patients were recruited from the weekly out-patient clinics of two consultant respiratory
physicians at Hove General Hospital, East Sussex. The main function of the clinic was to
provide a clinical assessment of patients who had previously been admitted to hospital
under the care of the consultant respiratory physician or had been referred as an out-
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patient by their GP. The clinics therefore catered for patients with a broad range of
respiratory disorders and were not targeted specifically at patients with asthma.
During a 3 month sampling period between March and May I 994, the medical notes of all
patients scheduled to attend the clinics were examined two weeks prior to the clinic date.
Patients whose medical notes specified a diagnosis of asthma of at least 3 months duration
and who had been prescribed one or more medicines for regular use over a period of at
least two months prior to the study, were included if they could read and understand the
study questionnaire. These patients were sent a letter inviting them to take part in a study
of patients' views about illness and treatment (The letter is shown in Appendix I)
On arrival at the clinic, patients informed the receptionist whether or not they wanted to
take part in the study. Those who agreed were referred to the researcher who explained
the study, elicited demographic details and then asked the patient to complete the study
questionnaire while waiting to see the clinic physician. At this stage patients were excluded
if they were unable to read the questionnaire because of a poor command of English or
due to very poor eye sight
Of 105 asthma patients on the clinic schedule 17 refused to take part in the study, 9 did
not attend the clinic and 1 who agreed to take part subsequently withdrew without
completing the questionnaire. Seventy-eight patients the study and completed the clinic
questionnaire. The overall response rate was therefore 78/105 = 74.3%.
The demographic characteristics of the asthma sample are shown in Table 6.1. The mean
age was 45.5 years (SD = 18.3; range 18-87) and the participants, 37% of whom were male,
had a range of educational experience (68% secondary, 22.7% tertiary and 9.3% higher).
Patients reported that they had been prescribed a mean of 3.5 (SD = 1.7) medicines for
their asthma. For 96.2% of patients this included an inhaled or oral corticosteroid
medication. The mean duration of asthma was 1.6 years (SD 1.3).
Test-retest sample: The asthma sample was also used to assess the test-retest reliability
of study measures assessing beliefs about medicines and self-reported adherence to
medication. Of 78 repeat questionnaires, 31 were returned giving a test-retest response
rate of 40%. The 31 responders were not significantly different from the 47 non-




Patients were recruited from the hospital out-patient diabetic clinic at Watford General
Hospital, London, by a post-graduate student, working under the supervision of the
author. Four diabetic clinics were held weekly for newly diagnosed patients; those
attending for clinical review, a clinic for pregnant diabetics and a "young diabetic" clinic
catering mainly for adolescent patients. As the study was primarily concerned with
medication beliefs of adults with chronic illness, data collection focused on the review
clinic.
A consecutive sample of attenders at the clinic were recruited over a six week period
during April and May 1994. Patients were eligible for inclusion in the study if they had a
history of diabetes of greater than 3 months, and had been prescribed one or more
medicines for regular use over a period of at least two months prior to the study. Patients
were excluded if they were unable to read the study questionnaire because of a poor
command of English or due to very poor eye-sight.
During a six week period, I 24 study-eligible patients were approached to take part in the
study. Twenty patients refused to take part and 104 patients returned the study
questionnaire. Five of the study questionnaires were rejected (>5% of responses to
questionnaire statements were missing or illegible). The remaining 99 questionnaires were
retained for analysis. The final completion rate was 79.8%.
The demographic characteristics of the sample are shown in Table 6.1. The mean age was
46.6 years (SD 18.5; range 20-84) and 39% were male. Sixty four (64.7%) of the patients
were insulin-treated while the remaining patients received oral hypoglycaemic medication
(tablet-treated). For the purposes of certain analyses, these groups were treated
separately. The demographic characteristics of the insulin-treated and tablet-treated
patients are shown separately in Table 6.2
Table 6.2 Demographic characteristics of the diabetic sample by treatment
type
Insulin- Treated Diabetic Clinic	 Tablet-Treated Diabetic Clinic
64	 35
Sex (% male)	 33	 47
Age (mean, SD)	 40.4 (18.2)	 57.9 (I 3.0)
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The clinic staff wished to keep the demands the research imposed on patients to a strict
minimum. For this reason details of current medication and educational experience were
not recorded. However, the clinic pharmacist reported that the majority of patients were
receiving only one medicine for their diabetes (insulin or a single oral hypoglycaemic
agent).
6.3.1.3 Renal Sample
The sample was recruited from the renal unit at St Mary's Hospital London, by a post-
graduate student, at the School of Pharmacy University of London, supervised by the
author. The aim was to recruit approximately half of the 103 patients on the hospital
dialysis list in June, 1994. Patients were eligible for entry if they could read and understand
the questionnaire, were well enough to complete it during the dialysis session and had
been receiving haemodialysis treatment with at least one associated medication, for at least
three months.
The hospital haemodialysis regime comprised three 8-hour dialysis sessions per week The
hospital haemodialysis patients were therefore a fairly 'static' population who attended the
clinic at regular intervals. Sampling on the basis of consecutive attendance was judged to be
inappropriate as approximately 17 patients would be undergoing dialysis at any given time.
Therefore, patients were randomly selected from the dialysis list and evaluated for entry
into the study until a sample of sufficient size had been attained. Twenty-one patients
whose names were randomly selected from the clinic list failed to meet the entry criteria
and were excluded from the study because they had insufficient command of English to
read the questionnaire (9), were too unwell to complete the questionnaire (8), or were no
longer receiving dialysis on the unit (4). Of 59 study-eligible patients who were randomly
selected from the list, I 2 refused to take part or did not complete the questionnaire. Forty
seven patients (23 male, 24 female) completed the study. Thus out of 59 randomly selected
study-eligible patients, 47 completed the questionnaire giving a response rate of 79.7%.
Sixteen (34.0%) had experienced at least one failed renal transplant and 18 (38.3%) were
on the waiting list for transplantation at the time of the study. The mean age was 49 years
(SD I 7.3; range = 20-84) and participants had a variety of educational (59.6% secondary,
21.3% tertiary and 19. 1% higher) and ethnic (14.9% Asian, 31 .9% Afro-Caribbean and,
53.2% Caucasian), backgrounds. The mean duration of dialysis treatment was 53 months
(range 3-216 months) and the mean number of prescribed medicines was 7 (range 3-I 2).
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6.3.1.4 Psychiatric sample
The sample were recruited as part of audit evaluating a medicines-information service at a
psychiatric out-patient clinic staffed by a consultant psychiatrist at Brighton General
Hospital. Questionnaire items assessing patient's beliefs about medicines and self-reported
adherence to medication were included as part of a base-line assessment conducted prior
to the provision of a medicines information service. Only data collected during the baseline
assessment were included in this thesis. Patients were eligible for inclusion in the study if
they had been under the care of local psychiatric services for longer than one year and if
their condition was stable enough to be managed on an out-patient basis. Further criteria
were that they had been prescribed at least one medication as part of their psychiatric
treatment programme for at least 6 months prior to the study and that they were able to
read and understand the study questionnaires.
Study-eligible patients, identified from the clinic list and hospital medical notes, were sent a
letter, signed by the consultant psychiatrist, inviting them to take part in an audit of a
medicines information service (A copy of the letter is included in Appendix 2). Those who
accepted were asked to attend a 'research clinic' at the hospital out-patient department
where they completed a questionnaire eliciting their views about various types and sources
of information about medicines and their satisfaction with medicines information they had
received to date. These data provided a baseline assessment for audit of the information
service and were not used in the present study. For the purposes of the present study,
patients were asked to complete questionnaire items addressing their views about
medicines and self-reported adherence to prescribed medication. (The medication belief
items and their use in the development of the BMQ are described in Chapter 7. The
adherence scale is described in Section 6.4.4 of this chapter). Patients who attended the
'research clinic' received a small payment to cover their travel costs
Pilot study: Items assessing beliefs about medicines were derived from studies which had
not involved psychiatric patients. It was therefore necessary to pilot these items on a sub-
group of the psychiatric sample. A pilot sample of 10 patients was randomly selected from
the study-eligible patients who agreed to take part and were asked to attend the 'research
clinic on the first day of the study. Of the 10 patients selected for the pilot sample, 3 failed
to attend the 'research clinic'. Although, data collected from this group were not included
in subsequent analyses, this sub-sample needs to be taken into account when calculating
the response rate.
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One hundred and twenty five patients were invited to attend the 'research clinic' 27 failed
to attend and 98 patients entered the study. Seven were included in the pilot sample and a
further 2 failed to legibly complete over 95% of the questionnaire items. The final study
sample therefore comprised 89 patients. Allowing for the 7 pilot study patients, the
response rate was 98/125=78.4%.
The demographic characteristics of the final sample (n=89) are shown in Table 6.1. The
mean age was 45.8 years (SD= 10.9; range 18-87). and the participants, 37.1 % of whom
were male, represented a range of educational experience (47.7% secondary, 28.4%
tertiary and 23.9% higher). Patients reported that they had been prescribed a mean of 2.2
(SD= 1.2) medicines for their psychiatric illness the mean duration of which was 10.2 years
(SD=8.4). Fifty four percent of the sample were diagnosed as having a psychotic illness and
46% were diagnosed as having a neurotic illness.
6.3.1.5 The cardiac and general medical inpatient samples:
Patients were recruited from general medical wards of two London teaching hospitals and
five district general hospitals in London and Brighton, over an 8 week period between
January-March, 1995, by seven pre-registration pharmacy students, working under the
supervision of the author. The inciLsion criteria were:
• patient aged 18 years or over
• patient admitted to the general medical ward with a clear primary diagnosis, for
which they had been prescribed one or more regular medicines
• patient judged by nursing staff to be well enough to complete the study
questionnaire
• Patient able to read and understand the study questionnaire
Study-eligible patients were identified from a list of new admissions obtained from the
nursing kardex or clinical pharmacy log-book, a record of patients and their medication
updated on a daily basis by the ward-based clinical pharmacist. Consecutive new
admissions were evaluated for inclusion in the study by the pre-registration pharmacist
who used the hospital medical notes to identify the primary diagnosis and number of
medicines prescribed for the patient and elicited the nurses' assessment of whether the
patient was well enough to participate. Of 254 study-eligible patients, 37 refused to take
part. and 217 entered in the study. Six of the study questionnaires were rejected (>5% of
responses to questionnaire statements were missing or illegible). The remaining 211
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questionnaires were retained for analysis. The final completion rate was therefore
21 l/254 83. 1%.
Separation into cardiac and general medical groups: The final sample obtained from
the general medical wards comprised patients from the diagnostic groups shown in Table
6.3.
Table 6.3 Diagnostic profile of the 'cardiac' and 'general medical inpatient'
samples
Sample	 Primary diagnosis	 n	 percentage of
sample
Cardiac	 Chronic cardiac diseases	 120	 56.8%
General medical inpatients	 Chronic respiratory diseases• 	 34	 16.2%




• respiratory patients = asthma/COAD (n=33) and cystic fibrosis (n= I)
Patients with chronic cardiac disease represented the single largest 'diagnostic group'
comprising 56.8% of the total sample. In subsequent analyses this group was treated as a
single illness group and the remaining patients (n91) were grouped together as the
'General medical inpatients'. Thus although the cardiac and general medical inpatient
samples were obtained from the same source, for the purposes of the present study they
were analysed as separate 'illness groups'. The sample characteristics of the cardiac and
general medical inpatient samples are shown in Table 6.1 and are described below.
Cardiac sample: The mean age of the sample was 63.6 years (SD= I 2.4; range 21 -86). and
participants, 70.7% of whom were male, had a range of educational experience (81.4%
secondary, I 1.5% tertiary and 7.1% higher). Patients had been prescribed a mean of 3.5
(SD=2.3) medicines for their cardiac condition
General medical sample: The mean age of the sample was 54.0 years (SD= I 9.8; range
I 8-86). and participants, 51.1% of whom were male, represented a range of educational
experience (71.8% secondary, 23.5% tertiary and 4.7% higher). Patients had been




The sample comprised undergraduate students at the University of Brighton attending the
following courses: Pharmacy, Engineering, Accounting and Finance, Social Policy and
Administration and Humanities. Permission to invite students to take part in the study was
obtained from relevant members of academic staff (e.g. course leaders). Students were
approached at the start of a core-lecture and invited to take part in the study by a third
year undergraduate pharmacy student, working under the supervision of the author. Those
who agreed were given five minutes to complete the study questionnaire before the
lecture began. Completed questionnaires were collected by the student-researcher. In
most courses, students were split into two main groups for ease of teaching and we aimed
to approach at least one group in each year. This was achieved for each year, but about
two thirds of students in year 3 of the Accounting and Finance were not eligible for
inclusion in the study as they were on placement during the recruitment period. All
students who were approached agreed to participate in the study but just over 5% of
returned questionnaires were incomplete or spoiled and were omitted with the analysis,
leaving a total of 600 completed questionnaires from 635 administered, giving a final
response rate of 600/635 = 94.5%. The sample characteristics are shown in Table 6.4.
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Matched Sample: One hundred and sixty participants Asian (n80) and European (n80)
were matched for age and sex and course as shown in Table 6.5 below.









• Accounting and Finance
• Social Policy
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The sample comprised consecutive attenders at an oncology out-patient clinic and hospital
ward at Guy's Hospital, London over a four week period between December and January
1995-I 996. Patients were eligible for the study if they could read and understand the
questionnaire and felt well enough to complete it. A total of 100 study eligible-patients
were approached and 91 completed the study questionnaire, giving a response rate of
91%. The study sample, recruited from the Oncology out-patient clinic (n =5 I), and ward
(n40). Comprised 47 males, and represented a range of ages (mean = 58.5 years;
range 19-85; SD= I 5.8), and educational experience (77.2% secondary; 14.2% tertiary and
7.6% higher). All patients were receiving at least one prescribed medication (mean=4.3;
range I -18; SD =2.7; mode2). The mean time since diagnosis of the present condition
was 20 weeks (range 1-249; SD = 34).
6.3.2.3. Allopathic/Complimentary sample: a matched group of patients seeking
care from allopathic (community pharmacy) and complimentary sources
(homeopathy/herbal clinic)
This sample was recruited in order to compare medication beliefs of allopathic and
complementary care seekers. Participants were recruited from a single community
pharmacy and a herbal and homeopathic clinic in Brighton. The inclusion criteria are
shown in Table 6.6. Patients were recruited over a four week period between January and
February 1996.
Table 6.6 Inclusion criteria for the Allopathic/Complementary sample
Allopathic Care (community pharmacy)	 Complimentary Care (herbal/homeopathic clinic)
• Presenting a prescription for dispensing at the
	 • Attending a herbal or homeopathic clinic
pharmacy which included at least one
medicine intended for regular personal use
• Judged by the pharmacist to be well enough	 • Judged by the herbalist/homeopath to be well
to complete the questionnaire 	 enough to complete the questionnaire
Able to read and understand the study questionnaire
Allopathic Care sample: was recruited from a community pharmacy during weekday
evenings. Consecutive patients presenting a prescription at a community pharmacy were
approached by the researcher while they were waiting for the prescription to be
dispensed. One hundred and twenty six study-eligible patients were approached, 22
refused to take part and 104 patients entered the study and returned completed
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questionnaires (>90% items answered legibly). The response rate for the Allopathic Care
sample was therefore 104/126 = 83%.
Complementary Care sample: was recruited from the clinics of a single herbalist and
single homeopath, in Brighton. Both practitioners felt that it would be inappropriate to
base a researcher in the clinic and so patients were invited to take part in the study by the
herbalist/homeopath. Those who agreed were asked to fill out the questionnaire and
return it to the author at the University of Brighton in the stamped addressed envelope
provided. Fifty-four questionnaires were given out and 36 completed questionnaires were
returned. The final response rate for the Complementary Care sample was therefore
36/53=67.9%
Matched samples: Seventy two participants were matched for age and sex and
educational experience. Patients from the Allopathic Care sample were selected to match
the age and gender profile of the Complimentary Care group. Matching was carried out
because of the large disparity in group sizes and the possible confounding effect of age and
gender. The characteristics of the matched samples are shown in Table 6.7 below. There
were no significant differences between Allopathic and Complimentary samples in terms of
age, and gender. The Complementary Sample had significantiy greater educational
experience (Pearson Chi-Square = 6.34; DF=2; p<O.OS) and had made significantly more
visits to homeopathic (t3.35; n=72; p<O.00I) and herbal (t4.84; n=72; p<O.00I)
practitioners in the 6 months prior to the study than had the Allopathic Care sample.
There were no significant differences between the samples in the number of reported
visits to NHS General Practitioners or hospital admissions. The latter finding was
interpreted as an indicator that the samples were comparable in terms of illness severity.




Allopathic Care Sample 	 Complementary Care Sample
36	 36
42.3(11.1)	 47.3 (18.6)















Mean (SD) number of visits over previous 6
months to:
• General practitioner 	 2 (1.8)	 1.7 (1.9)
• Homeopath	 0.03 (.17)	 0.78 (I .33)
• Herbalist	 0	 1.5 (1.9)




Where validated instruments could be found in the literature these were used or adapted.
However, few instruments had been developed to assess medication-related cognitions.
Thus part of the empirical work entailed the development and use of measures designed
for the study. These ranged from simple single item statements to more psychometrically
sophisticated scales. In particular, the empirical work resulted in the development of the
18 item Beliefs about Medicines Questionnaire which is described in detail in Chapter 7
and a four item Reported Adherence to Medication (RAM) scale which is described in this
section 6.4.4.
It was not possible to administer all the measures detailed below to all of study samples.
Rather, specific questions were addressed in particular illness groups. This was necessary
because for some illness samples, there were restrictions on the number of questionnaire
items. For example the psychiatric sample patients were also being asked to complete
questionnaires relating to another study as described above. The questionnaire
administered to the hospital inpatient samples was kept as brief as possible in order not to
place excessive demands on patients who were likely to be feeling more unwell than those
attending out-patient clinics.
6.4.1 The Illness Perception Questionnaire (IPQ) (Weinman et al, 1996)
The IPQ comprises five scales measuring the five components of illness representation
specified in Leventhal's self-regulatory model of illness (Leventhal et al, I 980). The five
scales assess identity (the symptoms the patient associates with the illness), cause (personal
ideas about aetiology), time line (the perceived duration of the illness), consequences
(expected effects and outcome), and cure/control (beliefs about potential for cure and
control i.e. how one controls or recovers from the illness). The psychometric properties
of the IPQ have been evaluated in 7 patient groups including asthma, diabetes and hospital
haemodialysis recipients (Weinman et al, I 996). The internal consistency, test-retest
reliability and the concurrent, discriminant and predictive validity of the IPQ scales are
within acceptable limits (Weinman et al, 1996). The full IPQ with instructions to subjects is
shown in Appendix 3. The scoring methods for the five scales, together with examples of
scale items are as follows.
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The Identity scale is comprised of I 2 core symptom items that the patient is asked to rate
for frequency on a four point scale (4 all of the time, 3 never, 2occassionally and
I =never), according to how often each symptom is experienced as part of the patient's
illness. This core list of items may be added to by researchers to tailor the scale to specific
illnesses. For example in the IPQ administered to the asthma sample, 4 additional
symptoms were added: tight chest, panic attacks, depression and anxiety. The Identity scale
score was obtained by summing the scores obtained for the individual items. High scores
indicate more severe symptomology and a strong illness 'identity'
The items from the four other IPQ scales are presented in a mixed order and rated by the
patient on a five point scale (I strongly disagree, 2= disagree, 3 = neither agree nor
disagree, 4 = agree and 5 strongly agree) After reverse scoring the appropriate items,
scores for the Time-line (3items e.g. 'My illness will last a long time'), Consequences (7 items
e.g. 'My illness is a serious condition') and Cure/Control (6 items e.g. 'My illness will improve with
time') scales are obtained by summing all the scale items and dividing by the number of
items.
For the Cause scale it is not appropriate to sum all of the items as each item represents a
specific causal belief. In the present study, patients beliefs about the cause of their illness
were assessed in two ways. The degree of endorsement of each of the 8 possible causes
included in the IPQ (chance, other people, genetic, stress, diet, pollution, own behaviour,
germ or virus) was assessed by the degree of agreement with relevant IPQ statement (e.g.
"My illness was inherited") scored on a linear scale from I = strongly disagree to 5 =
strongly agree. Additionally the total number of causal attributions endorsed by the patient
was computed. Endorsement of a causal belief was indicated by an agree/strongly agree
response to the individual causal item. Each item endorsed was given a score of I. Thus
the total number of causal attributions made by the patient was obtained by summing the
scores from 0-8. The present study was conducted before publication of the IPQ and an
early version of the question was used by permission. Subsequently, two further casual
belief items were added to the IPQ during its development Thus the Cause scale in the
published questionnaire comprises 10 items while the version used in the present study
was limited to 8 items (see Appendix 3 for details). In the most general version of the IPQ,
each item refers to "illness" In the present study this was replaced with the name of the
patient's illness (e.g. diabetes, asthma etc.) as recommended by Weinman et al, 1996.
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6.4.2 Beliefs about control over illness
These were assessed using a modified version of a the Perceived Control Over Recovery
scale (Partridge and Johnston, 1989). The wording of scale items was altered so that
questions related to perceived present and future control over a named illness (e.g. asthma
or diabetes). The 'asthma' version is shown in Appendix 4. Identical items were
administered to the dialysis sample, except that the phrase "my asthma" was replaced by
"my kidney condition". Item responses were scored on a 5-point Likert scale, where I =
strongly disagree to 5 = strongly agree. Response scores for individual variables were
summed to give a Perceived Control Over Illness score, with high scores indicating
stronger beliefs in internal control over the illness.
Note: In the version of this measure administered to the asthma group an additional item
was used to assess the extent to which control over asthma was attributed to medication
This was assessed on the basis of Likert scale responses to a single item statement
'Whether my asthma gets better or worse depends on how well my medicines work", scored
from I = strongly disagree to 5 = strongly agree where high scores indicate a stronger
belief that control over asthma depends on medication. The item was included with the
Perceived Control Over Illness Scale but was analysed separately.
6.4.3 Perceived lack of empathy from medical and nursing staff (PLE)
This was assessed by responses to the statement "Doctors and nurses do not know how it
feels to have asthma", scored on a 5-point Likert scale where I = strongly disagree and
5strongly agree. This statement was included as an additional item in the IPQ section of
the study questionnaire but was analysed separately.
6.4.4 Reported Adherence to Medication (RAM) scale
Published adherence self-report scales were thought to be unsuitable because they are not
specific to medication (DiMatteo et al, 1993, Kravitz et al, 1993) or because they do not
elicit self-report of the frequency of adjusting or altering dosages (Morisky, 1986). A
reported adherence to medication scale (RAM) was therefore devised for the present
study. This was a four-item composite self-report scale which assess two aspects of
adherence behaviour. The study requires a means of assessing both active non-adherence
(AnA) (e.g. tendency to deliberately alter the dose of medication) and passive non-
adherence (PnA) (e.g. the tendency to forget to take medication). See Section I .6 for a
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fuller explanation of these terms. Non-adherence was indicated by the tendency to forget
to take medication and to deliberately adjust or alter the dose from that recommended by
the physician. The RAM scale comprises four adherence statements. Two items are scored
on a 5-point Likert scale. A further two items are phrased as direct questions asking the
patient to report the frequency of adjusting or forgetting medication (scored on a 5-point
scale where I never and 5=very often). A total medication adherence score is obtained by
summing responses to each of the four individual items. Scores ranged from 4 to 20, with
higher scores indicating greater non-adherence. The items are shown in Table 6.8
Table 6.8 The reported adherence to medication scale (RAM)
• I sometimes forget to take my medicines
• I sometimes alter the dose of my medication to suit my own needs
Item responses were scored on a Likert scale where I = strongly disagree, 2 = disagree, 3 = uncertain, 4
agree and 5 = strongly agree
• Some people forget to take their medicines. How often does this happen to you?
• Some people I have talked to say that they miss out a dose of their medication or
adjust it to suit their own needs. How often do you do this?
Item responses are scored as I = never, 2 = rarely, 3 = sometimes, 4 often and 5 very often.
In an attempt to diminish the social pressure on patients to under-report non-adherence,
adherence questions were phrased in a non-threatening manner and patients were assured
that their responses to all questionnaire items were anonymous and confidential. In order
to limit "ordering effects" (Abraham and Hampson, I 995), adherence items were located
in separate sections of the questionnaire and were immediately preceded by statements
about medicines phrased in a positive or neutral way (e.g. "Whether I feel better of worse
depends on my medicines" "My medicines make me feel better"). The way in which
adherence items appeared in the context of items assessing medication beliefs can be seen
in Appendix 5 which provides an example of the study questionnaire.
The internal reliability of the RAM scale was evaluated using the Main sample. The
Cronbach alpha coefficients for each illness group are shown in Table 6.9. The insulin
treated and tablet-treated diabetic patients were considered separately because the RAM
scale is scored differently for insulin adherence as described below.
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Table 6.9 Cronbach alpha values as a measure of internal consistency of the
RAM scale
Sample	 nCronbach'salpha
Asthma clinic	 78	 0.60









Diabetes: Insulin treated*	 64	 0.73
Diabetes Tablet treated	 35	 0.50
*2 item scale (see below)
Table 6.9 shows that the RAM scale has acceptable internal reliability in all but one of the
illness groups. The low value obtained in the Tablet-treated diabetic patients indicates that
the scale should be used with caution in this group.
The test-retest reliability of this scale was evaluated in parallel with the BMQ factors in the
sample of asthma patients (n =3 I) described in Section 6.3. Spearman correlation between
RAM scores over a two week interval indicate that the test-retest reliability of the scale
was within acceptable limits (rhoo.72; n=3 I; p<O.00I).
6.4.4.1 Reported adherence to insulin (RAI scale)
The appropriate self-management of insulin entailed the regular adjustment of dosage in
response to diet and glucose testing. For these patients, adherence was indicated by a
composite scale comprising the two items assessing the frequency with which insulin
dosage was adjusted. The Cronbach alpha for these two items in the insulin-treated
sample was acceptable (0.73) and justified their incorporation into a 2-item scale assessing
the reported frequency of adjusting the dosage of insulin. In order to facilitate ease of
comparison between the RAI scale and the RAM scale described above, scores on each of
the items was reversed and the total score for the 2-item scale was doubled to create a
scale range of 4-20 with higher scores indicating greater non-adherence.
6.4.4.2 Using the RAM scale to separately assess Active and Passive non-
adherence
The passive and active aspects of adherence assessed by the RAM scale can be analysed as
separate 2-item constructs. Passive nonadherence (PnA) construct is assessed by
combining the two items concerning 'forgetting' medication. Scores range from 2-10 with
higher scores indicating more frequent forgetting. The active nonadherence (AnA) scale is
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computed by summing scores on the two items eliciting patients' self report of how often
they adjusted or altered the dose of their asthma medication outside the physicians
recommendations. Scores on the AnA scale thus range from 2-I 0 with higher scores
indicating more frequent adjusting.
6.4.5 Self-Rated Heath
This was a 7-item self-rated health scale adapted from the Medical Outcomes Study Short
Form Questionnaire (SF-36) which has been validated for use in abroad range of illness
groups (Jenkinson et al. I 994; Ware, Jr. and Sherbourne, I 992). The scale items and
scoring methods are shown are shown in Appendix 6. A Self-Rated Heath score is
computed by summing the scores obtained on the individual items, after reversing scores
on the appropriate items. Scale scores range from 7 to 35 with high scores indicating
perceptions of better health. The scale was used only in the asthma sample. It had an
acceptable degree of internal consistency with a Cronbach alpha value of 0.84 in the
asthma sample.
6.4.6 Perceived effect of prescribed medication on symptoms (PEMS)
This was assessed using two items:
. Whether I feel better or worse depends on my medicines
• My medicines make me feel better
Responses to each statement were scored on a 5-point Likert scale where I = strongly
disagree, 2 = disagree, 3 = uncertain, 4 agree and 5 = strongly agree.
Scores obtained for the individual items were summed to produce a Perceived Effect of
Medication on Symptoms Scale (PEMS). PEMS scores ranged from 2 to 10 with higher
scores indicating a greater perceived effect of medication upon symptoms.
This PEMS was administered to only two illness groups within the main sample: the cardiac
and general medical inpatient groups. Although the internal reliability of the scale was fairly
low - Cronbach alpha coefficients were 0.58 and 0.55 for the cardiac (n 120) and general
medical samples (n=9 I) - this scale was used because an alternative validated measure
could not be found in the literature.
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6.4.7 The Sensitive Soma (SS) Scale
The Sensitive Soma Scale (SS) assesses perceptions of personal sensitivity to the potential
adverse effects of medication. The scale is currently under development at Rutgers
University New Jersey, USA (Howard Leventhal personal communication, 1995) The SS
comprises five items, shown below, which assess abstract ideas about general sensitivity to
medication and the past experience of adverse symptoms which are perceived to be
associated with medicines usage.
• My body is very sensitive to medicines.
• My body over-reacts to medicines.
• I usually have stronger reactions to medicines than most people.
• I have had a bad reaction to medicines in the past
• Even very small amounts of medicine can upset my body.
Responses to the individual items are scored on a 5-point Likert scale where I = strongly
disagree, 2 = disagree, 3 = uncertain, 4 agree and 5 = strongly agree. Scores on the 5
individual items are summed to give a total sensitive some scale score from 5 to 25 where
high scores = high perceived sensitivity to the potential adverse effects of medication: This
Sensitive Soma scale was administered to the cardiac (n= I 20) and general medical in-patient
(n=9 I) samples. The internal reliability of the scale, as measured by Cronbach's alpha, was
high in both groups (general-medical = 0.80; cardiac = 0.78).
6.4.8 Single measures assessing medication-related cognitions
Two single item statements were used to assess certain medication-related cognitions.
They were included in addition to 34 single items representing commonly held beliefs
about medication, as shown in Appendix 5.
Satisfaction with amount of medicines information received
This was assessed by responses to the single statement
• I have been given enough information about my medicines
Responses were scored on a 5-point Likert scale where I = strongly disagree, 2 =
disagree, 3 = uncertain, 4 agree and 5 = strongly agree
Lack of trust in prescribed medication
This was assessed by responses to the single statement
• I cannot always trust my medicines
Ill
Responses were scored on a 5-point Likert scale where I = strongly disagree, 2 =
disagree, 3 = uncertain, 4 agree and 5 = strongly agree
6.4.9 Educational Experience
Patients experience of formal education was assessed by asking them to state their age on
finishing full-time education. Responses was coded on a scale of I to 3 where: I =
Secondary (finished at age I 6 or below); 2Tertiary (finished between 17 and 20 years
old); and 3Higher (finished at an age 21 years or greater).
6.5 Procedure
Each participant was invited to take part in a study of patients' views about their illness and
treatment The researcher stressed that the study was being conducted by the University
and was completely independent of the hospital in order to avoid any response bias which
might have resulted if patients had associated the researcher with the clinical team.
Patients were told that their responses were confidential and anonymous and it was
stressed that the completed questionnaires would not be seen by any of the staff involved
in their care. The instructions to participants - shown in the Appendix 5 - included a
description of explanation of how the term 'medicines should be interpreted in the
questionnaire.
Clinic patients were asked to complete the questionnaire while waiting to see the doctor.
Patients recruited from the ward (the cardiac and general medical patients form the main
sample and the oncology patients from the auxiliary sample) were asked to complete the
study questionnaire by the researcher who then arranged to collect it at a convenient
time.
6.6 Approach to statistical analyses
Data were analysed using the SPSS Windows 6. I statistical software package (Norusis,
1992). A variety of parametric and non-parametric techniques were used. Details of the
specific statistical procedures are provided in the Methods section of each study described
in Chapters 7,8 and 9. The present section provides an overview of the rationale for the
choice of statistical approaches.
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The data obtained from the measurement scales used were considered to be ordinal in
character, which is usually thought to preclude parametric statistical procedures such as
factor analysis, multiple regression, t-test or ANOVA & ANCOVA. However, several
investigations of the robustness of these procedures to violations of the parametric
assumptions have demonstrated that these procedures may be used with ordinal data if
certain conditions are met (Glass & Hopkins, 1984).
With respect to the t-test, ANOVA and ANCOVA procedures, it has been demonstrated
(Boneau 1960; Hsu & Feldt 1969) that for a t-test with n> I 5, the true level of significance
deviated from nominal (i.e. p<O.O5) by less than 1%, even with extremely skewed or
uniform distributions. Similarly, Glass et al. (I 972) have demonstrated that non-normality
of data does not seriously affect the true significance level (e.g. the error was rarely
greater than a few percent). With respect to correlation coefficients, on which the factor
analysis and multiple regression procedures rely, Glass & Hopkins (1984) report that, with
a large n, Pearson's r and Spearman's Rho differ by as little as 0.01 (see Appendix 7 for an
example using the data from this study). Hence the data were considered adequate for
factor analysis and multiple regression where n> 100. For the individual correlations
between measures reported, where for some groups n< 100, Spearman correlations where
used throughout for consistency and to allow meaningful comparisons between
coefficients.
Principal Components Analysis, was used to identify latent variables or factors underlying
items assessing beliefs about medication. Multivariate factor analytic techniques such as
PCA , are sensitive to outliers in the data. Therefore cases were checked for outliers on
all relevant variables using the Mahalanobis distance (Tabachnik & Fidell 1993). Cases were
excluded if the Mahalanobis distance was greater than 3 SD from the mean. A more
detailed discussion of the Principal Components Analysis is provided in Chapter 7.
Where comparisons were made between matched sample the Independents groups t-test
was used and not the Matched pairs test (Glass & Hopkins, 1984).
Missing data: Cases with missing data for the variables being analysed were omitted list-
wise (Norusis, 1992). In this method a case is eliminated from the analysis if it has a
missing value for a variable in the list which is being analysed. Thus, for some of the
analyses reported, it will be seen that there are minor inconstancies in the sample sizes
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reported for different analyses conducted on the same sample. This is due to the fact that
cases with missing data were eliminated from the analysis.
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CHAPTER 7
The nature of medication beliefs
This chapter describes a series of analyses exploring the nature of medication beliefs of
chronically ill patients. The analyses address four of the broad empirical questions
mentioned in Section 6.1, namely:
I. What are the main beliefs that patients with chronic illnesses hold about medicines
prescribed for them?
2. What are the main beliefs that patients with chronic illnesses hold about medicines in
general?
3. How do patients' beliefs about their prescribed medication relate to their beliefs about
medicines in general?
4. How are the main specific and general medication beliefs distributed within and across
illness groups? (i.e. What proportion of people hold these beliefs and how strongly are
they held?).
These questions were addressed by a series of analyses identifying the main specific and
general medication beliefs and developing a method for eliciting an scoring them. The
analyses are grouped in three sections. Sections I and 2 describe the process of identifying
some of the main medication beliefs and the subsequent development of a novel method
for assessing beliefs about medication: the Beliefs about Medicines Questionnaire BMQ.
Section I shows how the items comprising the BMQ were derived using Principal
Components Analysis (PCA) to identify the themes or factors underlying commonly held
beliefs about prescribed medication (specific beliefs) and about medicines in general
(general beliefs). Section 2 deals with the evaluation of the psychometric properties of the
BMQ. Finally, Section 3 describes the use of the BMQ factors to explore the distribution
of medication beliefs within and between illness groups.
The rationale for the approach was that the main medication beliefs which patients hold
could be identified by examining how these beliefs were cognitively organised. If commonly
held medication beliefs could be reduced to a few coherent factors which were consistent
and stable across illness groups, then these factors could be said to represent 'core
themes' of medication representations. The items loading on them could be thought of as
the main medication beliefs held by chronically ill patients.
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7.1 Using Principal Components Analysis (PCA) to identify
core-themes underlying commonly held beliefs about specific
and general medication
A series of PCA was performed to address the following specific research questions
I. Can commonly held beliefs about prescribed medication be reduced to simple factors
which are stable across illness groups
2. Can commonly held beliefs about medicines in general be reduced to simple factors
which are stable across illness groups
3. To what extent are representations of medication prescribed for personal use
cognitively differentiated from ideas about medication in general?
Questions I and 2 were addressed by seeing whether PCA factors identified in a sample of
patients with one chronic illness could be replicated if the same items were administered
to a sample of patients with a different illness. Question 3 was addressed by investigating
whether the factors underlying specific and general medication beliefs could be replicated if
their constituent specific and general items were entered into a single PCA. If the original
specific and general factor structures were replicated this would suggest that patients'
beliefs about prescribed medication and medicines in general were quite well
differentiated. Three sets of PCA were performed to address questions I ,2 and 3 in turn.
The method and results for each analysis are described in sequence. This is followed by a
general discussion of the findings from the three sets of analyses.
7.1.1 Analysis I: PCA of beliefs about medicines prescribed for personal
use (Specific)
The aim of this analysis was to test the hypothesis that patients' representations of their
personal prescribed medication are structured around common themes. In order to accept
this hypothesis representational structures identified in one diagnostic group would have
to be stable across various illness groups. Thus a factor structure identified by PCA in one
diagnostic group should remain consistent if factor items were administered to other
diagnostic groups and subjected to a further PCA.
7.1.1.1 Method
Participants The cardiac, asthma, renal and general medical inpatient samples described in
Sections 6.3.1.1, 6.3.1.3 and 6.3.1.5.
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Measures A pool of 34 items representing commonly held beliefs about specific and
general medication. The items were derived from beliefs identified from the literature
which appeared to be common to patients with a range of chronic illnesses. A further
series of interviews were conducted with 35 patients receiving regular medication for
chronic illness (20 haemodialysis patients and I 5 patients with myocardial infarction) in an
attempt to identify common beliefs which had not emerged in previous studies. Patients
were asked open questions eliciting their views about medicines prescribed for them and
their thoughts about medicines in general. This resulted in the pool of 34 items shown,
together with their origin, in Table 7.1. Responses to each statement were scored on a 5-
point Likert scale where I = strongly disagree, 2 = disagree, 3 = uncertain, 4 = strongly
agree and 5 = strongly agree. The items and instructions to participants are shown in
Appendix 5
NB Only the I 6 specific medication beliefs were used in the exploratory PCA of specific
beliefs described in this section. Items dealing with beliefs about medicines in general were
entered into a separate PCA described in Section 7.1. 1.2
Principal Component Analysis (PCA) Items were entered in a PCA setting Eigenvalue I
and using the non-orthogonal (OBLIMIN) method of rotation. Cases with missing data
were deleted listwise as described in Section 6.6. A non-orthogonal method of rotation of
factors was chosen in preference to an orthogonal method such as Varimax because the
latter technique has been criticised on the grounds that "forcing" variables into orthogonal
relationships in an attempt to provide clean and simple factors may obscure important
interactions between them (Kline, I 994). Conversely, non-orthogonal techniques such as
Direct Oblimin allow factors to rotate more freely. Although, this makes it more difficult
to identify separate factors it is thought that this technique is appropriate for the analysis
of variables which are likely to be related in the real world, such as beliefs, attitudes or
personality attributes (Cattell, 1995). Extraneous items were omitted on the basis of the
Kaiser Meyer 01km (KMO) statistic for each item, factor scree plot and final factor loading
as described below (Norusis, I 992).
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Table 7.1 Pool of Medication Statements Subjected to PCA including
details of source
STATEMENTS ABOUT SPECIFIC MEDICATION PRESCRIBED FOR THE PATIENT 	 Source
My health, at present, depends on medicines	 I
Having to take medicines worries me	 2,3,4
My life would be impossible without medicines	 I
My medicines are powerful 	 I
Without medicines I would be very ill 	 I
I sometimes worry about the long-term effects of my medicines 	 3,5
My medicines are a mystery to me	 I
My medicines are effective	 I
My medicines disrupt my life	 2,6,7
I sometimes worry about becoming too dependent on my medicines 	 2,3,8
My health in the future will depend on medicines 	 1.9
My medicines protect me from becoming worse. 	 1,2
I would like to change my present treatment	 I
It is difficult for me to take my medicines in exactly the way my doctor told me 	 I
I can cope without my medicines 	 1,2
.2,!0
STATEMENTS ABOUT MEDICINES IN GENERAL 	 Source
Without medicines doctors would be less able to cure people 	 I
Newer medicines are more effective than older ones 	 I
Most medicines are addictive	 3
People who take medicines should stop their treatment for a while every now	 2,3
and again
Medicines only work if they are taken regularly 	 I
Medicines do more harm than good 	 5
Medicines are not natural remedies	 1,3,4, 8,11,12
All medicines are poisons 	 4
It is better to do without medicines	 1,2.4,8
Natural remedies are safer than medicines 	 1,3,4,8,1 1.12,13
Stronger medicines are more dangerous than weaker medicines 	 14,15
Medicines are a necessary evil 	 4,13
Doctors place too much trust on medicines 	 1,16
If doctors had more time with patients they would prescribe fewer medicines 	 1,16
There is a big difference between a medicine and a drug 	 13,16
The medicine you get is more important than the doctor you see 	 I
Doctors use too many medicines 	 1,5,16
Most medicines are safe	 I
I. Interviews conducted with 35 chronically ill 	 9. Arluke, 1980
patients	 10. Helman,1988
2. Conrad, 1985	 II. Coulter, 1985
3. Morgan & Watkins, 1988 	 12. New & Senior, 1991
4. Fallsberg, 1991	 13. Gabe & Lipshitz-Phillips, 1982
5. Clinthorne etal,I986	 14. Lorish,1990
6. Becker et al, 1978	 IS. Leventhal, 1986
7. Cochran & Gitlin, 1988	 16. Rees-Jones, 1979
8. Donovan & Blake, 1992
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Extraneous items were omitted in two stages. First, the Kaiser Meyer 01km (KMO)
statistic was computed for each item. The KMO statistic of an individual item is a measure
of the amount of variance in that item which can be explained by combinations of all other
items within the group and is essentially a measure of the degree to which a particular
item "belongs" with the others. Items with a KMO statistic of <0.7 were rejected as
recommended by Norusis (1992). Items with a KMO statistic of >0.7 were retained and
re-entered into a second PCA using non-orthogonal (OBLIMIN) rotation and list-wise
omission of cases with missing values. Further items were omitted if they had a low or
diffuse loadings on the factors identified by scree plot analysis (Norusis, I 992). In order to
eliminate the influence of multi-dimensional outliers, items retained within the final factor
structure were cleaned by removal of multivariate outliers (Mahalanobis distance >3
standard deviations from the multi-dimensional mean) and removal of cases with greater
than five missing items (Tabachnick & Fidell, I 993).
Procedure: The analysis was performed on responses to the 16 items representing beliefs
about prescribed medication (Specific), shown in Table 7.1 above. The responses from the
cardiac sample (n= I 20) were analysed first. In order to test whether the factor structure
obtained in the cardiac group could be replicated in other illness groups, a further series of
PCA was carried on the responses to factor items obtained from the asthma, renal and
general medical inpatient samples. The reason for limiting initial exploratory factor analysis
of specific items to a single illness group was that the way in which people view medication
prescribed for a particular illness may, to some extent, depend on the nature of that
illness. Thus we could not assume that patients with one chronic illness perceive their
medication in the same way as those with another. The cardiac sample was chosen for
initial analysis on the grounds that it was the single largest diagnostic group within the main
sample.
7.1.1.2 Results: PCA of specific medication beliefs
Responses to the 16 items eliciting beliefs about prescribed medication (Specific beliefs
shown in in Table 7.1), obtained from the cardiac sample (n= I 20), were entered into
exploratory PCA. The mean and SD for each of the I 6 items is shown in Appendix 8 An
initial 4-factor structure was obtained which accounted for 53% of the variance but was
not meaningful. Four items with KMO values <0.7 were omitted and these are shown in
Table 7.2. The remaining I 2 items were re-entered into the analysis. setting Eigenvalue =
A screen plot analysis, suggested a 2-factor solution explaining 47.3% of the variance.
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Omission of two items ("I con cope without my medicines"; "My medicines are effective"),
which had a low loading spread across both factors resulted in a two factor solution
explaining 53% of the variance.
Table 7.2 Items omitted on the basis of low KMO scores
ITEM	 KMO STATISTIC
My medicines are powerful 	 0.58
It is difficult for me to ke my medicines in exactly the way my doctor told me	 0.66
I would like to change my present treaunent	 0.51
I am in control of my medication	 0.69
Having arrived at a core structure of two 5-item factors the data set was cleaned by
removal of multivariate outliers (Malanobis distance >3 standard deviations from the multi-
dimensional mean) and removal of cases with greater than five missing items. This
resulted in omission of 6 cases. Re-factoring on the 114 cases remaining produced a similar
two factor structure explaining SI % of the variance.
Factor labels The final 2-factor structure is shown in Table 7.3. Items were grouped in a
logically consistent factor structure. The first factor comprised items relating to the
positive effect of medication on health and were representative of the perceived necessity
of medication for maintaining health. This factor was labelled Specific-Necessity. The second
factor comprised items relating to concerns about the adverse consequences of
medication based on beliefs about the potential for dependence or harmful long-term
effects and that medication taking is disruptive. This factor was labelled Specific-Concerns.
Table 7.3 Factor structure obtained by principal components analysis of
BMQ-Specific items (n = I 14* patients with chronic heart diseases)
STRUCTURE MATRIX:	 Factor I	 Factor 2
with non-orthogonal (OBLIMIN) rotation 	 Specific-	 Specific-
Necessity	 Concerns
My life would be impossible without my medicines 	 .81	 -.06
Without my medicines I would be very ill 	 .78	 .09
My health, at present, depends on my medicines 	 .7 I	 -.02
My medicines protect me from becoming worse	 .67	 -.19
My health in the future will depend on my medicines 	 .62	 -.11
I sometimes worry about the long term effects of my medicines 	 -.00	 .80
Having to take my medicines worries me	 -.18	 .78
I sometimes worry about becoming too dependent on my 	 -.19	 .72
medicines
My medicines disrupt my life	 .05	 .67
My medicines are a mystery to me 	 -.00	 .58
Eigenvalue	 2.8	 2.4
Percentage variance explained	 28.5	 24.0
* 6 cases were removed during the cleaning procedure.
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Replication of factor structure PCA of the 10 items retained within the 2-factor
structure obtained in the cardiac sample were cleaned as detailed above and entered into a
PCA with non-orthogonal (OBLIMIN) rotation. The 2-factor structure was replicated by
PCA of the responses to the 10 items obtained from asthma, renal and general medical
inpatient samples (asthma: cleaned cases = 72, haemodialysis: cleaned cases = 41 and
general medical inpatients n =90). The factor structure obtained for each of the samples
contained identical items, although minor differences in individual factor loadings. The
factor loadings obtained for the asthma, renal and general medical inpatient samples are
shown in Appendix 8.
7.1.1.3 Discussion
The findings indicate that a simple, stable factor structure had been obtained. Replication
of the structure in different illness samples suggests that the factors represent 'core
themes' underpinning common representations of prescribed medication. Moreover the
results show that the individual belief items loading on the factors are some of the 'main'
beliefs which chronically ill patients hold about their prescribed medication.
The core constructs relating to medication prescribed for the patient were: beliefs about
the necessity of the medicines for maintaining health (Specific-Necessity) and concerns
about medication (Specific-Concerns). The Specific-Necessity construct is a cognitive
representation of the perceived role of medication in protecting against deterioration of
the present and future health status of the patient. It is interesting that the item "My
medicines are effective'" was not retained on this factor due to diffuse loading. This is
contrary to expectations since beliefs about efficacy seem to be implicit within the Specific-
Necessity construct. The reason for this finding may lie in patient's conceptions of 'efficacy'.
For example, an "effective" medicine may be one which cures completely. Thus a
medication which prevents deterioration of an already compromised health status, may be
necessary or even essential but not effective. Further work is needed to explore this in
more detail.
The Specific-Concerns construct comprises aspects of both emotional (eg "Having to take my
medicines worries me") and cognitive ("My medicines are a mystery to me") representation
and thus may provide access to both aspects of the parallel processing described by
Leventhal in the SRM (Leventhal et al, 1980)
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These preliminary findings obtained by PCA of specific beliefs will be discussed in more
detail in Section 7. 1.4 which provides a general discussion of the results obtained for the
PCA of specific and general beliefs and the PCA of combined of specific and general items
7.1.2. Analysis 2: PCA of Beliefs about medicines in general (General)
7.1.2.1 Method
Participants The 6 chronic illness groups comprising the main sample described in Section
6.3:
Measures The 18 items dealing with beliefs about medicines in general included in the
poll of 34 items representing commonly held beliefs about specific and general medication.
Described in Section 7.1.1. and shown in Table 7.1
Principal Component Analysis (PCA) was performed as described in Section 7.1.1
Procedure: The rationale for limiting initial exploratory factor analysis of specific items to
a single illness group did not apply to beliefs about medicines in general. Here, the aim was
to explore representations of medication as a broad concept, rather than beliefs which
might be unique to a particular illness group. In an attempt to obtain a factor structure
which was representative of patients with a range of chronic illnesses, data obtained from
three diagnostic groups (asthma, diabetes and haemodialysis) were amalgamated and
subjected to an exploratory PCA. The reason for selecting these particular diagnostic
groups for combination was that the cardiac and general hospital samples were derived
from the same population of hospital in-patients. Data was combined in order to
investigate themes underlying beliefs about medicines in general which would be common
across chronic illness populations. Thus combining the cardiac and general medical
inpatient samples may have reduced the 'scope' of the sample. The factor structure
obtained from the amalgamated data set (asthma, diabetes, renal samples) was verified by
investigating the extent to which the structure could be replicated when the factor items
were entered in 3 separate PCAs using data from the individual cardiac, general medical
and psychiatric samples.
7.1.2.2 Results: PCA of General medication beliefs
Eighteen items (shown in Table 7.1) eliciting beliefs about medicines in general were
entered into exploratory PCA in combined sample (n224) of asthma (n=78), diabetic



















Appendix 9. A factor structure could not be obtained within 25 rotations. Elimination of 8
items, shown in Table 7.4 below, which had a low KMO statistic (<0.7) and setting a two
factor solution as suggested by scree plot analysis, resulted in a 2-factor solution explaining
49% of the variance.
Table 7.4 Beliefs about medicines in general items rejected on the basis












Without medicines doctors would be less able to cure people
Newer medicines are more effective than older ones
Medicines only work if they are taken regularly
Stronger medicines are more dangerous than weaker medicines
Medicines are a necessary evil
There is a big difference between a medicine and a drug
The medicine you get is more important than the doctor you see
Most medicines are safe
Two items with low or diffuse factor loadings were omitted ("It is better to do without
medicines"; "Medicines are not natural remedies"). Entry of the 8 remaining items into PCA,
setting Eigenvalue = I, produced a 2-factor solution in 7 iterations, explaining 49% of the
variance. Cleaning the data by removal of 5 cases (Malanobis distance >3 standard
deviations from the multi-dimensional mean and cases with greater than five missing items)
increased the variance explained to 53%. The final factor structure is shown in Table 7.5.
Table 7.5 Factor structure obtained by PCA of BMQ-General items (n =
219 patients with chronic illnesses-asthma = 77, diabetes = 99,
haemodialysis recipients = 42)*
STRUCTURE MATRIX: 	 Factor I Factor 2
Principal components analysis with non--orthogonal (OBLIMIN) rotation.
	 General- General-
Overuse Harm
If doctors had more time with patients, they would prescribe fewer medicines
Doctors use too many medicines
Doctors place too much trust in medicines
Natural remedies are safer than medicines
Medicines do more harm than good
People who take medicines should stop their treatment for a while every now
and again
Most medicines are addictive
All medicines are poisons
Eigenvalue
Percentage variance explained
* Five cases were removed during the cleaning procedure
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Factor labels The first factor comprised items expressing beliefs about the way in which
medicines are used by doctors. The essence of this factor, labelled General-Overuse is the
notion that medicines are over-prescribed by doctors who place too much trust in them.
The second factor, labelled General-Harm concerns the potential of medication to harm.
Representations of medication as harmful, addictive, poisons appears on the same factor as
the belief that people who take medicines should stop their treatment every now again.
Replication of factor structure The factor structure was confirmed on cleaned data
from the cardiac group (n= I I 6) and the psychiatric outpatients (n=86) as shown in
Appendix 9. The factor structure obtained for the cardiac, psychiatric and combined
(asthma, diabetes, renal) samples contained identical items, although there were minor
differences in individual factor loadings. PCA of the data from the General Medical in-
patients, produced a similar factor structure, with the exception of one item: "Natural
remedies are safer than medicines" which had migrated from factor I to factor 2 as shown in
Table 7.6.
Table 7.6 Factor structure obtained by PCA of data from the General
Medical In-patient sample (n90)
STRUCTURE MATRIX: 	 Factor	 Factor 2
Principal components analysis with non--orthogonal (OBLIMIN) rotation.
	 General-	 General-
Harm	 Overuse
Most medicines are addictive 	 .71	 -.15
Medicines do more harm than good	 .68	 -.12
Natural remedies are safer than medicines 	 .65	 -.18
All medicines are poisons 	 .57	 -.10
People who take medicines should stop their treatment for a while every now
	 .43	 -.34
and again
If doctors had more time with patients they would prescribe fewer medicines
	 .12	 -.84
Doctors use too many medicines	 .19	 -.74
Doctors place too much trust on medicines 	 .22	 -.72
Eigenvalue	 2.33	 1.42
Percentage variance explained	 29. I	 17.8
7.1.2.3 Discussion
A simple, stable factor structure was obtained. The fact that the PCA factor structure
obtained in the combined sample was replicated on two other illness samples suggests that
the factors represent 'core themes' underlying common representations of medicines in
124
general. However, an exact replication of the factor structure was not obtained in the
general medical inpatient sample indicating that the General-Harm factor may have low
stability. This is discussed in more detail in Section 7.2 when the psychometric properties
of the factors are evaluated as components of the Beliefs about Medicines Questionnaire
(BMQ).
The arrangement of individual beliefs to form core representations of medicines in general
merits comment at his stage. The item "Medicines do more harm than good" had a high
loading on the General-Harm factor. The importance of this concept in treatment
cognitions is reinforced by an earlier study in which a similar Likert scale statement,
"Medicines do as much harm as good", was the highest loading item on a factor representing
Negative attitudes towards the profession of medicine, which included beliefs about
doctors, medicines and doctors' use of diagnostic tests and investigations (Marteau, I 990).
Furthermore it is notable that the item "People taking prescribed medication should stop their
treatment every now and again" is linked with a representation of medication as essentially
harmful, addictive poisons. The phenomenon of deliberately stopping medication was
noted by Morgan and Watkins (1988) in their qualitative study of British hypertensive
patients some of whom explained this activity as being necessary to avoid becoming too
dependent on or addicted to the medicines. The fact that these items factor together is
indicative of a coherent and complex representation of medication - the harmful effects of
medication are increased if it is taken continuously and so one should give the body a
break every now and then.
Considering the General-Overuse representation it may appear surprising that the belief that
"Natural remedies are safer than medicines" loads on this factor, as this statement seems to
relate to the intrinsic nature of medicines rather than the way in which they are used.
However, for all but one of our samples this item was associated with the General-Overuse
construct A possible explanation is that this construct represents a concept of treatment
which is essentially anti-medication and pro "natural remedies". In this representation the
belief that medication is overused by doctors is consistent with the view that natural
remedies as less harmful and implicitly more favourable than medicines. This may be
analogous to the first cluster obtained by Echabe and colleagues in their study of illness
and medication representations in which, health was represented as a balance between
body and mind and medicines were viewed negatively (Echabe et al. 1992).
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Although the clear factor structure obtained in all but one of the samples supports the
inclusion of this item in the General-Overuse factor, the fact that, in one sample, this item
migrated to the General-Harm factor warrants further investigation, and this is discussed in
more detail later in Section 6.4..
The absence of a "benefit" dimension
At first sight it may surprising that both general factors contain items relating to aspects of
medication which are essentially negative. A coherent "benefit" dimension did not emerge
from our original items. This may be because the items we used were not representative
of an underlying dimension of "benefit". Alternatively, it may simply be that a clear
representation of benefit is obscured by strong beliefs about the potential for harm. It is
salient that in most of the studies from which the source items were derived, the benefit
of medicines was often taken for granted. People who had generally negative views about
medication tended to cite the potential for harm, rather than the lack of "efficacy" or
"benefit" as a focus for their concerns about medication (Conrad, I 985; Morgan and
Watkins, I 988) and other authors have remarked on this (Britten, I 994).
At first sight, the representations of medicines in general described above seem to amount
to a rather negative view of medicines as harmful and overused by doctors. However, it is
important to bear in mind that this does not necessarily mean that most people see
medicines in this way. People can disagree with the statements on each factor and so
express a view of medication as essentially safe and appropriately used. The main point
here is that PCA has shown that certain beliefs link together to form coherent core
representations. In other words people seem to organise their ideas about medicines
(addiction, poison, harm, regular long term use) into coherent themes or components.
Although the specific content will vary between individuals (e.g. one sees medicines as
harmful and addictive, another thinks they are generally safe and non-addictive), the
components are consistent
7.1,3 PCA of combined Specific and General factor items
This analysis was designed to addressed the question of whether ideas about personal
prescribed medication (Specific) and medicines in genera! occupy separate cognitive
dimensions. This was tested by combining the items loading on the Specific and General
factors and entering them in a single PCA. The degree to which items separated into their
original factors could be used as indicator of the stability of the factors. It would also serve
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as a preliminary investigation of the extent to which patients tended to distinguish between
medication prescribed for them and medicines in general. A high degree of separation
between general and specific items would indicate that patients made clear distinctions
between specific and general medication.
7.1.3.1. Method
Participants The 6 chronic illness groups comprising the main sample described in Section
6.3:
Measures The 18 items loading on the 4 factors obtained by PCA of specific and general
medication beliefs described in Sections 7.1 . I and 7.1.2 above. The psychiatric and diabetic
samples had originally received only 16 and I 5 and of these items. Although they received
identical General items as the other illness groups , they received a slightly different set of
Specific belief items as shown in Table 7.7 below. The set of Specific beliefs items (16 in
total) administered to the psychiatric sample differed by one item and from that
administered to the asthma, cardiac, renal and general medical samples (shown in Table
7. I). The set which the diabetic patients received differed by two items. The items
concerned are shown in Table 7.7 below
Table 7.7 Differences in the pooi of Specific medication belief administered to
the psychiatric and diabetic samples (see table 7.1 for the full set of items)
Item omitted from the pool	 Item replacing it
Psychiatric sample (n=89)
. Without my medicines I would be very ill'	 • Only my medicines can control my mental health
Diabetic sample (n=99)
• My life would be impossible without my	 • My insulin* controls my diabetes
medicines'
• My medicines protect me from becoming	 • Insulin prevents my blood sugar from becoming low
worse'
* For tablet-treated diabetic patients the term 'insulin' was replaced 'medicines'
The above difference in the item pools arose from limitations of space within the study
questionnaire. In an effort to investigate issues which were thought to be particularly
pertinent to the diabetic and psychiatric diagnostic groups, they received a slightly different
set of Specific medication items from those administered to other illness samples.
Principal Component Analysis (PCA) was performed as described in Section 7.1.1
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Procedure Data from all six illness groups comprising the main sample was pooled.
Responses to the 18 items loading on the final general and specific factors described above
were combined and entered into a PCA with non-orthogonal (OBLIMIN) rotation, setting
a 4-factor solution. As mentioned above the psychiatric and diabetic samples had not
received two of the items loading on the Specific-Necessity construct. Thus, items which
were unique to these groups (shown in Table 7.7) were omitted from the analysis and
replaced with the mean score of the remaining items loading on the Specific-Necessity
factor.
7.1.3.3 Results of PCA of combined Specific and General factor items
PCA of pooled data from all 6 illness samples showed a clear separation of Specific and
General items. A 4-factor structure was obtained which closely resembled the original
Specific and General factor structures except that one item from the Specific-Concerns
factor 'My medicines are a mystery to me', loaded marginally higher on the General Harm
(0.55) than on Specific-Concerns (0.39). The factor structure obtained in shown in Appendix
10. Removal of the General Medical sample (n90) from the data set followed by a further
PCA on pooled data from the discreet diagnostic groups (asthma, diabetes, renal, cardiac
and psychiatric) yielded the factor structure shown in Table 7.8. which replicated the
original Specific and General factor structures.
7.1.3.4 Discussion of PCA of combined Specific and General items
The separation of items into the original factor structures offers preliminary support to
the notion that pateitns ideas about specific and general medication are well differentiated.
The apparent instability of one item 'My medicines are a mystery to me' may be an artefact
limited to the general medical sample. However, studies are necessary to clarify this point.
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Table 7.8 Structure matrix obtained by PCA on combined items from
the Specific and General medication belief factors*
ITEM	 Factor I	 Factor 2	 Factor 3:	 Factor 4
S refers to medicines prescribed for a specific illness 	 Specific	 Specific	 General	 General-
G refers to medicines in general	 Concerns Necessity Harm	 Overuse
S Having to take this medicine worries me
S I sometimes worry about becoming too dependent on my
medicines
S I sometimes worry about the long term effects of my medicines
5 My medicines are a mystery to me
















S My health, at present, depends on medicines
S My life would be impossible without medicines
S My health, in the future, will depend on medicines
S Without medicines I would be very ill
5 My medicines protect me from becoming worse
G Most medicines are addictive
G Medicines do more harm than good
G All medicines are poisons
G People who take medicines should stop their treatment for a
while every now and again
	
.03	 .79	 -.05	 -.09
	
.03	 .77	 -.14	 -.07
	
-.05	 .74	 -.09	 -.01
	
-.03	 .67	 -.12	 .07
	




.09	 -.12	 .77	 .17
	
.24	 -.15	 .73	 .19
	
.15	 -.18	 .63	 .35
G If doctors had more time they would prescribe fewer medicines
G Doctors place too much trust in medicines
G Doctors use too many medicines
















Percentage variance explained	 20.0	 14.0	 9.4	 7.6
Cumulative percentage variance explained 	 20.0	 34.0	 43.4	 5 1.0
*(pooled data from asthma, diabetic, renal cardiac and psychiatric samples n=433)
7.1.4 General discussion of PCA results
The key finding of the three PCA analyses was the attainment of a simple factor structure
for general and specific beliefs about medication. Although differences in the Eigenvalues
and the factor loadings of individual items were observed in different data sets, these were
as expected when using an iterative technique such as PCA (Cattell, I 995; Kline, 1994).
Moreover, variations in Eigenvalue and factor loadings did not change the interpretation of
the factors. Items loading on the individual factors were related in a logically coherent way
and the factors could be easily labelled. The identification of core dimensions of specific
and general representations of medication provided an insight into how patients from a
range of chronic illness groups were thinking about medication. However, a number of
outstanding questions arise from the limitations of this study.
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Limitations of the findings and implications for future research
The purpose of this study was to establish whether it was possible to identify discreet
dimensions in the cognitive representation of medication prescribed for personal use and
medicines in general. The stability of the factor structure described above suggests that
this was achieved. However, at this stage, it is worth pausing to consider the limitations of
PCA as a method of establishing the components of cognitive representation. PCA and
factor analytic techniques are designed to identify underlying factors which account for the
observed correlation between items. The aim is to obtain simple factor structures
comprising "core" items which are stable across data sets. In order to achieve a simple
structure, several interesting items were omitted from the analysis. The items were
derived from interviews with patients and are thus beliefs which are held by at least some
people. Thus the factors identified by the PCA described above are core dimensions rather
than the only components of medication representation. These issues were discussed in
more detail in Chapter I 0.
A further limitation of this study is that Specific statements related to the prescribed
regimen as a whole rather than the individual medicines. The participants were being asked
to provide a composite view of their treatment as a whole. The fact that no patients
reported difficulty or reluctance in doing this, may indicate a tendency to form a
"composite view of prescribed medication". However, we do not know how such a view is
formed or the degree to which patients' beliefs about Specific-Necessity and Specific-
Concerns vary between individual components of the regimen. Thus an important question
which was not addressed in this preliminary study is whether patients form beliefs which
are specific to individual medicines (e.g. aspirin) or types of medication (e.g. analgesics) and
how such beliefs might relate to the core dimension of Necessity and Concerns. For
example, patients may have concerns about particular medicines which are distinct from
the beliefs about dependence, long-term effects and disruption which comprise the Specific-
Concerns dimension. One example may be the notion that analgesics loose their efficacy if
taken regularly for long periods of time (Donovan and Blake, 1992; Lorish et al. I 990).
The discovery of core dimensions of medication beliefs leads us to question the extent of
inter- and intra-individual variation in these constructs and whether they are related to
other key variables such as illness beliefs and behaviours such as adherence to treatment
Furthermore, a basic question concerns the determinants of these core beliefs. For
example, to what extent are they influenced by the socio-demographic characteristics of
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the patients or by beliefs about illness. These issues are addressed in more detail in
Chapters 8 and 9.
PCA identified core dimensions underlying beliefs about medication which are common to
patients from several diagnostic groups and across a range of age and educational
characteristics. The isolation of a simple, stable, 4-factor structure provides a focus for
further investigations. The following section details the evaluation of the psychometric
properties of these factors as components of the Beliefs about Medicines Questionnaire
(BMQ).
7.2 Development of the Beliefs about Medicines
Questionnaire (BMQ)
The Principal Component Analyses described in the previous sections served two
purposes. The first was to increase our understanding of the way in which representations
of medication are cognitively structured. A second was to simplify the range of medication
beliefs, reported in the literature and identified in interviews with patients, into core
themes to form the basis of a questionnaire-based method for the quantitative assessment
of representations of medication. The core factors identified by PCA were therefore used
to compile an 18-item Beliefs about Medicines Questionnaire (BMQ) which provided an
assessment tool for further studies investigating the distribution and effects of medication
beliefs in chronic illness, described in Chapters 8 and 9. This section presents
psychometric data for the BMQ.
7.2.1 Description of the Beliefs about Questionnaire (BMQ)
The BMQ comprises the items loading on the final 4 factors, obtained by PCA of the 34
statements assessing specific and general medication beliefs, as described in the previous
section. The questionnaire is therefore split into two sections.
(a)	 The BMO-Specific assesses patients' beliefs about medication prescribed for
personal use in the treatment of their particular illness and comprises two 5-item
scales assessing personal beliefs about the necessity of prescribed medication for
maintaining health (Specific-Necessity) and concerns about prescribed medication
arising from beliefs about long-term adverse effects, the potential for dependence
and the disruptive effects of taking medication (Specific-Concerns).
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(b) The BMQ-General comprises two 4-item scales which deal with more general views
about medicines as a whole. The General-Overuse scale addresses views about the way
in which medicines are used by doctors and assesses personal beliefs about the extent
to which doctors place too much emphasis and trust in medicines and that natural
remedies are a safer alternative. The General-Harm scale assesses beliefs about the
nature of medicines and the degree to which they are perceived as harmful, addictive
poisons which should not be taken for long periods of time.
The BMQ items are shown in Table 7.9.
7.2.1.1 Scoring system for the BMQ
Respondents indicate their degree of agreement with each individual statement about
medicines on a 5 point Likert scale, where 1 = strongly disagree, 2 = disagree, 3 =
uncertain, 4 agree and 5 = strongly agree. Scores obtained for the individual items within
each scale are summed to give a scale score. Thus total scores for the BMQ-Specific scales
(Specific-Necessity and Specific-Concerns), range from 5 to 25. The BMQ-General scales
(General-Overuse and General-Harm) range from 4 to 16. Higher scores indicate stronger
beliefs in the concepts represented by the scale.
Factor scores were obtained by summing scores for the individual items loading on the
factor to form an ordinal scale. The resultant scores gave an indication of the strength of
belief in the dimension represented by the factor with high scores indicating stronger
beliefs. A further method for differentiating between individuals on the basis of their
medication beliefs was that those obtaining scores above the mid-point value of the scale
could be said to be in general agreement with the concepts represented by the statement.
BMQ-Specific scores range from 5-25. BMQ-General scores range from 4-20.
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Table 7.9 The Beliefs about Medicines Questionnaire (BMQ), showing
scale items
BMQ-SPECIFIC
-assesses beliefs about prescribed medication
Specific-Necessity	 Specific-Concerns
Beliefs about the necessity and efficacy of medicines	 Concerns about the harmful effects of medicines
prescribed for specific condition	 prescribed for specific condition
• My health in the future will depend on my medicines • Having to take my medicines worries me
• My health, at present, depends on my medicines 	 • I sometimes worry about the long-term effects of
my medicines
• My life would be impossible without my medicines	 • I sometimes worry about becoming too dependent
on my medicines
• Without my medicines I would be very ill 	 • My medicines are a mystery to me
• My medicines protect me from becoming worse	 • My medicines disrupt my life
BMQ-GENERAL
- assesses beliefs about medicines in general
General-Overuse	 General-Harm
Beliefs that medicines in general are over-used by	 Beliefs that medicines in general are harmful
doctors	 addictive poisons
• If doctors hod more time with patients they would
• Most medicines are addictiveprescnbe fewer medicines
• Doctors use too many medicines	 • Medicines do more harm than good
• Doctors place too much trust on medicines 	 • People who take medicines should stop their
treatment for a while every now and again
• Natural remedies are safer than medicines 	 • All medicines are poisons
7.2.2 Rationale for the evaluation of the BMQ
The BMQ factors, derived in Study I, represented constructs which could be easily
measured by summing Likert scale responses scores obtained for each item loading on a
particular factor (Kline, 1994), to obtain a composite factor score. A quantitative
evaluation of the psychometric properties of the questionnaire could thus be conducted on
the basis of inter-relations between factor scores and other variables.
Reliability: Before the BMQ scales could be used as a basis for further exploration of the
nature, determinants and effects of medication beliefs, it was necessary to demonstrate
two aspects of reliability. The scales should have an acceptable internal consistency
demonstrating that the items loading on each factor related to a single construct as well as
acceptable test-retest reliability.
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Criterion-Related Validity: Due to the lack of validated instruments for assessing
medication beliefs concurrent validity was evaluated on the basis of associations between
BMQ scales and other single items assessing views about prescribed and general
medication. The assessment of the criterion-related validity of each of the BMQ scales was
based on the following hypotheses:
Specific-Necessity:
I. Strong necessity beliefs would be negatively correlated with 'Perceived ability to cope
without medication'. Thus Specific-Necessity scores would be negatively correlated with
scores on the item: 'I can cope without my medicines').
2. Beliefs in the necessity of medication would be related to perceptions of illness. In
particular, patients who believed that their illness would last a long time and who
experienced more symptoms would have stronger beliefs in the necessity of the
medication prescribed to treat it. Thus Specific-Necessity scores would be positively
correlated with scores on the Identity and Timeline components of the IPQ (described
in section 6.4.1) which respectively assess perception of symptom severity and likely
duration of the illness.
Specific-Concerns
I. Patients with stronger concerns about their prescribed medication would be more
distrustful of it. Thus scores on the Specific-Concerns scale would be positively
correlated with scores on the 'Lack of trust in prescribed medication' measure described
in Section 6.4.8.
2. Patients with stronger concerns about their prescribed medication would be more
likely to want more information about it as information seeking may be a common
response to illness-related anxiety (Weinman, I 990). Thus scores on the Specific-
Concerns scale would be negatively correlated with scores on the 'Satisfaction with
amount of medicines information received' measure described in Section 6.4.8.
3. Patients with stronger concerns about their prescribed medication would be more
likely to want to change their treatment. Thus scores on the Specific-Concerns scale
would be positively correlated with scores on the 'Desire to change present treatment'
item shown in Table 7.10 below.
4. Patients who perceived themselves to be susceptible to potential adverse effects of
medication would have stronger concerns about medication prescribed for them. Thus
scores on the Specific-Concerns scale would be positively correlated with scores on the
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'Sensitive Soma Scale' described in Section 6.4.8, which assess perceptions of personal
sensitivity to the adverse effects of medication
General-Harm
I. A belief that medicines in general are intrinsically harmful wou'd be positively associated
with the view that it is better to avoid taking them. Thus scores on the General-Harm
scale would be positively correlated with scores on the 'It is better to do without
medicines' item shown in Table 7. 10 below.
2. Patents who believed that medicines in general are intrinsically harmful would be more
inclined to the view that they could cope without them. Thus scores on the General-
Harm scale would be positively correlated with scores on the 'I can cope without my
medicines' item shown in Table 7.10 below.
3. Patients who believed that medicines in general are intrinsically harmful would be more
likely to consider themselves to be susceptible to potential adverse effects of
medication. Thus scores on the General-Harm scale would be positively correlated with
scores on the 'Sensitive Soma Scale' described in Section 6.4.8, which assess perceptions
of personal sensitivity to the adverse effects of medication
General-Overuse
I. Patents who believed that medicines in general are overused by doctors would be more
inclined to the view that they could cope without them. Thus scores on the General-
Overuse scale would be positively correlated with scores on the 'I can cope without my
medicines' item shown in Table 7.10 below.
2. A belief that medicines in general are overused by doctors would be positively
associated with the view it is better to avoid taking them. Thus scores on the General-
Overuse scale would be positively correlated with scores on the 'It is better to do without
medicines' item shown in Table 7. 10 below.
Discriminant Validity: The discriminant validity of the BMQ-Specific scales was tested on
the basis of their ability to distinguish between different illnesses and hence treatment
modalities. The discriminant validity of the BMQ-General scales was tested on the basis of
their ability to distinguish between patients presenting a personal prescription at a




Specific-Necessity scores would be influenced by the type of treatment typically prescribed
for the illness. The characteristic effects of medication on symptoms may be particularly
important. For example, diabetic patients who fail to take their treatment may become
severely ill very quickly. Asthma medication often produces symptom relief which the
patient can clearly relate to taking of the medication. Similarly, omitting medication may
quickly result in adverse symptoms. Conversely, patients receiving medication for mental
health related problems may perceive a much more tenuous link between their medication
and concrete benefit in terms on symptoms. Thus it was hypothesised that
I. Specific-Necessity scores would discriminate between patients from different diagnostic
groups. In particular, diabetic patients would have higher scores than asthma patients
who in turn would have higher mean Specific-Necessity scores than psychiatric out-
patients
Specific-Concerns
Asthma treatment often incorporates corticosteroids. This is a large group of compounds,
some of which may produce adverse side effects. Additionally, other members of this
group are frequently misused in sport. In short, this class of drugs has a high "media-
profile" and patients' concerns could be influenced by this, particularly if they fail to
differentiate between steroids they are taking for asthma (which are generally inhaled and
therefore less "dangerous") and more potent formulations upon which media attention is
often focused. Similarly, psychiatric out-patients are often treated with "tranquillisers",
which have received adverse media attention (Cohen, I 983). Thus it was hypothesised
that
I. Specific-Concerns scores would discriminate between patients from different diagnostic
groups. In particular, asthma and psychiatric patients would have higher mean Specific-
Concerns scores than other illness groups.
General-Harm and General-Overuse
People who believe that medicines in general are intrinsically harmful substances which are
overused by doctors may be more inclined to seek care alternative methods of treatment.
I. The hypothesis used to test the discriminant validity of the BMQ-General scales was
that people seeking care from a homeopathic or herbal clinic would have higher mean
scores on the General-Harm and General-Overuse scales than those presenting a personal
prescription for dispensing by a community pharmacist
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7.2.3 Method used for the validation of the BMQ
Participants
• The 6 chronic illness groups comprising the main sample described in Section 6.3.
The Allopathic/Complementary care sample described in section 6.3.2.3.
Measures
• The Beliefs about Medicines Questionnaire (BMQ), described in section 7.1.
• The Illness Perception Questionnaire (IPQ) (Weinman et al, I 996- see Section 6.4.1)
• Measures of medication-related cognitions, shown in Table 7.10 above.
• Satisfaction with amount of medicines information received, described in Section 6.4.8.
• Lack of trust in prescribed medication, described in Section 6.4.8.
• The Sensitive Soma scale described in Section 6.4.7.
The psychometric evaluation of the BMQ utilised three of the single item statements from
the original 34-item pool described in section 7.1.1. The items had not loaded on the BMQ
factors and so did not represent a Specific-Necessity, Specific-Concern, General-Harm or
General-Overuse cognition. However, they seemed, at face value, to represent interesting
medication related cognitions as shown in Table 7.10. and so were retained for further
analysis.
Table 7.10 Items assessing medication-related cognitions which were retained
for further analysis
Item for original pool (see Table 7.1)
	 Medication-related cognition which item assess
. I would like to change my present treatment	 Dissatisfaction with present treatment
I con cope without my medicines	 Perceived ability to cope without prescribed medicines
• It is better to do without medicines	 General reluctance to use medicines
It was thought that these items could be used to test the criterion-related validity of the
BMQ factors. For example, a belief that one can cope without a medicine is likely to arise
from a rather complex cognitive process involving beliefs about illness, and perceived self-
efficacy as well as beliefs about the medicine itself. (Thus this item is clearly not just a
medication belief). However, it seems likely that a patient's perception of their ability to
cope without a medicine would be related to their belief in the necessity of that medication.
Thus the 'Perceived ability to cope without prescribed medication' construct could be used
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to test the Criterion-related validity of the Specific-Necessity factor as in the following
section. Three psychometric properties of the BMQ were evaluated. These were
reliability, criterion-related validity and discriminant validity.
Procedure
It is important to note that much of the psychometric evaluation presented here, was
conducted on the same data set from which the questionnaire was derived and which was
subsequently used for further analyses investigating the distribution and effects of
medication beliefs. The psychometric evaluation was conducted on the basis of interactions
between the BMQ factors and the above measures which had been administered to the
main sample at the same time as the pool of mediation belief items from which the BMQ
was derived.
The AllopathidComplementary Care sample were recruited after the BMQ had been
derived from the main sample (as detailed in Chapter 6). Only the 8-item BMQ-General
(comprising the General-Overuse and General-Harm scales) was administered to this sample.
The Sensitive Soma Scale was not available when the asthma, diabetic, renal and psychiatric
samples were recruited. The scale was however available when the cardiac and general
medical samples were recruited a few months later. Thus different samples were used to
evaluate different psychometric properties.
• The internal reliability of the scales was evaluated for all 6 illness groups comprising the
main sample
• Test-retest reliability was evaluated using the asthma sample. Repeat questionnaires
were sent to the patient, together with a stamped addressed envelope, two weeks
after they had been seen in clinic.
• Criterion-related validity of the BMQ-Specific scales was evaluated using the asthma
sample, except for interaction between the Specific-Concerns and Sensitive Soma scales
which were evaluated using the general medical inpatient samples
• The discriminant validity of the BMQ-Specific scales was evaluated in the main sample




• The internal consistency of the BMQ scales was evaluated using Cronbach's alpha
• The test-retest reliability was evaluated on the basis of Spearman correlations between
initial and repeated test scores for each scale.
• The hypotheses for criterion-related validity of the BMQ factors were tested using
Spearman (rho) correlation coefficients.
• Differences between BMQ- Specific and General scores across illness samples were
assessed using a series of one-way analysis of variance (ANOVA), followed by post-hoc
Tukey's HSD test Mukivariate analysis of variance (MANOVA) was not used for
analysis of differences in measures due to the moderate level of intercorrelatjon
between Specific-Concerns and General-Harm (rhoO.3 I; n=524: p,O.O I) and General-
Overuse (rhoO.24; n=524; p,O.O I).
• Differences in mean BMQ-General scores between Allopathic and Complementary
care seekers was assessed using an Independent samples t-test. A single tailed test was
used as the direction of association had been specified within the relevant hypothesis.
7.2.4. Results
7.2.4.1 Reliability and scale intercorrelation
Cronbach alpha values obtained for each of the diagnostic group are shown in Table 7. I I.
These data indicate that both the BMQ-Specific and the BMQ-General scales have
satisfactory internal consistency, with the exception of the General-Harm scale in three of
the diagnostic groups.







Clinic	 Clinic	 Haemo-	 in-	 out-patients
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(n=47)	 (n1 16)
	0.80	 0.74t	 0.55	 0.76	 0.74$
	
0.75	 0.80	 0.73	 0.76	 0.63
	
0.74	 0.80	 0.77	 0.74	 0.73
	










The diabetes and psychiatric out-patient samples completed shortened versions of the Specific-Necessity scale
(t4 items; 3 items)
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As previously described, the psychiatric and diabetic samples were not used included in the
PCA from which the BMQ-Specific scales were derived as they had received a slightly
different pool of items assessing specific beliefs (see Section 7. I .3. I for details). As both
the psychiatric and diabetic samples had received all the items which subsequently
comprised the Specific-Concerns scale Cronbach alpha values could be calculated for this
scale. However, only 3 of the 5 Specific-Necessity items were included in the original item-
pool administered to the diabetic sample and 4 of the 5 were included in the pool originally
administered to the psychiatric sample. Therefore, for the psychiatric and diabetic samples
Cronbach alpha values were calculated for a 3 and 4-item Specific-Necessity scale
respectively. A total of 31 of the asthma (n78) returned the repeat questionnaires, giving
a 40% response rate. The correlation coefficients shown in Table 7. I I indicate that the
test-retest reliability of the scales is within accepted limits.
7.2.4.2 Criterion-related validity
Specific-Necessity
I. Evidence for the criterion-related validity of the Specific-Necessity scale was provided by
the negative correlation between scale scores and responses to the statement: "I can
cope without my medicines" (rho = -0.44; n = 78; p<O.00l) as expected.
2. The hypothesis that patients who believed that their illness was a chronic condition and
those who reported more severe symptoms would have stronger beliefs in the
necessity of their asthma medication was confirmed by positive correlations between
Specific-Necessity scores and scores on the IPQ Timeline (rho = 0.49; n = 77; p<O.00I)
and Identity (rho = 0.24; n = 76; p<O.OS) scales which measure perceived duration and
subjective symptomatology of the illness.
Specific-Concerns
I. The hypothesis that patients with stronger concerns about their prescribed medicines
would be more distrustful of it was confirmed by the positive correlation between the
Specific-Concerns scale and the statement 'I cannot always trust my medicines' (rho = 0.33;
n= 78; p<O.005)
2. The hypothesis that Specific-Concerns would be associated with a desire for more
information about medicines was confirmed by the significant negative correlation
between the Specific-Concerns scale and the statement 'I have been given enough
information about my medicines' (rho = -0.45; n = 78; p<O.00I)
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3. The hypothesis that Specific-Concerns would be associated with dissatisfaction with
treatment was confirmed by significant positive correlation between Specific-Concerns
scores and responses to the statement "I would like to change my present treatment"
(rho = 0.37; n = 78; p<O.00I).
4. As hypothesised, significant positive correlation were obtained between Specific-
Concerns and beliefs about personal sensitivity to the adverse effects medication as
assessed by the Sensitive-Soma scale (rho = 0.5, n= 91, p<O.00I)
General-Harm and General-Overuse
I. Correlation between General-Harm scores and responses to a single item statement "It
is better to do without medicines" was as expected.
2. Responses to the statement "I can cope without my medicines" correlated, in the
predicted direction, with both the General-Harm (rho = 0,23; n = 77; p<O.O5) and
General-Overuse scales (rho = 0.34; n = 78; p<O.00S).
3. Correlations between the General-Harm and Sensitive-Soma scales (rho = 0.25, n 91,




Table 7.12 shows the results of a series of one-way analysis of variance (ANOVA),
followed by post-hoc Tukey's HSD test in which mean scores on the BMQ scales were
compared across illness samples. It can be seen that the BMQ scales were able to
distinguish between patients on the basis of illness (and treatment) groupings. The
hypothesis for discriminant validity of the Specific-Necessity' scale were confirmed by the
finding that diabetic group had significantly higher Specific-Necessity scores than all other
groups and the asthma patients had significantly higher scores than the psychiatric
outpatients who attained the lowest mean as predicated.
As was expected, the asthma and psychiatric samples had significantly higher Specific-
Concerns than the other illness groups, supporting the discriminant validity of this scale.
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Table 7.12 Scale means and standard deviations for BMQ scales for the
six illness groups comprising the main sample
Note: Means sharing a common subscript are not significantly different by HSD test (p>O.OS).
BMQ-General scales
As was hypothesised, patients attending Complementary clinic (Homeopath/herbalist) had
significantly higher scores on both the General-Overuse and General-Harm scales than those
presenting a personal prescription for dispensing at a community pharmacy,as shown in
Table 7.13.
Table 7.13 Group differences in BMQ-General scores for matched
samples of orthodox and complementary patients
Measure	 Allopathic	 Complementary	 t	 p
(n36	 (n36	 (df70)	 (I-tail
G-Overuse	 Mean	 12.44	 I 6.56	 5.89	 <0.001
SD	 3.26	 2.62




Measures of internal consistency and test-retest reliability of the BMQ were encouraging
as was the criterion-related and discriminent validity data. Expected correlations were
obtained between BMQ scale scores and other measures of illness and medication beliefs
and between Specific-Concerns and self-reported adherence to medication. The BMQ scales
were able to distinguish between different illness groups/treatment modalities, between
particular adherence behaviours and between users of allopathic and complimentary
therapies.
The scope of this evaluation is limited by the fact that the BMQ was not compared against
other validated measures of medication beliefs. In the absence of such measures, single
item constructs of attitudes to specific and general medication were used to test criterion-
related validity. Although, the relationships between BMQ sub-scales and these items
support the criterion-related validity of the questionnaire, this data should be interpreted
with caution. Single item attitude scales may be less reliable than multi-item scales as they
may be influenced by context, order of items or mood of the respondent (Abraham and
Hampson, I 995). For example, the consistency in responses observed above may be
partially attributed to the respondent's ability to understand that certain constructs
logically belong together and a subsequent desire to appear consistent in their responses
(Budd, 1987). In an attempt to diminish the influence of "ordering effects" items were not
presented in "conceptual" order. For example, items expressing a particular view were,
not grouped together. In order to diminish any effects of perceived "social desirability" of
certain responses, questionnaire items were presented in a context which sanctioned the
respondents "personal views" and assured the anonymity and confidentiality of responses,
as described in Study I.
The evaluation of the validity of the BMQ was also limited by the absence of data testing
the predictive validity of the measure. This is currently being evaluated by examining inter-
relations between BMQ scales and the items described above separated over a 3-month
period.
Instability of the General-Harm sub-scale
The internal reliability of the General-Harm sub-scale was disappointing in three data sets
(asthma, cardiac and general medical). Examination of individual item alphas showed that
this could not be attributed to a single "rogue item" but was a true reflection of low
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internal consistency of all items. However in other data sets this scale had a fairly high
degree of internal consistency. The reason for this apparent disparity is unclear but seems
to support the premise that representations of medicines in general may be complex and
diffuse, and not easily grouped into coherent structures. People may have different views
about particular types of medication so that it becomes difficult to identify consistent core
representations about the nature of medicines as a whole. It may also indicate that patients
with certain illnesses tend to develop a clearer representation of medication in general,
which is perhaps influenced by their personal experience with prescribed medication.
The conclusion from this study is that, despite the clear limitations of the data described
above, they provide preliminary evidence for criterion-related and discriminant validity and
reliability of the BMQ and support its cautious use as a research tool within the context of
the studies described in this thesis.
7.3 The distribution of medication beliefs among patients
with chronic illnesses
This study comprises a series of analyses addressing the following research question:
How are the main specific and general medication beliefs distributed within and across
illness groups?
Previous studies described in this Chapter used PCA to identify core themes or factors
underlying a selection of commonly-held beliefs about specific and general medication and
the psychometric evaluation of these factors as scales comprising the BMQ. These studies
provide preliminary evidence that the BMQ scales represent the 'main beliefs' which the
sample of chronically ill patients held about prescribed and general medication. Scores on
the BMQ scales could now be used to identify the proportion of people holding these
beliefs and how strongly are they held
7.3.1 Method
Participants
• The 6 chronic illness groups comprising the main sample described in Section 6.3.
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Measures
• The Beliefs about Medicines Questionnaire (BMQ), described in Section 7.2, using both
the BMQ-Specific and BMQ-General scales
Procedure:
A series of analyses were conducted on the pooled cross-sectional data from the six illness
groups comprising the main sample This was the data set from which the BMQ had been
derived and evaluated.
Statistical techniques
• The distribution of scores on the BMQ Specific and General scales was examined by
frequency histogram.
• Cross-tabulation of BMQ-scale scores, dichotomised around the mid-point, was used to
evaluate the degree of overlap between the dimensions of medication beliefs,
represented by the BMQ factors.
• Spearman correlations (rho) were used to assess interrelations between the BMQ
Specific and General factors.
7.3.2 Results
Frequency distribution of scores on BMQ scales
The distribution of scores on the four BMQ scales are shown In Figure 7. I. An interesting
pattern emerged. Whereas beliefs about General-Overuse, General-Harm and Specific-
Concerns were normally distributed, Specific-Necessity scores were heavily skewed towards
the positive. As can be seen from Table 7.14, over 86.5% of the total sample of 524
patients, had higher than mid-point scores on the Specific-Necessity scale, indicating overall
agreement with the view that their prescribed medicines were necessary for health. These
percentages are much higher than those obtained for the Specific-Concerns (37.1 %), General-
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Table 7.14 Scores on BMQ scales assessing beliefs about specific
and general medication for six illness groups comprising the main
sample (n=524)
Variable	 Mean	 SD	 Percentage of subjects
attaining scores above scale
mid-point
Specific-Necessity	 19.4	 3.5	 86.5
Specific-Concerns	 14.3	 3.9	 37.2
General-Harm	 9.9	 2.7	 16. I
General-Overuse	 I 2. I	 2.9	 43.8
Relations between Specific and General medication belie ft
Spearman correlation coefficients between BMQ-General and BMQ-Specific scales are
shown in Table 7.15. The degree of overlap within the Specific and General scales was
examined by cross-tabulation of scale scores dichotomised at the scale mid-point. Table
7.1 6 shows a third of patients with strong beliefs in the necessity of their medication also
harboured strong concerns about it. Considering beliefs about medicines in general, Table
7.17 shows that half the sample had lower than mid-point scores on both the General-
Overuse and General-Harm scales indicating a generally benign view of medication and 10%
had a very negative view of medication with strong beliefs that medicines in general are
essentially harmful and overused by doctors.
Table 7.15 Spearman correlation between BMQ scales (n=5 19)
Specific-Necessity	 Specific-Concerns General-Harm
Specific-Concerns	 -0.01
General-Harm	 -0.05	 0.31 *
General-Overuse 	 -0.17	 0.24*	 0.40*
Note: *p<jO I
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Specific-	 1 = Scores < scale Count	 48	 21	 69
Necessity mid-point	 % within Specific-Necessity 	 69.6%	 30.4%	 100.0%
%within Specific-Concerns	 149%	 11.0%	 13.5%
%ofTotal	 9.4%	 4.1%	 13.5%
2 = Scores> scale Count	 274	 170	 444
mid-point	 o,/o within Specific-Necessity 	 61.7%	 38.3%	 100.0%
% within Specific-Concerns 	 85.1%	 89.0%	 86.5%
% ofTotal	 53.4%	 33.1%	 86.5%
Total	 Count	 322	 191	 513
% within Specific-Necessity 	 62.8%	 37.2%	 100.0%
	
% within Specific-Concerns 100.0%	 100.0%	 100.0%
% of Total	 62.8%	 37.2%	 100.0%







General-	 = < scale mid-point Count	 261	 29	 290
Overuse	 % within General-Overuse	 90.0%	 10.0%	 100.0%
%within General-Harm	 60.3%	 34.9%	 56.2%
%of Total	 50.6%	 5.6%	 56.2%
2 > scale mid-point Count	 172	 54	 226
%withinGeneral-Overuse	 76.1%	 23.9%	 100.0%
%within General-Harm	 39.7%	 65.1%	 43.8%
%ofTotal	 33.3%	 10.5%	 43.8%
Total	 Count	 433	 83	 516
within General-Overuse	 83.9%	 16.1%	 100.0%
%within General-Harm	 100.0%	 100.0%	 100.0%
%ofTotal	 83.9%	 16.1%	 100.0%
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7.3.3 Discussion
The frequency distribution of BMQ factor scores provides an interesting insight into the
way patients were thinking about medication. To begin with it is perhaps unsurprising that
the great majority of this sample of chronically ill patients had strong beliefs in the
necessity of their prescribed medication. However, approximately a third had clear
concerns about their prescribed medication based on beliefs about dependence, long-term
effects and the disruptive aspects of taking medication. Furthermore cross-tabulation
showed a considerable overlap between necessity beliefs and concerns, in that 33% of
those with strong beliefs in the necessity of their prescribed medication also harboured
strong concerns.
Several things are striking about these findings. The first is that those patients with high
concerns, probably had quite a different representation of their medicines than the doctors
who had prescribed them. In the "medical view" none of the medicines which the patients
were receiving would be considered to cause dependence or addiction, and few would be
expected to cause serious long term adverse effects. Secondly, it is particularly salient that
concerns did not influence patients' perceptions of the necessity of their medication (89%
of patients with strong concerns believed that their medication was necessary). Rather, a
third of the sample seemed to hold a complex representation of medicine in which firm
beliefs about the necessity of medication were set against concerns about safety and the
disruptive effects of taking medication. These patients had a "dualistic" view of their
prescribed medication in which the potential for benefit is balanced by the potential for
harm. This provides systematic evidence that this representation, which was first identified
in small scale qualitative studies, conducted in individual diagnostic groups (Donovan and
Blake, 1992; Fallsberg, 1991; Morgan and Watkins, I 988; Conrad, 1985), seems to be
prevalent among chronically ill patients from a range of diagnostic groups.
Considering representations of medicines in general. Only I 6% of the sample had strong
beliefs that medicines were generally harmful, addictive poisons which should not be taken
for long periods for time (General-Harm). However, this represents a significant minority
when one considers that the sample comprised chronically ill patients, whose treatment
hinged around prescribed medication. In this context, the fact that almost half the sample
believed that medicines in general were overused by doctors (General-Overuse), is quite
startling, and raises the question of what lies behind this view and why so many people
hold it. This question could be addressed in a future research study using in-depth
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interviews. One hypothesis is that people see the prescription of a medicine as a substitute
for a patient-centred approach to care (Weinfield et al. 1996; Weinfield, 1992).
The correlations between BMQ scales, appeared to be the result of a logical 'common-
sense' interpretation on the patients' part. For example, patients who believed beliefs that
medicines in general are harmful, addictive poisons (General-Harm) which are overused by
doctors (General-Overuse) were more likely to be concerned about medication prescribed
for them. The very low correlation between beliefs about the necessity of prescribed
medication (Specific-Necessity) and other scales shows that concerns about the harmful
potential of specific prescribed medication and medicines in general are largely
independent of the perceived need for medication.
The finding that specific and general beliefs are correlated in a logically consistent way
does not answer the question of the direction of influence. For example beliefs about
medication prescribed for personal use might arise directly from more general beliefs
about medicines as a whole. Alternatively, beliefs arising from experience with specific
medication (personal or that of significant others) might be extrapolated to medicines in
general. It is however clear from this exploratory analysis of the relationship between
beliefs, that although general beliefs are significantly correlated with specific beliefs the
proportion of variance explained by the interaction is relatively small. This suggests that
medication representations are influenced by a complex set of determinants and this will
be investigated in more detail in Chapter 9.
In summary, these findings show a wide distribution of medication beliefs among
chronically ill patients indicating a large degree of inter-individual variation in beliefs about
specific and general medication. One of the questions arising from these data concerns the
similarities and differences in the distribution of beliefs about medicines in general among
well and ill populations. At a practical level, it is very clear that health care providers
should not assume that medication means the same thing to all patients. Many patients
were sceptical of the way in which medication is used by doctors. Furthermore, the need
to take medication was a clear cause of concern for almost of third of the participants in




The effects of medication beliefs in chronic
illness
The studies described in Chapter 7 quantified some of the main beliefs that chronically ill
patients hold about their prescribed medication and medicines in general. The current
chapter will now address the question of how these beliefs relate to treatment adherence.
It will describe a series of three studies addressing the following specific research
questions:
I. What is the relationship between patients' main beliefs about prescribed and general
medication and their reported adherence to medication prescribed for their illness?
2. To what extent are relations between medication beliefs and adherence specific to
medication adherence?
3. What is the relative influence of illness cognitions and medication beliefs on reported
active (adjusting the dose) and passive (forgetting doses) nonadherence to medication?
8.1 Investigating relations between medication beliefs and
medication adherence
This study set out to address question 1 above by conducting two sets of analyses. First,
the relationship between medication beliefs and adherence was investigated by examining
correlations between BMQ factors and reported adherence to medication in several illness
groups (Analysis A). This was followed by a second analysis in which the relative
contribution of medication beliefs and demographic factors (age, gender, educational
experience) to variance in reported adherence was examined using a series of multiple
linear regression analyses (Analysis B).
The hypotheses were that
I. The BMQ scales assessing negative views about medication (Specific-Concerns, Genera!-
Overuse and General-Harm) would be associated with lower reported adherence.
2. Higher scores on the Specific-Necessity scale would be associated with higher reported
adherence.
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3. The BMQ-Specific scales, which measure beliefs about prescribed medication would be
more strongly correlated with reported adherence than the BMQ-General scales which
assess more general beliefs about medicines as a whole.
8.1.1 Method
Participants
• The 6 chronic illness groups comprising the main sample described in Section 6.3.
Measures
• The Beliefs about Medicines Questionnaire (BMQ), described in Section 7.2. I.
• The Reported Adherence to Medication (RAM) scale, described in Section 6.4.4.
• The Reported Adherence to Insulin (RAI) scale, described in Section 6.4.4. I.
• Demographic characteristics of the patient age, gender and educational experience,
assessed using the method described in Section 6.4.8.
Procedure:
This study utilised the data set obtained from the six illness groups comprising the main
sample. This was the data set from which the BMQ had been derived and evaluated.
For the purposes of this study, insulin-treated diabetics (n=64) and tablet-treated diabetics
(n=35) were considered separately. This was necessary to reflect differences in the type of
adherence instructions. For patients receiving oral hypoglycaemic agents (tablet-treated), a
tendency to adjust or alter the dosage of medication is considered to be non-adherent. In
contrast, the insulin-treated diabetics were required to take an active role in adjusting the
dose of their insulin in response to dietary intake and blood/urine glucose measurements.
Thus for these patients, a tendency to adjust the dose of their insulin indicates adherence
to the treatment instructions. This essential difference was taken into account in the
adherence measures used as detailed in Section 6.4.4.1.
Statistical techniques
• Correlations between BMQ and RAM/RAI scales were investigated using Spearman
correlation coefficient (rho).
• The percentage variance in reported adherence explained by medication beliefs and
demographic variables was investigated by multiple linear regression using the stepwise
entry and removal method, setting probability F for entry and removal at 0.05 and 0.01.
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The rational for using this parametric technique with ordinal data (eg gender and the
BMQ, RAM/RAI scales) is presented in Section 6.6.
8.1.2 Results
Analysis A: Medication belie ft as correlates of medication adherence
The mean scores on the adherence self report scales are shown in Table 8. I. Spearman
correlations between BMQ scales and self-reported adherence are shown in Table 8.2.
Table 8.1	 Mean scores on the reported adherence to medication
(RAM/RAI) scales and Cronbach alpha values as a measure of internal
consistency
Sample	 n	 Mean	 SD	 Variance	 Cronbach's
alpha
Asthma clinic	 78	 10.47	 3.20	 10.25	 0.60
Psychiatric clinic	 89	 10.09	 3.49	 12.20	 0.73
General-medical IP	 90	 9.30	 3.18	 10.12	 0.67
Cardiac IP	 116	 8.72	 2.81	 7.92	 0.67
Dialysis IP	 47	 8.04	 3.67	 I 3.43	 0.83
Diabetes: Insulin treated*	 64	 11.68	 3.97	 I 5.77	 0.73
Diabetes Tablet treated	 35	 7.91	 2.30	 5.27	 0.50
* 2-item scale
Table 8.2	 Spearman correlation between self-reported adherence to
medication and BMQ factors
Asthma	 Diabetes	 Diabetes	 Renal	 Cardiac	 Psychiatric	 General
Insulin-	 Tablet-	 Medical
treated	 treated	 Inpatients
Specific-Necessity	 .23*	 .39°('	 ..•33*	 -.02	 .20*	 -.03
Specific-Concerns	 .23*	 .28*	 .49	 .39''	 .1 9*	 -0.1
General-Harm	 .09	 .17	 .36*	 .25	 .16	 .08	 .05
General-Overuse	 .1 7	 .08	 .48"°	 .30*	 .17	 .11	 .26*
p=<O.OS; p=<O.Ol
It can be seen from Table 8.2 that correlations between medication beliefs and reported
medication adherence were fairly consistent across illness groups. With the exception of
psychiatric out-patients, statistically significant correlations were obtained between BMQ-
Specific variables and adherence in all illness groups. Correlations were in the predicted
direction. Stronger beliefs in the necessity of prescribed medication (Specific-Necessity)
were associated with higher reported adherence whilst concerns about the potential
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adverse consequences of prescribed medication (Specific-Concerns) correlated with lower
reported adherence.
In most of the illness groups, beliefs about medicines in general had a relatively small effect
on adherence. Where significant correlations were noted between general beliefs and
adherence these were in the predicted direction. For example, renal, general medical and
tablet-treated diabetic patients with stronger beliefs that medicines in general are overused
by doctors, as indicated by higher scores on the General-Overuse scale, reported lower
medication adherence, as indicated by higher scores on the RAM scale. Similarly, tablet
treated diabetics who believed that medicines in general are harmful addictive poisons
which should not be taken for long periods of time also reported lower adherence.
Analysis B: Multiple linear regression
The purpose of analysis 2 was to assess the differential contribution of medication beliefs
to variance in self-reported adherence. Data from the asthma, dialysis, cardiac and general
medical inpatients samples were combined to form a larger sample. It was thought that this
larger sample representing a variety of common chronic illnesses would provide a "global
view" of how personal representations might influence reported adherence. The diabetic
and psychiatric samples were omitted from the analysis. The diabetic group were omitted
because 65% of the sample were treated with insulin and so completed a different
adherence scale (RAI scale). Data on educational experience was not available for the
diabetic sample and so the tablet-treated patients, who completed the RAM scale, were
also omitted from the combined data set. The psychiatric sample were omitted because no
significant correlations between beliefs and adherence were found in this data set.
Stepwise entry and removal of Specific and General medication beliefs and demographic
variables (age, gender and educational experience) resulted in a simple model in which
beliefs about prescribed medication (Specific) and age accounted for 27% of the variation
in reported adherence. The results, shown in Table 8.3, indicate that reported adherence
was strongly related to patient age and beliefs about medicines. Age alone accounted for
14% of the variance in reported adherence with younger patients reporting lower
adherence. Specific medication beliefs added a further I 3% to the explained variance.
Beliefs about specific medication prescribed for personal use had a much stronger
influence on reported adherence to those medicines than did global beliefs about
medicines in general, confirming hypothesis 3. Patients with stronger Specific-Concerns
about the potential adverse effects of their own medication tended to report lower
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adherence. Similarly those with stronger beliefs about the necessity of their medication
reported that they were less likely to depart from the treatment instructions confirming
hypothesis 2.
Table 8.3	 Linear regression model for self reported adherence
[combined data from the asthma, renal dialysis, cardiac and general
medical in-patients (n336)]
Variable	 B	 SE B	 Beta	 T	 Sig T	 Cumulative
R Square
Age	 -.06	 .01	 -.32	 -6.47	 <.01	 .14
Specific-Concerns	 .26	 .04	 .32
	 6.53	 <.01	 .23
Specific Necessity	 -.19	 .05	 -.20	 -4.09	 <.01	 .27
8. I .3 Discussion
Specific and General medication belie ft as correlates of adherence
The correlations between Specific and General medication beliefs and reported adherence
to treatment were logically consistent. In most of the illness samples, strong beliefs in the
necessity of prescribed medication for maintaining health (higher scores on the Specific-
Necessity scale) seemed to stimulate adherence and stronger concerns about the potential
adverse effects of prescribed medication (higher scores on the Specific-Concerns scale)
were associated with lower reported adherence. Although the magnitude of the
correlations varied, the pattern of correlations between BMQ-Specific scores and reported
adherence was fairly consistent across a range of chronic illnesses and associated
treatments.
Correlations between reported adherence and BMQ-General scales were less consistently
significant but were in the predicted direction. Views about medicines in general had a
more direct influence on reported adherence in some illness groups than others. General
beliefs were less influential for asthma, cardiac and insulin treated diabetic patients than for
renal, general medical , psychiatric and tablet treated diabetic patients. A possible
explanation for this is that the differential importance of general beliefs might be a function
of the "perceived salience" of the specific medication commonly prescribed for the
condition. For example, it may be that a negative orientation towards medicines, stemming
from beliefs that medicines in general are harmful addictive poisons which are overused by
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doctors, might be less influential if the patient perceives a clear link between their
prescribed medication and benefit or potential harm. This explanation is supported by the
finding that general beliefs were less influential in asthma, cardiac and insulin treated
diabetic samples where there is often a clear link between medication taking and
symptomatic benefit. Conversely, patients receiving oral treatment for diabetes, and renal
patients whose medication is secondary to "life-saving" haemodialysis sessions, are perhaps
likely to perceive a weaker link between prescribed medication and tangible benefit. For
these patients, the specific prescribed medication may be less salient so that views about
medicines as a whole become more prominent in adherence decisions. This explanation is
clearly tentative and further work is needed to test its validity. This may be best achieved
by prospective longitudinal studies, involving newly diagnosed patients with a range of
chronic illnesses. The differential effects of general and specific beliefs on adherence could
then be studied at various stages. Moreover, it would be possible to investigate patients'
views about their prescribed medication before and after they had observed its effects on
their condition.
Concerns and Necessity beliefs, as predictors of adherence
Regression analysis in the combined data set gave an indication of the broader contribution
of medication beliefs to adherence behaviour in the self-management of chronic illness.
The key finding here was that patients' beliefs about medication were predictive of
reported adherence, suggesting that many patients were making active decisions about
adherence, based on their own beliefs, rather than simply complying with treatment advice.
In particular, patients with stronger concerns about their medication reported lower
adherence. The relative influence of Specific-Concerns and Specific-Necessity beliefs on
reported adherence is interesting. In this sample of chronically patients, medication
adherence was much more strongly influenced by concerns about the potential of
prescribed medication to result in long term adverse effects, dependence and disruption
than by beliefs in its necessity. It is salient that, although the majority of patients believed
that their prescribed medication was necessary for maintaining health, approximately a
third had strong concerns about their medication and these patients were less adherent.
Thus, the interplay between concerns and necessity beliefs implies a risk-benefit analysis
and subsequent attempts to moderate the perceived potential for harm by taking less.
The relative contribution of concerns and necessity beliefs may vary in different clinical
situations. In the present sample of chronically ill patients, those with stronger Specific-
Necessity beliefs were more adherent. However, the variance explained was small with
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Specific-Necessity scores adding 4% to the total variance in adherence explained by the
other variables within the model. The relatively small correlations between Specific-
Necessity beliefs and adherence may be a function of the low degree of spread within this
data. As discussed in Section 7.5, over 85% of the sample had higher than mid-point scores
on this scale. Further studies are now needed to determine whether Specific-Necessity
beliefs show greater variation and have a stronger influence on adherence when
medication is prescribed for short term use or when the patient perceives the illness to be
of short duration.
Lack of interaction between beliefs and adherence in the psychiatric clinic sample
The lack of significant interactions between medication beliefs and adherence within the
psychiatric clinic sample was inconsistent with the above findings. Possible explanations for
this apparent anomaly are that other cognitions such as perceived vulnerability to relapse
or normative beliefs may be more influential than Specific-Concerns or Specific-Necessity
beliefs (Hogan et al. 1983; Budd et al. 1996; Cochran and Gitlin, I 988). In addition the type
of medication concerns which are addressed by the Specific-Concerns dimension may be
less salient for this group who may be more concerned about the present experience of
side-effects than future worries about dependence or long-term effects. These issues are
discussed in more detail in Chapter 10.
The effect of age on adherence
The observed relationship between age and adherence reported here is consistent with
more recent work showing that it is mistaken to regard older patients as a homogenous
group of low adherers (Lorenc and Branthwaite, 1993). Further work is needed to explain
why younger patients reported lower adherence. This may be an artefact attributable to a
greater willingness to report non-adherence. However, the context of adherence
questions was controlled to encourage truthful reporting. This finding adds to the growing
body of research linking lower adherence with younger age (Daniels et al. I 994;
Sherbourne et al. 1992; DiMatteo et al. 1993; Frazier et al. 1994; Lorenc and Branthwaite,
1993). The explanation for this effect may lie in cognitive differences in the approach to
illness associated with older age. Older people tend to adopt a more cautious approach to
the maintenance of health (Leventhal et al. I 993a; Cameron et al. I 993; Leventhal et al.
I 993b). Consequently, once the patient has accepted the advised behaviours as necessary
and valid, they tend to adhere to them more carefully and systematically (Leventhal and
Crouch, I 997). These issues were discussed in more detail in Chapter 10.
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Limitations of the study Several methodological limitations mean that these findings
should be interpreted with caution. The first concerns the method of assessing adherence
behaviour. In common with most "measures" of adherence, self-report does not detail the
exact number of medications taken. Moreover, the accuracy of self-report has been
questioned on the grounds that patients may be reluctant to admit to non-adherence and
that generally tends to over-estimate adherence by about 20% (Caron, 1985). However,
others have suggested that self-report is a useful method for grading patients according to
their "relative standing on the adherence dimension" (Ley and Llewellyn, 1995; Haynes et
al. 1980). In this study adherence questions were phrased in a non-threatening way so as
to diminish self-presentational bias and located in two different places within the
questionnaire to limit ordering effects. A further attempt to improve the validity of
patients' self-report was the use of continuous scales rather than simple dichotomous
variables and checking that the internal reliability and test-retest reliability of the scales
was adequate. However, the RAM scale has not been fully validated against other
measures of adherence behaviour. Until this is achieved, the results of this study should be
interpreted with caution and any conclusions reached about the effects of medication
beliefs on adherence are preliminary. The cross-sectional design of this study represents a
further limitation in that one cannot be sure about direction of influence between beliefs
and reported behaviour. Thus, the predictive effect of medication beliefs on medication
behaviour should now be examined using a longitudinal study design.
In summary, significant correlations were observed between medication beliefs and
reported adherence across a range of chronic illness groups. Although, the limitations of
the methodology used suggest the need for a cautionary approach when generalising from
these findings, they lend tentative support for the notion that patients' representation of
medication influence adherence decisions.
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8.2 Examining the differential relationship between
medication beliefs and adherence to medication and
fluid/dietary restrictions in a sample of hospital haemodialysis
recipients
The analyses described in the previous section showed that patients' beliefs about their
prescribed medication accounted for a significant amount of variance in their reported
adherence to medication. The present study set out to examine the degree to which these
relations were specific to medication adherence. Before concluding that beliefs about
medication directiy influence medication adherence it was necessary to exclude the
possibility that scores on the BMQ-Specific dimensions are merely "surrogate markers" for
other factors. In particular, it was necessary to question the degree to which the Specific-
Concerns dimension is measuring cognitive and emotional representations of prescribed
medication rather than negative attitudes to the illness and treatment as a whole. One way
of addressing this question is to investigate whether BMQ factor scores are also associated
with adherence to other aspects of the treatment regimen such as dietary control. If the
scale was addressing medication beliefs rather than general attitudes to treatment then the
BMQ-Specific factor scores would be more strongly associated with adherence to
medication than adherence to other aspects of treatment
The renal sample described in Section 6.3. 1.3, comprising patients receiving hospital
haemodialysis as a treatment for End Stage Renal Disease (ESRD), provided an opportunity
to study the effects of medication beliefs on separate treatment modalities. ESRD is a
chronic illness which necessitates continuous medical treatment Patients receiving
haemodialysis are required to adhere to a tripartite regimen of attendance at hospital
dialysis sessions, fluid and dietary restrictions and a complex medication schedule (Will and
Johnson, 1994). Although haemodialysis sessions are time-consuming and unpleasant, serial
non-attendance is relatively rare as missing only a few consecutive sessions may endanger
life. However, non-adherence to medication and fluid/diet restrictions is viewed as a major
issue (Lowry and Atchison, 1980). Thus the renal sample could be used to test the study
hypotheses that
I. Beliefs about medication would be significantly related to reported adherence to
medication, but not to adherence to fluid/diet restrictions.
2. Views about fluid/diet restrictions would be significantly related to adherence to




• The renal sample comprising recipients of hospital haemodialysis, described in Section
6.3.1.3.
Measures
• Beliefs about treatment
I. Beliefs about specific and general medication were assessed using the The
Beliefs about Medicines Questionnaire (BMQ), described in Section 7.2.1.
2. Views about the fluid and dietary restrictions were assessed by a single item:
'My fluid and dietary' restrictions are too strict'.
Responses were scored on a 5-point Likert scale where I = strongly disagree, 2
= disagree, 3 = uncertain, 4 agree and 5 = strongly agree. Thus higher scores
indicate stronger beliefs that fluid/diet restrictions are too strict.
• Adherence Indicators
3. Reported adherence to medication was assessed using the RAM scale,
described in Section 6.4.4
4. Adherence to fluid/diet restrictions was assessed using the clinical assessment
procedure employed by physicians on the renal unit. An inter-dialysis weight
gain of greater than 2Kg is indicative of low adherence to fluid/diet restrictions.
Records of inter-dialysis weight changes over a three month period immediately
prior to completion of the study questionnaire were retrospectively collected
from the medical notes. Patients were then assigned a fluid/diet adherence
score from I to 5 according to the percentage of results found to lie outside
the clinically acceptable range of less than 2Kg gain between dialysis sessions,
shown in Table 8.5 in the results section.
Demographic characteristics of the patient age, gender and educational experience,
assessed as described in Section 6.4.8.
Statistical techniques
Relationships between beliefs, sociodemographic data, self-reported medication adherence,
and fluid/diet adherence were quantified using the Spearman correlation coefficient for
ordinal data and by multiple linear regression.
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Procedure:
This was an analysis of cross-sectional and retrospective data collected from the renal
sample (n=47) This data set also contributed to the development and evaluation of the
BMQ as described in Chapter 7.
8.2.2 Results
Beliefs about treatment
Computed mean scores for BMQ Specific and General scales are shown in Table 8.4,
together with the percentage of the sample attaining scores above the scale mid-point. The
latter can be said to have stronger beliefs in the concept represented by the scale.
Table 8.4	 Scores on BMQ scales assessing beliefs about specific and
general medication for the Renal sample (n=47)
Variable	 Mean	 SD	 Percentage of subjects attaining
scores above scale mid-point
Specific-Necessity 	 19.5	 2.8	 89.4
Specific-Concerns 	 I 3.8	 4.3	 31.9
General-Harm	 9.9	 3.8	 19.1
General-Overuse	 12.7	 3.2	 57.4
It can be seen from Table 8.4 that the distribution of specific and general medication
beliefs were almost identical to those observed in the combined sample of six illness
groups, described in section 7.2. Almost 90% believed in the necessity of medication
prescribed for their renal condition, as indicated by higher than mid-point scores on the
Specific-Necessity scale. However, 32% of the sample also exhibited strong concerns.
Concerns about renal medication were not associated with lack of belief in its necessity,
since all patients with higher than mid-point scores on the Specific-Concerns scale also had
higher Specific-Necessity scores. Thus, a third of the sample had an ambivalent attitude to
their medication in which firm beliefs about necessity were tempered by more negative
attitudes arising from concerns about long-term safety, dependence and the perceived
disruptive effects of the medication regimen. Although Specific-Necessity belief scores were
skewed towards the positive, concerns about prescribed medication and beliefs about
medicines in general were normally distributed. Many patients had a fairly negative view of
medicines in general with 57.4% of the sample believing that these are overused by doctors
and I 9.1% that these are harmful addictive poisons which should not be taken for long
periods of time.
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Concerns about medicines prescribed for ESRD correlated with beliefs that medicines in
general are harmful, addictive poisons (rhoO.45; p<O.Ol) which are overused by doctors
(rhoO.6; p<O.00I). Most patients (9 1%) with strong concerns about renal medication
believed that medicines in general are over used by doctors and in 40% of cases this was
associated with a belief that medicines in general are harmful, addictive substances. Twenty
patients (43%) felt that their fluid/diet restrictions were too strict. Demographic variables
had little influence on beliefs about treatment except that younger patients were more
likely to believe that their fluid/diet restrictions were too strict (rhoO.39; pO.007).
Adherence to treatment
Self-reported adherence to medication
The frequency distribution of scores on the medication adherence self-report scale are
5.0	 7 5	 100	 125	 10.0	 170	 200
MEDICATION ADHERENCE (self report scale: high scores = low adherence)
Figure 7.1 Frequency distribution of scores for the medication
adherence self-report scale
Adherence to fluid/diet restrictions
The percentage of inter-dialysis weight gain measures outside the clinically acceptable
range is shown in Table 8.5.
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Table 8.5	 Adherence to fluid/diet restrictions
Weight changes over 2Kg as a percentageFluid/diet 	 Frequency	 Percentage
Adherence Score
none >2Kg	 Score =1	 7	 14.9
l%-33% > 2Kg	 Score =2	 17	 36.2
34%-66% >2Kg	 Score 3	 12	 25.5
67-99% >2Kg	 Score 4	 10	 21.3
00% >2Kg	 Score =5	 I	 2.1
Total	 47	 00.0
Relationships between patients' beliefs and treatment adherence
Patients' beliefs about their treatment were related to medication and fluid/diet adherence
in a coherent way. Concerns about renal correlated with lower medication adherence
(rhoO.39; pO.00B). Patients who believed that their fluid/diet restrictions were too strict
were less likely to adhere to them as indicated by the frequency of inter-dialysis weight
gain greater than 2Kg (rhoO.54; p<O.Ol). Younger patients were less adherent to
fluid/diet restrictions (rhoO.29; p<O.O5) and reported lower medication adherence
(rhoO.36; p<O.O5). Medication and fluid/diet adherence were not significantly correlated.
Spearman correlations between beliefs and adherence to medication and fluid/diet
restrictions shown in Table 8.6, indicate that, although specific beliefs about medicines
influenced adherence to medication and specific beliefs about fluid/diet restrictions
influenced adherence to them, these two areas of beliefs and behaviour were unrelated.
To investigate the differential contribution of beliefs about medicines and fluid/diet
restriction and demographic variables to variance in adherence behaviours, separate linear
regression analyses were performed using each type of adherence as the dependent
variable. In each analysis, the contribution of treatment beliefs, demographic variables (age,
gender, educational experience) and clinical factors (duration of dialysis and number of
prescribed medications), was tested by stepwise entry and removal. The linear regression
models, shown in Table 8.7, provide further evidence that beliefs about specific treatments
had a selective effect on adherence to those treatments. Patients' beliefs about treatment
were more closely associated with adherence than other variables such as duration of
illness, number of medications prescribed, or basic sociodemographic data such as age,
gender and educational experience. An exception was that younger patients reported
lower medication adherence independently of medication beliefs. The only variable
predicting adherence to fluid/diet restrictions was patients' personal beliefs about the
restrictions.
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Table 8.6 Spearman correlations between beliefs about treatment
and adherence (renal sample n=47)
BELIEFS ABOUT TREATMENT	 Self-Report of•	Inter-dialysis
Adherence to	 Weight Gain
Medication
Concerns about long-term effects and potential for 	 rho = 0.39	 rho = 0.02
dependency of renal medication (Specific-Concerns) 	 p = 0.008	 p = 0.89
Beliefs that fluid and dietary restrictions are too strict 	 rho = 0.04	 rho= 0.55
Table 8.7 Linear regression models for adherence to treatment
(renal sample n=47)
Self-reported adherence to medication as dependent variable
Variable	 B	 SE B	 Beta T	 Sig T R Square
Concerns about renal medication (Specific- 	 .32	 .11	 .37	 2.86	 .01	 17
Concerns)
Age	 -.07	 .03	 -.32	 -2.50	 .02	 10
Adherence to fluid/diet restrictions as dependent variable
Variable
Beliefs that fluid/diet restrictions are too strict 	 .46	 .11	 .55	 4.37	 .0001	 30
8.2.3 Discussion
The discussion of the above findings is structured around the assumption that beliefs
influence behaviours, in accordance with self-regulatory theory. However, since this was a
cross-sectional study it is equally possible that some of these beliefs were shaped by the
behaviour pattern (Gerrard et al. 1996). The pattern of relationships between beliefs and
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Figure 8.2 Diagrammatic representation of correlations between
beliefs and adherence behaviours
The fact that adherence to medication was not correlated with adherence to fluid/diet
restrictions shows that patients may adhere to some aspects of their treatment but not
others. The most important finding was that specific beliefs were related to specific
reported adherence behaviours in a meaningful and discriminating way. For example,
concerns about the long term effects and potential for dependence of prescribed
medication were associated with lower rates of self-reported medication adherence but
not with lower adherence to fluid and dietary restrictions. Similarly, patients who believed
that their fluid and dietary restrictions were too strict were less likely to adhere to them.
This finding confirmed the hypothesis that medication beliefs would have a specific effect
on medication adherence and is consistent with the notion that nonadherence may result
from a rational decision based on personal beliefs about individual aspects of the
treatment. In particular, patients who thought that their medicines were harmful took less
of them and those who believed that their fluid/diet restrictions were too strict exceeded
the recommendations for fluid intake. The observation that younger patients reported
lower medication adherence is consistent with findings reported in Section 8. I of this
chapter.
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8. 3 The selective influence of medication and illness beliefs
on active and passive non-adherence to medication
Section 8.1 and 8.2 showed that medication beliefs were selectively related to reported
medication adherence. These findings imply that patients' representations of treatment
should be considered as components of self-regulatory theory. Theory and research in this
area has focused on the role of representations of illness and has not specifically
considered beliefs about treatment (Leventhal et al. I 992; Skelton and Croyle, 1991)
Thus, the studies reported in this chapter raise several questions. The first concerns the
relative influence of illness and medication beliefs on medication adherence. A second
question concerns the type of adherence behaviour which is affected by these beliefs. A
distinction is sometimes drawn between two separate but related aspects of medication
non-adherence. Non-adherence may be unintentional or passive if the patient's plan to
take medication is thwarted by barriers such as forgetting, or the inability to follow
treatment instructions because of poor understanding or physical problems such as poor
eyesight or impaired manual dexterity. Alternatively, it may be the intentional result of a
decision not to take the treatment as instructed. In this case the non-adherence is active
(Weintraub, I 990; Cooper et al. I 982). The present study addresses these issues. The
specific questions were:
I. What is the relative contribution of beliefs about medication, illness representations
and beliefs about control over asthma to variance in passive and active nonadherence
to asthma medication?
2. What is the relation between clinical and subjective indicators of appraisal on coping
procedures (adherence) and representations?
The conceptualisation of beliefs, adherence (coping) and appraisal are detailed below and
shown in Figure 8.3.
Medication beliefs These were conceptualised as the BMQ Specific and General factors
described in Chapter 7. In common with the studies described earlier the concept of
Specific medication beliefs refers to the patients' representations of their medication
regimen (e.g. 'medicines prescribed for your heart condition') rather than their views
about the individual components (e.g. 'aspirin prescribed for your heart condition'). Thus,
Specific representations are the patients' composite view of their individual medicines. We
know little about the extent to which this composite view is influenced by individual
components of the regimen. In the asthma sample it was possible to explore this issue
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medication regimen. Thus two aspects of Specific medication were included: patients'
views about their prescribed medication regimen as a whole and their view about the
steroid component of the regimen. The method of assessing beliefs about steroids is
described later in Section 8.3.1
PATIENT CHARACTERISTICS
SOCIO-DEMOGRAPHIC	 CLINICAL
Number of Wescnbed medicines
Oender	
•Duration of diabetes (yeaxs)
•Edmabcied expenence
Figure 8.3	 Variables included in asthma study
Illness beliefs Several illness related cognitions were included. First, the content of the 5
components of illness representation described by Leventhal and colleagues (1980)
identity, cause, timeline, consequences and potential for cure/control. Patients' perceptions
of the degree of empathy conferred by medical and nursing staff were also evaluated as
this is thought to have an influence on adherence behaviours (Meichenbaum and Turk,
1987).
Control beliefs It has been suggested that those with high internal control beliefs would
be more likely to engage in health promoting activities (Norman and Bennett, I 996). One
might therefore expect high internals to be more adherent to medication. The degree of
internality in relation to perceived control of asthma was assessed as was the extent to
which patients attributed control over asthma to their medication.
Medication adherence Two aspects of medication adherence were distinguished. The
tendency to forget to take medication (passive nonadherence: PnA) and the tendency to
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deliberately alter the dose of medication outside the physicians recommendations (active
nonadherence: AnA) were considered separately.
Appraisal Two indicators of subjective appraisal were included: self-reported health and
perceived effects on symptoms.
Clinical measure of asthma severity Peak expiratory flow rate (PEFR).
8.3.1 Method
Participants
The asthma sample (n=78) detailed in Section 6.3.1.1.
Measures
• The Illness Perception Questionnaire (IPQ) (Weinman et al, 1996- see Section 6.4. I). Note:
In this study both methods for assessing causal beliefs were used ie scoring responses
to individual causal items and by summing the number of causal attributions made by
the patient.
• Beliefs about control over asthma: were assessed using a modified version of a the
Perceived Control Over Recovery scale (Partridge and Johnston, 1989) as described in
Section 6.4.2. The extent to which control over asthma was attributed to medication
was assessed on the basis of Likert scale responses to a single item statement
'Whether my asthma gets better or worse depends on how well my medicines work", scored
from I = strongly disagree to 5 = strongly agree as detailed in Section 6.4.2.
• The Beliefs about Medicines Questionnaire (BMQ), described in section 7.2. Specific-
Necessity and Specific-Concerns scales were used to assess patients' composite views
about their asthma medications. General-Harm and General-Overuse scales were used to
assess beliefs about medicines in general.
• Beliefs about Steroid Scales
The asthma sample completed the I 6 items assessing beliefs about medication
prescribed for their asthma in addition 18 items assessing beliefs about medicines in
general as described in Chapter 7 and shown in Table 7.1. In addition, patients receiving
regular steroid treatment for their (n=75) were asked to complete a further I 0 items
assessing their views about steroid treatment in particular. Due to restrictions on the
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number of items which could be administered to patients 10 items were selected to
represent positive (n =5) and negative (n=5) views about steroids. The majority of
these items were obtained by simply changing the phrasing of one of the I 6 Specific
items to reflect the steroid subject e.g. 'I sometimes worry about the long-term effects
of my steroids'. Others were included because they would provide data which were of
particular interest to the clinical staff e.g. 'I have been given enough information about my
steroids' and 'My steroids are the most important part of my treatment' The scale items are
shown in Appendix I I. The 10 items dealing with beliefs about steroid were entered
into a Principal Components Analysis with non-orthogonal (OBLIMIN) rotation which
resulted in two factors shown in Appendix I I. As these seemed to be analogous to the
Specific-Concerns and Specific-Necessity factors of the BMQ they were labelled: Steroid-
Concerns and Steroid-Necessity.
It should be noted that the Steroid-Concerns and Steroid-Necessity scales was
exploratory and was not originally intended to be developed as evaluated in measures
in the same way as the BMQ.
• Perceived lack of empathy from medical and nursing staff (PLE): described in Section 6.4.3.
• Reported adherence to medication: was assessed using the RAM scale described in
Section 6.4.4.2. However, the passive and active aspects of adherence elicited by this
scale were considered separately as two 2-item constructs as described in Section
6.4.4.2.
• Measures of subjective appraisal: Patients' appraisal of the effect of their medication on
symptoms was evaluated using responses to the single statement "My medicines make
me feel better", scored on a 5-point Likert scale where I = strongly disagree and 5
strongly agree. A further more general appraisal assessment was the 7-item self-rated
health scale adapted from the SF-36 measure (Jenkinson et al. 1994; Ware, Jr. and
Sherbourne, I 992) described in Section 6.4.5.
• Clinical outcome: An indication of clinical outcome was provided by Peak Expiratory
Flow Rate (PEFR, peak flow) measurements as a percentage of the expected value. This
is the clinical measure of asthma severity routinely used by the clinic physicians. PEFR
measurements were taken by the researcher before patient's completed the
questionnaires. Patients were asked to perform three serial peak flows as is usual
(Town et al. 1990). The highest value was then compared with the expected value for a
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non-asthmatic patients of similar age, sex and weight obtained from standard tables.
The result was expressed as a percentage of the expected value.
Procedure
Data collection was carried out as described in Section 6.5. The analysis of the data
preceded in two stages. First an exploratory analysis of correlations between measures of
adherence and other variables, to identify the statistically significant correlates of AnA and
PnA. This was followed by multiple linear regression analyses to identify the proportion of
variance in AnA and PnA explained by their significant correlates. The Self-rated Health
measure was introduced half-way throughout the study and so was completed by only 48
patients.
Statistical techniques
• Correlations between beliefs about inhaled steroid medication and the beliefs about the
asthma regimen as a whole were assessed by Spearman's correlation coefficent (rho)
• Correlations between RAM scales assessing PnA and AnA and measures of illness
perceptions, medication beliefs, appraisal processes and PEFR values were investigated
using Spearman's correlation coefficient (rho).
• The percentage variance in reported PnA and AnA explained by other study variables
was investigated by multiple linear regression using the stepwise entry and removal
method, setting probability F for entry an removal at 0.05 and 0.01. The rational for















Scale and item mean scores for the variables used in this study are shown in Table 8.8.
The frequency distributions of reported AnA and PnA are shown in Figures 8.4 and 8.5
respectively.
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Active nonadherence AsiA scale (range 2-10 higher scores greater AsiA)
Figure 8.3 Frequency distribution of reported active nonadherence
(AnA) (n=78, asthma clinic attenders)
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Passive nonadherence (PnA) scale (range 2-10, higher scores—greater PnA)
Figure 8.4 Frequency distribution of reported passive
nonadherence(PnA) (n78, asthma clinic attenders)
Interrelations between beliefs about inhaled steroid medication and beliefs about the
asthma regimen as a whole are shown in Table 8.9. Correlations showed fairly strong
associations between views about the steroid component and the regimen as a whole.
Spearman correlations were also computed between representations, appraisal indicators,
socio-demographic and clinical characteristics and the reported frequency of active and













































Table 8.8	 Scale responses and measures of internal consistency
(Asthma sample n=78)
Variable	 No. of	 Mean	 STD	 Cronbach
items	 alpha
chance	 I	 2.7	 1.3	 'F
other people	 I	 2.6	 1.1	 'F
inherited	 I	 3.1	 1.2	 'F
stress	 I	 3.1	 1.2	 'p
diet	 I	 2.4	 0.9	 'F
pollution	 I	 3.5	 1.1	 'F
own behaviour	 I	 2.3	 0.9	 'F
germ or virus	 I	 2.6	 1.1	 'F
Perceived control over asthma
	 9	 3.2	 0.5	 0.68
Medication control over asthma
	 I	 3.9	 0.8	 'F
Perceived lack of empathy (PLE)	 I	 2.3	 1.1	 'F
AEfl-WCE (pig pr*du*
Active nonadherence (AnA)
	 2	 2.8	 1.01	 0.70
Passive nonadherence (PnA) 	 2	 2.4	 0.9	 0.62
AfPM1AL. PROCES
Perceived effect of medication on	 I	 3.7	 I .03	 'F
symptoms PEMS
Self-rated health (n48)	 7	 2.6	 0.8	 0.84
PEFR(%)	 'F	 81.8	 20.4	 'F
P = not applicable
Note: For ease of comparison scale scores have been adjusted by dividing by number of scale items
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4	 Steroid-Concerns	 . 26*	 .29*	 75ICIc
5	 General-Harm	 -.04	 .10	 .13	 .13
6	 General-Overuse	 .26*	 -.04	 .04	 . I I	 .29*
*p<O.Os p<O.OI
Correlates of Active Nonadherence (AnA)
As can be seen from Table 8.10, statistically significant correlates of AnA were Specific-
Concerns (rho =0.3), Steroid-Concerns (rho0.24), Perceived lack of empathy from
doctors and nursing staff (PLE) (rho0.29) and age (rho-0.29). Thus, younger patients and
those with stronger concerns about their prescribed medication as a whole and steroids
were more likely to deliberately adjust or miss-out doses of asthma medication, as were
those who believed that doctors and nurses did not appreciate what it is like to have
asthma (PLE).
Correlates of Passive Nonadherence (PnA)
Patients were likely to report forgetting to take their asthma medication if they held
weaker beliefs in the necessity of prescribed medication (lower Specific-Necessity scores) or
thought that their asthma would be an illness of short duration, (lower Timeline scores),
which was caused by diet. PnA was also correlated with younger age Also patients who
believed that control over their asthma was dependent on medication were less likely to
forget to take it. In the sub-set of patients who completed the Self-Rated Health scale,
those who rated their health as better, forgot to take their medication more frequentiy.
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Table 8.10 Spearman correlation coefficients of self-reported
Active(adjusting dose) and Passive (forgetting doses) medication non-
adherence in a sample of patients attending an asthma out-patient clinic
(n=78)
Variable	 Frequency of AnA	 Frequency of PnA










I PQ-1 dentity	 -.04	 -.03
I PQ-Attributions	 -.01	 .04
I PQ-Timeline	 .02	 -.31"°"









own behaviour	 .07	 .18
germ or virus
Perceived Control Over Asthma (PCA) 	 .06	 .06
Medication Control Over Asthma (MCA)	 -.07
Perceived lack of empathy (PLE) 	 .29*	 .20
Perceived effect of medication on symptoms	 -.10	 -.19
PEMS





Educational experience	 .04	 .12
Number of prescribed medicines 	 -.02	 -.22
Duration of diabetes (years)	 .11	 -.16
*p <0 05 "°p<O.O I
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Key predictors of reports of passive and active non adherence to medication
These were identified from the results of two multiple linear regression analyses, using
AnA (see Table 8.11) and PnA (see Table 8.12), as the respective dependent variables.
Intentional nonadherence was predicted by perceived lack of empathy from medical and
nursing staff, concerns about the prescribed medication as a whole and younger age.
Together, these variables explained 22% of the variance, with Specific-Concerns alone
accounting for 8% of variance in AnA. The reported tendency to forget to take medication
was predicted by younger age and weaker beliefs in the necessity of asthma medication for
maintaining health, with these variables explaining 33% variance in PnA.
Table 8.11 Linear regression model using AnA as the dependent
variable
Variable	 B	 SE B	 Beta	 T	 Sig T	 Cumulative R2
Perceived lack of empathy	 .40	 .20	 .22	 2.00	 <.01	 .09
Specific-Concerns	 .14	 .05	 .28	 2.60	 <.01	 .17
Age	 -.03	 .01	 -.24	 -2.21	 <.05	 .22
Table 8.1 2	 Linear regression model using PnA as the dependent variables
Variable	 B	 SE B	 Beta	 T	 Sig T	 Cumulative R2
AGE	 -.05	 .01	 -.49	 -5.0	 <.01	 .28
Specific-Necessity	 -.13	 .06	 -.22	 -2.3	 <.05	 .33
(Constant)	 9.6	 1.2	 8.3	 <.01
8.3.3 Discussion
The major predictors of both active and passive nonadherence were patients' age and
personal beliefs. The finding that age and medication beliefs were correlated with reported
adherence in the asthma sample was reported in Study I in this chapter. The present study
augments this earlier analysis by identifying the differential predictors of two forms of
adherence behaviour. Whereas younger age was associated with both types of adherence
behaviour, the salient beliefs differed according to PnA and AnA. This exploratory study
has considerable limitations which are discussed in more detail below. However, it is one
of the first to investigate associations between representations of illness, beliefs about
medication and active and passive nonadherence to medication. The findings will be
discussed under the following headings:
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Interrelations between medication and illness beliefs Interactions between the identity,
timeline, consequences and cure/control components of asthma representation were
similar to those noted in previous studies (Moss-Morris et al. 1996; Petrie et al. 1996;
Weinman et al. 1996). Similarly, associations between illness and medication beliefs
suggest that patients' ideas about illness and treatment were logically connected. The use
of a modified form of the BMQ to assess patients beliefs about steroids, provided an
opportunity to evaluate the contribution of beliefs about an individual component to beliefs
about the regimen as a whole. Correlations between BMQ-Specific and Beliefs about
Steriods scales suggest that, in responding to the BMQ-Specific scales, patients are
presenting a view of their prescribed regimen which is a composite of beliefs about
individual components. It is interesting that steroids seem to make a greater contribution
to regimen concerns than to regimen necessity beliefs accounting for approximately 30%
of the variance in Specific-Necessity beliefs and 56% of the variance in Specific-Concerns
about the prescribed asthma regimen. The relative contribution of beliefs about steroids to
perceptions of the asthma regimen as a whole is discussed in more detail in, Chapter 9,
Study 2. The interaction between illness representation, control beliefs and
representations of prescribed medication is discussed in Chapter 9, Study 5.
The effect of age on adherence
The relatively strong associations between age and adherence in this sample were also
noted among other illness groups as discussed earlier in this Chapter. It is particularly
interesting that the effect of age on adherence was independent of medication beliefs. In
this sample age did not correlate with Specific-Concerns (rho-0. I; n=78; p>O. I) or
Specific-Necessity (rho=. 13; n=78; p>O.i) beliefs. Moreover, controlling for Specific-
Necessity beliefs had a negligible effect on the relationship between age and PnA reducing
the Spearman correlation coefficient from 0.51 to 0.49. The finding suggests a direct effect
of age on adherence. Further studies are now needed to explore the mechanism of this
interaction. In particular this might test the exploratory hypothesis suggested in Study I of
this Chapter, that elderly patients tend to have a more cautious approach to illness
management (Leventhal E, A. in press, Leventhal E, A, I 993 a,b).
Active non adherence This was associated with stronger concerns about asthma
medication and perceived lack of empathy (PLE) from medical and nursing staff. The data
suggest that patients with strong concerns about long term effects and the potential for
dependence attempt to reduce the perceived dangers by taking less. This appears
consistent with a self-regulatory approach to medication taking.
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If the PLE construct is interpreted as a marker of dissatisfaction with the HCP-patient
relationship, then the observed relationship with reported AnA is consistent with a
communication model of non-adherence in which dissatisfaction demotivates the patient
toward the therapy (Ley and Llewellyn, 1995). Alternatively, agreement with the
statement 'Doctors and nurses do not know what if feels like to have asthma' might simply
indicate a more independent approach to the management of the illness in which the
patient perceives their own judgement and experience to be much more pertinent than
the advice of HCP who cannot know 'what it is like' to experience the condition. It is
reasonable to assume that such a view might be associated with a tendency to adjust the
use of medication in line with personal beliefs rather than to simply follow the 'doctor's
orders'. One might also surmise that this approach would be associated with high internal
control beliefs, with patients seeing their own actions as influential in determining whether
their asthma gets better or worse. However, in these data relationships between beliefs
about control over asthma and AnA did not reach statistical significance and although they
were in the predicted direction -with high internals reporting greater AnA- correlations
were minuscule (rho.06).
Passive nonadherence Patients beliefs about illness and treatment were also related to
PnA. A direct relationship between beliefs and AnA is predicted by self regulatory theory
but it might seem surprising that beliefs were also related to the reported frequency of
forgetting to take medication. Patients reported that they forgot to their medication more
frequently if they saw their asthma medication as less necessary or if they thought that
asthma would be an illness of short duration which was caused by diet. One interpretation
of this finding is that an important determinant of PnA was the perceived salience of
medication. The correlates of PnA imply that patients had made a decision about the
importance of their medication and those patients who thought that medication was less
important, forgot to take it more often than those who believed it was salient to their
health status.
Control beliefs The relationship between control beliefs and medication adherence is
worthy of mention. Beliefs about control over asthma were not significantly related to
adherence to asthma medication, which was more strongly associated with beliefs that
medication controlled whether asthma got better or worse. This finding is consistent with
current thinking in relation to locus of control beliefs which are thought to become more
predictive with increasing specificity as discussed in Chapter 3 (Furnham and Steele, I 993).
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Perceived salience of medication The perceived salience of medication appears to be
based on a logical amalgamation of beliefs about the necessity of medication and beliefs
about the degree to which control of asthma depends on medication, as well as views
about the duration and cause of asthma. The notion of perceived salience may also explain
the fact that patients with higher self-rated health reported higher rates of PnA. Patients'
who see their health as relatively good think of their medication as less important. The
idea that relations between illness beliefs and PnA might operate through beliefs about the
salience of medication is given credence by the fact that only Specific-Necessity beliefs and
age were retained in the regression model and is further corroborated by correlations
between Specific-Necessity beliefs and medication control over asthma (rhoO.50; n78;
p<O.Ol), self-rated health (rho-O.56; n=46; p<O.Ol) and the relevant illness cognitions:
timeline (rho=-O.50; n=78; p<O.O I) and dietary causal attributions (rho-O.04; n=78;
p>O.l), though the later relationship was small and statistically insignificant.
Peak expiratory flow rate (PEFR) This was selected as an indicator of clinical outcome
because it is the routine measure of disease severity used by the asthma clinic which
hosted the research However, although there was considerable variance in the reported
frequency of active and passive nonadherence, this was not significantly related to PEFR.
This might be because levels of nonadherence were insufficient to reduce the clinical
benefit of the medication or that patients were correct in their judgement of optimal
intake of medication. However, these findings should be interpreted with caution as there
is increasing scepticism about the validity of single time-point determinants of peak flow as
a measure of disease severity and as accurate predictors of morbidity and mortality (Clark
et al. I 992; Apter et al. I 994).
Leventhal's self-regulatory theory How do these findings relate to the SRM? The fact
that adherence behaviours were associated with patients' cognitive representations. is in
keeping with the main principles of self-regulatory theory as applied to medication
adherence (Leventhal et al. 1992). However, several of the findings appear to be at odds
with a literal interpretation of the model. First, medication beliefs were more strongly
related to both active and passive nonadherence than illness representations. Second, the
appraisal process, operationalised here as perceived effects of mediation on symptoms and
self-rated health, was not related to adherence. The observation that medication beliefs
were clearly related to adherence is consistent with those reported in previous sections of
this chapter and together suggest that the explanatory power of the SRM may be
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enhanced by the inclusion of treatment beliefs. This issue will be discussed in greater detail
in the concluding chapter of this thesis.
Limitations of the study The results of this study should be interpreted with caution.
The difficulties of operationalising Leventhal's complex, model which specifies dynamic
interactions between illness cognitions behaviour and appraisal process were alluded to in
Chapter 4. It is particularly difficult to capture such dynamic psychological interactions in a
simple, exploratory cross-sectional study such as this. Although representations of asthma
were assessed using a validated questionnaire (Weinman et al. 1996), other measures
were less stringent. Beliefs about control over asthma were assessed using a questionnaire
which was designed and validated as a measure of control over recovery from physical
disability such as a stroke or orthopaedic fractures (Partridge and Johnston, 1989).
Although the adapted questionnaire used in this study was considered to have face validity
and had an acceptable degree of internal validity in this sample, it has not been fully
validated as a measure of control over asthma.
Similarly, the indicators of subjective appraisal used in this study are of questionable validity
for this purpose. Subjective appraisal was conceptualised as the perceived effect of
medication on well being. It was assumed that responses to the statement 'Whether I feel
better or worse depends on my medicines" would provide an indication of perceived
symptomatic effect of medication on symptoms (PEMS). Self-regulatory theory posits that
the subject appraisal of symptoms strongly influences the construction of cognitive and
emotional representations and provides a framework for the selection and evaluation of
coping procedures. However, the operationalisation of patients' subjective appraisal of the
effects of medication in asthma may be based on a range of factors of which PEMS is only
one. For example a patient may recognise that the steroid component of their medication
regimen is designed to prevent worsening of the asthma, rather than to relieve symptoms.
Thus, it is possible that important aspects of the appraisal process were not included in the
simple single PEMS item used in this study. It may be that the beliefs about medication
control over asthma construct could be interpreted as a component of appraisal and this
was related to adherence. Similarly, the inclusion of self-rated health as an appraisal
indicator can be criticised because this measure was added as an after-thought
approximately half way through the study. This was included as a measure of outcome
following the observation of a clinician colleague that PEFR measurements, although
routinely used as a marker of disease severity, were being subjected to increasing criticism
as discussed above. The available data, in which SRH was correlated with Specific-Necessity
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beliefs and directly with PnA suggest that SRH forms part of a cognitive appraisal of the
salience of medication.
8.3.4 Conclusions
Despite its limitations, this study provides preliminary evidence that adherence to
medication in asthma is influenced by patients' beliefs about their medication and illness.
Patients' cognitive models of their illness were associated with their views about
medication which in turn influenced their reported usage of it. It is significant that beliefs
were related to the frequency of forgetting medication as well as to more active non-
adherence. The tendency to deliberately adjust the medication regimen , outside the
instructions was associated with stronger concerns about the medication, providing further
evidence that AnA may be a strategy to minimise harm by taking less. The pattern of
correlations between beliefs and reported behaviour are consistent with the notion that
patients' beliefs about their illness and treatment are important determinants of adherence
behaviour as suggested by self-regulatory theory.
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CHAPTER 9
The determinants of medication beliefs
The identification of core dimensions of beliefs about general and specific medication and
the finding that medication beliefs were associated with adherence to medication, raises
questions about their determinants. A decade ago, Marteau and Johnston (I 986a)
suggested the need to "ascertain the factors that influence the formation of beliefs that are
the target for change." Representations of illness and treatment are developed within a
social and cultural context There is now increasing interest in the degree to which illness
beliefs are influenced by contextual variables such as age, gender, educational experience
and other socio-cultural factors. Several authors have suggested that knowledge of the
determinants of beliefs might inform the development of models explaining the interaction
between beliefs, behaviour and outcome (Leventhal et al. I 997). Yet, with a few notable
exceptions (e.g. Marteau and Johnston, I 986a), relatively few studies have explicitly set out
to systematically identify the determinants of health-related cognitions. However, enough
evidence has accumulated as a "by-product" of research focusing on the nature or effects
of health cognitions to suggest that socio-demographic characteristics factors may
influence cognition and behaviour. For example, Elaine Leventhal and colleagues (I 993a)
described approaches to health problems and care seeking behaviour which appear to be
characteristic of older patients. In another study of representations of health illness and
medicines in general among residents of the Basque Country, older patients were more
likely to have a more positive attitude to medication in general than their younger
counterparts (Echabe et al. 1992). However, other studies failed to demonstrate a
significant relationship between age and health beliefs (Lim et al. I 994), attitudes to
tranquillisers (Clinthorne, 1986) or asthma medication (Osman et al. 1993).
Although gender related differences in symptom reports and consultation rates have been
noted (Leventhal E, A. I 993a; Nerenz et al. 1986; Prohaska et al. 1987; Prohaska et al.
1985), none of the studies mentioned here has identified a consistent statistically significant
link between gender and health beliefs. Conversely, existing research suggests that
professional status (e.g. lay versus medical) (Marteau, I 990), educational experience
(Echabe et al. I 992; Lim et al. 1994), type of illness (Weinman et al. I 996), cultural origin
(Morgan and Watkins, 1988), trait characteristics such as mood (Croyle and Ditto, I 990)
and experience of the illness in question (Marteau and Johnston, I 986a), may be important
determinants of beliefs about illness and treatment.
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The aim of this final section of the experimental work was to identify some of the
determinants of specific and general medication beliefs. Several studies were therefore
conducted to investigate whether socio-demographic variables (gender, age and
educational experience) were related specific and general medication beliefs. Additionally
the impact of other cognitions such as beliefs about sensitivity to medication, and beliefs
about illness was evaluated. Studies were conducted at two levels. The first was
exploratory, examining interactions between individual variables and BMQ factor scores.
This was followed by a further analysis, using multiple linear regression to identify the
effect of combinations of determinants in explaining variance in the core dimensions of
medication representation. A further, preliminary investigation of the relationship
between medication beliefs and self-report measures of previous and current experience
of medication side-effects was also conducted.
9.1	 Demographic variables and medication beliefs
This study assessed the relationship between age, gender and educational experience on
specific and general beliefs about medicines.
9.1.1 Method
Participants The 6 chronic illness groups comprising the main sample described in Section
6.3:
Measures
• The Beliefs about Medicines Questionnaire (BMQ) (in Section 7.2.1).
• Patient demographic details: age, gender and educational experience assessed as in
Section 6.4.9.
Procedure:
The data collection procedure is described in Section 6.5.
Statistical techniques
• Relations between Gender and BMQ Specific and General scale scores were
investigated using Mann Whitney U
• The effect of age on BMQ Specific and General scale scores was investigated using
Spearman correlation.
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• One way Analysis of Variance with Post Hoc Tukeys HSD test was used to examine
the influence of educational experience on BMQ Specific and General scale scores.
Multivariate analysis of variance (MAN OVA) was not used for analysis of differences in
measures due to the moderate level of intercorrelation between Specific-Concerns and
General-Harm (rhoO.3 I; n524; p,O.O I) and General-Overuse (rhoO.24; n=524; p,O.O I).
9.1.2 Results
Gender There was no significant relation between gender and BMQ factor scores within
the data set at the global or individual diagnostic group level.
Age Spearman correlations between BMQ scores and age of the subject are shown in
Table 9.1. The influence of age on medication beliefs was modest and limited to certain
diagnostic groups. For example, in the pooled data set, age had a small but statistically
significant effect on general beliefs about medicines with older patients having a weak
tendency to attain higher scores on the General-Harm sub-scale. At the single diagnostic
group level, this relationship was only noted among psychiatric out-patients. However, age
on the General-Harm scores was small, accounting for only 4% of the variance in this
dimension
Table 9.1	 Spearman correlations between age and BMQ factors for
various diagnostic groups
Group total Asthma	 Diabetes	 Dialysis	 Cardiac	 Psychiatric	 General-
n =524	 Medical
Specific-	 -0.05	 0.13	 0.35b0	 -0.08	 0.07	 0.01	 0.11
Necessity






0.12	 0.07	 0.22*	 0.18
Harm
General-	 0.08	 0.05	 0.14	 -0.22	 0.03	 0.03	 0.03
Overuse
* p <0.05;	 p <0.01
The relationship between age and BMQ-Specific scores was inconsistent. No significant
correlations were found between age and specific medication beliefs in the combined data
set but, on conducting the analysis in individual diagnostic groups, a mixed picture
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emerged. Younger cardiac patients were more concerned about the potential adverse
effects of their prescribed medication as indicated by the negative correlation between age
and Specific-Concerns (rho = -0.26; n= 116; p<O.Ol), but this effect was not noted in other
diagnostic groups. Younger diabetic patients had stronger beliefs in the necessity of their
treatment (rho = -0.35; n=99; p<O.00I). This sample comprised insulin treated (n=64) and
tablet treated (n=35) diabetics and the effect of age on Specific Necessity beliefs ceased to
be statistically significant after controlling for treatment.
Educational experience Data on educational experience was not available for the
diabetic sample and a further I 2 cases were omitted from the subsequent analysis because
this aspect of the demographic data sheet had not been completed. A final sample of 408
patients (211 male) from several diagnostic groups (asthma n = 75; dialysis n = 47; cardiac
n = II 3; psychiatric n = 88 and general medical in-patients n = 85) was included in a one-
way analysis of variance, of BMQ factors by educational experience, as secondary (n= 190);
tertiary (n I 55); higher (n=63). A post-hoc Tukey's HSD showed that no two educational
groups were significantly different at the 0.05 significance level on the Specific Necessity,
Specific-Concerns or General-Overuse scales. However, educational status was significantly
related to scores on the General-Harm factor (p<O.00 I). People educated to tertiary level
were less likely to have a prototypic view of medication as harmful, whereas patients
educated to secondary level or below tended to have stronger beliefs that medicines are
"harmful, addictive poisons".
9. I .3 Discussion
The finding that gender was not related to medication beliefs is consistent with previous
work which has failed to establish a direct link between gender and health beliefs. Similarly,
age per-se had little effect on beliefs about prescribed medication with the exception of
the cardiac sample. Younger patients with chronic cardiac disease had stronger concerns
about their prescribed medication. Specific-Concerns arise from beliefs about the potential
of prescribed medication to cause dependence and long-term effects, and a representation
of medication as disruptive and mysterious. One explanation for this finding is that these
issues would be far more salient for younger patients. If this were so then why was this
relationship not noted in other groups? The answer to this question may lie in the fact the
cardiac group had a broad age range (21 to 86 years) and a significantly higher mean age
than all groups. (One-way analysis of variance with post-hoc Tukey's HSD p<O.00I). This
result implies that Specific-Concerns become less salient in older age. This is logically
consistent with the individual beliefs which comprise this representation. However, further
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studies in other samples are needed to verify this finding and support the explanatory
hypothesis.
The effect of age on Specific Necessity, limited to the diabetic sample, appears to be an
artefact arising from age-related differences in type of treatment Younger patients, who
had stronger beliefs in the necessity of their treatment were predominantly treated with
insulin as opposed to oral hypoglycaemic agents which were more commonly prescribed
for older patients. An explanatory hypothesis is that insulin-treated diabetics perceive their
illness as more severe and consequently see their treatment as more necessary than
tablet-treated patients. This sample also completed the Illness Perceptions Questionnaire
(IPQ) (Weinman et al. 1996), which assess the components of illness representation,
described by Leventhal (Leventhal et al. I 992a; Leventhal and Nerenz, 1985; Leventhal et
al. 1980). Thus, the explanatory hypothesis could be tested in that higher timeline, identity
and consequence scores would be consistent with this explanation. As expected, insulin-
treated patients had significantly stronger Identity scores (t = 2.26; df = 84; p<O.O5),
perceived their illness as more chronic (higher Timeline scores: t = 4.27; df = 96; p<O.00I)
with more severe consequences (higher Consequences scores: t = 3.78; df = 77; p<O.00I)
than tablet-treated patients. Moreover, the correlation between age and specific-necessity
beliefs was not statistically significant after controlling for Timeline and Consequence
scores. This finding, and that obtained in the cardiac sample, provide a preliminary insight
into the determinants of medication beliefs. It seems that any differences in medication
beliefs associated with age arose from a logical "common-sense" interpretation of age-
related differences in illness and treatment, rather than differences in cognition which arise
as a direct effect of ageing. Although, further studies are needed to test the generalisability
of this finding it is consistent with the view of the patient as a rational 'problem solver'
(Leventhal and Diefenback, 1991).
The pattern of relationships between demographic data and beliefs about medicines in
general is almost identical to that obtained by Lim, Schwarz & Lo (1994) who investigated
the prevalence of "traditional" Chinese health beliefs in a sample of over 900 Hong Kong
Chinese. Age and gender did not influence beliefs but those with less formal education
were more likely to have stronger Chinese health beliefs. In the present study, patients
with less formal education had a more negative view of medication. It may be that formal
education leads to a more positive orientation to "western" biomedicine with its emphasis
on drug treatment of disease and away from a more traditional "folk" interpretation of
health and illness such as those described by Patcher (1994). However, it should be noted
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that the effect of educational experience on general medication beliefs was small. Clearly,
age on finishing full time education is a proxy measure of educational experience as people
may continue their education on a part-time basis. Thus this measure might under-estimate
educational experience which in turn might have obscured a stronger relationship between
education and general views about medication. The impact of social class or occupation
upon medication beliefs was not evaluated, and is a target for future research.
In conclusion, this study suggests that, demographic variables are not strong determinants
of beliefs about specific or general medication. Rather, a close examination of the findings
hints that medication beliefs may be more strongly influenced by other cognitions arising
from characteristics of the illness and treatment, than by demographic variables. The role
of cognitions as determinants of medication beliefs is explored in more detail in further
studies described below.
9.2 Effect of the type of illness and number of prescribed
medications on medication beliefs
Fallsberg, in her qualitative study of conceptions of medication among three groups of
Swedish patients, noted that certain representations seemed to be associated with
particular illness and treatments. In particular, she noted the propensity of asthma patients
to worry about the potential adverse of cortisone (Fallsberg, 1991). Other studies indicate
that the number and dose of prescribed medications might affect perceptions of illness
severity (Donovan and Blake, 1992) and it is interesting to question whether this
relationship might be extended to representations of medication.
Aims of the study
I. To examine whether the characteristic features of particular illnesses and their
associated treatments might influence patients' perceptions of medication and whether
the effect on Specific beliefs would be more profound than on General beliefs.
2. To investigate whether the number of medicines prescribed for the patient were
related to beliefs about specific or general medication.
9.2.1 Method
Participants
• The 6 chronic illness groups comprising the main sample described in Section 6.3.
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Measures
• The Beliefs about Medicines Questionnaire (BMQ) (described in Section 7.2.1).
• Number of medicines prescribed for the patient.
Data on the number of prescribed medicines were obtained from two sources. For
hospitalised patients (the renal, cardiac and general medical inpatient samples), information
on the number of medicines prescribed was obtained from the medical notes and
prescriptions chart. For the out-patient clinic samples (asthma and psychiatric samples)
details about prescribed medication were obtained by asking the patient as the medical
notes were being used by the clinic consultant. Accurate details of the number of
medicines used by the diabetic were not available. However the clinic pharmacist reported
that the majority of patients were prescribed only medication for their diabetes (insulin or
a single oral hypoglycaemic agent.
Procedure
The data collection procedure is described in Section 6.5.
Statistical techniques
• Differences between BMQ- Specific and General scores across illness samples were
assessed using a series of one-way analysis of variance (ANOVA), followed by post-hoc
Tukey's HSD test. Multivariate analysis of variance (MANOVA) was not used for
analysis of differences in measures due to the moderate level of intercorrelation
between Specific-Concerns and General-Harm (rhoO.3 I; n=524; p,O.O I) and General-
Overuse (rhoO.24; n=524; p<O.Ol).
• Relations between the number of prescribed medicines and the BMQ-Specific and
General scales was examined using Spearman correlation.
There was a possibility that any associations between medication beliefs and number of
medicines would be confounded by recall bias. Patients who think their prescribed
medication is more important or are more concerned about its potential harmful effects
may recall more of them. In order to control for this, correlations between BMQ scores
and number of medicines were examined in two ways: first as a total sample of 5 illness
groups (asthma, renal, cardiac, general medical and psychiatric samples), then separately
according to whether information about number of prescribed medicines was obtained
from the medical notes (hospital inpatients: renal, cardiac and general medical) or patient
recall (asthma and psychiatric clinic samples).
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9.2.2 Results
Type of illness/treatment and medication beliefs: One way analysis of variance with
post-hoc Tukey's HSD, revealed significant differences in BMQ-Specific scores according
to diagnostic group. These data were used as evidence for the discriminant validity of the
BMQ and are provided in Table 7.12. However for ease of reference, these data are
repeated in Table 9.2 and as box plots in Figure 9.1 The diabetic group had significantiy
higher Specific-Necessity scores than all other groups and the asthma patients had
significantly higher scores than the psychiatric outpatients who attained the lowest mean
Specific-Necessity score of all the groups. Asthma and psychiatric patients also had
significantly higher scores on the Specific-Concerns scale. Diabetic patients who, as a group
had higher scores on the Specific-Necessity scale were also significantly less likely to believe
that medicines in general were overused by doctors (General-Overuse) than did patients
with chronic heart disease or general hospital inpatients (p<O.OS). Conversely beliefs about
the general nature of medicines as opposed to how they are used by doctors (General-
Harm), were independent of type of illness.
Number of prescribed medicines The effect of number of prescribed medications on
beliefs about medicines was evaluated in the asthma, renal, cardiac psychiatric general
medical inpatients groups. The number of medications was positively correlated with
Specific Necessity beliefs (rhoO.38; n=399; p<O.Ol), but there was no significant
relationship with other BMQ factors. Considered separately as hospital (renal, cardiac and
general medical) and clinic (asthma, psychiatric) samples, correlations between Specific-
Necessity and number of prescribed medicines were significant for both the hospital group
where information on the number of medicines was obtained from the medical notes
(rhoO.32; n=238; p<O.Ol), and the clinic group where information was recalled by the
patient (rhoO.49; n= I 61; p<O.Ol).
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Table 9.2 Scale means and standard deviations for BMQ scales for the
six illness groups comprising the main sample
Note: Means sharing a common subscript are not significantly different by HSD test (p>O.OS).
9.2.3 Discussion
The observed interactions between type of illness and medication beliefs are salient when
one considers the type of medication prescribed for each illness and its likely effect on
symptoms. For example, diabetic patients who had significantly higher Specific Necessity
scores than all other groups, are usually aware that, without treatment (insulin or oral
hypoglycaemic agents), their condition will deteriorate rapidly. The finding that asthma
patients had stronger Specific Necessity beliefs than psychiatric out-patients might be
partially attributed to the perceived relationship between medication taking and symptoms.
Leventhal, H and Leventhal, E (I 993) have pointed out the importance of concrete
symptom experience in guiding peoples' representations of illness and this might also be
true for representations of prescribed medication. Each of these conditions tends to
produce very different concrete symptom experiences in relation to medication. Symptom
relief in asthma can often be closely linked to using prescribed medication. Similarly,
omitting medication may quickly result in adverse symptoms. Conversely, patients
receiving medication for mental health related problems may perceive a much more
tenuous link between their medication and concrete benefit in terms on symptoms.
Conclusions from these data are clearly tentative and more work is needed to complete
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Figure 9.1 Comparison of Specific-Concerns and Specific-Necessity scores
between diagnostic groups
Variations in scores on the Specific-Concerns scale across diagnostic groups might also be
explained by the perceived characteristics of specific types of medication, used in the
treatment of these conditions. Asthma patients had the highest scores on this scale,
followed in close second place by psychiatric outpatients. Asthma treatment often
incorporates corticosteroids. Steroids are a large group of compounds, some of which may
produce adverse side effects. Additionally, other members of this group are frequently
misused in sport. In short, this class of drugs has a high "media-profile" and patients'
concerns might be influenced by this, particularly if they fail to differentiate between
steroids they are taking for asthma (which are generally inhaled and therefore less
"dangerous") and more potent formulations upon which media attention is often focused.
This explanation is supported by the finding that in this sample, concerns about steroids
were particularly salient, explaining over 50% of the variance in concerns about the asthma
regimen as a whole, as detailed in Chapter 8, study 3. Moreover, a recent study has also
identified worries about steroids as a cultural determinant of treatment use in asthma
(Hand and Bradley, 1996). This idea can also be extended to help explain higher concern in
the psychiatric out-patient sample, as these patients are often treated with "tranquillisers",
which have also received adverse media attention (Cohen, I 983). The notion that patients'
cognitive representations of medication arise, at least in part, from a logical interpretation
of perceived characteristics and effects of specific medication is reinforced by the finding
that scores on the General-Harm scale were not influenced by the type of illness. This scale
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assesses beliefs about the harmful nature of medicines in general rather than medication
prescribed a particular illness.
In conclusion, the findings support the hypothesis that the illness and treatment influences
representations of prescribed medication. The observation that Specific Necessity beliefs
were positively correlated with the number of medicines prescribed concurs with previous
reports that patients may interpret the number of prescribed medication as markers for
disease severity or treatment necessity (Donovan and Blake, I 992; Morgan and Watkins,
I 988; Leventhal et al. 1991). Moreover, this relationship was held in the hospital samples
where data were obtained from the medical notes -supporting the premise that it is a true
effect, rather than a confounder arising from recall bias.
In summary, the present study provides tentative support for the role of the perceived
characteristics of the treatments associated with particular illnesses as determinants of
medication beliefs. It also focuses attention on the possible role of perceived adverse or
beneficial effect of medication upon symptoms as a determinant of beliefs about prescribed
medication. A related question is whether the level of concern about prescribed
medication is related to beliefs about personal susceptibility. These questions were
addressed in Study 3 which is described below.
9.3 The role of beliefs about personal susceptibility to the
adverse effects of medication and perceived effects of
medication on symptoms
This study set out to explore the role of two aspects of cognition as antecedents of
medication representations. These are detailed below, together with a brief rationale for
their inclusion in the study:
Perceived effect of prescribed medication on illness symptoms
Pennebaker (1982), has shown that illness-related cognitions and the interpretation of
physical symptoms are closely related . Also, self-regulatory theory suggests that illness
representations and the selection and appraisal of coping procedures are influenced by
current and past experience of symptoms, and there is evidence to support this (Gonder-
Frederick and Ccx, I 991; Love et al. I 989; Leventhal et al. I 986). Thus, it is salient to
question whether representations of medicines might also be influenced by their perceived
effects on symptoms. In particular, it might be anticipated that a perception that prescribed
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medication made one "feel better" by improving symptoms would result in stronger beliefs
in its necessity. Conversely, one would not anticipate a strong interaction between a
patient's perception of how the medication affected the symptoms of their illness and
beliefs about the danger of dependence or long-term effects attributed to the medication
represented by the Specific-Concerns dimension.
Perceptions of personal susceptibility to the adverse effects of medication
The HBM stresses the importance of beliefs and personal susceptibility in the
interpretation of health threats (Rosenstock, 1974). In questioning the determinants of
concerns about adverse effects of medication, it therefore seems apposite to examine the
role of perceived susceptibility to the adverse effects of medication as health threats.
The study hypotheses were that
I. Specific-Necessity beliefs would be positively influenced by the perceived symptomatic
benefit of prescribed medication (i.e. significant positive correlations would be obtained
between Specific-Necessity and scores on the Perceived effect of prescribed medication
on symptoms (PEMS) scale.
2. Patients with stronger beliefs in their personal vulnerability to the adverse effects of
prescribed medication would have stronger concerns about medication prescribed for
their illness; (i.e. significant positive correlations would be obtained between Specific-
Concerns and scores on the Sensitive Soma (SS) Scale).
3. The cognitive variables specified in I and 2 above (i.e. the PEMS and SS constructs)
would be stronger determinants of medication beliefs than patient demographic
characteristics (age, gender, educational experience).
9.3.1 Method
Participants
Participants were patients comprising the Cardiac and General-Medical In-patient samples
described in Section 6.3.1.5.
Measures
• The Beliefs about Medicines Questionnaire (BMQ) described in Section 7.2. I.
• Perceived effect of prescribed medication on symptoms (PEMS) described in Section
6.4.6.
• The Sensitive Soma scale described in Section 6.4.7.
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Patient demographic details: age, gender and educational experience assessed as in
Section 6.4.9.
Statistical techniques
• Relations between BMQ Specific and General scale scores and SS and PEMS scales
were investigated using Spearman correlation.
• The percentage variance in BMQ Specific and General scores explained by SS, PEMS
and demographic variables was investigated by multiple linear regression using the
stepwise entry and removal method, setting probability F for entry an removal at 0.05
and 0.01. The rationale for using this parametric technique with ordinal data (e.g.
gender and the BMQ, SS and PEMS scales) is presented in Section 6.6.
Procedure
The data collection procedure is described in Section 6.5. Analyses were performed in two
stages. Spearman correlations between the SS scale, PEMS scores and BMQ factors scores
were first assessed separately in the cardiac (n = I 20) and general medical samples (n =9 I).
The relative role of these variables and other factors, such as age, educational experience
and number of prescribed medicines in predicting the dimensions of specific and general
beliefs about medicines, was then investigated by multiple linear regression analysis of
pooled data from both groups. A series of regression analyses were computed using each
BMQ factor as the dependent variable. In each cases the three other BMQ factors were
entered using a stepwise method along with SS scores, SE scores, age, educational
experience, and the number of prescribed medicines.
9.3.2 Results
Frequency distributions of scores on the SS and PEMS scales are shown in Figures 9.2 and
9.3. Spearman correlations between BMQ factor scores, SS scores, PEMS scores and
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Table 9.3 Spearman correlations between BMQ factor scores, SS scores
and PEMS scores in the general medical inpatients sample (upper-level
figures; n=9 I) and the cardiac sample (lower level figures; n= 119)
Sensitive	 PEMS	 Number of	 Specific-	 Specific-	 General-
Soma Scale	 medicines	 Necessity	 Concerns	 Harm
(SS)	 prescribed
Specific-	 -.01	 .52	 0.45



















* p <0.05;	 p <0.01;
PEMS: Perceived Effects of prescribed medication on symptoms scale (higher scores indicating
greater perceived effect)
Sensitive Soma Scale: assesses perceptions about personal sensitivity to the adverse effects of
medication (higher scores indicating greater perceived sensitivity)
A similar pattern of correlations was obtained for both samples. Significant correlations
were obtained between Specific Necessity beliefs and the perceived effect of medication on
symptoms and the number of medicines prescribed. Perceived sensitivity to the potential
adverse effects of medication (SS scores) were related to Specific-Concerns about
prescribed medication accounting for 19% and 25% of variance in this dimension. SS scores
also correlated with more general beliefs about medication, in the predicted direction, but
here the relationship was weaker. Correlations between specific and general beliefs about
medicines were similar to those reported in the combined data set from 6 diagnostic
groups reported in Chapter 7 and show that Specific-Concerns were related to General-
Harm and General-Overuse scores.
The fact that a similar pattern of correlations was obtained in both cardiac and general-
medical data sets justified pooling the data from both samples for the regression analyses.
Table 9.4 shows the results of linear regression analyses using the BMQ factors as the
dependent variables and entering the three other BMQ factors, SS scores, SE scores,
number of prescribed medicines, age, and educational experience as the dependent
variables. The table shows only those variables retained within the model after step-wise
entry and removal.
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Table 9.4. Linear regression analyses of determinants of beliefs about
specific and general medication in pooled data from the cardiac and
general medical in-patient samples (n=2 I I)
BMQ factor Variable	 B	 SE B	 Beta	 T	 Sig I	 CumulativeAdjusted
R square
Specific	 PEMSV	 1.44	 .15	 .55	 9.5	 <0.01	 .35
Necessity	 MEDS*	 .31	 .08	 .23	 3.9	 <0.01	 .39
Specific	 Sensitive-Soma	 .42	 .06	 .42	 7.14	 <0.01	 .24
Concerns	 General-Harm	 .44	 .08	 .31	 5.01	 <0.01	 .34
Age	 -3.7E-02	 .01	 -.16	 -2.80	 <0.01	 .36
General-Overuse	 .18	 .08	 .13	 2.17	 <0.05	 .37
General	 Specific-Concerns	 .27	 .05	 .38	 5.74	 <0.01	 .16
Harm	 General-Overuse	 .21	 .06	 .22	 3.28	 .<0.0l	 .21
Age	 2.95E-02	 .01	 .19	 2.89	 <0.01	 .24
General	 General-Harm	 .25	 .08	 .25	 3.31	 <0.01	 .10
Overuse	 Specific Necessity	 -.12	 .05	 -.16	 -2.37	 <0.05	 .12
Specific-Concerns	 .11	 .05	 .16	 2.14	 <0.05	 .14
Perceived Effect of Medication on Symptoms Scale (PEMS)
* MEDS = number of prescribed medicines
The key determinants of Specific Necessity beliefs were the perceived effects of specific
medication on symptoms and the number of medicines prescribed for the patient. These
variables accounted for 40% of the variance in the Specific Necessity dimension. Specific-
Concerns were determined by perceived sensitivity to the potential adverse of medication
(Sensitive Soma scores), and beliefs that medicines in general are harmful, addictive
poisons which should not be taken for long periods of time (General-Harm). These two
cognitive variables alone explained 35% of the variance in Specific-Concerns. Adding age and
educational experience to the model explained an additional 4% of the variance in this
factor. The major determinants of general beliefs about medication also turned out to be
other cognitions. Specific-Concerns and General-Overuse accounted for 22%, with age adding
a further 3%, to the explained variance in the General-Harm dimension. The determinants
of beliefs that medicines are overused by doctors were General-Harm and Specific Necessity
beliefs which accounted for I 3% of the variance in the General-Overuse factor.
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9.3.3 Discussion
Relations between beliefs about prescribed medication (BMQ-Specific) and perceptions of
symptomatic benefit (PEMS) and susceptibility to adverse effects (SS) confirmed the study
hypotheses. Patients who associated their medication with greater symptomatic benefit
had stronger beliefs in its necessity for maintaining health. Patients who perceived
themselves to be more sensitive to the potential adverse effects of medicines had stronger
concerns about medication which had been prescribed for them. Moreover, cognitive
variables such as the perceived effects of medication on symptoms and perceived
susceptibility to the adverse effects of medicines were far stronger determinants of the
core dimensions of medication representation than were the socio-demographic variables
studied. Although age and educational experience were determinants of Specific-Concerns
and age of General-Harm they added little to the explained variance in these dimensions.
Moreover, linear regression analyses of the determinants of each of the BMQ factors
revealed a logically coherent pattern of interactions between specific and general beliefs
about medication and other cognitive variables.
The determinants of each BMQ factor imply that patients' ideas about medication are
coherent in "common-sense" terms. For example, patients were more likely to have
strong beliefs in the necessity of their medication if it was perceived to affect their
symptoms. Similarly, necessity beliefs tended to be stronger with more medicines
prescribed. There is evidence that some patients use the number of medicines prescribed
for them as an indication of disease severity (Donovan and Blake, I 992; Morgan and
Watkins, I 988; Leventhal et al. 1991). Presumably, this in turn, influences the perception of
the necessity of their medication. Unfortunately, data on illness representations was not
available for the cardiac and general medical samples used in this study and so the validity
of this explanation could not be tested. However relations between medication beliefs and
the components of illness representation are explored in Section 9.5. One might expect
that Timeline, Identity, Consequences and Cure scores would be positively correlated with
Specific Necessity beliefs and would add to the variance in these beliefs which is explained
by perceived symptom effects. However, the effect of the number of prescribed medicines
may then cease to add significantly to the model, if, as suggested, patients' interpret this as
a proxy measure of the severity of their illness.
The key determinants of Specific-Concerns were beliefs about the harmful nature of
medicines in general (General-Harm) and beliefs about personal susceptibility to such effects
(Sensitive Soma). The General-Harm factor may represent a prototypic view of medication,
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analogous to the disease prototypes noted in studies of lay representation of illness
(Bishop, 1987; Bishop and Converse, 1986). Thus these concerns about specific prescribed
medication are linked to more general beliefs that medicines are intrinsically harmful and
perceived vulnerability to there effects.
The frequency histogram of Sensitive Soma scores obtained for the study sample (Figure
9.3) indicates a wide variation in the degree to which patients believe that they are
susceptible to the adverse effects of medication. The utility of this scale as a determinant
of Specific-Concerns about prescribed medication focuses interest on the origin and
determinants of Sensitive Soma beliefs. Sensitive Soma representations are grounded in the
past experience of adverse medication effects. For example, one of the items asks the
respondent to state their level of agreement with the statement "I have had a bad reaction
to medicines in the past". (In the combined cardiac and general hospital in-patient samples
69% disagreed with this statement, 8% were uncertain and 23% agreed). However, the
item to scale correlation is 0.7 indicating that other factors also determine Sensitive Soma
beliefs. In this context, it is interesting to speculate whether Specific-Concerns, and Sensitive
Soma beliefs share an underlying dispositional factor, such as Negative Affectivity (Watson
and Pennebaker, 1991).
The relationships between general beliefs about overuse and harm and specific beliefs
about prescribed medication were logically coherent. Although, it is difficult to be certain
about the direction of influence between general and specific beliefs, the data described is
consistent with a multi-directional path. For, example the level of agreement with the
notion that doctors overuse medication (General-Overuse) was influenced by prototypic
views about medicines as essentially harmful (General-Harm) but also by beliefs about the
necessity of medication which had been prescribed for current use in the treatment of the
patient's illness. Conversely, Specific Necessity beliefs were not significantly influenced by
General-Overuse beliefs. The interaction between Specific-Concerns and General-Harm was bi-
directional. This form of interaction between prototypic beliefs and specific beliefs, having
experiential and cognitive components, is consistent with self-regulation (Leventhal et al.
I 992a).
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9.4 The experience of medication side-effects as a
determinant of medication beliefs
This study address relations between patients' reported experience of adverse effects
attributed to medication and their beliefs about their prescribed medication and about and
medicines in general. Self-regulatory theory suggests that illness representations have both
abstract and experiential components. The latter, in the form of symptoms are important
in the formation of illness representations (Cameron et al. 1993; Baumann et al. I 989).
The previous study had shown that concerns about medication were related to abstract
ideas about personal susceptibility to the adverse effects of medication. In line with self-
regulatory theory one might therefore expect the perceived experience of medication
side-effects to influence representations of medication, particularly concerns about
prescribed medicines. The present study set out to investigate this question in a sample of
oncology patients. Furthermore, data collected on the number of medication and
sociodemographic data made it possible to investigate the extent to which inter-relations
between BMQ factors and socio-demographic variables described in previous studies
above could be confirmed in a sample of oncology patients.
9.4.1 Method
Participants
The oncology patients described in Section 6.3.2.2.
Measures
• The Beliefs about Medicines Questionnaire (BMQ) described in Section 7.2. I.
• Patient demographic details: age, gender and educational experience assessed as in
Section 6.4.9.
• Current experience of medication side-effects (Present-ESE) was assessed by
responses to the single statement 'The side-effects of my medication sometimes make me
unwell'. Responses were scored on a 5-point Likert scale where I = strongly disagree, 2
= disagree, 3 = uncertain, 4 agree and 5 = strongly agree. Thus higher scores indicate
greater experience of side-effects from present medication.
• Past experience of medication side effects (Past-ESE) was assessed by
responses to the single statement 'I have experienced side-effects from medication in the
past' Responses were scored on a 5-point Likert scale where I = strongly disagree, 2 =
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disagree, 3 = uncertain, 4 agree and 5 = strongly agree. Thus higher scores indicate
greater experience of side-effects from past medication.
Procedure:
The data collection procedure is described in Section 6.5.
Statistical techniques
• Relations between reported experience of side-effects and medication beliefs were
investigated using Spearman correlation.
• In order to explore the relationship between Specific-Concerns and Present-ESE in more
detail a test-for equality of means was conducted on the Specific-Concerns sub-scale and
a dichotomised version of the Present-ESE scale. (Group I strongly agree/agree; Group
2= uncertain/disagree/strongly disagree).
9.4.2 Results
Scores on the BMQ sub-scales and experience of side-effects statements are shown in
Tables 9.5 and 9.6 below.
Table 9.5 Profile of BMQ scores and response to side effect statements













Table 9.6 Percentage responses to statements eliciting perceived
experience of side-effects
Experience of side-effects (ESE) 	 Strongly	 Agree	 Uncertain	 Disagree	 Strongly
agree	 disagree
The side-effects of my medication sometimes 	 13.3	 50.6	 6.0	 21.7	 8.4
make me unwell (Present-ESE)
I have experienced side-effects from medication 8.0	 44.8	 4.6	 36.8	 5.7
in the past (Past-ESE)
Note: some of the questionnaires were not entirely complete and correlations were
computed using the available data. Thus for some tests, the number of subjects is less
than the total sample (n=9 I).
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A significant positive correlation was observed between Present-ESE scores and Specific-
Concerns (rho = 0.34; n=8 I; p<O.005), but with no other BMQ factor. No significant
interactions were observed between Past-ESE and any of the BMQ factors.
In order to explore the relationship between Specific-Concerns and Present-ESE in more
detail a test-for equality of means was conducted on the Specific-Concerns sub-scale and a
dichotomised version of the Present-ESE scale. (Group I =strongly agree/agree; Group 2=
uncertain/disagree/strongly disagree). Patients in Group I had significantly higher mean
Specific-Concerns scores than those in Group in 2 (14. I vs I I .6, t = -3.1; df = 79; p<O.00S).
In this study an interesting difference was seen in the pattern of correlation between
specific and general medication beliefs. As with previous data sets General-Overuse and
General-Harm beliefs were significantly correlated (rho = 0.44; n=88; p<O.00I). However,
in contrast to earlier findings, Specific-Concerns were not significantly correlated with
General-Harm or General-Overuse beliefs. There was a weak negative correlation between
Specific Necessity and General-Overuse beliefs which did not reach significance at the 0.05
level (rho = 0.21; n=88; p<O.O6). As in previous data sets Specific Necessity beliefs were
weakly positively correlated with the number of prescribed medicines (rho= 0.22; n=88;
p<O.O5).
The relationship between demographic variables and BMQ-Specific factors was similar to
previous data sets with no significant difference in scores according to age, sex or
educational experience. Similarly General-Overuse and General-Harm scores were positively
correlated with age (rho0.3; n=88; p<O.OI and rho0.26; n88; p<O.OS). In contrast to all
other data sets studied to date, significant gender differences were noted in General-
Overuse scores with women attaining significantly higher mean scores that men (I 2.7 vs
1.4 t = -2.6; df = 8.6; p<O.OS). No gender related differences were seen in any other
BMQ-scores or in reported experience of side-effects.
9.4.3 Discussion
This study provides additional evidence in support of a coherent interaction between
experience, attribution and individual BMQ dimensions. Consistent with self-regulatory
theory, patients who reported having experienced side-effects associated with their
current medication were much more likely to be concerned about current disruption and
future harm and dependence (Specific-Concerns). However, this relationship was limited to
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experience with current prescribed medication and was not extrapolated from
experiences in the past. An interesting finding was that, although a similar distribution of
beliefs about medicines in general was found among oncology patients and patients from
other diagnostic groups, these did not influence Specific-Concerns in the oncology sample.
One interpretation of this finding is that in the oncology group concerns arise from beliefs
about a class of medicines (anti-cancer drugs) which are distinguished from medicines in
general. In this case prototypic beliefs about anti-cancer drugs may have a stronger
influence on beliefs about prescribed medication than more general beliefs about medicines
as a whole. This explanatory hypothesis is supported by data from the asthma clinic
sample (n=78), described in Section 8.3 in which beliefs about steroids (a specific class of
drugs included as a component of the asthma regimen) had a much stronger effect on
beliefs about the prescribed regimen than beliefs about medicines in general. This issue
should be investigated in more detail. For example semantic differential techniques could
be used to assess the degree to which people differentially attribute certain properties
(e.g. long-term adverse effects, dependence, disruption, worry) to particular classes of
drugs (e.g. anti-cancer medication vs. aspirin, vs. insulin etc.).
In the main, this study of oncology patients confirms previous findings in other illness
groups that demographic factors do not influence beliefs about specific prescribed
medication, but may be weakly related to more general medication beliefs. The
observation that women had significantly higher scores on the General-Overuse dimension,
conflicts with previous findings and cannot easily be explained. Further work is necessary
to determine whether this is an anomaly.
9.5 The effect of illness cognitions on medication beliefs
Recent research on illness perceptions has found congruent associations between the five
components of illness representation (Petrie et al. 1996; Weinman et al. 1996). For
example, in Petrie and colleagues' prospective study of first time myocardial infarction
patients, those who considered their heart condition to be of long duration, perceived it to
have more severe personal consequences and were less likely to believe that it could be
controlled or cured. These parameters might also influence the perception of prescribed
medication. The present study examined associations between medication beliefs and
these aspects of illness cognition: the five components of illness representation identified
by Leventhal and beliefs about control over illness. This was an exploratory study which
set out to examine correlations between illness perceptions, beliefs about control over
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illness and beliefs about specific and general medication. The effect of reported duration of
the patients' current illness on their medication beliefs was also examined.
9.5.1 Method
Participants
The asthma (n=78), diabetic (n=99) and renal (n=47) samples described in Chapter 6.3. I.
Owing to limitations on the number of questionnaire items which could be administered to
the illness groups, the IPQ had only been given to the above three samples. In particular
we aimed to limit the number of items for those pateitns who were acutely ill in hospital.
Thus the cardiac and general medical inpatients did not complete the IPQ. The number of
items which could be administered to the psychiatric sample was limited by the fact that
they were already taking part in an audit questionnaire. Thus the asthma, diabetic and renal
groups completed the IPQ were chosen for inclusion on this basis.
Measures
• The Beliefs about Medicines Questionnaire (BMQ) (in Section 7.2. I).
• The Illness Perception Questionnaire (IPQ) (Weinman et al, I 996- see Section 6.4. I)
• Beliefs about control over illness as described in Section 6.4.2.
• Duration of illness: Estimates of the duration of illness were obtained by asking the
patient how long the current illness had lasted.
Statistical techniques
• Relations between illness perceptions, control beliefs, duration of illness and medication
beliefs were investigated using Spearman correlation.
Procedure
The data collection procedure is described in Section 6.5.
9.5.2 Results
Spearman correlations between BMQ factor scores, the five components of illness
representation, central beliefs are shown in Table 9.7. Although certain correlations
between medication and illness beliefs were significant, the relationships were inconsistent.
Despite, this mixed picture several trends emerged. Interactions were more extensive in

































beliefs and the 5-components of illness representation and control over illness beliefs will
be considered in turn.
Table 9.7 Spearman correlations between BMQ factors and illness and
control beliefs for three diagnostic groups: asthma (n=78), diabetes (n=99)
and renal (n=47). Data in columns relates to asthma, diabetic and dialysis
samples in order.
Specific Necessity 	 Specific-Concerns	 General-Harm	 General-Overuse
Number of	 .00	 .15	 .24*
causal	 -.20	 .19	 .18	 .14
Attributions	 .04	 .18	 .17
IPQ Timeline	 .19	 -.16	 -.20
.41	 -.12	 -.04
.21	 .03	 -.08	 .08





IPQ Control	 .07	 .20	 .18	 .07
.18
-.06	 .06	 .22	 -.02
Control Over	 -.04	 -0.1	 .09
Illness Beliefs
-.07	 -.11	 -.26	 .08
Duration of)	 .14	 .18	 -.11	 -.10
illness (years	 -.13	 -.14	 .14
.27	 .08	 -.03	 .25
Identity Patients who endorsed a larger number of symptoms as being part of their illness
had stronger beliefs in the necessity of their medication but this effects was limited to the
asthma and diabetic groups. The Identity dimension was also positively correlated with
Specific-Concerns in two samples . Asthma and renal patients who held strong Identity beliefs
also had stronger concerns about prescribed medication. In contrast, to beliefs about
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prescribed medicines, Identity scores were not correlated with beliefs about medicines in
general.
Causal attributions The number of causal attributions made by patients was generally not
strongly related to medication representation. An interesting exception was that in the
renal sample, the number of causal attributions was positively correlated with Specific-
Concerns.
Individual causal beliefs Spearman correlations between individual causal beliefs and
BMQ scales are shown in Table 9.8. The relationship between beliefs about individual
causal factors and representations of specific and general medication were particularly
salient for diabetic patients. Those who endorsed other people, stress, diet, pollution of
the environment and personal behaviour as causal factors were less likely to perceived
their medication as necessary for maintaining health. The relationship between causal
beliefs and Specific-Concerns was interesting. Those who attributed the cause of their illness
to chance, other people, pollution of the environment, or their own behaviour had
stronger concerns about their prescribed medicines. In the renal sample this relationship
was extended to include attributions of viral or germ related causes. In this sample this
attribution was also linked to a more negative view of medicines in general as evidenced by
higher scores on the General-Overuse and General-Harm dimensions.
Timeline Views about the chronicity of illness were associated with medication beliefs.
Asthmatic and diabetic patients who expected their condition to last a long time had
stronger beliefs about the necessity of their prescribed medication. Diabetic patients who
thought that their illness would be short-lived had fewer concerns about the long-term
effects or risks of dependent (lower Specific-Concerns scores).
Consequences Diabetics who attributed more severe personal consequences to their
illness had stronger Specific Necessity beliefs. These patients also tended to be more
concerned about the perceived adverse effects of their medication, and this relationship
was also found in the renal group. In the asthma group, patients with stronger beliefs in
the potential for control or cure had slightiy fewer concerns about prescribed medication
and tended to have more positive views about medication in general.
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Table 9.8 Spearman correlations between BMQ factors and Causal beliefs for
three diagnostic groups: asthma (n=78); diabetes (n=99) and renal (n=47).
(Data in columns relates to asthma, diabetic and dialysis samples in order).
Sp ecific-Necesity	 Specific-Concerns	 General-Harm	 General-Overuse









Other people	 -.10	 -.10	 .01	 .16
-.32	 .14	 .01












.15	 .16	 -.09	 .27
Diet	 -.04	 .06	 .12	 .00
-.42°	 .16	 .10	 .09
.15	 .09	 -.09	 .20
Pollution of environment	 .07	 .24*	 .03	 .16
.21 *	 .16	 .03
.03	 .17	 .05	 .29
Own behaviour	 -.16	 -.08	 .03	 .01
.24*	 .25*	
-.11
.14	 -.26	 -.27	 .15
germ orvirus	 -.03	 .04	 .08	 -.04
.14	 .07	 .11	 .19
.17	 •4510	 .40I*	 35*
Control/curability beliefs were not strongly related to medication beliefs. Statistically
significant correlations between IPQ-Control-Cure and BMQ scales were obtained in only
one sample. Diabetic pateitns who perceived low potential curability control had stronger
concerns about prescribed medication.
Perceived control over illness Few relations were found between perceived control over
recovery and medication beliefs. The one exception was that a weak, but statistically
significant, negative correlation between Perceived Control and Specific-Concerns was
observed in the asthma sample, indicating that those with external control beliefs, were
slightly more likely to be concerned about their medication.
206
Duration of illness Significant correlations between reported duration of illness and
medication beliefs were noted in the diabetic sample but not in the asthma or dialysis
sample.
9.5.3 Discussion
This exploratory study is one of the first to link the five components of illness
representations with the core dimensions of medication beliefs. It is immediately striking
that, although illness and medication beliefs were related, there were variations in the
pattern of correlations across the three diagnostic groups. In particular illness and
medication beliefs were more closely associated in the asthma and diabetic samples than in
the renal dialysis sample. This is clearly illustrated by the finding that beliefs about the
nature and severity of symptoms attributed to the illness (Identity) and a more chronic
view of the illness (Timeline) correlated with Specific Necessity beliefs in the asthma and
diabetic samples but not in the renal group.
The explanation for the finding might be found in the features of illness and treatment
which are characteristic of the respective conditions. In asthma and diabetes, medication is
the mainstay of treatment. In contrast, dialysis patients are subjected to a tri-partite regime
of haemodialysis, medication and diet/fluid restrictions. For these patients dialysis is the
primary treatment and the main purpose of diet fluid restrictions and medication is on
maintaining body electrolytes (Will and Johnson, 1994). The primary role of dialysis is
reinforced to the patient by the knowledge that they will die if they miss even a few
successive dialysis sessions. In such circumstances it is perhaps unsurprising that views
about illness identity and timeline beliefs are not closely associated with beliefs about the
medication. For dialysis patients, perceptions of illness might be more closely associated
with representations of haemodialysis then other components of the treatment regimen.
More negative views about personal (Specific-Concerns) and general medication (General-
Harm and General-Overuse ) tended to be associated with more negative views about
illness. Diabetic and asthma patients who perceived their illness to have more severe
personal consequences were more likely to worry about the harmful effects of their
medication. Similarly strong illness Identity beliefs, a larger number of causal attributions
and a low perception of illness controllability (IPQ Cure/Control) were all associated with
stronger Specific-Concerns. Likewise, asthma patients who believed that external factors had
greater control over their illness than factors under internal, personal control were slightly
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more inclined to worry about the perceived adverse effects of their medication. The
negative correlation between Timeline and Specific-Concerns observed in the diabetic sample
appears to be counter-intuitive. One might expect the view of a long term illness to be
associated with increased concerns about the potential for dependence and long-term
effects. However, correlation was weak and limited to this sample and further work is
necessary to ascertain whether this finding is meaningful.
The attribution of symptomatic benefit to medication was positively related to beliefs in its
necessity in all three samples. This is consistent with self-regulatory theory which suggests
that somatic experience exerts an important influence on illness-related cognitions. The
identity component, which measures the perceived experience of symptoms associated the
illness, was also correlated with beliefs about necessity, adding further support to the
notion that beliefs about the necessity of prescribed medication are influenced by
symptoms which are associated with the illness and whether medication is thought to
alleviate them.
It is also interesting that perceptions of the likely duration of illness (Timeline scores) were
more strongly associated with medication beliefs than the actual duration of the disease.
Statistically significant correlation between duration of illness and medication beliefs were
found in only one sample. Diabetic patients who reported a longer duration of illness had
stronger beliefs in the necessity of their prescribed medication (rho0.44; n=99; p<O.Ol).
However, the magnitude of the association was greatly reduced when controlling for
timeline beliefs (rhoo.24; n=99; p<O.05).
9.6 Culture and medication beliefs
Culture is the collective noun for the conventional patterns of thought and behaviour,
including values beliefs and rules of conduct, which distinguish a particular social group and
that are learned rather than inherited (Tattersall, 1995). Culture may thus have a powerful
influence on many aspects of peoples' lives including those relating to health (Helman,
1990). The emergence of culture as a key concept in social research owes much to
anthropologists who have observed and documented beliefs and behaviours which appear
to be characteristic of particular cultural groups. The work of Kleinman has highlighted the
potential role of culture as a determinant of health beliefs. In particular, he asserts that
peoples' 'explanatory models' of illness may be characteristic of a particular culture
(Klein man, I 980; Klein man et al. I 978).
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Explanatory models are lay theories about the causes and mechanisms of disease and
illness which inform beliefs about strategies to promote, maintain or restore health. In
Kleinman's view explanatory models are held by individuals but are strongly influenced by
culture. They may pertain to diseases which are recognised by "western medicine" such as
hypertension (Heurtin-Roberts, 1992) Aids (Farmer, 1994; Farmer and Good, 1991) and
the common cold (Kim and Lagakos, 1994) or to maladies which appear to be unique to
the culture in question and which have no biomedical equivalent. The latter have been
called folk illnesses and Patcher, provides several examples in a review of this topic (I 994).
He also points out that physicians and other health care providers constitute a "cultural
group" on account of their specialised training, language, and codes of ethics and
behaviour. He refers to this as the "culture of biomedicine".
Certain illness beliefs may be characteristic of particular cultures (Sissons-Joshi, I 995).
Futhermore, it is suggested that culturally-specific explanatory models of illness might
influence health related behaviours (Hilbrands et al. I 995; Pachter et al. 1992; Pachter,
I 994; AmaraSingham, 1980). Interest in the role of culture in health beliefs and behaviour
has increased among health psychologists. In a recent paper, Leventhal and colleagues
(1997) suggest that many culturally bound explanatory models may have a common
cognitive basis. For example, notions of "hot- cold" seem to be common to a variety of
explanatory models of illness in several cultures.
Although there is some evidence that notions of modern medicines may be incorporated
into the explanatory models adopted by particular cultural groups (Morgan, I 983; Robbins
and Kirmayer, I 991; Kruse et al. 1994), the effect of culture on medication representations
has yet to be investigated quantitatively. The present study set out to explore interactions
between culture and two aspects of medication beliefs: representations of medicines in
general and beliefs about personal sensitivity to the potential adverse effects of medicines.
It addressed the question of whether people from different cultural groups had
quantitatively different views about the nature and use of medication. Two cultural groups
were chosen for comparison . The first was based on a measure of "cultural background"
according to whether participants classified their cultural background as Asian or
European. The study also addressed the impact of "professional culture" on medication
beliefs by investigating whether students' beliefs about medication differed according to the
university course they had chosen. This follows the notion that professional groups
constitute cultures. The aims of this study were therefore:
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I. To investigate whether representations of medicines in general and beliefs about
personal sensitivity to the potential adverse effects of medicines, differed according to
cultural origin (Asian vs. European).
2. To determine whether representations of medicines in general and beliefs about
personal sensitivity to the potential adverse effects of medicines, differed according to
course attended (pharmacy vs. mechanical engineering, vs. accounting and finance vs.
social policy vs. humanities).
9.6.1 Method
Overview An exploratory cross-sectional study in which undergraduate students at
Brighton University UK, completed questionnaires assessing beliefs about medicines in
general together with demographic details and past and current experience of taking
medication. Five university courses were selected in an attempt to represent a broad range
of chosen topics of study. Topic of study was considered to be a proxy measure of
'professional culture'. The courses were: Pharmacy, Engineering, Accounting and Finance,
Social Policy and Administration, Humanities. The aim was to include a sample of students
from the academic year of each course.
Participants
University undergraduate student sample (n600) described in Section 6.3.2. I.
Measures
• Beliefs about medicines in general assessed using the General-Harm and General-Overuse
scales of the Beliefs about Medicines Questionnaire (BMQ) described in Section 7.2.1.
In order to investigate beliefs about the potential benefits of medicines four statements,
shown in Table 9.9, pertaining to the possible benefits of medication were added to the
BMQ-General. Responses were scored on a 5-point Likert scale where I strongly
disagree and 5 = strongly agree. Although this scale has not yet been fully evaluated or
validated in relation to the BMQ it is here, for convenience, labelled as General-Benefit.
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Table 9.9 Statements assessing beliefs about the benefits of medicines in
general (General-Benefit)
• Medicines help many people to live better lives
• In the future medicines will be developed to cure most diseases
• In most cases the benefits of medicines outweigh the risks.
• Medicines help many people to live longer
Cronbach alpha = 0.54: n=588 (12 sub j ects had missing data)
• The Sensitive Soma scale was used to assess beliefs about personal sensitivity to the
potential adverse effects of medication as detailed in Section 6.4.7.
• Past and present experience of taking medication was assessed by responses to the
following questions:
Are you currently taking prescribed medication (yes/No)
Have you ever received a prescribed medicine (yes/no)
Participants were asked to select their cultural origin by from the following list Afro
Caribbean, African, Asian, European, Other.
• Participant demographic details: age, gender, course attended, year of study.
Procedure
Permission to invite students to take part in the study was obtained from relevant
members of academic staff (e.g. course leaders). Students were approached at the start of
a core-lecture and invited to take part in the study by a third year undergraduate
pharmacy student. Those who agreed were then given five minutes to complete the study
questionnaire before the lecture began. Completed questionnaires were collected by the
student. In most courses students were split into two main groups for ease of teaching and
we aimed to approach at least one group in each year. This was achieved for each year,
but about two thirds of students in year 3 of the Accounting and Finance were not eligible
for inclusion in the study as they were absent on placement during the recruitment period.
Analysis
The analysis was conducted in four stages:
I. The interaction between professional culture (course attended) and medication beliefs
was investigated in the total data set (n600), using analysis of variance with post-hoc
Tukey's HSD.
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2. The effect of cultural background on beliefs was evaluated in a sample of Asian and
European students matched according to course attended, age and gender. Independent
sample t-tests were used to investigate differences in BMQ-General and Sensitive Soma
scale scores using cultural background as the independent variable.
3. Further analyses were conducted to assess the extent to which interactions between
beliefs and cultural background were independent of past and present experience of
taking prescribed medicines. Partial correlations between cultural background (Asian vs.
European) and scores on the BMQ and SS scales, were examined controlling for past
and present experience with prescribed medication.
4. Finally, the combined effect on medication beliefs of cultural background, professional
culture and experience with medication was examined within the matched group (n =
160), by linear regression of the culture and experience variables against each of the
BMQ and SS scales.
9.6.2 Results
The demographic characteristics of the sample are shown in Table 6.4 in the Methodology
chapter. The results of the statistical evaluation of medication beliefs according to cultural
background are described below.
The effect of "professional culture" on medication belie ft
The results of ANOVA with post-hoc Tukey's HSD shown in Table 9. 10 and graphically in
Figure 9.4, indicate that beliefs about medicines in general were significantly influenced by
the course attended. A clear pattern emerged with a distinct ordering effect. The
pharmacy students were significantly more likely to have strong beliefs in the overall
benefits of medication and significantly less likely to believe that medicines in general are
harmful and overused by doctors than all other groups. Moreover, this group were
significantly less likely to perceive themselves as being sensitive to the potential adverse
effects of prescribed medication as indicated by lower group mean scores on the Sensitive
Soma scale. Moreover, positive views about medication in general increased in the
following order humanities, social policy, accountancy, mechanical engineering, pharmacy.
A similar ordering effect was noted for Sensitive Soma scores with pharmacy students
having lower mean scores than all other groups and significantly lower mean scores than




Table 9.10 Scale means and standard deviations for BMQ -General and
Sensitive Soma scales for five undergraduates of five "cultural groups"
Scale	 Pharmacy	 Humanities	 Mechanical	 Accounting	 Social policy &	 F	 p -
Engineering	 & finance	 administration
n154	 n75	 n120	 n133	 n111
General-	 Mean	 8.5	 l0.2	 l0.2	 IO.4	 IO.0	 15.8	 <0.0
Harm	 SD	 2..3	 2.2	 2.4	 2.4	 2.1
General-	 Mean	 13.1 b.c	 14.1 c	 3°b	 33b,c	 2.8	 <0.0
Overuse	 SD	 2.7	 2.8	 2.3	 2.5	 2.5
General-	 Mean	 lS.8	 13.8e	 i4.8	 l4.6	 '44e,f	 15.2	 <0.0
Benefit	 SD	 1.9	 1.8	 2.4	 2.2	 2.0
Sensitive	 Mean	 I I	 2.8	 I I •3 h,	 2h,,	 2.0g,i	 6.3	 <0.0
Soma	 SD	 3.2	 3.4	 3.4	 3.1	 3.4
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Figure 9.4 Box-plot of medication beliefs scores by course
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The effect of cultural background on medication belieft
Cultural background had a clear influence on medication beliefs. Asian participants had a
more negative view about medicines in general than those who had indicated a European
cultural background. Table 9.11 shows that the Asian cultural group had significantly higher
mean scores on the General-Harm and General-Overuse scales indicating stronger beliefs in
the notion that medicines in general are harmful, addictive poisons which should not be
taken for long periods of time and that they are overused by doctors. The Asian group
also had significantly lower scores on the General- Benefit scale indicating less agreement
with the idea that medicines in general have primarily beneficial effects upon health.
Table 9.11 Mean (SD) scores on beliefs about medicines scales in a
sample of Asian and European undergraduate students matched for age,
gender and course attended
Variable	 Asian	 European	 t value	 P value
....(80)(n0)
General-Harm	 10.28 (21)	 9.39 (2.6)	 2.34	 <0.05
General Overuse	 I 3.52 (2.3)	 I 2.40 (2.5)	 2.91	 <0.01
General-Benefit 	 14.57 (2.2	 15.66 (2.0)	 -3.29	 <0.01
.05(3.2.........
The influence of past and present experience of medication taking on cultural
effects
Significantly fewer Asian than European students reported first hand experience with
prescribed medication in the past (34% vs. 56%; Chi square = 8.2; p <0.01) and present
(15% vs. 27% Chi square = 3.7; p <0.05). However, partial correlations between cultural
background and BMQ and SS scales, controlling for past and present experience showed
that differences in belief scores among cultural groups could not simply be attributed to
differences in relative experience of medication (see Table 9.1 2 below).
Table 9.12 Partial correlations between cultural background (Asian vs.
European ) and medication beliefs controlling for past and present
experience with prescribed medication
General-	 General-	 General-	 Sensitive
Harm	 Overuse	 Benefit	 Soma
Cultural Background (Asian vs 	 -.23''	 -.24	 .24'"	 -.06
European)
Cultural Background -controlling	 -.1 6*.	 .20*	 27""	 -.02
for past and present experience
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Evaluation of the combined effects of cultural background, professional culture and
experience of prescribed medication
The results of linear regression analysis within the matched data set (n= I 60), shown in
Table 9.1 3, demonstrate that cultural background had a small but statistically significant
influence on beliefs about medicines in general but not beliefs about personal sensitivity to
the potential adverse effects of medication (Sensitive Soma scores). Moreover, experience
with medication did not add significantly to the variance in belief dimensions, explained by
cultural background and professional culture (course attended).
Table 9.13 Multiple linear regression analyses of BMQ-general and
Sensitive Soma scale scores
Variable	 B	 SE B Beta T	 Sig T R2
General-Harm	 Course	 -.98	 .35	 -.21	 -2.77	 .01	 .10
Culture	 .54	 .12	 .33	 4.36	 .00	 .15
General-Overuse Culture	 -1.15	 .38	 -.23	 -3.02	 .00	 .05
Course	 .28	 .13	 .17	 2.15	 .03	 .08
General-Benefit	 Culture	 1.07	 .32	 .25	 3.33	 .00	 .06
Course	 -.38	 .1 I	 -.26	 -3.42	 .00	 .06
Sensitive-Soma	 None of the entered variables were retained within the
equation at the .05 significance level
Variables included in the analysis:
• Culture = cultural background; Asian vs. European
• Course = Course attended (pharmacy, mechanical engineering, finance and accounting, social policy and
administration, and humanities)
• Past experience of taking prescribed medication
• Currently taking prescribed medication
Variables shown in the table those retained after stepwise removal and entry at the .05 significance level.
9.6.3 Discussion
This study is one of the first to quantify the effect of cultural factors on medication beliefs.
The findings show that both professional culture and cultural background were
determinants of beliefs about medicines and, in the case of professional culture, beliefs
about personal sensitivity to the adverse effects of medication.
Cultural background influenced beliefs about medicines as a whole but not perceptions of
personal susceptibility to their adverse effects. The selectivity of this effect reinforces the
view that differences in orientation to medication, are mediated by the influence of culture
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on beliefs about medicines rather than by fears about personal sensitivity or past
experience of adverse effects.
It is relevant that Asian respondents had significantly less experience with prescribed
medication than their European counterparts. In the total student group (n600), current
and previous experience of taking medication was associated with a more positive
orientation to medicines in general. Similar findings have been reported in the literature
relating to attitudes towards benzodiazepine tranquillisers, with users reporting more
favourable attitudes towards these drugs than no-users (Mansbridge and Fisher, 1984;
Clinthorne, 1986). However, the clear differences in betiefs about medicines between
Asian and European participants could not be accounted for by differential experience of
taking medication. This study corroborates an earlier qualitative study in which differences
in attitudes to the treatment of hypertension were noted between Afro-Caribbean and
Anglo-Saxon Londoners (Morgan and Watkins, 1988).
In this study I did not distinguish between South-East Asian (eg Vietnam Taiwan and Indian
or Pakistani Asian. Our notion of Asian culture, thus encompasses a range of separate
cultures and explanatory systems. However, both Asian cultures are associated with
explanatory models and attitudes to illness which are alien to Western biomedicine and
which may predispose against it (Khajuria and Thomas, 1992; Uba, I 992). This simple,
exploratory study sheds little light on why Asian students had a more negative orientation
to medicines. However, it is interesting that the traditional Hindu Ayuvedic system of
medicine emphasises herbal remedies (Schechtrnan and Gordon, I 994; Sissons-Joshi, I 995)
and beliefs that modern pharmaceutical carry the risk of dependence has been noted in
rural communities in Pakistan (Hunte and Sultana, 1993). It noteworthy that the majority
of respondents who gave their cultural origin as Asian would have been naturalised UK
residents. It is therefore likely that culturally related attitudes have been passed on from
parents or grandparents. Culturally-related differences in medication beliefs may be even
stronger for older members of the Asian culture.
It was quite surprising that such clear differences existed between students on the basis of
their chosen courses (here taken as a marker for future professional activity). In the case
of pharmacy students, positive orientation towards medicines might have influenced their
choice of degree. However, the same could not be said for mechanical engineers (few of
whom would admit to being "failed pharmacists"), who had more positive views about
medicines than all other groups - except pharmacy. This raised a 'nature-nurture' question.
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Did pharmacy students start out with a more positive view of medicines (nature) or were
their attitudes 'shaped' by the course (nurture)? If the course shaped these attitudes one
would expect to see changes between first and third year students. This was investigated
by using a 3 (year) by 5 (course) ANOVA. This showed no significant effect of year of
course and no significant interaction between course and year suggesting that students'
attitudes were formed before they arrived at University. This was confirmed by a further
ANOVA of year of study and medication beliefs which showed no significant effect of year
of study on medication beliefs. The generalisability of this finding is limited by the cross-
sectional nature of the data. One needs to follow students from day I of the course to
confirm these explanations. However, the preliminary findings reported here suggest that
the prototypic views about medication may be formed fairly early on, possibly during
adolescence and this could be addressed in future research.
The fact that pharmacy students had a quantitatively different view of medication then
their colleagues, at such an early stage in their career, may have implications for patient-
pharmacist communication. If differences in views about medication are maintained once
the student is qualified and practising pharmacy in a health care setting, then they could
become a barrier to effective communication between pharmacist and patient. If the
pharmacist assumes that the patient shares their own positive orientation towards
medicines then there may be little incentive to elicit the patient's personal concerns about
prescribed medication. The earlier finding that less experience of formal education was
associated with a more negative view of medicines in general (reported in Study 7.1)
suggests that discrepancies between "professional" and "lay" views about medicines may
be even more marked than those observed in this study.
The generalisability of the findings to professional-lay differences in the real world is, of
course, limited by the use of students' choice of course as a marker for "professional
culture". Further work is needed to establish whether this pattern of differences is
observed between health care professionals and the lay public and between individual
professions (e.g. pharmacy vs. medicine vs. nursing) and to clarify the implications for
service delivery. Another outstanding question relates to the mechanism of interaction
between choice of course and medication beliefs. Why are scientists (pharmacists and
mechanical engineers) more positively orientated towards to medication than their
colleagues working in finance, policy of other areas? To what extent are views about
medication linked with beliefs about science and technology? Moreover, how does this
influence interaction with the medical establishment if it is perceived as having a technical-
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scientific orientation? Further work is now justified to investigate this issues in more detail.
In particular to discover whether cultural influences on orientation to medicines as a
whole influence views about medication prescribed for particular illnesses and medicine




Summary of findings and general discussion
The empirical work which underpins this thesis used quantitative research methodologies
to investigate medication beliefs in a sample of patients drawn from six chronic illness
groups: asthma, diabetes, end-stage renal failure, chronic heart disease, psychiatric
outpatients patients and a sample of general medical in-patients. Data collected from these
samples provides the core data for the subsequent investigation of the structure, effects
and determinants of medication beliefs. In some studies these core data were augmented
by data collected from additional samples including oncology patients, undergraduate
students and people seeking care from community pharmacies or complementary
therapists.
I 0.1 The nature of medication representations
I 0.1.1 Are cognitive representations of specific and general medication
structured around coherent themes?
Previous studies of medication beliefs had identified a fairly large number of beliefs about
medication. (Conrad, I 985; Morgan and Watkins, 1988; Lorish et al. I 990; Fallsberg, 1991;
Donovan and Blake, 1992; Echabe et al. 1992; WoIler et al. 1993; Britten, 1994). Initial
studies described in Chapter 7 were concerned with identifying the core dimension
underlying medication beliefs. A series of Principal Components Analyses (PCA) revealed
that beliefs about medication prescribed for the patient's illness (Specific) and more
general beliefs about medicines as a whole (General) were structured around four factors
or dimensions.
PCA revealed a clear distinction between Specific and General medication beliefs. The first
dimension underlying beliefs about prescribed medication related to the perceived necessity
of medication for maintaining health (Specific-Necessity). The second factor comprised items
relating to concerns about the adverse consequences of medication based on beliefs about
the potential for dependence or harmful long-term effects and that medication taking is
disruptive (Specific-Concerns).
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Beliefs about medicines in general also resolved into two factors. The first comprised items
expressing beliefs about the way in which medicines are used by doctors. The essence of
this factor, labelled General-Overuse was the notion that medicines are over-prescribed by
doctors who place too much trust in them. The second factor, labelled General-Harm
related to the intrinsic properties of medicines and included representations of medication
as harmful, addictive, poisons grouped with the belief that people who take medicines
should stop their treatment every now and again.
These factors were used to form the Beliefs about Medicines Questionnaire (BMQ) which
proved to have acceptable psychometric properties within the study sample. The BMQ
factors were fairly stable across a range of illness groups and in, the case of General-
Overuse beliefs, healthy undergraduate students. The identification of simple stable factors
is only of value if the factors are meaningful. So what meaning could be assigned to the
BMQ factors? A key issue here was whether the factors were the core components of
specific and general representations of medication analogous to the five components of
illness representation identified by Leventhal and colleagues (I 980). Accepting this premise
would imply that ideas about medication are predominantly structured around necessity,
concerns (for prescribed medication) and harm and overuse (for medicines in general). An
alternative possibility is that the BMQ factors are some, but not all, of the underlying
dimensions of medication beliefs. There are, however, important differences between the
medication belief constructs identified in this study and Leventhal's five components of
illness representation arising from the way in which they were derived.
PCA and factor analytic techniques, used in the present study to identify core medication
beleifs, are designed to identify underlying factors which account for the observed
correlation between items. The aim is to obtain simple factor structures which are stable
across data sets. This has the obvious advantage of reducing complex variables to core
themes upon which to focus further study. However, the attainment of simple stable
structure often results in the loss of items which do not load on the underlying factors or
which have non-linear relationships with the other items. Simplicity of structure is obtained
at the cost of complexity of information. In contrast, the multidimensional scaling (MDS)
techniques used to identify the core dimensions of illness representation (Leventhal and
Nerenz, 1985) are designed to identify clusters within data sets. The emphasis is on
grouping by proximity rather than simplification to common latent factors (Croyle and
Barger, 1993).
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The cost of simplification is illustrated in the General beliefs data set by the loss of several
interesting items such as "Medicines are a necessar,' evil", "It is better to do without
medicines' "Stronger medicines are more effective than older ones' "Stronger medicines are
more dangerous than weaker ones". It is interesting that the General-Harm factor was slightly
unstable in the general medical sample and had low internal consistency in others. This
indicates that peoples' representations of medicines are complex and varied and are not
easily "condensed" into simple factors. A further point of interest was that a coherent
"General-Benefit" dimension did not arise which is consistent with the observation from
interview studies that people often appear to take the benefits of "modern medicines" for
granted (Conrad, I 985; Morgan and Watkins, I 988; Britten, I 994). However, the failure to
identify a benefit dimension might simply reflect the fact that the items selected for initial
analysis were inappropriate. A broader range of beliefs items might have facilitated the
emergence of a benefit dimension.
Given this limitation of PCA, why was this technique chosen? The answer to this
reasonable question is that the benefits of simplicity were perceived to outweigh the costs.
The literature review identified a fairly complex array of lay beliefs but very few studies
had systematically assessed quantitative relationships between medication beliefs and other
variables. In contrast to the extensive literature suggesting the salience of illness cognition
to health behaviour, there was relatively little evidence to support the utility of medication
beliefs (e.g. Eagleton et al, I 993). Thus it was felt that an initial priority was to investigate
the utility of medication beliefs in health-related cognition and behaviour rather than a full
description of the components of medication cognitions.
So how do the BMQ factors inform our understanding of the cognitive organisation of
medication beliefs? To answer this question we need to distinguish between Specific and
General medication beliefs. Most of the beliefs relating to prescribed medication which
have been described in the literature can be summarised as notions of necessity or
concerns about negative effects. Although these themes are not all inclusive, they are
perhaps the core dimensions underpinning attitudes to prescribed medication. However,
other Specific medication cognitions may also be salient. For example, ideas about efficacy
and how one decides whether the medication is working properly are not represented by
the BMQ factors. Efficacy cognitions might inform necessity beliefs and concerns. For
example, the belief that a medicine is not working may be a source of Specific-Concerns if
the patient perceives the medication to be necessary for maintaining their health.
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Alternatively, the perception that the medication is not working might reduce beliefs in its
necessity, particularly if the patient feels well. Thus efficacy beliefs may be thought of as
core representations in their own right. An alternative view is that efficacy beliefs might
be "secondary beliefs" which inform the core dimensions of necessity and concerns. (A
similar concept is that beliefs about the seventy of a disease might inform the Consequences
component of illness representations). The fact that in the present study an "efficacy" item
("My medicines are effective") was not retained within the PCA may be consistent with the
latter explanation, but further studies are necessary to confirm this.
The BMQ-General factors, are likely to be more limited in scope as they were derived
from a sample of chronically ill patients with experience of medication. The General-Harm
factor is particularly problematic. The internal consistency of this factor was low, even in
some of the illness samples from which it was derived. Low internal consistency was also
noted in the undergraduate student sample (Cronbach alphaO.54; n600) and among
those seeking care from community pharmacies and complimentary practitioners
(Cronbach alphaO.55; n1 39). As mentioned earlier, this suggests that peoples' tend to
have fairly complex ideas about medicines as a whole which cannot easily be condensed
into simple core factors relating to the intrinsic nature of medicines. In contrast, the
General-Overuse factor was more stable having a higher internal consistency in both the
undergraduate (Cronbach alphaO.64; n600) and community pharmacy/complimentary
practitioner samples (Cronbach alphaO.78; n I 39). Further work is therefore needed to
confirm the stability of the General-Harm factor structure.
At least one important belief identified in the literature was not represented in the BMQ-
General. This is the idea that one can become "immune" or tolerant to the beneficial
effects of medication is they are taken regularly (Fallsberg, 1991). This belief might be
important. As a concern about prescribed medication, this might become a barrier to
adherence. This notion was not included in the original items subjected to PCA. In studies
where this belief has been noted it seems to arise in relation to specific classes of drugs:
antibiotics and analgesics (Britten, 1994, Donovan & Blake, I 992, Fallsberg, I 991, Lorish et
al, I 990). However, its omission from the study raises several issues. This would seem to
be one of the salient medication beliefs which is absent from the BMQ as it does not relate
to concepts of intrinsic harm (General-Harm) and is not specifically about overuse of
medicines by doctors ,although it is clearly related to this issue and might inform views
about overuse.
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The fact that the final BMQ factor structure does not include some of the beliefs about
medication which described in the literature, suggests that these factors are not the only
components of medication representation. However, they may represent the important
dimensions of belief which inform attitudes to medication.
10.1.2 The distribution of medication beliefs
The face validity of the BMQ constructs justified further investigations of the distribution
of these beliefs among chronically ill patients. Whereas beliefs about General-Overuse,
General-Harm and Specific-Concerns were normally distributed, Specific-Necessity were
heavily skewed towards the positive. The lack of variance in necessity beliefs is
unsurprising given the study sample was limited to patients with severe illnesses, many of
whom have been in treatment for some time. One might expect to find that such patients
believed that their medication was necessary, after all, medication was a prominent part of
their treatment regimen. Thus, the sample is in some ways self-selecting in that they were
patients who had remained in treatment and who were therefore more likely to be
perceive their medication as necessary. One of the problems with this is that the utility of
the construct may be diminished because it does not differentiate between individuals. A
greater variance in the Specific-Necessity dimension might have been obtained by the
inclusion of other chronic illnesses where medication is prescribed as prophylaxis rather
than treatment such as hypertension, or the treatment of chronic infectious diseases such
as tuberculosis.
The next question addressed by the analysis was how medication beliefs were related to
one another and whether this might reveal something of the way patients were thinking
about medication. Although, they were conceptually distinct the BMQ factors were related
in a fairly consistent way which seemed to suggest a logical interaction between beliefs.
For example, those who saw medicines in general as intrinsically harmful (General-Harm
were more likely to believe that they are overused by doctors (General-Overuse). Similarly,
negative views about medicines in generally were associated with stronger concerns about
prescribed medication. Correlations between specific medication beliefs, suggested that,
for a third of the total chronic illness sample strong beliefs in necessity coincided with
strong concerns. These patients seemed to have a rather complex view of their prescribed
medication in which high benefit was balanced by high cost. In an earlier qualitative study
of medication beliefs, Fallsberg (1991), noted that some of her sample of Swedish asthma,
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epilepsy and chronic pain patients held a similar "dualistic view" in which medicines were
seen as a "necessary evil". The present finding confirms the relevance of this notion and
quantifies its prevalence in a UK sample.
10.2 The effects of medication beliefs as correlates of
medication adherence.
The Specific-Concerns construct contains items related to the long-term adverse effects of
medication and its potential to cause dependence. Several qualitative studies have
suggested that these beliefs might influence adherence (Morgan and Watkins, 1988;
Donovan and Blake, 1992; Conrad, 1985). Additionally, in WoOer and colleagues' (1993)
study of German patients with asthma, beliefs about addiction contributed to the
"threatening aspects" of steroids which were related to low adherence. The next step
therefore was to investigate relations between medication beliefs and adherence. This was
done in a series of analyses described in Chapter 8. To begin with, correlations between
the four medication belief factors and reported adherence to medication were examined in
each diagnostic group.
An interesting pattern of correlations emerged. Although correlations between reported
adherence and BMQ-General scales were in the predicted direction, the coefficients were
small and rarely reached statistical significance In contrast, beliefs about prescribed
medication were significantiy correlated with reported medication adherence in all but one
of the illness samples. Patients with stronger beliefs in the necessity of their prescribed
medication reported higher adherence rates and those with stronger concerns reported
lower adherence rates.
Multiple linear regression analysis showed that age and medication beliefs accounted for
27% of the variance in reported medication adherence, with beliefs about prescribed
medication contributing I 3% to the total variance explained. It is interesting that people's
views about the specific medication regimen prescribed for them were much more
strongly related to adherence reports than were more general views about medicines as a
whole. Moreover, the interplay between concerns and necessity beliefs implied a risk-
benefit analysis and subsequent attempts to moderate the perceived potential for harm by
taking less. It is also interesting to note that the association between medication beliefs
and reported adherence was of a similar magnitude to that attributed to HBM variables in
a previous study of medication adherence (Ried and Christensen, 1988).
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Additionally two findings emerged from the analyses which merit further attention. First
younger patients reported lower adherence. Second, no significant associations were found
between medication beliefs and adherence in the psychiatric clinic sample. These findings
will now be discussed in more detail.
10.2.1 Age and reported adherence to medication
The consistent finding that younger patients reported lower adherence is contrary to the
commonly held view that older patients are less adherent (Griffith, 1990). However,
earlier research examining the effect of age on adherence is inconclusive (Haynes et al.
1979) and the observed relationship between age and adherence reported here is
consistent with more recent work showing that it is mistaken to regard older patients as a
homogenous group of low adherers (Lorenc and Branthwaite, I 993).
Why are younger patients less adherent to medication? One possibility is that the finding is
an artefact attributable to a greater willingness to report non-adherence. Although the
context of adherence questions was controlled to encourage truthful reporting, it is not
certain that this strategy was effective. However, a number of other recent studies have
also found higher rates of adherence in older patients (Daniels et al. I 994; Sherbourne et
al. 1992; DiMatteo et al. I 993; Frazier et al. I 994; Lorenc and Branthwaite, I 993). The
explanation for this effect may lie in cognitive differences in the approach to illness
associated with older age. There is evidence that older people tend to adopt a more
cautious approach to the maintenance of health (Leventhal EA et al. I 993a; Cameron et al.
1993; Leventhal EA et al. I 993b). Consequently, once the patient has accepted the advised
behaviours as necessary and valid, they tend to adhere to them more carefully and
systematically (Leventhal EA and Crouch, in press). Elderly patients may thus be more
averse to risk and less willing to act on their concerns by adopting the "risky" strategy of
altering their medication (Leventhal et al. I 992b).
Other factors may also explain the link between older age and adherence. Brownlee-
Duffeck and colleagues (1987) noted age related differences in illness cognition in a sample
of insulin treated-diabetics. There were distinct differences in the type of cognitions which
predicted adherence. Whereas the bamers dimension of the HBM predicted adherence in
younger patients, perceived benefits were much more salient in the older group, suggesting
that the priority assigned to particular cognitions may vary with age. This argument can be
applied to specific medication beliefs. In the present study the relationship between
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concerns and reported adherence was independent of age. Elders had similar concerns as
their younger counterparts which were related to adherence in a similar way. However, it
may be that other cognitions were more salient for elderly patients and resulted in an
stronger effect on reported adherence.
Concerns about the risk of dependence and long term effects of medication may have a
lower priority for elderly patients than other factors such as the perceived vulnerability to
the adverse effects of omitting medication. Another possibility is that normative beliefs
attain greater salience with advancing age. In support of this notion there is evidence that
elders tend to have stronger beliefs in the powerful others dimension of the locus of
control construct, perceiving doctors to have a high degree of control over their health
(Lachman, 1986; Lumpkin, 1986). Elderly patients may therefore be more reluctant to
depart from their doctors instructions. Furthermore, these cognitions might mitigate
against the effect of other- as yet undefined adherence related cognition which are salient
for younger adults.
Finally it is interesting to note that the tendency of older patients to be more "respectful"
of their doctors may be a cohort effect specific to the current generation of elders rather
than a true effect of age on illness-related cognitions. It is possible that the introduction of
the NHS, with its paternalistic culture of health provision had a formative effect on health-
related attitudes which is unique to the generation which experienced its inception.
10.2.2 Beliefs and adherence in the psychiatric clinic sample
The psychiatric out-patient sample provided a notable exception to the other illness
samples studied in that no significant correlations were noted between medication beliefs
and adherence. A clear reason for this apparent anomaly could not be found within the
data. The lack of interaction could not be attributed to disruptions in cognitive processes
linked to psychotic illness. The sample comprised roughly equal numbers of patients with
neurotic and psychotic illness and the pattern of interactions was similar in both groups.
Moreover, in both groups, correlations between specific and general medical beliefs were
similar to those found in the other chronic illness samples studied with logical "common-
sense" associations between beliefs (e.g. stronger beliefs that medicines are generally
harmful substances which are overused by doctors tended to be associated, albeit fairly
weakly, with greater concerns about prescribed medication).
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Previous studies in which SCMs were applied to medication adherence in this area may
help to interpret these findings. Although few in number these studies give a fairly clear
indication of the types of cognition which might influence medication in this area. Cochran
and GitJin (1989) applied the Theory of Reasoned Action (TRA) to reported lithium
adherence in patients with bipolar affective disorders. Although a modified version of the
TRA explained 53% of reported adherence to lithium, patients' beliefs about taking lithium
did not contribute directly to this. Rather, patients' attitudes and intentions towards
medication and their reported behaviour were much more strongly influenced by the
perceived views of significant others such as their family, friends and doctor than by their
own beliefs about the treatment. Similarly, a recent study conducted in the USA found that
positive attitudes to medication adherence were associated with social support and a
broader array of daily activities (Draine and Solomon, 1994). Other studies suggest that
patients' beliefs about the severity of relapse and their personal susceptibility to it are fairly
strong predictors in this group (Coulter and McPherson, I 986). Moreover, the experience
of adverse medication side-effects may be important determinants of adherence to
medication in this group (Budd et al. 1996; Hogan et al. 1983). Concerns about immediate
side-effects may therefore be much more important than the future-oriented concerns
about dependence or long-term adverse effects measured by the Specific-Concerns
construct.
This highlights two deficits within the current study. The first relates to the failure to
incorporate variables from existing models such as the HBM and TRA as recommended in
the literature (Marteau and Johnston, 1987). The justification for this omission was that the
aim study was to explore the nature, determinants and effects of medication beliefs, rather
than to identify the determinants of adherence. However, the salience of the medication
beliefs described here depends on their association with adherence and the thesis is
grounded within this domain and so the criticism of omission is justified. The second
limitation relates to the Specific-Concerns construct. The items loading on this factor were
derived from studies of patients with a variety of chronic illness and from informal
interviews with renal and cardiac patients. It is perhaps not surprising that these were less
salient for the psychiatric patients. Although as a group the psychiatric patients had higher
Specific-Concerns scores than most other groups, other factors were clearly more
influential in adherence decisions. These data suggest that although Specific-Concerns may
be a core dimension of medication beliefs the content may vary. For example, the current
experience of medication side-effects may be of greater concern for psychiatric patients
than for patients with asthma. Asthma patients on the other hand may be more worried
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about the long term harmful effects of their steroid inhaler than about the current
experience of side-effects which are minimal.
10.2.3 The specificity of associations between beliefs and reported
adherence
A further analysis, conducted on the renal dialysis data set, suggested that the association
between treatment beliefs and adherence behaviour was highly specific. The key finding to
emerge was that specific beliefs were related to specific reported adherence behaviours in
a meaningful and discriminating way. For example, concerns about prescribed medication
were associated with lower rates of self-reported medication adherence but not with
lower adherence to fluid and dietary restrictions. Similarly, patients who believed that their
fluid and dietary restrictions were too strict were less likely to adhere to them.
Furthermore, the observation that adherence to medication was not correlated with
adherence to fluid/diet restrictions provided additional evidence that patients may adhere
to some aspects of their treatment but not others. This reinforces the view that narrowing
the focus of investigation to beliefs which are directly related to the behaviour in question
might enhance that explanatory power of psychological models (Marteau, I 995).
10.2.4 The relative effect of illness and medication beliefs on active and
passive nonadherence
The literature identified two broad categories of adherence behaviour. For some patients
nonadherence was a strategic attempt to control aspects of the illness or treatment by
deliberately altering the amount of medication used (Morgan and Watkins, I 988; Conrad,
1985). This was labelled Active nonadherence to distinguish it from a more Passive type of
nonadherence attributed to a lack of motivation to remember to take the treatment or to
the presence of barriers which prevent the patient from carry out their intention to take
the medication as instructed.
In Study 3, Chapter 8, the key predictors of reports of passive and active non adherence
to medication were identified from the results of two multiple linear regression analyses,
using reported AnA and PnA as the respective dependent variables in the asthma clinic
sample. Medication beliefs had a stronger effect on adherence than beliefs about asthma
(as defined by Leventhal's five components of illness representation) or perceptions about
future control over the disease. AnA was predicted by perceived lack of empathy from
medical and nursing staff, concerns about the prescribed medication as a whole and
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younger age. PnA was predicted by younger age and weaker beliefs in the necessity of
asthma medication for maintaining health. These findings will now be discussed in more
detail
Passive nonadherence and the perceived salience of medication
Although only medication beliefs were retained in the regression analysis, both medication
and illness representations were associated with passive nonadherence as indicated by the
reported frequency of forgetting to take medication. The pattern of correlation between
illness and medication beliefs and PnA suggested that these beliefs contributed to the
patient's perceptions of the salience of their medication which was in turn related to how
often they forgot to take it. Patients who believed that their asthma would last along time
and have severe personal consequences also had stronger beliefs in the necessity of their
prescribed medication and reported lower rates of PnA.
Active nonadherence as self-regulation
In his qualitative study of medication beliefs in epilepsy Conrad (1985) noted that patients
adjusted the amount of medication they took in attempt to gain control over the illness or
to avoid becoming "too dependent on their anticonvulsant medication. In the present
study, the differential effect of beliefs about medicines, beliefs about illness and locus of
control over asthma on reports of Active (AnA) and Passive (PnA) suggest that this form
of "self-regulation" is more widespread.
The observation that Specific-Concerns were predictive of the reported frequency of
deliberately altering the dose of medication but not of forgetting it is consistent with self-
regulatory theory. It supports Leventhal's view of the patient as an active problem solver
whose behaviour represents an attempt to minimise perceived threat by employing specific
coping procedures (Leventhal et al. I 992a), in this case taking less medication in an
attempt to lessen the risk of dependence and long term effects. The fact that medication
representations had a more direct effect on adherence than illness beliefs has implications
for the further development of the SRM and this will be discussed later in this chapter.
A further point of note in these data was the effects of perceived lack of empathy from
medical and nursing staff (PLE) on AnA to medication. This implies that adherence
decisions arose from a rather complex interplay between personal beliefs about treatment
and views about the quality of the patient-practitioner relationship. This finding suggests
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that adherence may best be understood by an approach which combines SCMs, SRM and
features of the communication model exemplified by the work of Ley (1988, I 982).
Before accepting this premise it is important to rule out possible confounders. The
logically consistent interactions between the PLE construct, Specific concerns and reported
adherence might simply reflect a response bias. Budd (1987) has identified this as a
potential problem in questionnaires assessing the TRA. He suggests that the TRA forms
part of a 'intuitive lay psychology of intention' and that people filling out questionnaires
assessing TRA components will attempt to create consistency between their responses, so
appearing to validate the model. A similar process could account for the apparent
coherence between beliefs and reported behaviour observed in the present study.
However, the differential effect of beliefs on AnA and PnA mitigates against this
explanation. An opposing view is that the TRA is part of our 'intuitive model of intention'
because it reflects real psychological processes and fundamental interactions between the
way in which people think and behave and the same could be true of the interactions
noted in the present study. Moreover, an attempt was made to diminish the influence of
ordering effects by not presenting items in "conceptual" order within the questionnaire.
However, the possibility that ordering effects were present within these data cannot be
totally discounted given that this was a cross-sectional study. Further studies are needed
to clarify this issue. A prospective design in which assessment of cognition and adherence
were temporally separated would reduce patterned responses. However, prospective
studies may pose different problems as discussed under Implications for further research.
10.3 The determinants of medication beliefs
Marteau and Johnston (I 986a) have suggested that interventions to change dysfunctional
beliefs could address factors which influence their formation. The studies described above
provide preliminary evidence that beliefs about prescribed medication , especially concerns
about the potential for dependence, long-term effects and disruption are associated with
nonadherence. Correlation coefficients between the BMQ factors computed during
psychometric testing showed that Specific-Concerns are related to negatives beliefs about
medicines as whole. However, it is clear from the small size of the correlation coefficients
obtained that these are not the only determinants of concerns. The final section of the
empirical work was therefore devoted to an exploration of some of the possible
determinants of medication beliefs, with particular emphasis on Specific medication beliefs
as these were more strongly related to adherence than beliefs about medicines as a whole.
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10.3.1 The perceived effect of medication on illness symptoms as a
deterrni nant of Specific-Necessity beliefs
The selection of variables for initial evaluation as potential determinants was informed by
theory. Pennebaker (I 982), has shown that illness-related cognitions and the interpretation
of physical symptoms are closely related. Self-regulatory theory posits that illness
representations and the selection and appraisal of coping procedures are influenced by
current and past experience of symptoms (Gonder-Frederick and Cox, 1991; Love et al.
1989; Leventhal et al. I 986). Thus, one question was whether representations of medicines
might also be influenced by their perceived effects on symptoms. In particular, it was
anticipated that a perception that prescribed medication made one "feel better" by
improving symptoms would result in stronger beliefs in its necessity. The determinants of
each BMQ factor which were identified in this study imply that patients' ideas about
medication are coherent in "common-sense" terms. For example, patients were more
likely to have strong beliefs in the necessity of their medication if it was perceived to affect
their symptoms. Similarly, necessity beliefs tended to be stronger with more medicines
prescribed. There is evidence that some patients use the number of medicines prescribed
for them as an indication of disease severity (Donovan and Blake, I 992; Morgan and
Watkins, I 988, Leventhal et al. I 991). Presumably, this in turn, influences the perception of
the necessity of their medication.
10.3.2 Perceived susceptibility to the adverse effects of medication and
reported experience of medication side-effects as determinants of
Specific-Concerns
Earlier studies had identified patient concerns about the potential adverse effects of
prescribed medication. This implies a perception of medication side effects as a health
threat The Health Belief Model suggests that notions of perceived susceptibility may
influence these concerns. A Sensitive Soma scale (SS) was therefore used to assess
perceived susceptibly to the adverse effect of medication on symptoms. In the present
study, cognitive variables such as the perceived effects of medication on symptoms and
perceived susceptibility to the adverse effects of medicines were far stronger determinants
of the core dimensions of medication representation than were the socio-demographic
variables studied. Although age and educational experience were determinants of Specific-
Concerns and age of General-Harm they added little to the explained variance in these
dimensions
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The key determinants of Specific-Concerns were beliefs about the harmful nature of
medicines in general (General-Harm) and beliefs about personal susceptibility to such effects
(Sensitive Soma). The General-Harm factor may represent a prototypic view of medication,
analogous to the disease prototypes noted in studies of lay representation of illness
(Bishop, 1987; Bishop and Converse, 1986).
Further studies investigating relations between reported past and present experience of
medication side-effects suggested that Specific-Concerns had both abstract (perceived
susceptibility and concrete (past or present experience of medication side-effects)
antecedents. This finding is consistent with self-regulatory theory which proposes that
illness representation have abstract (e.g. an illness label- asthma) and concrete (e.g.
shortness of breath) components. The SRM suggests that the experience of symptoms
plays a pivotal role in the formation of illness representations (Cameron et al. I 993;
Baumann et al. 1989). The finding in the present study, that the perceived effect of
medication on symptoms accounted for a significant proportion of the variance in Specific-
Necessity beliefs, provides tentative support for the notion that medication belief are also
partially determined by symptom experience.
However, limitations in the design of this simple exploratory study mean that the finding
must be interpreted with caution. The relationship between disease schema and symptom
experience may be bi-directional. For example, being given information that one has a
disease may initiate a search for confirmatory symptoms (Bishop et al. I 987; Pennebaker,
I 982). It is difficult to identify causal relationships between medication beliefs and
symptomatic experience. Underlying concerns about medication might stimulate a search
for confirmatory "side-effects". Similarly positive perceptions that medication makes one
feel better might be stimulated by strong beliefs in its necessity (Lundh, 1987).
10.3.3 Cultural factors and medication beliefs?
The final section of the empirical work (Section 9.6), investigated the effects of cultural
factors on beliefs about medicines in general in 600 undergraduate students. Course of
study- as a marker of 'professional cultural group' and stated cultural origin were
predictors of beliefs about medicines in general but not of beliefs about personal
susceptibility to their adverse effects. Asian students were significantly more likely to
perceive medicines as intrinsically harmful and it is possible that participants who assigned
themselves to be of Asian cultural origin may have been influenced in their views about
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medicines by the Hindu Ayuvedic system of medicine which stresses notions of balance
and "herbal" rather than pharmaceutical treatments (Hawthorne et at. 1993; Keltner and
Folks, 1992, Khajuria and Thomas, 1992; Uba, 1992).
A rather striking finding was that pharmacy students have significantly more positive views
about medication than all other groups, even when controlling for cultural origin. This is
consistent with previous observations that the beliefs of health practitioners (or in this
case-student practitioners) may be differ from their patients (johnston and Marteau, I 987)
and reinforces the need to focus greater attention on the beliefs of health practitioners as
determinants of care and of patient cognition and behaviour (Marteau and Johnston,
I 986b; Marteau and Johnston, 1987). Before summarising the theoretical implications of
the empirical section of the thesis I will outline some of the major limitations and
implications for further studies.
10.4 Limitations of the empirical work
The empirical work contributing to this thesis has several limitations many of which have
been described in the relevant empirical sections of the thesis. However, it is worth
drawing attention to significant methodological limitations which need to borne in mind
when considering the implications of the findings.
10.4.1 Measurement of medication adherence
In common with most "measures" of adherence, self-report does not detail the exact
number of medications taken. Moreover, the accuracy of self-report has been questioned
on the grounds that patients may be reluctant to admit to non-adherence and that it
generally tends to over-estimate adherence by about 20% (Caron, 1985). However, others
have suggested that self-report is a useful method for grading patients according to their
"relative standing on the adherence dimension" (Haynes et al, I 980; Ley, 1995).
Adherence questions were phrased in a non-threatening way so as to diminish self-
presentational bias and located in two different places within the questionnaire to limit
ordering effects. A further attempt to improve the validity of patients' self-report was the
use of continuous scales rather than simple dichotomous variables and checking that the
internal reliability and test-retest reliability of the scales was adequate.
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The test-retest reliability of the RAM scale was within acceptable limits, but it has not
been fully validated against other measures of adherence behaviour and it may be that high
scores on the RAM scale are representative of negative attitudes to the treatment
programme as a whole rather than a true estimate of adherence to medication. This
hypothesis was tested in Study 8.2 in which the effects of treatment beliefs on adherence
was assessed for two separate components of a haemodialysis treatment programme.
Despite these measures it should be recognised that the RAM has not been fully validated
by comparison with other adherence measures. Until this is achieved, the results of this
study should be interpreted with caution and any conclusions reached about the effects of
medication beliefs on adherence are preliminary.
10.4.2 Cross-sectional design
The cross-sectional design of this study represents a further limitation in that one cannot
be sure about the direction of influence between beliefs and reported behaviour. Thus, the
predictive effect of medication beliefs on medication behaviour should now be examined
using a longitudinal study design. However, the optimum separation of assessments of
beliefs and behaviour over time is by no means clear especially in relation to "feedback"
models such as the SRM. It may be that today's beliefs have a greater impact on today's
behaviour than yesterday's beliefs. However, this point does not obviate the fact that the
inclusion of a prospective study would have strengthened the empirical section of this
thesis. Most of the work focused on beliefs and adherence in chronic illness and it is likely
that inter-relations between beliefs and behaviour would have stabilised in such patients
and would not fluctuate greatly. Therefore, separating belief and adherence measures, even
by a week or so, would have proved advantageous, even if only to reduce the possibility of
response bias.
10.4.3 Lack of cross-checks for confounding variables
The 'logically coherent' relationships observed within the various data sets may be partially
attributed to the respondent's ability to understand that certain constructs logically belong
together and a subsequent desire to appear consistent in their responses (Sheeran and
Orbell, I 996). In an attempt to diminish the influence of ordering effects, items were not
presented in 'conceptual' order in that items expressing a particular view were not
grouped together. In order to diminish any effects of perceived social desirability of certain
responses, questionnaire items were presented in a context which sanctioned the
respondents 'personal views' and assured the anonymity and confidentiality of responses
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(Abraham and Hampson, 1996). However, there is no way of checking whether this had
been successfully achieved. Furthermore it is known that desire for social acceptance
varies between individuals. Thus there is a possibility that social desirability bias may have
influenced response, particularly to the RAM and Specific-Necessity scales. The
methodology would have been strengthened by the inclusions of cross-checks, such as the
Marlowe Crowne measure of social desirability, (Reynolds, I 982) and subsequent cross-
comparison between social desirability scores and other variables, particularly self-
reported adherence and Specific-Necessity scores
The association of negative views about illness and medication raises the question of
whether these are manifestations of common underlying state characteristics such as
depression or hopelessness or personality traits such as pessimism and cynicism. Recent
studies investigating the role of personality in symptom reporting have shown that the trait
characteristic of Negative Affectivity (NA) is associated with increased symptom reporting
(Watson and Pennebaker, 1991). Trait NA individuals tend to focus on the negative side of
things, having a less favourable self image and a greater tendency to depressed mood and
reduced satisfaction with life. Thus it follows that trait NA individuals might tend towards a
more negative view about their illness and treatment as well as of medication in general.
Including a measure of trait NA would have allowed a check on whether the observed
relationships between negative attitudes to general and specific medication and to low
adherence were explained by high Trait NA.
103 Implications for future research
The empirical studies described in Chapters 7 to 9 provide an insight into the nature,
effects and determinants of specific and general medication beliefs. However, this is a
relatively new area of investigation and the results described are limited and preliminary. A
priority for future research therefore is to confirm some of the above findings on other
data sets while addressing the key methodological limitations within the current design. In
particular, prospective studies are needed to examine how specific medication beliefs
develop during the course of a chronic illness and how they relate to more general beliefs
about medicines as a whole. Additionally, there is need for prospective longitudinal studies
to clarify the dynamic interaction between patients' representations of illness and
treatment and their adherence to treatment over time. One hypothesis is that beliefs
about general and specific medication will influence treatment preferences and initial
orientation to prescribed medication. However, continued adherence will be determined
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by a dynamic interplay between abstract beliefs and concerns about medication and the
degree to which the patient's concrete experience of symptoms is influenced by the
medication.
There is need to evaluate interactions between medication beliefs adherence and other
social cognition variables, particularly normative beliefs. Such studies could also be used to
investigate the possible mechanisms of the observed association between younger age and
lower reported adherence. Thus future researchers may wish to incorporate the BMQ
factors as belief variables within the TRAITPB and HBM detailed earlier in this chapter
An important question which were not thoroughly addressed in this preliminary study is
whether patients form beliefs which are specific to individual medicines (e.g. aspirin) or
types of medication (e.g. analgesics) and how such beliefs might relate to the core
dimension of Necessity and Concerns. For example, patients may have concerns about
particular medicines which are distinct from the beliefs about dependence, long-term
effects and disruption which comprise the Specific-Concerns dimension. One example may
be the notion that analgesics loose their efficacy if taken regularly for long periods of time
(Lorish et al 1990). It may be that differential beliefs about individual aspects of the
treatment might explain the variance in adherence to individual component treatment
regimens. This work is also needed to determine whether the failure of the Specific-
Concerns to predict adherence in the psychiatric clinic sample can be attributed to the
items currently included in this factor or whether the construct itself is flawed. A
theoretical suggestion is that the Specific-Concerns construct is valid for a range of
treatments (e.g. antibiotic medications, surgery and physiotherapy) and situations but the
actual concerns loading on this dimension will differ between individuals and across
treatments. A similar argument may apply to the Specific-Necessity construct Thus a focus
for future investigations is to establish the type of concerns which are most salient in
particular situations.
This draws attention to a more fundamental questions relating to the cognitive
representations of medication. For example, how do people arrive at the view that their
prescribed medication is "necessary" or a cause of concern? The components underlying
the cognitive representations of illness (e.g. timeline, causes, consequences,) might also
underpin representations about necessity of medication or concerns about potential
dangers (Leventhal, in press) and this is an empirical question. A further line of inquiry for
future research is a more detailed investigation of individual concepts loading on the four
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dimensions described above. This might include a more detailed exploration of the
cognitive process underlying individual concepts, within the core constructs identified by
PCA. For instance, what to patients mean by "dependence" and "addiction"? These terms
appear to be used interchangeably by patients in the studies reported to date, yet we
know little about whether these concepts are differentiated or how people judge the
"dependence potential" of medication?
Although this thesis has focused on medication beliefs, the findings emphasise the
importance of patients' beliefs about treatment in general, and justify further investigation
of patients views about individual treatment options. In particular, we need to establish the
extent to which representations of individual treatment options are accurate and are
predictive of future adjustment and adherence. Here it may be particularly salient to
explore patients' perceptions of relative risk associated with various treatment modalities
and this may have implications for the issue of informed consent and shared decision
making. The BMQ constructs may also form the basis for an investigation of the role of
treatment representations in the placebo effect. The clinical importance of placebo effects
is well recognised (Horwitz et al. I 990; Horwitz and Horwitz, 1993), but the phenomenon
is poorly understood and further studies are needed to gain a fuller understanding of the
psychological mechanisms underpinning this effect.
Future studies might address the determinants of beliefs about medicines in general. The
study of the medication beliefs of undergraduate students described above, suggested that
students had fairly firm ideas about medication before attending university. Further studies
are needed to verify this and establish the origins of medication beliefs among children and
adolescents.
Finally, finding associations between medication beliefs and reported adherence raises the
question of how amenable these beliefs are to change and whether changing beliefs alter
adherence. Such questions are of fundamental importance to the future development of
this area of research.
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10.6 Theoretical implications
The limitations of the empirical work described within this thesis mean that any
conclusions drawn from the data are tentative. However, the preliminary findings relating
to the nature, effects and determinants of medication beliefs in chronic illness have several
theoretical implications. These are linked to SCMs and self-regulatory theory.
10.6.1 Social Cognition Models (SCMS)
Health Belief Model (HBM) In most of the illness samples studied necessity beliefs and
concerns seem to function in an analogous way to the benefit and barriers dimensions of the
HBM which were found to influence medication adherence in previous studies (Ried et al.
1985; Ried and Christensen, 1988; Harris and Linn, I 985). The HBM has been criticised for
not specifying the cognitions which underpin the cost-benefit analysis implicit in the
benefit/barriers constructs (Leventhal, I 993). The observation that the BMQ-Specific
scales were associated with reported adherence to medication suggests that in applying
the HBM to medication adherence the benefit construct might be operationalised as
Specific-Necessity beliefs and the barriers as Specific-Concerns.
Theory of Reasoned Action/Theory of Planned Behaviour (TRAITBP) The fact that
relevant cognitions about medication (e.g. efficacy, tolerance), are not included in the BMQ
factors confirms that they do not represent the only components of cognition about
medicines. However, it is suggested that the General and Specific factors represent the
core dimensions of beliefs which inform peoples' attitudes about medication. As such the
BMQ factors may be incorporated into the TR.A/TPB as belief constructs. Notions of
necessity and concerns about negative effects underpin attitudes to prescribed medication.
Peoples' attitudes towards medicines in general are informed by views about the intrinsic
nature of medicines and the way in which they are used within society.
As mentioned earlier in this chapter, the use of the term "worry" in the Specific-Concerns
items, adds an affective element to the cognitive dimension. Eagly and Chaiken (I 993)
conceptualise attitudes as tn-dimension having a cognitive, affective and conative
component It is possible that beliefs about Specific Necessity (e.g. "My medicines are
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necessary for health") and Specific-Concerns ("I sometimes worry about the long-term
effects of my medicines") are the key determinants of the patient's attitude (e.g. positive or
negative orientation to prescribed medication). Furthermore the findings of this study
suggest that the conative dimension might be manifested as the degree of willingness to
take medication according to the prescriber's instructions (indicated by reported
adherence)
Control beliefs In the asthma clinic sample, reported adherence to medication was more
strongly associated with necessity beliefs and concerns than with beliefs about control
over asthma. However, when control beliefs were made very specific to the behaviour (le
"Whether my asthma gets better or worse depends on well my medicines work") these were
then correlated with reported adherence. The findings suggest patients own beliefs about
their illness and treatment may have a more direct influence on medication adherence in
chronic illness that notions of internal vs external control.
10.6.2 Self-regulatory model (SRM)
The key finding in relation to the SRM was that in the asthma data set, representations of
prescribed medication were more strongly associated with reported adherence than illness
representations. However, the relationships between medication beliefs and reported
adherence were broadly consistent with self-regulatory theory, particularly the finding that
Specific-Concerns were associated with strategic alterations in the medication dose (active
nonadherence). This seems to be an attempt to reduce the perceived risk by taking less
and implies that active nonadherence is a coping procedure in response to the potential
adverse effects of medication as a perceived threat to health. This is consistent with
Leventhal's notion of the patient as an "active problem solver" and with the selecting of
coping strategies based on representations of health threats.
A further point of theoretical interest is that illness and medication representations were
related in a logically consistent pattern (e.g. those who believed their illness would be long-
lasting with severe consequences had stronger beliefs in the necessity of their medication).
However beliefs about prescribed medication were stronger predictors of reported
adherence than illness beliefs suggested that the utility of the SRM as a framework for
understanding treatment adherence may be enhanced by inclusion of treatment beliefs.
The preliminary data described in thesis suggest that medication beliefs may have concrete
and abstract dimensions and be influenced by past and present experience in a similar way
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to illness representations (Leventhal et al I 992a). Moreover, beliefs about prescribed
medication correlated, albeit fairly weakly, with coping procedures (adherence) and
indicators of subjective appraisal. The use of the term "worry" to elicit Specific-Concerns
hints that representations of medication may also have emotional as well as cognitive
dimensions. Figure 10. I shows the theoretical inter-relations between existing components
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Figure I 0.1: Illustration of how treatment beliefs may be incorporated into
Leventhal's SRM
A further point of relevance to self-regulatory theory relates to the notion of disease
prototypes. The fact that people seemed to have broad, and fairly complex ideas about
medicines as whole (represented in the General-Harm and General-Overuse constructs) is
somewhat similar to the disease prototypes described by Bishop and colleagues (Bishop
and Converse, 1986; Bishop et al. 1987). These are models of particular diseases derived
from personal exposure to past episodes or from more general assumptions about the
typical characteristics of a disease. Prototypic beliefs about disease inform the
interpretation of symptoms or information. For example, a person who accepts that
"coughs and sneezes spread diseases" might believe that all infectious diseases are
transmitted in this way. Their prototypic view of infectious diseases as airborne might
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make them reluctant to work closely with someone who is HIV positive. It may be the
BMQ-General factors represent prototypic views about the intrinsic nature of medicines
and how they are used.
The empirical finding that these beliefs were related to indicators of "cultural grouping"
supports Landrine and Klonoff (I 992) suggestion that the impact of culture on health-
related beliefs deserves more attention.
10.7 Implications for practice
Significant correlations were observed between medication beliefs and reported adherence
across a range of chronic illness groups. Although, the limitations of the methodology used
suggest the need for a cautionary approach when generalising from these findings, the
preliminary research described in thesis has identified the types of medication beliefs which
are associated with nonadherence. These beliefs may now form the target of interventions
to enhance adherence. What would be the nature of these interventions?
There is currently increasing interest in the inclusion of detailed standardised information
leaflets as part of the packaging of medicines. This thesis might inform this initiative in two
ways. First, by providing measures to assess the impact of this type of information on
patients' representations of medicines especially Specific-Concerns. This is necessary
because, although the aim of improving patient access to medicines information is laudable,
standardised information alone may not meet the needs of all patients (Weinman, I 990).
Moreover, Specific-Concerns may arise from individual beliefs about the potential for
dependence or long-term effects which might not be dealt with in the leaflet and it may
therefore be appropriate to include this type of information in package inserts. Secondly,
patient education about medicines is likely to be enhanced if health professionals, such as
doctors and pharmacists, elicit patients' own concerns about their medication and address
these issues on an individual basis rather than by relying on standardised written
information alone.
Although a recent study has described an intervention which enhanced adherence to
antipsychotic medication by targeting cognitions (Kemp et al, 1995) , this was time-
consuming requiring, over 5 hours per patient. Although this may seem like an excessive
outlay of resources, the input of resources to enhance adherence should be balanced
against the costs of nonadherence. Over the course of a chronic illness such an outlay may
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be justified. However, intensive "therapy" to change negative attitudes to prescribed
medication may not be necessary. An alternative approach may be to elicit patients' views
early on. This might uncover initial preferences and concerns and open a dialogue between
patient and practitioner in which subsequent problems may be addressed. Allowing
patients to feedback the effects of treatment during regular periodic review of the
medication may limit the formation of mistaken beliefs and exaggerated concerns and so
facilitate adherence.
Barber (1991,1995) has suggested that respecting patient choices is essential to good
prescribing. In practice, this should entail closer attention to the patients initial perspective
on medication with periodic feedback of experiences and concerns. Eliciting patients'
beliefs about their medicines may provide the basis for closer partnership in medicine
taking (Royal Pharmaceutical Society of Great Britain, in press).
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Appendix I
Letter of introduction to study participants
ASTHMA RESEARCH STUDY





I am writing to tell you about a research study
which we are undertaking with our colleagues from Brighton University. We are trying to
find out more about patients' views of asthma and its treatment and the effects of this
upon their lives. We would like to invite you to take part in this study.
The study will involve a brief interview with a researcher when you attend your out-
patient appointment at Hove General Hospital. The researcher will ask you to fill out a
questionnaire regarding your views about asthma and its treatment Filling out the
questionnaire will mainly involve ticking boxes and will take about twenty minutes. Two
weeks after your out-patient appointment, the researcher will send you a similar set of
questionnaires to fill out at home. Again this will take about twenty minutes. You will be
asked to return the completed questionnaires in a stamped address envelope provided by
the researcher.
Any information you give will be ANONYMOUS and CONFIDENTIAL and will be
seen only by the research staff. The questionnaires will not be seen by the doctors, nurses
or other staff at the clinic.
There is no need for you to reply to this letter. You can simply tell the clinic receptionist
whether you wish to be involved or not when you next attend the out-patient clinic at
Hove. If you agree to take part in the study you can withdraw at any time without having
to give a reason.
If you do not wish to take part or if you decide to withdraw after joining the study, this
will not affect your care in any way.















Two pharmacy colleagues and I are hoping to embark on a small study, looking at the
advantages of giving patients more information about the medication they are
receiving. In order to ensure that the questionnaires we plan to use are not bothersome
I wonder if you would be kind enough to spend 3 0-40 minutes seeing one of two
colleagues, Mr Railton Scott or Mr Rob Home, when you next come and see me. If
you are willing and able to do this I would be grateful if you would let me know as






The Illness Perception Questionnaire (IPQ) (Weinman et al, 996)
Illness Identity (Core symptom list)
(Please indicate how frequently you now experience the following symptoms as part of your
(illness) Rated: All of the time, frequently, occasionally, never.
Pain, Nausea, Breathlessness, Weight Loss, Fatigue, Stiff Joints, Sore Eyes , Headaches,, Upset
Stomach, Sleep Difficulties, Dizziness, Loss of Strength
We are interested in your own personal views of how you now see your illness). Please
indicate how much you agree or disagree with the following statements about your
illness.
Rated: Strongly agree, agree, neither agree nor disagree, disagree, strongly disagree
Cause
• A germ or virus caused my illness
• Diet played a major role in causing my illness
• Pollution of the environment caused my illness
• My illness is heredity - it runs in my family
• It was just by chance that I became ill
• Stress was a major factor in causing my illness
• My illness is largely due to my own behaviour
• Other people played a large role in causing my illness
• My illness was caused by poor medical care in the past *
• My state of mind played a major part in causing my illness*
*(NB The last two cause items have been added since some of the earlier studies and hence do
not appear in table 6).
Time-line
• My illness will last a short time ®
• My illness is likely to be permanent rather than temporary
• My illness will last for a long time
Consequences
• My illness is a serious condition
• My illness has had major consequences on my life
• My illness has become easier to live with ®
• My illness has not had much effect on my life
• My illness has strongly affected the way others see me
• My illness has serious economic and financial consequences
• My illness has strongly affected the way I see myself as a person
Control/Cure
• My illness will improve in time.
• There is a lot which I can do to control my symptoms
• There is very little that can be done to improve my illness ®
• My treatment will be effective in curing my illness
• Recovery from my illness is largely dependent on chance or fate




Perceived Control Over Asthma Scale
(Adapted from Perceived Control Over Recovery Scale (Partridge&
Johnston, 1989)
RI How I manage in the future depends on me not on what other people can do for me.
It is often best to just wait and see what happens.
R3 It's what I do to help myself that's really going to make all the difference.
R4 My own efforts are not very important, control over asthma really depends on others.
It is up to me to make sure I control my asthma as well as possible under the
circumstances.
R6 My own contribution to the control of my asthma doesn't amount to much.
R7 Controlling my asthma now is a matter of my own determination rather than anything
else.
R8 I have littie control over my progress from now on.
R9 It doesn't realty matter how much help you get, in the end it's your own efforts that
count
Cronbach alpha =0.68 (0.73 if R2 removed)
R2, R4, R6 and R8 are reverse scored
High scores indicate high internal control beliefs
Low scores indicate high external control beliefs
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Appendix 5
Sample of study questionnaire showing orginal pool of 34
medication belief items and 4 RAM scale items
What the questionnaire is about
• This questionnaire will help us to fmd out more about what you think
about medicines.
• There are no right or wrong answers to the questions.
• We are interested in your personal views rather than what your doctor
or anyone else might think.
This questionnaire is completely confidential.
It will be seen only by the researchers and not by any
of the staff who are looking after you.
How to fill it out
• Please answer the questions as completely and honestly as possible.
• Most of the questions can be answered by ticking a box
• Answer each of the questions in turn
• Please don't feel that you have to spend a long time over each
question. Often the first answer that comes to you is the best.
• Please answer every question
•
WHAT WE MEAN BY MEDICINES
In this questionnaire we talk about "medicines' By medicines we
mean all tablets, pills, inhalers, liquids, creams, injections etc that
have been prescribed for you.
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YOUR VIEWS ABOUT MEDICINES FOR ASTHMA
We would like to ask you about your personal views about medicines for asthma.
These are statements other people have made about medicines for asthma.
Please show how much you agree or disagree with them by ticking the appropriate box.
There are no right and wrong answerN
We ar nteres,d in your personal view
- VIEWS ABOUT MEDICINES FOR ASTHMA 	 STRONGLY AGREE	 UNCERTAIN DISAGREE STRONGLY
AGREE	 DISAGREE
My health, at present, depends on my medicines
Having to take my medicines worries me
MA)	 My life would be impossible without my medicines
My medicines are powerful
A.5	 Without my medicines I would be very ill
I sometimes worry about the long-term effects of my
medicines
' My medicines are a mystery to me
MAA	 My medicines are effective
MA9	 I would like to change my present treatment
I am in control of my medication
Mr Whether I feel better or worse depends on my medicines
MA 2 I sometimes forget to take my medicines
My medicines disrupt my life
My medicines make me feel better
MA 5 I sometimes alter the dose of my medication to suit my own
needs
I sometimes worry about becoming too dependent on my
medicines
MAI7 My health in the future will depend on my medicines
I can cope without my medicines.
MA	 My medicines protect me from becoming worse.
MA2O It is difficult for me to take my medicines in exactly the way my
doctor told me
1A2	 I cannot always trust my medicines
F1A22 I have been given enough information about my medicines
Note: the print size of this questionnaire has been reduced to fit this page
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QUESTIONS ABOUT TAKING MEDICINES
Most people find a way of using their medicines which suites them. We would like
to ask you a few questions about how you use your medicines
I) Some people forget to take their medicines. How often does this happen to
you?
Very often ............Often	 Sometimes	 Rarely ...........Never
2) Some of the people I have talked to say that they miss out a dose of their
medication, or adjust it to suit their own needs. How often do you do this?
Veryoften ...........Often ...........Sometimes ............Rarely 	 Never ...........
3) If you DON'T do this can you explain why not?
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YOUR VIEWS ABOUT MEDICINES IN GENERAL
These are statements that other people have made about medicines in
general.
Please show how much you agree or disagree with them by ticking the
appropriate box.
There are no right and wrong answers
We are Interested in your personaJ views
- VIEWS ABOUT MEDICINES IN GENERAL 	 SONGLY	 UNcTAU'1 DISAGREE STRONGLY
Without medicines doctors would be less able	 - ______ _____
tocure people	 _______	 ______ _____ ________
Newer medicines are more effective than older
ones_______	 ______ _____ ________
Most medicines are addictive
People who take medication should stop their
- treatment for a while every now and again	 _______	 ______ _____ _______
Medicines only work if they are taken regularly
G6 Medicines do more harm than good 	 - ______	 _______
Medicines are not natural remedies
All medicines are poisons
It is better to do without medicines
Gb Natural remedies are safer than medicines
Gil Stronger medicines are more dangerous than
weakermedicines	 _______	 ______ _____ _______
G12 Medicines are a necessary evil
Doctors place too much trust on medicines 	 -
G14 If doctors had more time with patients they would
prescribe less medicines
There is a big difference between a medicine and a
drug________	 ______ _____ ________
GI The medicine you get is more important than the
doctor you see
G17 Doctors use too many medicines




(Jenkinson et al. 1994; Ware, Jr. and Sherbourne, 1992).






Compared to one year ago, how would you rate your health in general now:
much worse now than one year ago
2	 somewhat worse now than one year ago
3	 about the same as one year ago
4	 somewhat better now than one year ago
5	 much better than one year ago
• During the past 4 weeks, how much of the time has your physical health interfered with
your normal social activities with family, friends, neighbours or groups?
all of the time
2	 mostofthetime
3	 some of thetime
4	 alittJeofthetime
5	 none of the time
The following four items are included and scored from I to 5 where I = Definitely true, 2
= Mostly true, 3 = don't know, 4 = Mostly false and 5 = Definitely false
• I seem to get ill a little more easily than other people
• I am as healthy as anybody I know®
• I expect my health to get worse
• My health is excellent®
•
® Items are reverse scored
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Appendix 7
Pearson and Spearman correlations for BMQ factors and
adherence for cardiac (n= 115) and dialysis (n=47) groups
BMQ scales	 Cardiac Sample Renal Sample
(n1 IS)	 (n47)
r	 rho	 r	 rho
Specific-Necessity	 -0.21	 -0.20	 -0.04	 -0.02
Specific-Concerns 	 0.26	 0.20	 0.40	 0.39
General-Harm	 0.17	 0.16	 0.32	 0.25
General--Overuse	 0.19	 0.17	 0.30	 0.30
275
Appendix 8
Principal Components Analysis (PCA) of items assessing beliefs about
prescribed medication(Specific)
Beliefs about prescribed medication (Specific):
Exploratory factor analysis
Sample













Number of regular medicines
mean
	 3.5
range	 I - 14
mode	 3.0










range	 0 - 24
mode	 6
Item pool of 18 statements about prescribed medication (specific subjected to PCA
showing mean and standard deviation for the Cardiac sample (n= 120)
Statements about prescribed medication	 Mean SD
It is difficult for me to take my medicines in exactly the way my doctor told me 	 2.09	 .75
My medicines disrupt my life	 2.31	 .92
Having to take medicines worries me	 2.70	 I .07
I sometimes worry about becoming too dependent on my medicines 	 2.82	 I .10
My medicines are a mystery to me	 3.00	 .98
I sometimes worry about the long-term effects of my medicines	 3.11	 I .1 5
My medicines are powerful	 3.33	 .77
I would like to change my present treatment 	 3.44	 1.01
My life would be impossible without medicines	 3.51	 .95
My health in the future will depend on medicines 	 3.62	 .93
I can cope without my medicines	 3.62	 .96
Without medicines I would be very ill 	 3.66	 .88
I am in control of my medication 	 3.73	 .85
My medicines protect me from becoming worse. 	 3.9 I	 .71
My medicines are effective	 3.94	 .56
ui health at present. depends on medicines 	 3	 ..73
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Eigenvalues < I rejected.
I 6 items entered gave four-factor solution, accounting for 53.0 % of variance.
Four items rejected because Kaiser Meyer 01km (KMO) statistic <0.7
Questionnaire item	 KMO statistic
My medicines are powerful
	
0.58
It is difficult for me to take my medicines in exactly the way my doctor told me
	 0.66
I would like to change my present treatment
	 0.51
I am in control of my medication	 0.69
Exploratory factor analysis: Stage 2
Factor	 Eigenvalue	 % variance	 Cumulative
explained	 % variance explained
3.38	 28.2	 28.2
2	 2.30	 19.1	 47.3
3	 1.07	 8.9	 56.2
Structure matrix
Questionnaire item	 Factor I	 Factor 2	 Factor 3





My life would be impossible without medicines 	 0.79	 -0.16
	
0.30
My health in the future will depend on medicines	 0.68	 -0.16
	
0.19
I sometimes worry about the long-term effects of my medicines 	 0.04
	
0.82	 -0.06
Having to take medicines worries me	 -0.07
	
0.81	 -0.30
I sometimes worry about becoming too dependent on my medicines 	 -0.11
	
0.71	 -0.19
My medicines disrupt my life	 0.19
	
0.61	 -0.41
My medicines are effective	 0.29	 -0.14	 0.73
My medicines are a mystery to me	 0.28	 0.41	 -0.62
My health at present depends on my medicines	 0.41	 -0.07	 0.57
I can cope without my medicines 	 -0.22	 0.48	 -0.50
My medicines protect me from becoming worse 	 0.59	 .0.13	 0.62
277





Factor	 Eigenvalue	 % variance explained	 Cumulative
. %v...lance exp!ained
3.38	 28.2	 28.2
2	 2.30	 19.1	 47.3
Structure matrix
Questionnaire item	 Factor I	 Factor 2
My life would be impossible without medicines 	 0.77	 -0.10
My medicines protect me from becoming worse 	 0.75	 -0.21
Without medicines I would be very ill 	 0.73	 0.14
My health in the future will depend on medicines 	 0.64	 -0.09
My health at present depends on my medicines 	 0.58	 -0.17
My medicines are effective 	 0.55	 -0.29
Having to take medicines worries me 	 -0.22	 0.78
I sometimes worry about the long-term effects of my medicines 	 -0.03	 0.73
My medicines disrupt my life 	 -0.04	 0.68
I sometimes worry about becoming too dependent on my medicines	 -0.20	 0.65
My medicines are a mystery to me	 -0.06	 0.59
.0.4.....
Exploratory factor analysis: Stage 4
Remove unsatisfactory items
I can cope without my medicines
High degree of spread
Factor I Factor 2
-.41	 .54
My medicines are effective
High degree of spread
Factor I Factor 2
.55	 -.29
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Factor	 Eigenvalue	 % variance explained	 Cumulative
.%vanance explained
2.85	 28.4	 28.4
2	 2.27	 22.7	 51.1
Structure matrix
Questionnaire item	 Factor I	 Factor 2
My life would be impossible without medicines 	 0.81	 -0.09
Without medicines I would be very ill 	 0.76	 0.14
My medicines protect me from becoming worse 	 0.71	 -0.18
My health in the future will depend on medicines 	 0.68	 -0.09
My health at present depends on my medicines	 0.58	 -0.15
Having to take medicines worries me 	 -0.20	 0.78
I sometimes worry about the long-term effects of my medicines 	 -0.03	 0.77
My medicines disrupt my life	 -0.02	 0.69
I sometimes worry about becoming too dependent on my medicines	 -0.19	 0.68
are .mystery to me	 .:9:9.0.58
KMO (sampling adequacy) = 0.75
Bartlett's Test of Sphericity = 28 1.22 (P<0.000 I)
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BMQ-SPECIFIC: Replication of factor structure
I. Procedure
. Remove multivariate outliers Malanobis distance > 3 Std-dev from multi-
dimensional mean
• Remove if> 5 items missing
• Re-factor on "cardiac" group
• Confirm factor structure on other diagnostic groups
BMQ-SPECIFIC: Replication of factor structure
2. Results
Cardiac group





Factor	 Eigenvalue	 % variance explained	 Cumulative
%vaanceexpined
2.85	 28.5	 28.5
2	 2.40	 24.0	 52.5
Structure matrix
Questionnaire item	 Factor I	 Factor 2
My life would be impossible without medicines 	 0.81	 -0.06
Without medicines I would be very ill	 0.78	 0.09
My health at present depends on my medicines	 0.71	 -0.02
My medicines protect me from becoming worse	 0.67	 -0.19
My health in the future will depend on medicines 	 0.62	 -0.11
I sometimes worry about the long-tern, effects of my medicines 	 0.00	 0.80
Having to take medicines worries me	 -0.18	 0.78
I sometimes worry about becoming too dependent on my medicines 	 -0.19	 0.72
My medicines disrupt my life	 0.05	 0.67
My medicines are am/ster7tom.	 I0...
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Factor	 Eigenvalue	 % variance explained	 Cumulative
plained
3.46	 34.6	 34.6
2	 1.98	 19.8	 54.4
Structure matrix
Questionnaire item	 Factor I	 Factor 2
Having to take medicines worries me	 0.79	 0.24
I sometimes worry about becoming too dependent on my medicines	 0.78	 0.22
I sometimes worry about the long-term effects of my medicines 	 0.77	 0.21
My medicines disrupt my life 	 0.62	 0.18
My medicines are a mystery to me	 0.60	 -0.10
My life would be impossible without medicines 	 0.17	 0.85
My health at present depends on my medicines 	 0.17	 0.84
Without medicines I would be very ill 	 0.35	 0.70







Factor	 Eigenvalue	 % variance explained 	 Cumulative
% variance explained
3.60	 35.9	 35.9
2	 2.30	 22.9	 58.9
Structure matrix
Questionnaire item	 Factor I	 Factor 2
My health at present depends on my medicines 	 0.88	 0.10
Without medicines I would be very ill 	 0.84	 0.28
My life would be impossible without medicines 	 0.81	 0.32
My medicines protect me from becoming worse 	 0.80	 0.06
My health in the future will depend on medicines 	 0.79	 -0.06
I sometimes worry about becoming too dependent on my medicines 	 0.00	 0.78
I sometimes worry about the long-term effects of my medicines 	 0.1 2	 0.78
My medicines disrupt my life 	 0.16	 0.70
Having to take medicines worries me	 0.10	 0.70
My medicines are a myste to me	 ...	 0.09	 0.40
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Appendix9
Principal Components Analysis (PCA) of items assessing
beliefs about medicines in general
BMQ GENERAL exploratory factor analysis
_gnostic groupings	 n	 %
Chronic asthma	 77	 36
Diabetes	 97	 44
Haemodialysis	 42	 20









Range	 17.0 - 87.0
BMQ General: Core items
Questionnaire statement	 ___________________
Without medicines doctors would be less able to cure people
Newer medicines are more effective than older ones
Most medicines are addictive
People who take medicines should stop their treatment for a while every now and again
Medicines only work if they are taken regularly
Medicines do more harm than good
Medicines are not natural remedies
All medicines are poisons
It is better to do without medicines
Natural remedies are safer than medicines
Stronger medicines are more dangerous than weaker medicines
Medicines are a necessary evil
Doctors place too much trust on medicines
If doctors had more time with patients they would prescribe fewer medicines
There is a big difference between a medicine and a drug
The medicine you get is more important than the doctor you see
Doctors use too many medicines
Most medicines are safe
282
BMQ General: Pool of items
Item	 Mean Std
Dev
Without medicines doctors would be less able to cure people	 3. I 3	 I .54
Newer medicines are more effective than older ones 	 3.37	 0.84
Most medicines are addictive 	 2.73	 0.89
People who take medicines should stop their treatment for a 	 2.54	 0.91
while every now and again
Medicines only work if they are taken regularly 	 3.75	 0.80
Medicines do more harm than good 	 2.24	 0.85
Medicines are not natural remedies 	 3. I 3	 0.92
All medicines are poisons	 2.24	 0.97
It is better to do without medicines	 2.61	 1.08
Natural remedies are safer than medicines	 2.88	 0.91
Stronger medicines are more dangerous than weaker medicines 	 3.24	 0.90
Medicines are a necessary evil 	 3.06	 1.10
Doctors place too much trust in medicines	 2.90	 0.93
If doctors had more time with patients they would prescribe 	 3. 17	 0.98
fewer medicines
There is a big difference between a medicine and a drug	 3.24	 0.88
The medicine you get is more important than the doctor you see 2.87 	 I . 14
Doctors use too many medicines
	 2.84	 0.91
Most medicines are safe	 2.72	 0.92
Kaiser-Meyer-Olkin Measure of Sampling Adequacy = 0.78
Bartlett's Test of Sphericity = 710.56, P <0.00 I
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Eigenvalues < I rejected.
18 items entered, 6 items rejected due to Kaiser Meyer 01km (KMO) statistic <
0.7
Questionnaire item	 KMO statistic
Without medicines doctors would be less able to cure people 	 0.45
Newer medicines are more effective than older ones 	 0.55
Medicines only work if they are taken regularly 	 0.57
There is a big difference between a medicine and a drug 	 045
The medicine you get is more important than the doctor you see 	 0.57
Most medicines are safe	 0.42




Eigenvalues < I rejected.
Medicines are not natural remedies 0.44 0.48 0.50
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Exploratory factor analysis: Stage 4
Method
• Principal components analysis
• Non-orthogonal rotation (Oblimin)
• Forced two-factor solution.
Structure matrix
Factor	 Eigenvalue	 % variance	 Cumulative
...........................................................
3.73	 31.1	 31.1
2	 1.58	 13.1	 44.2
3	 1.01	 8.4	 52.6
Structure matrix
Item	 Factor I	 Factor 2	 Factor 3
If doctors had more time with patients they would prescribe fewer
medicines
Doctors place too much trust on medicines
Doctors use too many medicines
Natural remedies are safer than medicines
It is better to do without medicines
Medicines are a necessary evil
Medicines do more harm than good
People who take medicines should stop their treatment for a while
every now and again
All medicines are poisons
Most medicines are addictive








































Forced 2 factor solution based on Scree plot analysis
Factor	 Eigenvalue	 % variance	 Cumulative
.........................
explained 	 ...ancc explained
3.73	 31.1	 31.1
2	 1.58	 13.1	 44.2
Item	 Factor I Factor 2
If doctors had more time with patients they would prescribe fewer medicines 	 0.78	 0.16
Doctors place too much trust on medicines 	 0.74	 0.27
Doctors use too many medicines 	 0.72	 0.16
Natural remedies are safer than medicines 	 0.69	 0.37
It is better to do without medicines	 0.53	 0.38
Medicines are a necessary evil 	 0.48	 0.08
Medicines do more harm than good	 0.32	 0.71
People who take medicines should stop their treatment for a while every now	 0.19	 0.68
and again
All medicines are poisons	 0.26	 0.67
Most medicines are addictive	 0.00	 0.67









Eigenvalues < I rejected.
Factor	 Eigenvalue	 % variance	 Cumulative
explained	 lance explained
I	 2.85	 28.4	 28.4
2	 2.27	 22.7	 51.1
Structure matrix
Item code	 Factor I	 Factor 2
If doctors had more time with patients they would prescribe fewer medicines	 0.81	 0.13
Doctors use too many medicines	 0.79	 0.15
Doctors place too much trust on medicines 	 0.75	 0.26
Natural remedies are safer than medicines 	 0.70	 0.32
Medicines do more harm than good	 0.32	 0.72
People who take medicines should stop their treatment for a while every now 	 0.20	 0.71
and again
All medicines are poisons 	 0.27	 0.69
Most medicines are addictive 	 0.02	 0.69
Kaiser-Meyer-Olkin Measure of Sampling Adequacy = 0.79
Bartlett's Test of Sphericity = 342.65, p< 0.000 I
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Factor Eigenvalue % variance	 Cumulative
explained%variance explained
	3.18	 39.7	 39.7
2	 1.40	 17.5	 57.2
Structure matrix
Item	 Harm Overuse
Medicines do more harm than good 	 0.75 0.27
Most medicines are addictive	 0.75	 0.04
All medicines are poisons 	 0.74	 0.25
People who take medicines should stop their treatment for a 	 0.62 0.43
while every now and again
Doctors place too much trust on medicines	 0. I I	 0.83
If doctors had more time with patients they would prescribe	 0.21	 0.82
fewer medicines
Doctors use too many medicines	 0.46	 0.70
Natural remedies are safer than medicines 	 0.54	 0.58
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BMQ GENERAL: REPLICATION OF FACTOR
STRUCTURE
2. Cardiac patients





Factor Eigenvalue % variance	 Cumulative
explained	 % variance explained
	2.66	 33.2	 39.7
2	 1.30	 16.2	 49.5
Structure matrix
Item	 Harm Overuse
Medicines do more harm than good
Most medicines are addictive
All medicines are poisons
People who take medicines should stop their treatment for a








Doctors place too much trust on medicines 	 0.22	 0.83
If doctors had more time with patients they would prescribe
fewer medicines	 0.10	 0.79
Doctors use too many medicines	 0.33	 0.68
Natural remedies are safer than medicines	 0.26	 0.63 -.
BMQ-General factor scores
Range of scale = 4-20, high scores indicate strong beliefs
!sjjping	 n	 General-Overuse General-Harm
Combined	 214	 11.8	 9.8
Asthma	 76	 11.7	 10.3
Cardiac	 112	 12.8	 10.0
Dialysis	 42	 12.8	 9.7
Diabetes	 96	 11.5	 9.3
Psychiatric	 84	 ......0..
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	.80	 .07	 .15	 .19
	
.78	 -.02	 .14	 .20
	
.76	 .07	 .17	 .15
	
.60	 .16	 -.06	 .33
	
.12	 .81	 -.07	 .01
	
.10	 .76	 -.04	 -.04
	
.17	 .74	 -.08	 .11
	
.00	 .70	 -.09	 -.01
	
-.11	 .65	 -.22	 -.04
Appendix I 0
Principal Components Analysis (PCA) of combined BMQ-Specific and
BMQ-General items
Table AlO Structure matrix obtained by PCA on combined items from
the Specific and General medication belief factors on pooled data from
the six illness groups comprising the main sample (total n = 524)
ITEM	 Factor I	 Factor 2	 Factor 3:	 Factor 4
S refers to medicines prescribed for a specific illness 	 Specific	 Specific	 General	 General-
Concerns	 Necessity	 Harm	 Overuse
f
.!.r.2..T!1ra...............................................................................................
S	 Having to take this medicine worries me
S	 I sometimes worry about becoming too dependent on my
medicines
S	 I sometimes worry about the long term effects of my medicines
S	 My medicines disrupt my life
My life would be impossible without medicines
S	 My health, at present, depends on medicines
S	 Without medicines I would be very ill
S	 My health, in the future, will depend on medicines
S	 My medicines protect me from becoming worse
G	 If doctors had more time they would prescribe fewer medicines 	 .1 6	 -.10	 .81	 .09
G	 Doctors place too much trust in medicines 	 .04
	
-.10	 .75	 .23
G	 Doctors use too many medicines	 .26
	
-.13	 .7 I	 .17
G	 Natural remedies are safer than medicines	 .01
	
-.12	 .47	 .45
G	 Most medicines are addictive	 .07	 .06	 .05	 .71
G	 Medicines do more harm than good	 .22	 -.11	 .22	 .67
G	 All medicines are poisons 	 .16	 .14	 .21	 .58
S	 Mymedicinesareamystertome 	 .39	 .00	 -.09	 .55
G	 People who take medicines should stop their treatment for a 	 .33	 -.12	 .20	 .51
while every now and again
Eigenvaiue	 3.38	 2.92	 1.60	 1.44
Percentage variance explained	 8.8	 16.2	 8.9	 8.0
Cumulative percentage variance explained 	 18.8	 35.0	 43.9	 51 .9
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Appendix I I
Beliefs about Steroids Scales (BSS)
Steroid-Necessity
• My health at present depends on steroids
• My steroids are the most important part of my treatment
• Without my steroids I would be very ill
• Whether I feel better or worse depends on my steroids
• My steroids control my asthma symptoms
Cronbach alpha0.83 n75
Steroid-Concerns
• I sometimes worry about the long term effects of my steroids
• Having to take steroids worries me
• I sometimes worry about becoming too dependent on my steroids
• My steroids do more harm than good
• I have been given enough information about my steroids (REVERSE SCORING)
Cronbach alpha =0.78 n=75
SCORING:
Each of the 10 items was scored on a 5-point Likert scale where I = strongly disagree, 2 =
disagree, 3 = uncertain, 4 agree and 5 = strongly agree, reversed where indicated. Thus
higher scores on each scale represent stronger beliefs in the concept represented by the
scale
Results of Principal Component Analysis from which the scales were derived (see
Section 8.3.1)






My health at present depends on steroids 	 0.82	 0.23
My steroids are the most important part of my treatment 	 0.77	 0.04
Without my steroids I would be very ill 	 0.77	 0.29
Whether I feel better or worse depends on my steroids	 0.73	 -0.03
My steroids control my asthma symptoms	 0.72	 0.1 6
I sometimes worry about the long term effects of my steroids
Having to take steroids worries me
I sometimes worry about becoming too dependent on my steroids
My steroids do more harm than good











Percentage variance explained 	 38.3	 2 1.2
Cronbach alpha	 0.83	 0.78
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